{"PMC5759945": [["IntroductionLeukemia is a group of cancers that affects the lymphoid system, blood, and bone marrow as well as the differentiation of normal hematopoietic cells.", [["cancers", "ANATOMY", 35, 42], ["lymphoid system", "ANATOMY", 60, 75], ["blood", "ANATOMY", 77, 82], ["bone marrow", "ANATOMY", 88, 99], ["hematopoietic cells", "ANATOMY", 141, 160], ["IntroductionLeukemia", "DISEASE", 0, 20], ["cancers", "DISEASE", 35, 42], ["cancers", "CANCER", 35, 42], ["lymphoid system", "MULTI-TISSUE_STRUCTURE", 60, 75], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 88, 99], ["normal hematopoietic cells", "CELL", 134, 160], ["normal hematopoietic cells", "CELL_TYPE", 134, 160], ["a group of cancers", "PROBLEM", 24, 42], ["blood, and bone marrow", "PROBLEM", 77, 99], ["cancers", "OBSERVATION", 35, 42], ["lymphoid system", "ANATOMY", 60, 75], ["blood", "ANATOMY", 77, 82], ["bone marrow", "ANATOMY", 88, 99], ["normal hematopoietic cells", "OBSERVATION", 134, 160]]], ["Leukemia cells are unable to undergo terminal differentiation, growth arrest, and apoptosis in response to appropriate environmental stimuli.1 Based on the cell lineage transformation and clinical features, 4 main types of leukemia have been determined, namely acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).2IntroductionAcute myeloid leukemia arises within the bone marrow from a malignant hematopoietic progenitor cell.", [["Leukemia cells", "ANATOMY", 0, 14], ["cell", "ANATOMY", 156, 160], ["leukemia", "ANATOMY", 223, 231], ["acute lymphocytic leukemia", "ANATOMY", 261, 287], ["ALL", "ANATOMY", 289, 292], ["acute myeloid leukemia", "ANATOMY", 295, 317], ["AML", "ANATOMY", 319, 322], ["chronic lymphocytic leukemia", "ANATOMY", 325, 353], ["CLL", "ANATOMY", 355, 358], ["chronic myeloid leukemia", "ANATOMY", 365, 389], ["CML", "ANATOMY", 391, 394], ["Acute myeloid leukemia", "ANATOMY", 409, 431], ["bone marrow", "ANATOMY", 450, 461], ["malignant hematopoietic progenitor cell", "ANATOMY", 469, 508], ["Leukemia", "DISEASE", 0, 8], ["leukemia", "DISEASE", 223, 231], ["acute lymphocytic leukemia", "DISEASE", 261, 287], ["ALL", "DISEASE", 289, 292], ["acute myeloid leukemia", "DISEASE", 295, 317], ["AML", "DISEASE", 319, 322], ["chronic lymphocytic leukemia", "DISEASE", 325, 353], ["CLL", "DISEASE", 355, 358], ["chronic myeloid leukemia", "DISEASE", 365, 389], ["CML", "DISEASE", 391, 394], ["Acute myeloid leukemia", "DISEASE", 409, 431], ["Leukemia cells", "CELL", 0, 14], ["cell", "CELL", 156, 160], ["leukemia", "CANCER", 223, 231], ["acute lymphocytic leukemia", "CANCER", 261, 287], ["ALL", "CANCER", 289, 292], ["acute myeloid leukemia", "CANCER", 295, 317], ["AML", "CANCER", 319, 322], ["chronic lymphocytic leukemia", "CANCER", 325, 353], ["CLL", "CANCER", 355, 358], ["chronic myeloid leukemia", "CANCER", 365, 389], ["CML", "CANCER", 391, 394], ["Acute myeloid leukemia", "CANCER", 409, 431], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 450, 461], ["malignant hematopoietic progenitor cell", "CELL", 469, 508], ["Leukemia cells", "CELL_TYPE", 0, 14], ["malignant hematopoietic progenitor cell", "CELL_TYPE", 469, 508], ["Leukemia cells", "PROBLEM", 0, 14], ["terminal differentiation", "PROBLEM", 37, 61], ["growth arrest", "PROBLEM", 63, 76], ["apoptosis", "PROBLEM", 82, 91], ["the cell lineage transformation", "PROBLEM", 152, 183], ["leukemia", "PROBLEM", 223, 231], ["acute lymphocytic leukemia", "PROBLEM", 261, 287], ["acute myeloid leukemia", "PROBLEM", 295, 317], ["AML)", "PROBLEM", 319, 323], ["chronic lymphocytic leukemia", "PROBLEM", 325, 353], ["CLL)", "PROBLEM", 355, 359], ["chronic myeloid leukemia", "PROBLEM", 365, 389], ["CML", "PROBLEM", 391, 394], ["Acute myeloid leukemia", "PROBLEM", 409, 431], ["the bone marrow", "PROBLEM", 446, 461], ["a malignant hematopoietic progenitor cell", "PROBLEM", 467, 508], ["growth arrest", "OBSERVATION", 63, 76], ["cell", "OBSERVATION", 156, 160], ["lineage transformation", "OBSERVATION", 161, 183], ["leukemia", "OBSERVATION", 223, 231], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["lymphocytic leukemia", "OBSERVATION", 267, 287], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["myeloid leukemia", "OBSERVATION", 301, 317], ["AML", "OBSERVATION", 319, 322], ["chronic", "OBSERVATION_MODIFIER", 325, 332], ["lymphocytic leukemia", "OBSERVATION", 333, 353], ["CLL", "OBSERVATION", 355, 358], ["chronic", "OBSERVATION_MODIFIER", 365, 372], ["myeloid leukemia", "OBSERVATION", 373, 389], ["CML", "OBSERVATION", 391, 394], ["Acute", "OBSERVATION_MODIFIER", 409, 414], ["myeloid leukemia", "OBSERVATION", 415, 431], ["bone", "ANATOMY", 450, 454], ["marrow", "OBSERVATION", 455, 461], ["malignant", "OBSERVATION_MODIFIER", 469, 478], ["hematopoietic progenitor cell", "OBSERVATION", 479, 508]]], ["It has an annual overall incidence of 3.8 cases per 100 000 in the United States and Europe.3 AML is primarily a disease of the elderly, with an incidence of 15 cases per 100 000 for those older than 60 years.3 Unfortunately, the 5-year overall survival in patients older than 75 years is less than 10%.4 Several factors have been implicated in the causation of AML, including antecedent hematologic disorders, familial syndromes, environmental exposures, and drug exposures.", [["AML", "ANATOMY", 94, 97], ["AML", "ANATOMY", 362, 365], ["hematologic", "ANATOMY", 388, 399], ["AML", "DISEASE", 94, 97], ["AML", "DISEASE", 362, 365], ["hematologic disorders", "DISEASE", 388, 409], ["familial syndromes", "DISEASE", 411, 429], ["Europe.3 AML", "CANCER", 85, 97], ["patients", "ORGANISM", 257, 265], ["AML", "CANCER", 362, 365], ["patients", "SPECIES", 257, 265], ["AML", "PROBLEM", 94, 97], ["AML", "PROBLEM", 362, 365], ["antecedent hematologic disorders", "PROBLEM", 377, 409], ["familial syndromes", "PROBLEM", 411, 429], ["environmental exposures", "PROBLEM", 431, 454], ["annual", "OBSERVATION_MODIFIER", 10, 16], ["overall", "OBSERVATION_MODIFIER", 17, 24], ["incidence", "OBSERVATION_MODIFIER", 25, 34], ["AML", "OBSERVATION", 94, 97], ["disease", "OBSERVATION", 113, 120], ["AML", "OBSERVATION", 362, 365]]], ["Though a number of experimental drugs have been designed for the therapy of AML, most have failed in clinical trials.", [["AML", "ANATOMY", 76, 79], ["AML", "DISEASE", 76, 79], ["AML", "CANCER", 76, 79], ["experimental drugs", "TREATMENT", 19, 37], ["the therapy", "TREATMENT", 61, 72], ["AML", "PROBLEM", 76, 79]]], ["Except for gemtuzumab ozogamicin that has been recently withdrawn from the market, no new agent has yet been approved for AML in the past 40 years.5 Thus, the discovery of more effective therapeutic agents is needed for AML.IntroductionNumerous herbs used in traditional Chinese medicine may be of great value.", [["AML", "ANATOMY", 122, 125], ["AML", "ANATOMY", 220, 223], ["gemtuzumab ozogamicin", "CHEMICAL", 11, 32], ["AML", "DISEASE", 122, 125], ["AML", "DISEASE", 220, 223], ["gemtuzumab ozogamicin", "CHEMICAL", 11, 32], ["gemtuzumab ozogamicin", "SIMPLE_CHEMICAL", 11, 32], ["AML", "CANCER", 122, 125], ["AML", "CANCER", 220, 223], ["gemtuzumab ozogamicin", "TREATMENT", 11, 32], ["AML", "PROBLEM", 122, 125], ["more effective therapeutic agents", "TREATMENT", 172, 205], ["AML", "PROBLEM", 220, 223], ["Numerous herbs", "TREATMENT", 236, 250], ["traditional Chinese medicine", "TREATMENT", 259, 287], ["gemtuzumab ozogamicin", "OBSERVATION", 11, 32], ["no", "UNCERTAINTY", 83, 85], ["new", "OBSERVATION_MODIFIER", 86, 89]]], ["Toona sinensis Roem (Meliaceae) widely distributed in Asia has been used as a nutritious food for a long time.", [["Toona sinensis Roem", "CHEMICAL", 0, 19], ["Meliaceae", "CHEMICAL", 21, 30], ["Toona sinensis", "ORGANISM", 0, 14], ["Toona sinensis", "SPECIES", 0, 14], ["Toona sinensis", "SPECIES", 0, 14]]], ["The edible leaves were used as an oriental medicine with no significant side effects for treatment of enteritis, dysentery, and dermatitis.6 The pharmacological and biological activities of extract of Toona sinensis (TS) have been reported, including anticancer,7,8 antioxidant,9 antiatherosclerotic/inflammatory,10 antidiabetic,11 antivirus,12,13 as well as inhibiting Leydig cell steroidogenesis and SARS (severe acute respiratory syndrome) coronavirus replication.14 The phytochemical analyses of TS have isolated of triterpenes and phenolic compounds.6 Fifteen compounds of TS were identified, including methyl gallate, gallic acid, kaempferol, quercitin, quercitrin, ritin, catechin, epicatechin, oleic acid, palmitic acid, linoleic acid, and linolenic acid 15.", [["leaves", "ANATOMY", 11, 17], ["anticancer", "ANATOMY", 251, 261], ["Leydig cell", "ANATOMY", 370, 381], ["enteritis", "DISEASE", 102, 111], ["dysentery", "DISEASE", 113, 122], ["dermatitis", "DISEASE", 128, 138], ["extract of Toona sinensis", "CHEMICAL", 190, 215], ["SARS", "DISEASE", 402, 406], ["acute respiratory syndrome) coronavirus", "DISEASE", 415, 454], ["methyl gallate", "CHEMICAL", 608, 622], ["gallic acid", "CHEMICAL", 624, 635], ["kaempferol", "CHEMICAL", 637, 647], ["quercitin", "CHEMICAL", 649, 658], ["quercitrin", "CHEMICAL", 660, 670], ["ritin", "CHEMICAL", 672, 677], ["catechin", "CHEMICAL", 679, 687], ["epicatechin", "CHEMICAL", 689, 700], ["oleic acid", "CHEMICAL", 702, 712], ["palmitic acid", "CHEMICAL", 714, 727], ["linoleic acid", "CHEMICAL", 729, 742], ["linolenic acid", "CHEMICAL", 748, 762], ["triterpenes", "CHEMICAL", 520, 531], ["phenolic", "CHEMICAL", 536, 544], ["methyl gallate", "CHEMICAL", 608, 622], ["gallic acid", "CHEMICAL", 624, 635], ["kaempferol", "CHEMICAL", 637, 647], ["quercitin", "CHEMICAL", 649, 658], ["quercitrin", "CHEMICAL", 660, 670], ["ritin", "CHEMICAL", 672, 677], ["catechin", "CHEMICAL", 679, 687], ["epicatechin", "CHEMICAL", 689, 700], ["oleic acid", "CHEMICAL", 702, 712], ["palmitic acid", "CHEMICAL", 714, 727], ["linoleic acid", "CHEMICAL", 729, 742], ["linolenic acid", "CHEMICAL", 748, 762], ["Toona sinensis", "ORGANISM", 201, 215], ["anticancer", "CANCER", 251, 261], ["Leydig cell", "CELL", 370, 381], ["triterpenes", "SIMPLE_CHEMICAL", 520, 531], ["phenolic compounds", "SIMPLE_CHEMICAL", 536, 554], ["TS", "SIMPLE_CHEMICAL", 578, 580], ["methyl gallate", "SIMPLE_CHEMICAL", 608, 622], ["gallic acid", "SIMPLE_CHEMICAL", 624, 635], ["kaempferol", "SIMPLE_CHEMICAL", 637, 647], ["quercitin", "SIMPLE_CHEMICAL", 649, 658], ["quercitrin", "SIMPLE_CHEMICAL", 660, 670], ["ritin", "SIMPLE_CHEMICAL", 672, 677], ["catechin", "SIMPLE_CHEMICAL", 679, 687], ["epicatechin", "SIMPLE_CHEMICAL", 689, 700], ["oleic acid", "SIMPLE_CHEMICAL", 702, 712], ["palmitic acid", "SIMPLE_CHEMICAL", 714, 727], ["linoleic acid", "SIMPLE_CHEMICAL", 729, 742], ["linolenic acid", "SIMPLE_CHEMICAL", 748, 762], ["Toona sinensis", "SPECIES", 201, 215], ["Toona sinensis", "SPECIES", 201, 215], ["SARS (severe acute respiratory syndrome) coronavirus", "SPECIES", 402, 454], ["The edible leaves", "TREATMENT", 0, 17], ["an oriental medicine", "TREATMENT", 31, 51], ["significant side effects", "PROBLEM", 60, 84], ["enteritis", "PROBLEM", 102, 111], ["dysentery", "PROBLEM", 113, 122], ["dermatitis", "PROBLEM", 128, 138], ["inflammatory", "PROBLEM", 300, 312], ["antivirus", "TREATMENT", 332, 341], ["inhibiting Leydig cell steroidogenesis", "TREATMENT", 359, 397], ["SARS (severe acute respiratory syndrome", "PROBLEM", 402, 441], ["coronavirus replication", "PROBLEM", 443, 466], ["The phytochemical analyses", "TEST", 470, 496], ["TS", "PROBLEM", 500, 502], ["triterpenes and phenolic compounds", "PROBLEM", 520, 554], ["methyl gallate", "TREATMENT", 608, 622], ["gallic acid", "TREATMENT", 624, 635], ["kaempferol", "TREATMENT", 637, 647], ["quercitin", "TREATMENT", 649, 658], ["quercitrin", "TREATMENT", 660, 670], ["ritin", "TREATMENT", 672, 677], ["catechin", "TREATMENT", 679, 687], ["epicatechin", "TREATMENT", 689, 700], ["oleic acid", "TREATMENT", 702, 712], ["palmitic acid", "TREATMENT", 714, 727], ["linoleic acid", "TREATMENT", 729, 742], ["linolenic acid", "TREATMENT", 748, 762], ["enteritis", "OBSERVATION", 102, 111], ["dysentery", "OBSERVATION", 113, 122], ["dermatitis", "OBSERVATION", 128, 138], ["inflammatory", "OBSERVATION_MODIFIER", 300, 312], ["Leydig cell steroidogenesis", "OBSERVATION", 370, 397], ["severe", "OBSERVATION_MODIFIER", 408, 414], ["acute", "OBSERVATION_MODIFIER", 415, 420], ["respiratory syndrome", "OBSERVATION", 421, 441], ["phenolic compounds", "OBSERVATION", 536, 554]]], ["It has been demonstrated that the phenolic acid, gallic acid, a major component of TS leaf extracts possesses antioxidant and anticancer activities.16,17 The biologically active compound in TS extracts may be similar to natural compounds such as phenolic compounds, flavonoids, alkaloids, polysaccharides, and glycoproteins, which are known to induce cell death in cancer cells.18,19 The safety levels and nontoxic characteristics of TS were evaluated using acute and subacute toxicity studies in mice and rats, and no lethal effects were found at concentrations as high as 1 g/kg body weight.20,21 Although various bioactivity studies of TS have been carried out, there is no report addressing the effects of TS on the regulation of immune responses and antileukemia activity in murine leukemia WEHI-3 cells.", [["leaf extracts", "ANATOMY", 86, 99], ["anticancer", "ANATOMY", 126, 136], ["extracts", "ANATOMY", 193, 201], ["cell", "ANATOMY", 351, 355], ["cancer cells", "ANATOMY", 365, 377], ["body", "ANATOMY", 581, 585], ["leukemia WEHI-3 cells", "ANATOMY", 787, 808], ["phenolic acid", "CHEMICAL", 34, 47], ["gallic acid", "CHEMICAL", 49, 60], ["death", "DISEASE", 356, 361], ["cancer", "DISEASE", 365, 371], ["toxicity", "DISEASE", 477, 485], ["leukemia", "DISEASE", 787, 795], ["phenolic acid", "CHEMICAL", 34, 47], ["gallic acid", "CHEMICAL", 49, 60], ["phenolic", "CHEMICAL", 246, 254], ["flavonoids", "CHEMICAL", 266, 276], ["phenolic acid", "SIMPLE_CHEMICAL", 34, 47], ["gallic acid", "SIMPLE_CHEMICAL", 49, 60], ["leaf extracts", "ORGANISM_SUBSTANCE", 86, 99], ["anticancer", "CANCER", 126, 136], ["TS extracts", "ORGANISM_SUBSTANCE", 190, 201], ["phenolic compounds", "SIMPLE_CHEMICAL", 246, 264], ["flavonoids", "SIMPLE_CHEMICAL", 266, 276], ["alkaloids", "SIMPLE_CHEMICAL", 278, 287], ["polysaccharides", "SIMPLE_CHEMICAL", 289, 304], ["cell", "CELL", 351, 355], ["cancer cells", "CELL", 365, 377], ["mice", "ORGANISM", 497, 501], ["rats", "ORGANISM", 506, 510], ["body", "ORGANISM_SUBDIVISION", 581, 585], ["TS", "SIMPLE_CHEMICAL", 710, 712], ["murine", "ORGANISM", 780, 786], ["leukemia WEHI-3 cells", "CELL", 787, 808], ["cancer cells", "CELL_TYPE", 365, 377], ["murine leukemia WEHI-3 cells", "CELL_LINE", 780, 808], ["mice", "SPECIES", 497, 501], ["rats", "SPECIES", 506, 510], ["murine", "SPECIES", 780, 786], ["mice", "SPECIES", 497, 501], ["the phenolic acid", "TEST", 30, 47], ["gallic acid", "TREATMENT", 49, 60], ["TS leaf extracts", "TREATMENT", 83, 99], ["The biologically active compound in TS extracts", "PROBLEM", 154, 201], ["natural compounds", "PROBLEM", 220, 237], ["phenolic compounds", "PROBLEM", 246, 264], ["flavonoids", "PROBLEM", 266, 276], ["alkaloids", "TREATMENT", 278, 287], ["polysaccharides", "PROBLEM", 289, 304], ["glycoproteins", "PROBLEM", 310, 323], ["cell death in cancer cells", "PROBLEM", 351, 377], ["The safety levels", "TEST", 384, 401], ["TS", "PROBLEM", 434, 436], ["acute and subacute toxicity studies", "PROBLEM", 458, 493], ["lethal effects", "PROBLEM", 519, 533], ["various bioactivity studies of TS", "TEST", 608, 641], ["immune responses", "TREATMENT", 734, 750], ["antileukemia activity in murine leukemia WEHI", "PROBLEM", 755, 800], ["phenolic acid", "OBSERVATION", 34, 47], ["anticancer activities", "OBSERVATION", 126, 147], ["active", "OBSERVATION_MODIFIER", 171, 177], ["compound", "OBSERVATION", 178, 186], ["phenolic compounds", "OBSERVATION", 246, 264], ["cancer cells", "OBSERVATION", 365, 377], ["subacute", "OBSERVATION_MODIFIER", 468, 476], ["antileukemia activity", "OBSERVATION", 755, 776], ["murine leukemia WEHI", "OBSERVATION", 780, 800]]], ["In these studies, we show the effects of TS on induction of apoptosis of WEHI-3 cells and the promotion of immune responses, and its antileukemia activity in WEHI-3 leukemia BALB/c mice in vivo.Chemicals ::: Materials and MethodsRPMI-1640 medium was obtained from Gibco BRL (Grand Island, NY, USA), anti-mouse Bax, anti-mouse \u03b2-actin, anti-rabbit Bcl-2, anti-rabbit caspase-3, and anti-rabbit cytochrome c antibodies were purchased from Santa Cruz Biotechnology, Inc (Heidelberg, Germany).", [["WEHI-3 cells", "ANATOMY", 73, 85], ["WEHI-3 leukemia", "ANATOMY", 158, 173], ["WEHI-3 cells", "CELL", 73, 85], ["WEHI-3 leukemia BALB/c mice", "ORGANISM", 158, 185], ["Bax", "GENE_OR_GENE_PRODUCT", 310, 313], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 326, 333], ["anti-rabbit Bcl-2", "GENE_OR_GENE_PRODUCT", 335, 352], ["anti-rabbit caspase-3", "GENE_OR_GENE_PRODUCT", 354, 375], ["cytochrome c antibodies", "GENE_OR_GENE_PRODUCT", 393, 416], ["WEHI-3 cells", "CELL_LINE", 73, 85], ["anti-mouse Bax", "PROTEIN", 299, 313], ["anti-mouse \u03b2-actin", "PROTEIN", 315, 333], ["anti-rabbit Bcl-2", "PROTEIN", 335, 352], ["anti-rabbit caspase-3", "PROTEIN", 354, 375], ["anti-rabbit cytochrome c antibodies", "PROTEIN", 381, 416], ["mice", "SPECIES", 181, 185], ["anti-mouse", "SPECIES", 299, 309], ["anti-mouse", "SPECIES", 315, 325], ["anti-rabbit", "SPECIES", 335, 346], ["anti-rabbit", "SPECIES", 354, 365], ["anti-rabbit", "SPECIES", 381, 392], ["mice", "SPECIES", 181, 185], ["these studies", "TEST", 3, 16], ["apoptosis of WEHI", "TREATMENT", 60, 77], ["immune responses", "PROBLEM", 107, 123], ["its antileukemia activity", "PROBLEM", 129, 154], ["WEHI", "TEST", 158, 162], ["MethodsRPMI", "TEST", 222, 233], ["anti-mouse Bax", "TREATMENT", 299, 313], ["anti-mouse \u03b2-actin", "TREATMENT", 315, 333], ["anti-rabbit Bcl", "TEST", 335, 350], ["anti-rabbit caspase", "TREATMENT", 354, 373], ["anti-rabbit cytochrome c antibodies", "TREATMENT", 381, 416], ["antileukemia activity", "OBSERVATION", 133, 154]]], ["All other chemicals were of the highest grade commercially available and supplied either by Merck (Darmstadt, Germany) or Sigma (St Louis, MO, USA).Cell Culture ::: Materials and MethodsWEHI-3 cells, a murine myelomonocytic leukemic cell line, were obtained from the American Type Culture Collection (Rockville, MD, USA).", [["Cell", "ANATOMY", 148, 152], ["MethodsWEHI-3 cells", "ANATOMY", 179, 198], ["myelomonocytic leukemic cell line", "ANATOMY", 209, 242], ["myelomonocytic leukemic", "DISEASE", 209, 232], ["Cell", "CELL", 148, 152], ["MethodsWEHI-3 cells", "CELL", 179, 198], ["murine", "ORGANISM", 202, 208], ["myelomonocytic leukemic cell line", "CELL", 209, 242], ["MethodsWEHI-3 cells", "CELL_LINE", 179, 198], ["murine myelomonocytic leukemic cell line", "CELL_LINE", 202, 242], ["murine", "SPECIES", 202, 208], ["Cell Culture", "TEST", 148, 160], ["Materials", "TEST", 165, 174], ["MethodsWEHI", "TEST", 179, 190], ["a murine myelomonocytic leukemic cell line", "PROBLEM", 200, 242], ["myelomonocytic leukemic cell line", "OBSERVATION", 209, 242]]], ["These cells were grown in RPMI-1640 supplemented with 10% heat-inactivated FBS, 2 mM glutamine, and 1% penicillin-streptomycin-neomycin in a 5% CO2 humidified incubator at 37\u00b0C. Cultures were harvested and cell numbers enumerated by hemocytometer analysis of cell suspensions.Toona sinensis Preparation and Extraction ::: Materials and MethodsThe leaves of Toona sinensis (TS) were sourced from Fooyin University, Kaohsiung, Taiwan.", [["cells", "ANATOMY", 6, 11], ["FBS", "ANATOMY", 75, 78], ["cell", "ANATOMY", 206, 210], ["cell", "ANATOMY", 259, 263], ["leaves", "ANATOMY", 347, 353], ["RPMI-1640", "CHEMICAL", 26, 35], ["glutamine", "CHEMICAL", 85, 94], ["penicillin", "CHEMICAL", 103, 113], ["streptomycin", "CHEMICAL", 114, 126], ["neomycin", "CHEMICAL", 127, 135], ["CO2", "CHEMICAL", 144, 147], ["glutamine", "CHEMICAL", 85, 94], ["penicillin", "CHEMICAL", 103, 113], ["streptomycin", "CHEMICAL", 114, 126], ["neomycin", "CHEMICAL", 127, 135], ["CO2", "CHEMICAL", 144, 147], ["cells", "CELL", 6, 11], ["RPMI-1640", "CELL", 26, 35], ["FBS", "ORGANISM_SUBSTANCE", 75, 78], ["glutamine", "AMINO_ACID", 85, 94], ["penicillin-streptomycin-neomycin", "SIMPLE_CHEMICAL", 103, 135], ["CO2", "SIMPLE_CHEMICAL", 144, 147], ["cell", "CELL", 206, 210], ["cell suspensions", "CELL", 259, 275], ["Toona sinensis", "ORGANISM", 276, 290], ["Toona sinensis", "ORGANISM", 357, 371], ["Toona sinensis", "SPECIES", 276, 290], ["Toona sinensis", "SPECIES", 357, 371], ["Toona sinensis", "SPECIES", 276, 290], ["Toona sinensis", "SPECIES", 357, 371], ["RPMI", "TEST", 26, 30], ["FBS", "TEST", 75, 78], ["2 mM glutamine", "TREATMENT", 80, 94], ["penicillin", "TREATMENT", 103, 113], ["streptomycin", "TREATMENT", 114, 126], ["neomycin", "TREATMENT", 127, 135], ["a 5% CO2 humidified incubator", "TREATMENT", 139, 168], ["Cultures", "TEST", 178, 186], ["cell numbers", "TEST", 206, 218], ["hemocytometer analysis", "TEST", 233, 255], ["cell suspensions", "TREATMENT", 259, 275], ["Materials", "TREATMENT", 322, 331], ["cell suspensions", "OBSERVATION", 259, 275]]], ["A voucher specimen was characterized by Dr Horng-Liang Lay, Graduate Institute of Biotechnology, National Pingtung University of Science and Technology, Pingtung County, Taiwan.22 The aqueous extracts of TS were prepared by adding 1000 mL of water to 1000 g of the leaves of fresh TS and boiling until 100 mL remained, as previously described.23 The crude extracts were centrifuged at 3000 rpm for 12 minutes and the supernatant used for this study.", [["specimen", "ANATOMY", 10, 18], ["aqueous extracts", "ANATOMY", 184, 200], ["leaves", "ANATOMY", 265, 271], ["extracts", "ANATOMY", 356, 364], ["supernatant", "ANATOMY", 417, 428], ["aqueous extracts", "ORGANISM_SUBSTANCE", 184, 200], ["TS", "SIMPLE_CHEMICAL", 204, 206], ["extracts", "ORGANISM_SUBSTANCE", 356, 364], ["fresh TS", "TREATMENT", 275, 283], ["The crude extracts", "TREATMENT", 346, 364], ["the supernatant", "TREATMENT", 413, 428], ["this study", "TEST", 438, 448], ["aqueous", "OBSERVATION_MODIFIER", 184, 191], ["extracts", "OBSERVATION_MODIFIER", 192, 200]]], ["The crude extracts (50 g) were concentrated in a vacuum and freeze dried to form powder, with the stock subsequently stored at \u221220\u00b0C for subsequent analysis of its anticancer properties.", [["extracts", "ANATOMY", 10, 18], ["anticancer", "ANATOMY", 164, 174], ["extracts", "ORGANISM_SUBSTANCE", 10, 18], ["C", "GENE_OR_GENE_PRODUCT", 131, 132], ["anticancer", "CANCER", 164, 174], ["The crude extracts", "TREATMENT", 0, 18], ["a vacuum and freeze", "TREATMENT", 47, 66], ["subsequent analysis", "TEST", 137, 156], ["anticancer properties", "OBSERVATION", 164, 185]]], ["The yield of TS extracts was 5%.8MTT Assay ::: Materials and MethodsThe effect of TS on WEHI-3 cell viability was monitored using the MTT colorimetric assay.", [["extracts", "ANATOMY", 16, 24], ["WEHI-3 cell", "ANATOMY", 88, 99], ["MTT", "CHEMICAL", 33, 36], ["MTT", "CHEMICAL", 134, 137], ["TS extracts", "ORGANISM_SUBSTANCE", 13, 24], ["WEHI-3 cell", "CELL", 88, 99], ["The yield of TS extracts", "TREATMENT", 0, 24], ["Methods", "TREATMENT", 61, 68], ["TS on WEHI", "TEST", 82, 92], ["the MTT colorimetric assay", "TEST", 130, 156]]], ["In brief, 2 \u00d7 105 cells/well were plated in 12-well plates, and they were pretreated with or without various concentrations of TS (10-75 \u03bcg/mL) for 24 hours.", [["cells", "ANATOMY", 18, 23], ["TS", "CHEMICAL", 127, 129], ["cells", "CELL", 18, 23], ["various concentrations of TS", "TREATMENT", 101, 129]]], ["After treatment, the cells were incubated with 400 \u03bcL of 0.5 mg/mL MTT in phosphate-buffered saline (PBS) for 2 hours.", [["cells", "ANATOMY", 21, 26], ["phosphate", "CHEMICAL", 74, 83], ["MTT", "CHEMICAL", 67, 70], ["phosphate", "CHEMICAL", 74, 83], ["cells", "CELL", 21, 26], ["MTT", "SIMPLE_CHEMICAL", 67, 70], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 74, 99], ["treatment", "TREATMENT", 6, 15], ["phosphate-buffered saline (PBS", "TREATMENT", 74, 104]]], ["Culture supernatants were removed and resuspended in 400 \u03bcL of isopropanol to dissolve the MTT formazan, and the absorbance was measured at 570 nm using an enzyme-linked immunosorbent assay (ELISA) microplate reader.", [["supernatants", "ANATOMY", 8, 20], ["isopropanol", "CHEMICAL", 63, 74], ["MTT formazan", "CHEMICAL", 91, 103], ["isopropanol", "CHEMICAL", 63, 74], ["MTT formazan", "CHEMICAL", 91, 103], ["isopropanol", "SIMPLE_CHEMICAL", 63, 74], ["MTT", "SIMPLE_CHEMICAL", 91, 94], ["formazan", "SIMPLE_CHEMICAL", 95, 103], ["Culture supernatants", "TEST", 0, 20], ["isopropanol", "TREATMENT", 63, 74], ["the MTT formazan", "TEST", 87, 103], ["the absorbance", "TEST", 109, 123], ["an enzyme", "TEST", 153, 162], ["immunosorbent assay", "TEST", 170, 189]]], ["The effect of TS on cell viability was assessed as the percent of viable cells compared to the vehicle-treated control group, which was arbitrarily assigned to represent 100% viability.", [["cell", "ANATOMY", 20, 24], ["cells", "ANATOMY", 73, 78], ["cell", "CELL", 20, 24], ["cells", "CELL", 73, 78], ["viable cells", "CELL_TYPE", 66, 78], ["TS on cell viability", "PROBLEM", 14, 34], ["viable cells", "PROBLEM", 66, 78]]], ["This assay was performed in triplicate for each concentration.Determination of Apoptotic Cells by Annexin V/PI Staining ::: Materials and MethodsDouble staining for Annexin V-FITC and PI (propidium iodide) was performed to estimate the apoptotic rate of WEHI-3 leukemia cells.", [["Cells", "ANATOMY", 89, 94], ["WEHI-3 leukemia cells", "ANATOMY", 254, 275], ["Annexin V", "CHEMICAL", 165, 174], ["propidium iodide", "CHEMICAL", 188, 204], ["leukemia", "DISEASE", 261, 269], ["FITC", "CHEMICAL", 175, 179], ["propidium iodide", "CHEMICAL", 188, 204], ["Apoptotic Cells", "CELL", 79, 94], ["Annexin V", "GENE_OR_GENE_PRODUCT", 98, 107], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 165, 179], ["PI", "SIMPLE_CHEMICAL", 184, 186], ["propidium iodide", "SIMPLE_CHEMICAL", 188, 204], ["WEHI-3 leukemia cells", "CELL", 254, 275], ["Apoptotic Cells", "CELL_TYPE", 79, 94], ["WEHI-3 leukemia cells", "CELL_LINE", 254, 275], ["This assay", "TEST", 0, 10], ["Apoptotic Cells", "PROBLEM", 79, 94], ["MethodsDouble staining", "TEST", 138, 160], ["Annexin V", "TREATMENT", 165, 174], ["FITC and PI (propidium iodide", "TREATMENT", 175, 204], ["leukemia cells", "PROBLEM", 261, 275], ["Apoptotic Cells", "OBSERVATION", 79, 94], ["WEHI", "OBSERVATION", 254, 258], ["leukemia cells", "OBSERVATION", 261, 275]]], ["Briefly, cells were incubated with TS (75 \u03bcg/mL) for 0 to 24 hours.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["TS", "TEST", 35, 37]]], ["Cells were trypsinized, washed twice with PBS, and centrifuged at 800 rpm for 5 minutes.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PBS", "TREATMENT", 42, 45]]], ["Then, cells (2 \u00d7 105cells/10-cm dish) were suspended in binding buffer (500 \u03bcL) and double-stained with Annexin V-FITC and PI for 15 minutes at room temperature.", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 20, 25], ["Annexin V", "CHEMICAL", 104, 113], ["FITC", "CHEMICAL", 114, 118], ["cells", "CELL", 6, 11], ["cells", "CELL", 20, 25], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 104, 118], ["PI", "SIMPLE_CHEMICAL", 123, 125], ["cells", "TEST", 6, 11], ["Annexin V", "TREATMENT", 104, 113], ["FITC and PI", "TREATMENT", 114, 125]]], ["Then the result green (FITC) and red (PI) fluorescence of each sample was quantitatively analyzed by FACS Caliber flow cytometer (Becton Dickinson, San Jose, CA, USA) and Cell Quest software.", [["sample", "ANATOMY", 63, 69], ["Cell", "ANATOMY", 171, 175], ["FITC", "CHEMICAL", 23, 27], ["FITC", "SIMPLE_CHEMICAL", 23, 27], ["PI", "SIMPLE_CHEMICAL", 38, 40], ["Cell", "CELL", 171, 175], ["each sample", "TEST", 58, 69], ["Caliber", "OBSERVATION_MODIFIER", 106, 113]]], ["The obtained results were interpreted as follows: (Q3) cells negative for both PI and Annexin V-FITC staining were considered normal live cells.", [["Q3) cells", "ANATOMY", 51, 60], ["cells", "ANATOMY", 138, 143], ["FITC", "CHEMICAL", 96, 100], ["cells", "CELL", 55, 60], ["PI", "SIMPLE_CHEMICAL", 79, 81], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 86, 100], ["cells", "CELL", 138, 143], ["cells", "TEST", 55, 60], ["PI", "TEST", 79, 81], ["Annexin V", "TEST", 86, 95], ["FITC staining", "TEST", 96, 109], ["FITC staining", "OBSERVATION", 96, 109]]], ["(Q4) PI-negative, Annexin V-FITC-positive stained cells were considered in early apoptosis.", [["cells", "ANATOMY", 50, 55], ["Q4) PI", "GENE_OR_GENE_PRODUCT", 1, 7], ["Annexin V", "GENE_OR_GENE_PRODUCT", 18, 27], ["cells", "CELL", 50, 55], ["Annexin V-FITC-positive stained cells", "CELL_LINE", 18, 55], ["PI", "TEST", 5, 7], ["Annexin V-FITC", "TEST", 18, 32], ["positive stained cells", "PROBLEM", 33, 55], ["early apoptosis", "PROBLEM", 75, 90], ["stained cells", "OBSERVATION", 42, 55], ["early", "OBSERVATION_MODIFIER", 75, 80], ["apoptosis", "OBSERVATION", 81, 90]]], ["(Q2) PI positive, Annexin V-FITC-positive stained cells were considered in late apoptosis.", [["cells", "ANATOMY", 50, 55], ["Q2) PI", "GENE_OR_GENE_PRODUCT", 1, 7], ["Annexin V", "GENE_OR_GENE_PRODUCT", 18, 27], ["cells", "CELL", 50, 55], ["Annexin V-FITC-positive stained cells", "CELL_LINE", 18, 55], ["PI", "TEST", 5, 7], ["Annexin V-FITC", "TEST", 18, 32], ["positive stained cells", "PROBLEM", 33, 55], ["stained cells", "OBSERVATION", 42, 55], ["late apoptosis", "OBSERVATION", 75, 89]]], ["(Q1) PI positive, Annexin V-FITC-negative stained cells were considered in necrosis.Protein Isolation and Western Blot Analysis ::: Materials and MethodsWEHI-3 cells (2 \u00d7 106 cells) were seeded in a 10-cm dish.", [["cells", "ANATOMY", 50, 55], ["MethodsWEHI-3 cells", "ANATOMY", 146, 165], ["cells", "ANATOMY", 175, 180], ["necrosis", "DISEASE", 75, 83], ["FITC", "CHEMICAL", 28, 32], ["Q1) PI", "GENE_OR_GENE_PRODUCT", 1, 7], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 18, 32], ["cells", "CELL", 50, 55], ["MethodsWEHI-3 cells", "CELL", 146, 165], ["2 \u00d7 106 cells", "CELL", 167, 180], ["Annexin V-FITC-negative stained cells", "CELL_LINE", 18, 55], ["MethodsWEHI-3 cells", "CELL_LINE", 146, 165], ["PI", "TEST", 5, 7], ["Annexin V", "TEST", 18, 27], ["FITC", "TEST", 28, 32], ["stained cells", "PROBLEM", 42, 55], ["necrosis", "PROBLEM", 75, 83], ["Materials", "TEST", 132, 141], ["MethodsWEHI", "TEST", 146, 157], ["stained cells", "OBSERVATION", 42, 55], ["necrosis", "OBSERVATION", 75, 83], ["10-cm", "OBSERVATION_MODIFIER", 199, 204]]], ["Once the cells reached 80% confluence, they were incubated with or without the indicated concentrations of TS for 24 hours.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14]]], ["The treated cells were washed once in cold PBS and suspended in 100 \u00b5L of lysis buffer (10 mM Tris-HCl [pH 8], 0.32 M sucrose, 1% Triton X-100, 5 mM ethylenediamine tetra-acetic acid (EDTA), 2 mM DTT, and 1 mM phenyl methyl sulfonyl fluoride).", [["cells", "ANATOMY", 12, 17], ["Tris-HCl", "CHEMICAL", 94, 102], ["sucrose", "CHEMICAL", 118, 125], ["Triton X-100", "CHEMICAL", 130, 142], ["ethylenediamine tetra-acetic acid", "CHEMICAL", 149, 182], ["EDTA", "CHEMICAL", 184, 188], ["DTT", "CHEMICAL", 196, 199], ["phenyl methyl sulfonyl fluoride", "CHEMICAL", 210, 241], ["Tris-HCl", "CHEMICAL", 94, 102], ["sucrose", "CHEMICAL", 118, 125], ["ethylenediamine tetra-acetic acid", "CHEMICAL", 149, 182], ["EDTA", "CHEMICAL", 184, 188], ["DTT", "CHEMICAL", 196, 199], ["phenyl methyl sulfonyl fluoride", "CHEMICAL", 210, 241], ["cells", "CELL", 12, 17], ["sucrose", "SIMPLE_CHEMICAL", 118, 125], ["Triton X-100", "SIMPLE_CHEMICAL", 130, 142], ["ethylenediamine tetra-acetic acid", "SIMPLE_CHEMICAL", 149, 182], ["EDTA", "SIMPLE_CHEMICAL", 184, 188], ["DTT", "SIMPLE_CHEMICAL", 196, 199], ["phenyl methyl sulfonyl fluoride", "SIMPLE_CHEMICAL", 210, 241], ["treated cells", "CELL_LINE", 4, 17], ["The treated cells", "TREATMENT", 0, 17], ["cold PBS", "TREATMENT", 38, 46], ["lysis buffer", "TREATMENT", 74, 86], ["pH", "TEST", 104, 106], ["sucrose", "TREATMENT", 118, 125], ["5 mM ethylenediamine tetra-acetic acid (EDTA", "TREATMENT", 144, 188], ["2 mM DTT", "TREATMENT", 191, 199], ["1 mM phenyl methyl sulfonyl fluoride", "TREATMENT", 205, 241]]], ["The suspension was vortexed, kept on ice for 20 minutes, and then centrifuged at 15000 \u00d7 g for 20 minutes at 4\u00b0C. Total protein content was quantified using the Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA), with bovine serum albumin (BSA) as the standard.", [["serum", "ANATOMY", 233, 238], ["bovine", "ORGANISM", 226, 232], ["serum", "ORGANISM_SUBSTANCE", 233, 238], ["albumin", "SIMPLE_CHEMICAL", 239, 246], ["BSA", "SIMPLE_CHEMICAL", 248, 251], ["bovine", "SPECIES", 226, 232], ["bovine", "SPECIES", 226, 232], ["The suspension", "TREATMENT", 0, 14], ["Total protein content", "TEST", 114, 135], ["the Bio", "TEST", 157, 164], ["Bio", "TEST", 192, 195], ["Hercules", "TEST", 201, 209], ["CA", "TEST", 211, 213], ["bovine serum albumin (BSA", "TEST", 226, 251], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["The protein extracts were reconstituted in sample buffer (0.062 M Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% glycerol, and 5% \u03b2-mercaptoethanol), and the mixture was boiled at 94\u00b0C for 5 minutes.", [["extracts", "ANATOMY", 12, 20], ["Tris-HCl", "CHEMICAL", 66, 74], ["sodium dodecyl sulfate", "CHEMICAL", 79, 101], ["glycerol", "CHEMICAL", 113, 121], ["\u03b2-mercaptoethanol", "CHEMICAL", 130, 147], ["Tris-HCl", "CHEMICAL", 66, 74], ["sodium dodecyl sulfate", "CHEMICAL", 79, 101], ["SDS", "CHEMICAL", 103, 106], ["glycerol", "CHEMICAL", 113, 121], ["\u03b2-mercaptoethanol", "CHEMICAL", 130, 147], ["extracts", "ORGANISM_SUBSTANCE", 12, 20], ["Tris-HCl", "SIMPLE_CHEMICAL", 66, 74], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 79, 101], ["SDS", "SIMPLE_CHEMICAL", 103, 106], ["glycerol", "SIMPLE_CHEMICAL", 113, 121], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 130, 147], ["The protein extracts", "TEST", 0, 20], ["Tris", "TEST", 66, 70], ["2% sodium dodecyl sulfate", "TREATMENT", 76, 101], ["SDS", "TEST", 103, 106], ["glycerol", "TREATMENT", 113, 121]]], ["Equal amounts (50 \u00b5g) of the denatured proteins were loaded into each lane, separated by electrophoresis on 8% to 15% SDS polyacrylamide gels, and the proteins were transferred to PVDF (polyvinylidine fluoride) membranes overnight.", [["polyvinylidine fluoride", "CHEMICAL", 186, 209], ["polyacrylamide", "CHEMICAL", 122, 136], ["PVDF", "CHEMICAL", 180, 184], ["polyvinylidine fluoride", "CHEMICAL", 186, 209], ["polyvinylidine fluoride", "SIMPLE_CHEMICAL", 186, 209], ["denatured proteins", "PROTEIN", 29, 47], ["the denatured proteins", "TREATMENT", 25, 47], ["electrophoresis", "TEST", 89, 104], ["15% SDS polyacrylamide gels", "TREATMENT", 114, 141], ["the proteins", "TREATMENT", 147, 159], ["PVDF (polyvinylidine fluoride) membranes", "TREATMENT", 180, 220]]], ["The membranes were blocked with 0.1% Tween-20 in Tris-buffered saline containing 5% nonfat dry milk for 20 minutes at room temperature, and then incubated with the indicated primary antibody for 2 hours.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 95, 99], ["Tween-20", "CHEMICAL", 37, 45], ["Tween-20", "CHEMICAL", 37, 45], ["Tris", "CHEMICAL", 49, 53], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["Tween-20", "SIMPLE_CHEMICAL", 37, 45], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 49, 69], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["primary antibody", "PROTEIN", 174, 190], ["Tris-buffered saline", "TREATMENT", 49, 69]]], ["The membranes were then incubated with a horseradish peroxidase\u2013conjugated goat anti-rabbit or anti-mouse antibody for 2 hours and developed using a chemiluminescence substrate (Millipore, Billerica, MA, USA).", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["horseradish peroxidase\u2013conjugated goat anti-rabbit", "PROTEIN", 41, 91], ["anti-mouse antibody", "PROTEIN", 95, 114], ["horseradish", "SPECIES", 41, 52], ["goat", "SPECIES", 75, 79], ["anti-rabbit", "SPECIES", 80, 91], ["anti-mouse", "SPECIES", 95, 105], ["goat", "SPECIES", 75, 79], ["anti-rabbit", "SPECIES", 80, 91], ["a horseradish peroxidase\u2013conjugated goat anti-rabbit", "TREATMENT", 39, 91], ["anti-mouse antibody", "TREATMENT", 95, 114], ["a chemiluminescence substrate", "TREATMENT", 147, 176]]], ["For densitometric analysis, band intensities were quantified using commercially available software (AlpaEaseFc 4.0; Genetic Technologies, Inc, Miami, FL, USA).Animal Experiments ::: Materials and MethodsA total of 18 male BALB/c mice, 8 weeks of age were purchased from GlycoNex Inc in Taiwan and were maintained in cage housing in a specifically designed pathogen-free isolation facility with a 12/12-h light/dark cycle and fed rodent chow and water ad libitum.", [["BALB/c mice", "ORGANISM", 222, 233], ["mice", "SPECIES", 229, 233], ["rodent", "SPECIES", 429, 435], ["mice", "SPECIES", 229, 233], ["densitometric analysis", "TEST", 4, 26], ["band intensities", "TEST", 28, 44], ["AlpaEaseFc", "TEST", 100, 110]]], ["All experiments were conducted in accordance with the guidelines of the China Medical University, Animal Ethics Research Board.Tumor Cell Inoculation ::: Materials and MethodsBALB/c mice were injected with WEHI-3 cells (3 \u00d7 106/100 \u00b5L) via the tail vein.", [["Tumor Cell", "ANATOMY", 127, 137], ["WEHI-3 cells", "ANATOMY", 206, 218], ["tail vein", "ANATOMY", 244, 253], ["Tumor Cell", "CELL", 127, 137], ["MethodsBALB/c mice", "ORGANISM", 168, 186], ["WEHI-3 cells", "CELL", 206, 218], ["tail vein", "MULTI-TISSUE_STRUCTURE", 244, 253], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 182, 186], ["Materials", "TREATMENT", 154, 163], ["MethodsBALB/c mice", "TREATMENT", 168, 186], ["WEHI-3 cells", "TREATMENT", 206, 218], ["tail vein", "ANATOMY", 244, 253]]], ["Experiments were carried out using cells less than 15 passages.", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40]]], ["BALB/c mice were divided into 3 groups (n = 6).", [["BALB/c mice", "ORGANISM", 0, 11], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 7, 11], ["BALB/c mice", "TREATMENT", 0, 11]]], ["Group I was control, group II was injected with WEHI-3 cells, and group III was injected with WEHI-3 cells and then treated with TS extracts (0.2 mL/mouse) dissolved in PBS at 50 mg/kg every 2 days, while the control group received daily injections of vehicle only.", [["WEHI-3 cells", "ANATOMY", 48, 60], ["WEHI-3 cells", "ANATOMY", 94, 106], ["extracts", "ANATOMY", 132, 140], ["WEHI-3 cells", "CELL", 48, 60], ["WEHI-3 cells", "CELL", 94, 106], ["extracts", "ORGANISM_SUBSTANCE", 132, 140], ["mouse", "ORGANISM", 149, 154], ["WEHI-3 cells", "CELL_LINE", 48, 60], ["WEHI-3 cells", "CELL_LINE", 94, 106], ["mouse", "SPECIES", 149, 154], ["mouse", "SPECIES", 149, 154], ["WEHI-3 cells", "TREATMENT", 48, 60], ["WEHI-3 cells", "TREATMENT", 94, 106], ["TS extracts", "TREATMENT", 129, 140], ["PBS", "TREATMENT", 169, 172]]], ["After 21 days of treatment, the animals were then weighed and sacrificed.", [["animals", "ORGANISM", 32, 39], ["treatment", "TREATMENT", 17, 26]]], ["Blood was collected from all animals at the end of the experiments for hematological analysis.Hematological Analysis ::: Materials and MethodsBlood samples (1 mL) were collected from animals of each group at the end of the experiments, and were treated immediately with ammonium chloride buffer for lysing of the red blood cells followed by centrifugation for 15 minutes at 1500 rpm at 4\u00b0C for the isolation of peripheral blood mononuclear cells and analyzed by flow cytometry.Liver and Spleen Samples ::: Materials and MethodsAll the animals (control and experimental groups) were weighed before whole blood was drawn.", [["Blood", "ANATOMY", 0, 5], ["Blood samples", "ANATOMY", 142, 155], ["red blood cells", "ANATOMY", 313, 328], ["peripheral blood mononuclear cells", "ANATOMY", 411, 445], ["Liver", "ANATOMY", 477, 482], ["whole blood", "ANATOMY", 597, 608], ["ammonium chloride", "CHEMICAL", 270, 287], ["ammonium chloride", "CHEMICAL", 270, 287], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["ammonium chloride", "SIMPLE_CHEMICAL", 270, 287], ["red blood cells", "CELL", 313, 328], ["C", "SIMPLE_CHEMICAL", 388, 389], ["peripheral blood mononuclear cells", "CELL", 411, 445], ["Liver", "ORGAN", 477, 482], ["animals", "ORGANISM", 535, 542], ["blood", "ORGANISM_SUBSTANCE", 603, 608], ["red blood cells", "CELL_TYPE", 313, 328], ["peripheral blood mononuclear cells", "CELL_TYPE", 411, 445], ["Blood", "TEST", 0, 5], ["hematological analysis", "TEST", 71, 93], ["Hematological Analysis", "TEST", 94, 116], ["MethodsBlood samples", "TEST", 135, 155], ["ammonium chloride buffer", "TREATMENT", 270, 294], ["the red blood cells", "TREATMENT", 309, 328], ["peripheral blood mononuclear cells", "PROBLEM", 411, 445], ["flow cytometry", "TEST", 462, 476], ["Materials", "TREATMENT", 506, 515], ["Methods", "TREATMENT", 520, 527], ["whole blood", "TEST", 597, 608], ["peripheral", "ANATOMY_MODIFIER", 411, 421], ["blood", "ANATOMY", 422, 427], ["mononuclear cells", "OBSERVATION", 428, 445], ["flow cytometry", "OBSERVATION", 462, 476], ["Spleen", "ANATOMY", 487, 493]]], ["The tissues of liver and spleen were isolated and weighed for each animal.24Histopathology ::: Materials and MethodsTissue sample (spleen) of each group was fixed in 4% formaldehyde and embedded in paraffin.", [["tissues", "ANATOMY", 4, 11], ["liver", "ANATOMY", 15, 20], ["spleen", "ANATOMY", 25, 31], ["MethodsTissue sample", "ANATOMY", 109, 129], ["spleen", "ANATOMY", 131, 137], ["formaldehyde", "CHEMICAL", 169, 181], ["formaldehyde", "CHEMICAL", 169, 181], ["paraffin", "CHEMICAL", 198, 206], ["tissues", "TISSUE", 4, 11], ["liver", "ORGAN", 15, 20], ["spleen", "ORGAN", 25, 31], ["spleen", "ORGAN", 131, 137], ["formaldehyde", "SIMPLE_CHEMICAL", 169, 181], ["MethodsTissue sample", "TEST", 109, 129], ["tissues", "ANATOMY", 4, 11], ["liver", "ANATOMY", 15, 20], ["spleen", "ANATOMY", 25, 31], ["spleen", "ANATOMY", 131, 137]]], ["Five-millimeter sections were stained with hematoxylin and eosin as described previously.24Statistical Analysis ::: Materials and MethodsThe results of in vitro and in vivo experiments are presented as mean and standard deviation (mean \u00b1 SD) or mean and standard error (mean \u00b1 SE), respectively.", [["sections", "ANATOMY", 16, 24], ["hematoxylin", "CHEMICAL", 43, 54], ["eosin", "CHEMICAL", 59, 64], ["sections", "MULTI-TISSUE_STRUCTURE", 16, 24], ["hematoxylin", "SIMPLE_CHEMICAL", 43, 54], ["eosin", "SIMPLE_CHEMICAL", 59, 64], ["hematoxylin", "TREATMENT", 43, 54], ["eosin", "TREATMENT", 59, 64], ["mean", "TEST", 245, 249]]], ["All study data were analyzed using analysis of variance (ANOVA), followed by Dunnett\u2019s test for pairwise comparison.", [["All study data", "TEST", 0, 14], ["Dunnett\u2019s test", "TEST", 77, 91], ["pairwise comparison", "TEST", 96, 115]]], ["Statistical significance was defined as P < .05 for all tests.The Antiproliferative Effect of TS in Leukemia WEHI-3 Cells ::: ResultsTo evaluate the cell viability of human leukemia cancer cells, WEHI-3 cells were treated with various concentrations (10, 25, 50, and 75 \u00b5g/mL) of TS for 24 hours and cells survival were evaluated by MTT assay.", [["Leukemia WEHI-3 Cells", "ANATOMY", 100, 121], ["cell", "ANATOMY", 149, 153], ["leukemia cancer cells", "ANATOMY", 173, 194], ["WEHI-3 cells", "ANATOMY", 196, 208], ["cells", "ANATOMY", 300, 305], ["Leukemia", "DISEASE", 100, 108], ["leukemia cancer", "DISEASE", 173, 188], ["MTT", "CHEMICAL", 333, 336], ["Leukemia WEHI-3 Cells", "CELL", 100, 121], ["cell", "CELL", 149, 153], ["human", "ORGANISM", 167, 172], ["leukemia cancer cells", "CELL", 173, 194], ["WEHI-3 cells", "CELL", 196, 208], ["cells", "CELL", 300, 305], ["human leukemia cancer cells", "CELL_TYPE", 167, 194], ["WEHI-3 cells", "CELL_LINE", 196, 208], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["all tests", "TEST", 52, 61], ["TS in Leukemia WEHI", "PROBLEM", 94, 113], ["human leukemia cancer cells", "PROBLEM", 167, 194], ["WEHI", "TEST", 196, 200], ["various concentrations", "TREATMENT", 227, 249], ["cells survival", "TREATMENT", 300, 314], ["MTT assay", "TEST", 333, 342], ["Antiproliferative", "OBSERVATION_MODIFIER", 66, 83], ["Leukemia WEHI", "OBSERVATION", 100, 113], ["cell viability", "OBSERVATION", 149, 163], ["human leukemia cancer", "OBSERVATION", 167, 188]]], ["Treatment of TS with WEHI-3 cells resulted in a dose-dependent inhibition of WEHI-3 cell proliferation with the IC50 value of 21.9 \u00b1 0.6 \u03bcg/mL (Figure 1A).", [["WEHI-3 cells", "ANATOMY", 21, 33], ["WEHI-3 cell", "ANATOMY", 77, 88], ["WEHI-3 cells", "CELL", 21, 33], ["WEHI-3 cell", "CELL", 77, 88], ["WEHI-3 cells", "CELL_LINE", 21, 33], ["WEHI-3 cells", "TREATMENT", 21, 33], ["WEHI", "TEST", 77, 81], ["the IC50 value", "TEST", 108, 122]]], ["This result suggests that TS was cytotoxic to murine WEHI-3 leukemia cells.TS Induces Apoptosis of WEHI-3 Leukemia Cells ::: ResultsNext, we determined the induction of apoptosis in WEHI-3 cells using Annexin-v/PI staining.", [["WEHI-3 leukemia cells", "ANATOMY", 53, 74], ["WEHI-3 Leukemia Cells", "ANATOMY", 99, 120], ["WEHI-3 cells", "ANATOMY", 182, 194], ["leukemia", "DISEASE", 60, 68], ["Leukemia", "DISEASE", 106, 114], ["murine", "ORGANISM", 46, 52], ["WEHI-3 leukemia cells", "CELL", 53, 74], ["WEHI-3 Leukemia Cells", "CELL", 99, 120], ["WEHI-3 cells", "CELL", 182, 194], ["Annexin-v/PI", "GENE_OR_GENE_PRODUCT", 201, 213], ["murine WEHI-3 leukemia cells", "CELL_LINE", 46, 74], ["WEHI-3 cells", "CELL_LINE", 182, 194], ["murine", "SPECIES", 46, 52], ["cytotoxic", "PROBLEM", 33, 42], ["murine WEHI", "TEST", 46, 57], ["leukemia cells", "PROBLEM", 60, 74], ["apoptosis", "PROBLEM", 169, 178], ["Annexin", "TEST", 201, 208], ["PI staining", "PROBLEM", 211, 222], ["leukemia cells", "OBSERVATION", 60, 74], ["WEHI", "OBSERVATION", 99, 103], ["Leukemia Cells", "OBSERVATION", 106, 120], ["PI staining", "OBSERVATION", 211, 222]]], ["The results showed that TS treatment resulted in a significant increase in late apoptotic cells (Q2), whereas no significant change in the necrotic cells was seen (Q1) (Figure 1B).", [["cells", "ANATOMY", 90, 95], ["necrotic cells", "ANATOMY", 139, 153], ["TS", "CHEMICAL", 24, 26], ["necrotic", "DISEASE", 139, 147], ["cells", "CELL", 90, 95], ["necrotic cells", "CELL", 139, 153], ["apoptotic cells", "CELL_TYPE", 80, 95], ["necrotic cells", "CELL_TYPE", 139, 153], ["TS treatment", "TREATMENT", 24, 36], ["a significant increase in late apoptotic cells", "PROBLEM", 49, 95], ["significant change in the necrotic cells", "PROBLEM", 113, 153], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["late apoptotic cells", "OBSERVATION", 75, 95], ["no", "UNCERTAINTY", 110, 112], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["change", "OBSERVATION_MODIFIER", 125, 131], ["necrotic cells", "OBSERVATION", 139, 153]]], ["These results demonstrate that TS exerts its cytotoxic effect on WEHI-3 leukemia cells via the induction of apoptotic cell death.TS Upregulates Mitochondria-Mediated Apoptotic Cascades ::: ResultsTo further delineate the manner in which TS induces apoptosis in WEHI-3 cells, mitochondria-dependent apoptotic protein markers were examined using Western blot analyses.", [["WEHI-3 leukemia cells", "ANATOMY", 65, 86], ["cell", "ANATOMY", 118, 122], ["Mitochondria", "ANATOMY", 144, 156], ["WEHI-3 cells", "ANATOMY", 261, 273], ["mitochondria", "ANATOMY", 275, 287], ["TS", "CHEMICAL", 31, 33], ["leukemia", "DISEASE", 72, 80], ["death", "DISEASE", 123, 128], ["TS", "SIMPLE_CHEMICAL", 31, 33], ["WEHI-3 leukemia cells", "CELL", 65, 86], ["cell", "CELL", 118, 122], ["Mitochondria", "CELLULAR_COMPONENT", 144, 156], ["WEHI-3 cells", "CELL", 261, 273], ["mitochondria", "CELLULAR_COMPONENT", 275, 287], ["WEHI-3 leukemia cells", "CELL_LINE", 65, 86], ["WEHI-3 cells", "CELL_LINE", 261, 273], ["apoptotic protein markers", "PROTEIN", 298, 323], ["its cytotoxic effect", "PROBLEM", 41, 61], ["WEHI-3 leukemia cells", "TREATMENT", 65, 86], ["apoptotic cell death", "PROBLEM", 108, 128], ["apoptosis", "PROBLEM", 248, 257], ["mitochondria", "TEST", 275, 287], ["Western blot analyses", "TEST", 344, 365], ["cytotoxic", "OBSERVATION_MODIFIER", 45, 54], ["effect", "OBSERVATION_MODIFIER", 55, 61], ["leukemia cells", "OBSERVATION", 72, 86], ["apoptotic cell death", "OBSERVATION", 108, 128]]], ["Initially, the levels of cytochrome c in the cytosolic fraction were examined.", [["cytosolic fraction", "ANATOMY", 45, 63], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 25, 37], ["cytochrome c", "PROTEIN", 25, 37], ["cytochrome c in the cytosolic fraction", "TEST", 25, 63]]], ["Result indicates that TS treatment (10-75 \u00b5g/mL) for 24 hours significantly as well as dose-dependently increased the protein expression levels of cytochrome c in the cytoplasm (Figure 2A).", [["cytoplasm", "ANATOMY", 167, 176], ["TS", "CHEMICAL", 22, 24], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 147, 159], ["cytoplasm", "ORGANISM_SUBSTANCE", 167, 176], ["cytochrome c", "PROTEIN", 147, 159], ["TS treatment", "TREATMENT", 22, 34], ["cytochrome c in the cytoplasm", "PROBLEM", 147, 176]]], ["Because cytochrome c is reportedly involved in the activation of the downstream caspases, which trigger apoptosis,25 we investigated the effects of WEHI-3 cells on the downstream effector cascades of cytochrome c, including caspase-3.", [["WEHI-3 cells", "ANATOMY", 148, 160], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 8, 20], ["caspases", "GENE_OR_GENE_PRODUCT", 80, 88], ["WEHI-3 cells", "CELL", 148, 160], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 200, 212], ["caspase-3", "GENE_OR_GENE_PRODUCT", 224, 233], ["cytochrome c", "PROTEIN", 8, 20], ["downstream caspases", "PROTEIN", 69, 88], ["WEHI-3 cells", "CELL_LINE", 148, 160], ["cytochrome c", "PROTEIN", 200, 212], ["caspase-3", "PROTEIN", 224, 233], ["cytochrome c", "PROBLEM", 8, 20], ["the downstream caspases", "TREATMENT", 65, 88], ["WEHI-3 cells", "TREATMENT", 148, 160], ["cytochrome c", "TREATMENT", 200, 212], ["caspase", "TREATMENT", 224, 231]]], ["Western blot analyses revealed that treatment of WEHI-3 cells with TS significantly reduced the levels of procaspase-3 in a dose-dependent manner (Figure 2A).", [["WEHI-3 cells", "ANATOMY", 49, 61], ["WEHI-3 cells", "CELL", 49, 61], ["TS", "SIMPLE_CHEMICAL", 67, 69], ["procaspase-3", "GENE_OR_GENE_PRODUCT", 106, 118], ["WEHI-3 cells", "CELL_LINE", 49, 61], ["procaspase-3", "PROTEIN", 106, 118], ["Western blot analyses", "TEST", 0, 21], ["treatment of WEHI-3 cells", "TREATMENT", 36, 61], ["TS", "PROBLEM", 67, 69], ["procaspase", "TEST", 106, 116]]], ["Taken together, these data suggest that TS-induced apoptosis in WEHI-3 cells was accompanied by cytochrome c release and caspase-3 activation.TS Dysregulates the Bcl-2 and Bax Protein Ratio ::: ResultsBcl-2 family proteins have been shown to play an important regulatory role in (mitochondria-mediated) apoptosis, either as activators (Bax, Bad, and Bok) or as inhibitors (Bcl-2, Bcl-xL, and Bcl-w).26 To assess whether TS (0-75 \u00b5g/mL) promoted cell death was due to induction of apoptosis in WEHI-3 cells, we investigated apoptosis related protein by Western blotting.", [["WEHI-3 cells", "ANATOMY", 64, 76], ["mitochondria", "ANATOMY", 280, 292], ["cell", "ANATOMY", 445, 449], ["WEHI-3 cells", "ANATOMY", 493, 505], ["death", "DISEASE", 450, 455], ["TS", "SIMPLE_CHEMICAL", 40, 42], ["WEHI-3 cells", "CELL", 64, 76], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 96, 108], ["caspase-3", "GENE_OR_GENE_PRODUCT", 121, 130], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["Bax", "GENE_OR_GENE_PRODUCT", 172, 175], ["ResultsBcl-2", "GENE_OR_GENE_PRODUCT", 194, 206], ["mitochondria", "CELLULAR_COMPONENT", 280, 292], ["Bax", "GENE_OR_GENE_PRODUCT", 336, 339], ["Bad", "GENE_OR_GENE_PRODUCT", 341, 344], ["Bok", "GENE_OR_GENE_PRODUCT", 350, 353], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 373, 378], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 380, 386], ["Bcl-w", "GENE_OR_GENE_PRODUCT", 392, 397], ["cell", "CELL", 445, 449], ["WEHI-3 cells", "CELL", 493, 505], ["WEHI-3 cells", "CELL_LINE", 64, 76], ["cytochrome c", "PROTEIN", 96, 108], ["caspase-3", "PROTEIN", 121, 130], ["Bcl-2", "PROTEIN", 162, 167], ["ResultsBcl-2 family proteins", "PROTEIN", 194, 222], ["Bax", "PROTEIN", 336, 339], ["Bad", "PROTEIN", 341, 344], ["Bok", "PROTEIN", 350, 353], ["Bcl-2", "PROTEIN", 373, 378], ["Bcl", "PROTEIN", 380, 383], ["xL", "PROTEIN", 384, 386], ["Bcl-w", "PROTEIN", 392, 397], ["WEHI-3 cells", "CELL_LINE", 493, 505], ["these data", "TEST", 16, 26], ["TS-induced apoptosis in WEHI-3 cells", "PROBLEM", 40, 76], ["cytochrome c release", "PROBLEM", 96, 116], ["the Bcl", "TEST", 158, 165], ["Bax Protein Ratio", "TEST", 172, 189], ["ResultsBcl", "TEST", 194, 204], ["apoptosis", "PROBLEM", 303, 312], ["Bcl", "TEST", 373, 376], ["Bcl", "TEST", 380, 383], ["Bcl", "TEST", 392, 395], ["TS", "TEST", 420, 422], ["cell death", "PROBLEM", 445, 455], ["apoptosis in WEHI", "PROBLEM", 480, 497], ["apoptosis related protein", "PROBLEM", 523, 548]]], ["As shown in Figure 2, the anti-apoptosis protein Bcl-2 was decreased and pro-apoptosis protein Bax was increase by TS treatment (10-75 \u00b5g/mL) for 24 hours.", [["TS", "CHEMICAL", 115, 117], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 49, 54], ["Bax", "GENE_OR_GENE_PRODUCT", 95, 98], ["TS", "SIMPLE_CHEMICAL", 115, 117], ["anti-apoptosis protein", "PROTEIN", 26, 48], ["Bcl-2", "PROTEIN", 49, 54], ["pro-apoptosis protein", "PROTEIN", 73, 94], ["Bax", "PROTEIN", 95, 98], ["the anti-apoptosis protein Bcl", "TEST", 22, 52], ["pro-apoptosis protein Bax", "TREATMENT", 73, 98], ["TS treatment", "TREATMENT", 115, 127]]], ["Furthermore, TS treatment increased Bax/Bcl-2 ratio in WEHI-3 cells (Figure 2B).", [["WEHI-3 cells", "ANATOMY", 55, 67], ["Bax", "GENE_OR_GENE_PRODUCT", 36, 39], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 40, 45], ["WEHI-3 cells", "CELL", 55, 67], ["Bax", "PROTEIN", 36, 39], ["Bcl", "PROTEIN", 40, 43], ["WEHI-3 cells", "CELL_LINE", 55, 67], ["TS treatment", "TREATMENT", 13, 25], ["Bax", "TEST", 36, 39], ["Bcl", "TEST", 40, 43], ["WEHI", "TEST", 55, 59]]], ["These results indicate that TS may disturb the Bcl-2 and Bax protein ratio and induce apoptosis.Injection of WEHI-3 cells induces leukemia in BALB/c mice ::: ResultsBALB/c mice were injected with WEHI-3 cells (3 \u00d7 106/ 100 \u00b5L) via the tail vein and treated with TS (50 mg/kg) by gavaged tube for 3 weeks.", [["WEHI-3 cells", "ANATOMY", 109, 121], ["leukemia", "ANATOMY", 130, 138], ["WEHI-3 cells", "ANATOMY", 196, 208], ["tail vein", "ANATOMY", 235, 244], ["leukemia", "DISEASE", 130, 138], ["TS", "CHEMICAL", 262, 264], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["Bax", "GENE_OR_GENE_PRODUCT", 57, 60], ["WEHI-3 cells", "CELL", 109, 121], ["leukemia", "CANCER", 130, 138], ["BALB/c mice", "ORGANISM", 142, 153], ["ResultsBALB/c mice", "ORGANISM", 158, 176], ["WEHI-3 cells", "CELL", 196, 208], ["tail vein", "MULTI-TISSUE_STRUCTURE", 235, 244], ["tube", "TISSUE", 287, 291], ["Bcl-2", "PROTEIN", 47, 52], ["WEHI-3 cells", "CELL_LINE", 109, 121], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 172, 176], ["the Bcl", "TEST", 43, 50], ["Bax protein ratio", "TEST", 57, 74], ["apoptosis", "PROBLEM", 86, 95], ["Injection of WEHI", "TREATMENT", 96, 113], ["leukemia", "PROBLEM", 130, 138], ["ResultsBALB/c mice", "TREATMENT", 158, 176], ["TS", "TREATMENT", 262, 264], ["apoptosis", "OBSERVATION", 86, 95], ["leukemia", "OBSERVATION", 130, 138], ["tail vein", "ANATOMY", 235, 244]]], ["Animals were sacrificed for examination of liver and spleen tissues; they were individually photographed and weighed.", [["liver", "ANATOMY", 43, 48], ["spleen tissues", "ANATOMY", 53, 67], ["Animals", "ORGANISM", 0, 7], ["liver", "ORGAN", 43, 48], ["spleen tissues", "TISSUE", 53, 67], ["examination", "TEST", 28, 39], ["liver", "ANATOMY", 43, 48], ["spleen tissues", "ANATOMY", 53, 67]]], ["After 19 days of treatment, the WEHI-3 injected group (all mice) exhibited hind leg paralysis, body curl, changes in hair brightness, and decrease in mouse activity, whereas the TS treated group had decreased paralysis and body curl, and improved hair brightness (Figure 3).Effect of TS on spleen and liver ::: ResultsThe weights of spleens and livers are presented in Figure 4 and 6, respectively.", [["hind leg", "ANATOMY", 75, 83], ["body", "ANATOMY", 95, 99], ["hair", "ANATOMY", 117, 121], ["body", "ANATOMY", 223, 227], ["hair", "ANATOMY", 247, 251], ["spleen", "ANATOMY", 290, 296], ["liver", "ANATOMY", 301, 306], ["spleens", "ANATOMY", 333, 340], ["livers", "ANATOMY", 345, 351], ["WEHI-3", "CHEMICAL", 32, 38], ["paralysis", "DISEASE", 84, 93], ["paralysis", "DISEASE", 209, 218], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 32, 38], ["mice", "ORGANISM", 59, 63], ["hind leg", "ORGANISM_SUBDIVISION", 75, 83], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["curl", "ORGANISM_SUBDIVISION", 100, 104], ["hair", "TISSUE", 117, 121], ["mouse", "ORGANISM", 150, 155], ["body", "ORGANISM_SUBDIVISION", 223, 227], ["hair", "ORGAN", 247, 251], ["spleen", "ORGAN", 290, 296], ["liver", "ORGAN", 301, 306], ["spleens", "ORGAN", 333, 340], ["livers", "ORGAN", 345, 351], ["mice", "SPECIES", 59, 63], ["mouse", "SPECIES", 150, 155], ["mice", "SPECIES", 59, 63], ["mouse", "SPECIES", 150, 155], ["treatment", "TREATMENT", 17, 26], ["the WEHI", "TREATMENT", 28, 36], ["hind leg paralysis", "PROBLEM", 75, 93], ["body curl", "PROBLEM", 95, 104], ["hair brightness", "PROBLEM", 117, 132], ["decrease in mouse activity", "PROBLEM", 138, 164], ["decreased paralysis", "PROBLEM", 199, 218], ["body curl", "PROBLEM", 223, 232], ["hind leg", "ANATOMY", 75, 83], ["paralysis", "OBSERVATION", 84, 93], ["hair brightness", "OBSERVATION", 117, 132], ["decrease", "OBSERVATION_MODIFIER", 138, 146], ["mouse activity", "OBSERVATION", 150, 164], ["paralysis", "OBSERVATION", 209, 218], ["spleen", "ANATOMY", 290, 296], ["liver", "ANATOMY", 301, 306], ["spleens", "ANATOMY", 333, 340], ["livers", "ANATOMY", 345, 351]]], ["WEHI-3 injected groups significantly increased the weight of spleen and liver as compared with control groups (Figures 4 and 6).", [["spleen", "ANATOMY", 61, 67], ["liver", "ANATOMY", 72, 77], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["spleen", "ORGAN", 61, 67], ["liver", "ORGAN", 72, 77], ["Figures", "TEST", 111, 118], ["spleen", "ANATOMY", 61, 67], ["liver", "ANATOMY", 72, 77]]], ["This is due to metastasis of WEHI-3 cells toward liver and spleen, which increased their sizes significantly.", [["WEHI-3 cells", "ANATOMY", 29, 41], ["liver", "ANATOMY", 49, 54], ["spleen", "ANATOMY", 59, 65], ["WEHI-3 cells", "CELL", 29, 41], ["liver", "ORGAN", 49, 54], ["spleen", "ORGAN", 59, 65], ["WEHI-3 cells", "CELL_LINE", 29, 41], ["metastasis of WEHI-3 cells toward liver and spleen", "PROBLEM", 15, 65], ["due to", "UNCERTAINTY", 8, 14], ["metastasis", "OBSERVATION", 15, 25], ["WEHI", "OBSERVATION", 29, 33], ["liver", "ANATOMY", 49, 54], ["spleen", "ANATOMY", 59, 65], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["sizes", "OBSERVATION_MODIFIER", 89, 94], ["significantly", "OBSERVATION_MODIFIER", 95, 108]]], ["Whereas, treatment with TS (50 mg/kg) groups statistically decreased the weight of spleen and liver in tumor-bearing mice (Figures 4 and 6).", [["spleen", "ANATOMY", 83, 89], ["liver", "ANATOMY", 94, 99], ["tumor", "ANATOMY", 103, 108], ["TS", "CHEMICAL", 24, 26], ["tumor", "DISEASE", 103, 108], ["TS", "SIMPLE_CHEMICAL", 24, 26], ["spleen", "ORGAN", 83, 89], ["liver", "ORGAN", 94, 99], ["tumor", "CANCER", 103, 108], ["mice", "ORGANISM", 117, 121], ["mice", "SPECIES", 117, 121], ["TS", "TREATMENT", 24, 26], ["Figures", "TEST", 123, 130], ["spleen", "ANATOMY", 83, 89], ["liver", "ANATOMY", 94, 99], ["tumor", "OBSERVATION", 103, 108]]], ["Histopathology results suggested that TS-treated spleen tissues display increased megakaryocytes and decreased numbers of neoplastic cells.", [["spleen tissues", "ANATOMY", 49, 63], ["megakaryocytes", "ANATOMY", 82, 96], ["neoplastic cells", "ANATOMY", 122, 138], ["spleen tissues", "TISSUE", 49, 63], ["megakaryocytes", "CELL", 82, 96], ["neoplastic cells", "CELL", 122, 138], ["megakaryocytes", "CELL_TYPE", 82, 96], ["neoplastic cells", "CELL_TYPE", 122, 138], ["Histopathology", "TEST", 0, 14], ["TS-treated spleen tissues", "PROBLEM", 38, 63], ["increased megakaryocytes", "PROBLEM", 72, 96], ["decreased numbers of neoplastic cells", "PROBLEM", 101, 138], ["spleen", "ANATOMY", 49, 55], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["megakaryocytes", "OBSERVATION", 82, 96], ["decreased", "OBSERVATION_MODIFIER", 101, 110], ["numbers", "OBSERVATION_MODIFIER", 111, 118], ["neoplastic cells", "OBSERVATION", 122, 138]]], ["Neoplastic cells contained large irregular nuclei accompanied by clumped chromatin and prominent nucleoli, and abundant clear and light eosinophilic cytoplasm.", [["Neoplastic cells", "ANATOMY", 0, 16], ["nuclei", "ANATOMY", 43, 49], ["chromatin", "ANATOMY", 73, 82], ["nucleoli", "ANATOMY", 97, 105], ["eosinophilic cytoplasm", "ANATOMY", 136, 158], ["Neoplastic cells", "CELL", 0, 16], ["nuclei", "CELLULAR_COMPONENT", 43, 49], ["chromatin", "CELLULAR_COMPONENT", 73, 82], ["nucleoli", "CELLULAR_COMPONENT", 97, 105], ["cytoplasm", "ORGANISM_SUBSTANCE", 149, 158], ["Neoplastic cells", "CELL_TYPE", 0, 16], ["Neoplastic cells", "PROBLEM", 0, 16], ["large irregular nuclei", "PROBLEM", 27, 49], ["clumped chromatin", "PROBLEM", 65, 82], ["prominent nucleoli", "PROBLEM", 87, 105], ["light eosinophilic cytoplasm", "PROBLEM", 130, 158], ["large", "OBSERVATION_MODIFIER", 27, 32], ["irregular nuclei", "OBSERVATION", 33, 49], ["clumped chromatin", "OBSERVATION", 65, 82], ["prominent", "OBSERVATION_MODIFIER", 87, 96], ["nucleoli", "OBSERVATION", 97, 105], ["abundant", "OBSERVATION_MODIFIER", 111, 119], ["clear", "OBSERVATION_MODIFIER", 120, 125], ["light", "OBSERVATION_MODIFIER", 130, 135], ["eosinophilic cytoplasm", "OBSERVATION", 136, 158]]], ["Often mitotic figures were also noted; further there was a marked expansion in the red pulp, but little change in white pulp were seen in spleen tissues (Figure 5).Hematology in WEHI-3-Injected Mice ::: ResultsThe results of hematological analysis after TS treatment are shown in Table 1.", [["red pulp", "ANATOMY", 83, 91], ["white pulp", "ANATOMY", 114, 124], ["spleen tissues", "ANATOMY", 138, 152], ["red pulp", "TISSUE", 83, 91], ["pulp", "TISSUE", 120, 124], ["spleen tissues", "TISSUE", 138, 152], ["WEHI-3", "CELL", 178, 184], ["Mice", "ORGANISM", 194, 198], ["Mice", "SPECIES", 194, 198], ["Often mitotic figures", "PROBLEM", 0, 21], ["a marked expansion in the red pulp", "PROBLEM", 57, 91], ["little change in white pulp", "PROBLEM", 97, 124], ["hematological analysis", "TEST", 225, 247], ["TS treatment", "TREATMENT", 254, 266], ["mitotic figures", "OBSERVATION", 6, 21], ["marked", "OBSERVATION_MODIFIER", 59, 65], ["expansion", "OBSERVATION_MODIFIER", 66, 75], ["red pulp", "OBSERVATION", 83, 91], ["little", "OBSERVATION_MODIFIER", 97, 103], ["change", "OBSERVATION_MODIFIER", 104, 110], ["white pulp", "OBSERVATION", 114, 124], ["spleen", "ANATOMY", 138, 144]]], ["The WEHI-3 injected group showed a significant increase in white blood cell (WBC) count as compared with control group, whereas treatment in the TS-treated group dramatically decreased the WBC count compared with the WEHI-3 group alone.", [["white blood cell", "ANATOMY", 59, 75], ["WBC", "ANATOMY", 77, 80], ["WBC", "ANATOMY", 189, 192], ["TS", "CHEMICAL", 145, 147], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 4, 10], ["white blood cell", "CELL", 59, 75], ["WBC", "CELL", 77, 80], ["TS", "SIMPLE_CHEMICAL", 145, 147], ["WBC", "CELL", 189, 192], ["The WEHI", "TEST", 0, 8], ["a significant increase in white blood cell", "PROBLEM", 33, 75], ["WBC) count", "TEST", 77, 87], ["treatment", "TREATMENT", 128, 137], ["the TS", "TEST", 141, 147], ["the WBC count", "TEST", 185, 198], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["white blood cell", "OBSERVATION", 59, 75], ["WBC count", "OBSERVATION", 189, 198]]], ["Furthermore, the TS-treated group increased the concentration of red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), and mean corpuscular volume (MCV) levels compare to WEHI-3 group alone.", [["red blood cells", "ANATOMY", 65, 80], ["RBC", "ANATOMY", 82, 85], ["corpuscular", "ANATOMY", 132, 143], ["WEHI-3", "CHEMICAL", 175, 181], ["TS", "SIMPLE_CHEMICAL", 17, 19], ["red blood cells", "CELL", 65, 80], ["RBC", "CELL", 82, 85], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 88, 98], ["Hb", "SIMPLE_CHEMICAL", 100, 102], ["hematocrit", "SIMPLE_CHEMICAL", 105, 115], ["Hct", "SIMPLE_CHEMICAL", 117, 120], ["corpuscular", "ORGANISM_SUBSTANCE", 132, 143], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 175, 181], ["red blood cells", "CELL_TYPE", 65, 80], ["RBC", "CELL_TYPE", 82, 85], ["hemoglobin", "PROTEIN", 88, 98], ["Hb", "PROTEIN", 100, 102], ["hematocrit", "PROTEIN", 105, 115], ["the TS", "TEST", 13, 19], ["red blood cells", "TEST", 65, 80], ["RBC", "TEST", 82, 85], ["hemoglobin", "TEST", 88, 98], ["Hb", "TEST", 100, 102], ["hematocrit", "TEST", 105, 115], ["Hct", "TEST", 117, 120], ["mean corpuscular volume", "TEST", 127, 150], ["MCV", "TEST", 152, 155], ["WEHI", "TEST", 175, 179]]], ["In contrast, TS treatment reduced the concentration of mean corpuscular hemoglobin (MCH), and MCH concentration (MCHC) levels.", [["corpuscular", "ANATOMY", 60, 71], ["corpuscular hemoglobin", "GENE_OR_GENE_PRODUCT", 60, 82], ["MCH", "SIMPLE_CHEMICAL", 84, 87], ["MCH", "SIMPLE_CHEMICAL", 94, 97], ["MCHC", "SIMPLE_CHEMICAL", 113, 117], ["hemoglobin", "PROTEIN", 72, 82], ["TS treatment", "TREATMENT", 13, 25], ["mean corpuscular hemoglobin", "TEST", 55, 82], ["MCH concentration (MCHC) levels", "TEST", 94, 125]]], ["Our results indicated that TS has antileukemia capacity and promoted the immune response in WEHI-3 bearing mice in vivo.Leukocyte Differentiation ::: ResultsTo determine the effect of TS on leukocyte differentiation, lymphocyte, neutrophil, monocyte, eosinophil, basophil, and nucleated RBC were analyzed.", [["WEHI-3", "ANATOMY", 92, 98], ["Leukocyte", "ANATOMY", 120, 129], ["leukocyte", "ANATOMY", 190, 199], ["lymphocyte", "ANATOMY", 217, 227], ["neutrophil", "ANATOMY", 229, 239], ["monocyte", "ANATOMY", 241, 249], ["eosinophil", "ANATOMY", 251, 261], ["basophil", "ANATOMY", 263, 271], ["nucleated RBC", "ANATOMY", 277, 290], ["WEHI-3", "CELL", 92, 98], ["mice", "ORGANISM", 107, 111], ["Leukocyte", "CELL", 120, 129], ["leukocyte", "CELL", 190, 199], ["lymphocyte", "CELL", 217, 227], ["neutrophil", "CELL", 229, 239], ["monocyte", "CELL", 241, 249], ["eosinophil", "CELL", 251, 261], ["basophil", "CELL", 263, 271], ["RBC", "CELL", 287, 290], ["lymphocyte", "CELL_TYPE", 217, 227], ["neutrophil", "CELL_TYPE", 229, 239], ["monocyte", "CELL_TYPE", 241, 249], ["eosinophil", "CELL_TYPE", 251, 261], ["basophil", "CELL_TYPE", 263, 271], ["nucleated RBC", "CELL_TYPE", 277, 290], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["antileukemia capacity", "PROBLEM", 34, 55], ["Leukocyte Differentiation", "TEST", 120, 145], ["TS on leukocyte differentiation", "TEST", 184, 215], ["lymphocyte", "TEST", 217, 227], ["neutrophil", "TEST", 229, 239], ["monocyte", "TEST", 241, 249], ["eosinophil", "TEST", 251, 261], ["basophil", "TEST", 263, 271], ["nucleated RBC", "TEST", 277, 290], ["antileukemia capacity", "OBSERVATION", 34, 55], ["immune response", "OBSERVATION", 73, 88], ["nucleated RBC", "OBSERVATION", 277, 290]]], ["As shown in Table 2, the TS-treated group had significantly decreased expression of lymphocytes as compared with WEHI-3 alone group.", [["lymphocytes", "ANATOMY", 84, 95], ["WEHI-3", "CHEMICAL", 113, 119], ["TS", "SIMPLE_CHEMICAL", 25, 27], ["lymphocytes", "CELL", 84, 95], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 113, 119], ["lymphocytes", "CELL_TYPE", 84, 95], ["the TS", "TEST", 21, 27], ["significantly decreased expression of lymphocytes", "PROBLEM", 46, 95], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["lymphocytes", "ANATOMY", 84, 95]]], ["In contrast, eosinophils were shown to be statistically decreased as compared with control and WEHI-3 injected mice.", [["eosinophils", "ANATOMY", 13, 24], ["eosinophils", "CELL", 13, 24], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 95, 101], ["mice", "ORGANISM", 111, 115], ["eosinophils", "CELL_TYPE", 13, 24], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["eosinophils", "TEST", 13, 24], ["decreased", "OBSERVATION_MODIFIER", 56, 65]]], ["The observed changes in eosinophils could be due to excessive production of steroids (natural chemicals produced by the body and released into the blood).", [["eosinophils", "ANATOMY", 24, 35], ["body", "ANATOMY", 120, 124], ["blood", "ANATOMY", 147, 152], ["steroids", "CHEMICAL", 76, 84], ["steroids", "CHEMICAL", 76, 84], ["eosinophils", "CELL", 24, 35], ["steroids", "SIMPLE_CHEMICAL", 76, 84], ["body", "ORGANISM_SUBDIVISION", 120, 124], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["eosinophils", "CELL_TYPE", 24, 35], ["The observed changes in eosinophils", "PROBLEM", 0, 35], ["steroids", "TREATMENT", 76, 84], ["natural chemicals", "TREATMENT", 86, 103], ["eosinophils", "OBSERVATION", 24, 35], ["could be due to", "UNCERTAINTY", 36, 51], ["excessive", "OBSERVATION_MODIFIER", 52, 61], ["production", "OBSERVATION_MODIFIER", 62, 72]]], ["Furthermore, segmented neutrophils were increased in both the WEHI-3 injected and TS-treated groups as compared with control.", [["neutrophils", "ANATOMY", 23, 34], ["WEHI-3", "CHEMICAL", 62, 68], ["neutrophils", "CELL", 23, 34], ["TS", "SIMPLE_CHEMICAL", 82, 84], ["neutrophils", "CELL_TYPE", 23, 34], ["segmented neutrophils", "TEST", 13, 34], ["segmented", "OBSERVATION_MODIFIER", 13, 22], ["neutrophils", "OBSERVATION", 23, 34], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["WEHI", "ANATOMY", 62, 66]]], ["The WEHI-3 injected group had increased nucleated RBC count, whereas the TS-treated group had decreased expression of RBC level (Table 2).DiscussionIt is well known that many natural compounds from food and plants have chemopreventive and chemotherapeutic efficacy in human cancer.27,28 A number of natural products isolated from Chinese herbs have been found to induce apoptosis, suppress angiogenesis, inhibit proliferation, retard metastasis and enhance chemotherapy, exhibiting anti-cancer potential both in vitro and in vivo.29,30 The different components in a given herb may have synergistic activities to offer greater therapeutic or preventive activity in combination.31 In our previous study, we demonstrated that the aqueous extracts of TS (10-75 \u00b5g/mL) and gallic acid (5-10 \u00b5g/mL) promoted apoptosis against human premyelocytic leukemia (HL-60) cells.8 To verify the possible anticancer effects of TS as a first step toward the development of a novel putative anticancer agent, we further investigated for its capacity to inhibit murine leukemia WEHI-3 cells growth and associated with immune responses in WEHI-3 cells injected via tail vein of mice model.", [["nucleated RBC", "ANATOMY", 40, 53], ["RBC", "ANATOMY", 118, 121], ["cancer", "ANATOMY", 274, 280], ["aqueous extracts", "ANATOMY", 727, 743], ["premyelocytic leukemia (HL-60) cells", "ANATOMY", 826, 862], ["anticancer", "ANATOMY", 888, 898], ["anticancer", "ANATOMY", 972, 982], ["leukemia WEHI-3 cells", "ANATOMY", 1049, 1070], ["WEHI-3 cells", "ANATOMY", 1118, 1130], ["tail vein", "ANATOMY", 1144, 1153], ["cancer", "DISEASE", 274, 280], ["TS", "CHEMICAL", 747, 749], ["gallic acid", "CHEMICAL", 768, 779], ["premyelocytic leukemia", "DISEASE", 826, 848], ["gallic acid", "CHEMICAL", 768, 779], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 4, 10], ["RBC", "CELL", 50, 53], ["RBC", "CELL", 118, 121], ["human", "ORGANISM", 268, 273], ["cancer", "CANCER", 274, 280], ["aqueous extracts", "ORGANISM_SUBSTANCE", 727, 743], ["TS", "SIMPLE_CHEMICAL", 747, 749], ["gallic acid", "SIMPLE_CHEMICAL", 768, 779], ["human", "ORGANISM", 820, 825], ["premyelocytic leukemia", "CANCER", 826, 848], ["HL-60) cells", "CELL", 850, 862], ["anticancer", "CANCER", 888, 898], ["TS", "SIMPLE_CHEMICAL", 910, 912], ["anticancer", "CANCER", 972, 982], ["murine", "ORGANISM", 1042, 1048], ["leukemia WEHI-3 cells", "CELL", 1049, 1070], ["WEHI-3 cells", "CELL", 1118, 1130], ["tail vein", "MULTI-TISSUE_STRUCTURE", 1144, 1153], ["mice", "ORGANISM", 1157, 1161], ["nucleated RBC", "CELL_TYPE", 40, 53], ["RBC", "CELL_TYPE", 118, 121], ["human premyelocytic leukemia (HL-60) cells", "CELL_LINE", 820, 862], ["murine leukemia WEHI-3 cells", "CELL_LINE", 1042, 1070], ["WEHI-3 cells", "CELL_LINE", 1118, 1130], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 820, 825], ["murine", "SPECIES", 1042, 1048], ["mice", "SPECIES", 1157, 1161], ["human", "SPECIES", 268, 273], ["human premyelocytic leukemia (HL-60", "SPECIES", 820, 855], ["mice", "SPECIES", 1157, 1161], ["increased nucleated RBC count", "PROBLEM", 30, 59], ["the TS", "TEST", 69, 75], ["RBC level", "TEST", 118, 127], ["chemopreventive", "TREATMENT", 219, 234], ["chemotherapeutic efficacy in human cancer", "PROBLEM", 239, 280], ["natural products", "TREATMENT", 299, 315], ["Chinese herbs", "TREATMENT", 330, 343], ["apoptosis", "PROBLEM", 370, 379], ["inhibit proliferation", "PROBLEM", 404, 425], ["retard metastasis", "PROBLEM", 427, 444], ["enhance chemotherapy", "TREATMENT", 449, 469], ["synergistic activities", "TREATMENT", 586, 608], ["our previous study", "TEST", 682, 700], ["the aqueous extracts", "TEST", 723, 743], ["TS", "TEST", 747, 749], ["gallic acid", "TEST", 768, 779], ["apoptosis", "PROBLEM", 802, 811], ["human premyelocytic leukemia", "PROBLEM", 820, 848], ["HL", "TEST", 850, 852], ["cells", "TEST", 857, 862], ["TS", "TREATMENT", 910, 912], ["a novel putative anticancer agent", "TREATMENT", 955, 988], ["its capacity", "PROBLEM", 1018, 1030], ["murine leukemia WEHI", "PROBLEM", 1042, 1062], ["cells growth", "PROBLEM", 1065, 1077], ["immune responses", "PROBLEM", 1098, 1114], ["WEHI", "TEST", 1118, 1122], ["nucleated RBC count", "OBSERVATION", 40, 59], ["cancer", "OBSERVATION", 274, 280], ["retard", "OBSERVATION_MODIFIER", 427, 433], ["metastasis", "OBSERVATION", 434, 444], ["different", "OBSERVATION_MODIFIER", 540, 549], ["components", "OBSERVATION_MODIFIER", 550, 560], ["premyelocytic leukemia", "OBSERVATION", 826, 848], ["leukemia WEHI", "OBSERVATION", 1049, 1062], ["tail vein", "ANATOMY", 1144, 1153]]], ["Leukemic animals have been used to explore for anticancer agents because of the low cost that promotes a short time to develop antileukemic agents in vivo.", [["anticancer", "ANATOMY", 47, 57], ["anticancer", "CANCER", 47, 57], ["Leukemic animals", "PROBLEM", 0, 16], ["anticancer agents", "TREATMENT", 47, 64], ["the low cost", "PROBLEM", 76, 88], ["antileukemic agents", "TREATMENT", 127, 146], ["antileukemic agents", "OBSERVATION", 127, 146]]], ["Our results indicated that TS significantly inhibited the WEHI-3 cells and induced apoptosis through the mitochondrial death pathway in vitro and immune response in vivo.DiscussionThe mitochondrial death pathway is controlled by members of the Bcl-2 protein class and proapoptotic Bax proteins.32 The proto-oncogene Bcl-2 antagonizes apoptosis in many cancers.", [["WEHI-3 cells", "ANATOMY", 58, 70], ["mitochondrial", "ANATOMY", 105, 118], ["mitochondrial", "ANATOMY", 184, 197], ["cancers", "ANATOMY", 352, 359], ["mitochondrial death", "DISEASE", 105, 124], ["mitochondrial death", "DISEASE", 184, 203], ["cancers", "DISEASE", 352, 359], ["TS", "SIMPLE_CHEMICAL", 27, 29], ["WEHI-3 cells", "CELL", 58, 70], ["mitochondrial", "CELLULAR_COMPONENT", 105, 118], ["mitochondrial", "CELLULAR_COMPONENT", 184, 197], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 244, 249], ["Bax", "GENE_OR_GENE_PRODUCT", 281, 284], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 316, 321], ["cancers", "CANCER", 352, 359], ["WEHI-3 cells", "CELL_LINE", 58, 70], ["Bcl-2 protein class", "PROTEIN", 244, 263], ["proapoptotic Bax proteins", "PROTEIN", 268, 293], ["proto-oncogene Bcl-2", "DNA", 301, 321], ["induced apoptosis", "PROBLEM", 75, 92], ["the mitochondrial death pathway", "PROBLEM", 101, 132], ["The mitochondrial death pathway", "PROBLEM", 180, 211], ["the Bcl", "TEST", 240, 247], ["proapoptotic Bax proteins", "PROBLEM", 268, 293], ["The proto-oncogene Bcl", "TREATMENT", 297, 319], ["apoptosis", "PROBLEM", 334, 343], ["many cancers", "PROBLEM", 347, 359], ["immune response", "OBSERVATION", 146, 161], ["proto-oncogene Bcl", "OBSERVATION", 301, 319], ["many", "OBSERVATION_MODIFIER", 347, 351], ["cancers", "OBSERVATION", 352, 359]]], ["On the contrary, overexpression of Bax accelerates apoptotic death.33 Loss of mitochondrial membrane potential induces cytochrome c release from mitochondria to cytoplasm, which leads to the activation of caspase-9 and downstream cleavage of caspase-3.34 Caspase-9 and caspase-3 are the main effector and executor caspases involved in apoptosis and play a pivotal role in the disintegration of the cells undergoing apoptosis.35 Our finding showed that TS-induced apoptosis was associated with the downregulation of Bcl-2 and upregulation of Bax in murine WEHI-3 cells, and the changes of these proteins disrupted mitochondria membrane permeability and released cytochrome c into cytosol, leading to apoptosis via caspases activation (Figure 2).DiscussionThe immune system is the vital defense against cancer growth, tumor, and infectious diseases.", [["mitochondrial membrane", "ANATOMY", 78, 100], ["mitochondria", "ANATOMY", 145, 157], ["cytoplasm", "ANATOMY", 161, 170], ["cells", "ANATOMY", 398, 403], ["WEHI-3 cells", "ANATOMY", 555, 567], ["mitochondria membrane", "ANATOMY", 613, 634], ["cytosol", "ANATOMY", 679, 686], ["immune system", "ANATOMY", 758, 771], ["cancer", "ANATOMY", 801, 807], ["tumor", "ANATOMY", 816, 821], ["death", "DISEASE", 61, 66], ["cancer", "DISEASE", 801, 807], ["tumor", "DISEASE", 816, 821], ["infectious diseases", "DISEASE", 827, 846], ["Bax", "GENE_OR_GENE_PRODUCT", 35, 38], ["mitochondrial membrane", "CELLULAR_COMPONENT", 78, 100], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 119, 131], ["mitochondria", "CELLULAR_COMPONENT", 145, 157], ["cytoplasm", "ORGANISM_SUBSTANCE", 161, 170], ["caspase-9", "GENE_OR_GENE_PRODUCT", 205, 214], ["caspase-3.34", "GENE_OR_GENE_PRODUCT", 242, 254], ["Caspase-9", "GENE_OR_GENE_PRODUCT", 255, 264], ["caspase-3", "GENE_OR_GENE_PRODUCT", 269, 278], ["caspases", "GENE_OR_GENE_PRODUCT", 314, 322], ["cells", "CELL", 398, 403], ["TS", "SIMPLE_CHEMICAL", 452, 454], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 515, 520], ["Bax", "GENE_OR_GENE_PRODUCT", 541, 544], ["murine", "ORGANISM", 548, 554], ["WEHI-3 cells", "CELL", 555, 567], ["mitochondria membrane", "CELLULAR_COMPONENT", 613, 634], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 661, 673], ["cytosol", "CELLULAR_COMPONENT", 679, 686], ["caspases", "GENE_OR_GENE_PRODUCT", 713, 721], ["cancer", "CANCER", 801, 807], ["tumor", "CANCER", 816, 821], ["Bax", "PROTEIN", 35, 38], ["cytochrome c", "PROTEIN", 119, 131], ["caspase-9", "PROTEIN", 205, 214], ["caspase-3", "PROTEIN", 269, 278], ["executor caspases", "PROTEIN", 305, 322], ["Bcl-2", "PROTEIN", 515, 520], ["Bax", "PROTEIN", 541, 544], ["murine WEHI-3 cells", "CELL_LINE", 548, 567], ["cytochrome c", "PROTEIN", 661, 673], ["caspases", "PROTEIN", 713, 721], ["murine", "SPECIES", 548, 554], ["Bax accelerates apoptotic death", "PROBLEM", 35, 66], ["cytochrome c release", "PROBLEM", 119, 139], ["caspase", "TEST", 205, 212], ["downstream cleavage of caspase", "TREATMENT", 219, 249], ["Caspase", "TREATMENT", 255, 262], ["caspase", "TREATMENT", 269, 276], ["executor caspases", "TREATMENT", 305, 322], ["apoptosis", "PROBLEM", 415, 424], ["TS-induced apoptosis", "PROBLEM", 452, 472], ["Bcl", "TEST", 515, 518], ["Bax in murine WEHI", "TEST", 541, 559], ["these proteins disrupted mitochondria membrane permeability", "PROBLEM", 588, 647], ["released cytochrome c into cytosol", "PROBLEM", 652, 686], ["apoptosis", "PROBLEM", 699, 708], ["cancer growth", "PROBLEM", 801, 814], ["tumor", "PROBLEM", 816, 821], ["infectious diseases", "PROBLEM", 827, 846], ["apoptotic death", "OBSERVATION", 51, 66], ["mitochondrial membrane", "OBSERVATION", 78, 100], ["murine WEHI", "OBSERVATION", 548, 559], ["proteins disrupted", "OBSERVATION", 594, 612], ["mitochondria membrane permeability", "OBSERVATION", 613, 647], ["tumor", "OBSERVATION", 816, 821], ["infectious", "OBSERVATION_MODIFIER", 827, 837]]], ["The adjustment of immune responses to alleviate such diseases has been of great interest for several years.36 Recently, several medicinal plants and their products have been used to modulate immune response.37 Furthermore, immunomodulation induced by medicinal plants can provide potential alternatives to conventional chemotherapies for various diseases, especially when the host defense mechanism needs to be activated under the conditions of impaired immune response.38 Leukemia is the type of cancer in which bone marrow cells that produce white blood cells (leukocytes, the immune system cells) undergo neoplasia.", [["Leukemia", "ANATOMY", 473, 481], ["cancer", "ANATOMY", 497, 503], ["bone marrow cells", "ANATOMY", 513, 530], ["white blood cells", "ANATOMY", 544, 561], ["leukocytes", "ANATOMY", 563, 573], ["immune system cells", "ANATOMY", 579, 598], ["neoplasia", "ANATOMY", 608, 617], ["Leukemia", "DISEASE", 473, 481], ["cancer", "DISEASE", 497, 503], ["neoplasia", "DISEASE", 608, 617], ["Leukemia", "CANCER", 473, 481], ["cancer", "CANCER", 497, 503], ["bone marrow cells", "CELL", 513, 530], ["white blood cells", "CELL", 544, 561], ["leukocytes", "CELL", 563, 573], ["immune system cells", "CELL", 579, 598], ["neoplasia", "CANCER", 608, 617], ["bone marrow cells", "CELL_TYPE", 513, 530], ["white blood cells", "CELL_TYPE", 544, 561], ["leukocytes", "CELL_TYPE", 563, 573], ["immune system cells", "CELL_TYPE", 579, 598], ["immune responses", "TREATMENT", 18, 34], ["such diseases", "PROBLEM", 48, 61], ["several medicinal plants", "TREATMENT", 120, 144], ["their products", "TREATMENT", 149, 163], ["medicinal plants", "TREATMENT", 251, 267], ["conventional chemotherapies", "TREATMENT", 306, 333], ["various diseases", "PROBLEM", 338, 354], ["impaired immune response", "PROBLEM", 445, 469], ["Leukemia", "PROBLEM", 473, 481], ["cancer", "PROBLEM", 497, 503], ["bone marrow cells", "TEST", 513, 530], ["white blood cells", "TEST", 544, 561], ["leukocytes", "TEST", 563, 573], ["neoplasia", "PROBLEM", 608, 617], ["medicinal plants", "OBSERVATION", 128, 144], ["immune response", "OBSERVATION", 454, 469], ["Leukemia", "OBSERVATION", 473, 481], ["cancer", "OBSERVATION", 497, 503], ["bone", "ANATOMY", 513, 517], ["marrow cells", "OBSERVATION", 518, 530], ["white blood cells", "OBSERVATION", 544, 561], ["neoplasia", "OBSERVATION", 608, 617]]], ["The transformed cells unconditionally produce abnormal amounts of WBC, mainly in an immature form.", [["cells", "ANATOMY", 16, 21], ["WBC", "ANATOMY", 66, 69], ["cells", "CELL", 16, 21], ["WBC", "CELL", 66, 69], ["transformed cells", "CELL_LINE", 4, 21], ["WBC", "CELL_TYPE", 66, 69], ["abnormal amounts of WBC", "PROBLEM", 46, 69], ["abnormal", "OBSERVATION_MODIFIER", 46, 54], ["amounts", "OBSERVATION_MODIFIER", 55, 62], ["immature form", "OBSERVATION", 84, 97]]], ["The neoplastic cells crowd out the other cells in the marrow which leads to decreases in production of red cells, platelets, and other lines of WBCs.", [["neoplastic cells", "ANATOMY", 4, 20], ["cells", "ANATOMY", 41, 46], ["marrow", "ANATOMY", 54, 60], ["red cells", "ANATOMY", 103, 112], ["platelets", "ANATOMY", 114, 123], ["WBCs", "ANATOMY", 144, 148], ["neoplastic cells", "CELL", 4, 20], ["cells", "CELL", 41, 46], ["marrow", "ORGAN", 54, 60], ["red cells", "CELL", 103, 112], ["platelets", "CELL", 114, 123], ["WBCs", "CELL", 144, 148], ["neoplastic cells", "CELL_TYPE", 4, 20], ["red cells", "CELL_TYPE", 103, 112], ["platelets", "CELL_TYPE", 114, 123], ["WBCs", "CELL_TYPE", 144, 148], ["The neoplastic cells", "PROBLEM", 0, 20], ["the other cells in the marrow", "PROBLEM", 31, 60], ["red cells", "PROBLEM", 103, 112], ["platelets", "TEST", 114, 123], ["WBCs", "TEST", 144, 148], ["neoplastic cells", "OBSERVATION", 4, 20], ["marrow", "ANATOMY", 54, 60], ["decreases", "OBSERVATION_MODIFIER", 76, 85], ["production", "OBSERVATION_MODIFIER", 89, 99], ["red cells", "OBSERVATION", 103, 112]]], ["The destructive aspects of the disease are often exhibit by the lack of these other cell types, which leads to formation of hemorrhage and anemia.", [["cell", "ANATOMY", 84, 88], ["hemorrhage", "DISEASE", 124, 134], ["anemia", "DISEASE", 139, 145], ["cell", "CELL", 84, 88], ["the disease", "PROBLEM", 27, 38], ["hemorrhage", "PROBLEM", 124, 134], ["anemia", "PROBLEM", 139, 145], ["destructive", "OBSERVATION_MODIFIER", 4, 15], ["disease", "OBSERVATION", 31, 38], ["cell types", "OBSERVATION", 84, 94], ["hemorrhage", "OBSERVATION", 124, 134], ["anemia", "OBSERVATION", 139, 145]]], ["Importantly, the internal organs (liver and spleen) bulge up with increased white cells.", [["internal organs", "ANATOMY", 17, 32], ["liver", "ANATOMY", 34, 39], ["spleen", "ANATOMY", 44, 50], ["white cells", "ANATOMY", 76, 87], ["organs", "ORGAN", 26, 32], ["liver", "ORGAN", 34, 39], ["spleen", "ORGAN", 44, 50], ["cells", "CELL", 82, 87], ["white cells", "CELL_TYPE", 76, 87], ["the internal organs (liver and spleen) bulge", "PROBLEM", 13, 57], ["increased white cells", "PROBLEM", 66, 87], ["internal", "ANATOMY_MODIFIER", 17, 25], ["organs", "ANATOMY", 26, 32], ["liver", "ANATOMY", 34, 39], ["spleen", "ANATOMY", 44, 50], ["bulge", "OBSERVATION_MODIFIER", 52, 57], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["white cells", "OBSERVATION", 76, 87]]], ["Furthermore, leukemic cells have markedly reduced immune functions, leading to excess incidence of infections.39DiscussionThe in vivo model of mice injected with WEHI-3 has been well established.40 Murine monomyelocytic WEHI-3 leukemia cells were derived from the BALB/c mouse41 and used as an ideal system for the study of potential anticancer agents.42 The effects of TS in vivo on WEHI-3 tumor cells in BALB/c mice were also examined.", [["leukemic cells", "ANATOMY", 13, 27], ["monomyelocytic WEHI-3 leukemia cells", "ANATOMY", 205, 241], ["BALB/c mouse41", "ANATOMY", 264, 278], ["anticancer", "ANATOMY", 334, 344], ["WEHI-3 tumor cells", "ANATOMY", 384, 402], ["infections", "DISEASE", 99, 109], ["WEHI-3", "CHEMICAL", 162, 168], ["leukemia", "DISEASE", 227, 235], ["tumor", "DISEASE", 391, 396], ["WEHI-3", "CHEMICAL", 162, 168], ["leukemic cells", "CELL", 13, 27], ["mice", "ORGANISM", 143, 147], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 162, 168], ["Murine", "ORGANISM", 198, 204], ["WEHI-3 leukemia cells", "CELL", 220, 241], ["BALB/c mouse41", "ORGANISM", 264, 278], ["anticancer", "CANCER", 334, 344], ["WEHI-3 tumor cells", "CELL", 384, 402], ["BALB/c mice", "ORGANISM", 406, 417], ["leukemic cells", "CELL_TYPE", 13, 27], ["Murine monomyelocytic WEHI-3 leukemia cells", "CELL_LINE", 198, 241], ["BALB/c mouse41", "CELL_LINE", 264, 278], ["WEHI-3 tumor cells", "CELL_LINE", 384, 402], ["mice", "SPECIES", 143, 147], ["Murine", "SPECIES", 198, 204], ["mice", "SPECIES", 413, 417], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 413, 417], ["leukemic cells", "PROBLEM", 13, 27], ["markedly reduced immune functions", "PROBLEM", 33, 66], ["infections", "PROBLEM", 99, 109], ["leukemia cells", "PROBLEM", 227, 241], ["the BALB/c mouse41", "TREATMENT", 260, 278], ["the study", "TEST", 311, 320], ["potential anticancer agents", "TREATMENT", 324, 351], ["WEHI", "TEST", 384, 388], ["BALB/c mice", "TREATMENT", 406, 417], ["leukemic cells", "OBSERVATION", 13, 27], ["markedly", "OBSERVATION_MODIFIER", 33, 41], ["reduced", "OBSERVATION_MODIFIER", 42, 49], ["immune functions", "OBSERVATION", 50, 66], ["infections", "OBSERVATION", 99, 109], ["leukemia cells", "OBSERVATION", 227, 241], ["anticancer agents", "OBSERVATION", 334, 351]]], ["We selected the 50 mg/kg TS for in vivo studies based on our pretest (data not shown).", [["vivo studies", "TEST", 35, 47]]], ["The results indicated that TS significantly decreased the weights of liver and spleen in the examined animals (Figures 4 and 6).", [["liver", "ANATOMY", 69, 74], ["spleen", "ANATOMY", 79, 85], ["liver", "ORGAN", 69, 74], ["spleen", "ORGAN", 79, 85], ["TS", "PROBLEM", 27, 29], ["Figures", "TEST", 111, 118], ["liver", "ANATOMY", 69, 74], ["spleen", "ANATOMY", 79, 85]]], ["A notable reason for use of this model is the elevation of peripheral monocytes and granulocytes with immature morphology, causing enlarged and infiltrated spleens compared with the normal group.", [["peripheral monocytes", "ANATOMY", 59, 79], ["granulocytes", "ANATOMY", 84, 96], ["spleens", "ANATOMY", 156, 163], ["peripheral monocytes", "CELL", 59, 79], ["granulocytes", "CELL", 84, 96], ["spleens", "ORGAN", 156, 163], ["peripheral monocytes", "CELL_TYPE", 59, 79], ["granulocytes", "CELL_TYPE", 84, 96], ["the elevation of peripheral monocytes and granulocytes", "PROBLEM", 42, 96], ["immature morphology", "PROBLEM", 102, 121], ["enlarged and infiltrated spleens", "PROBLEM", 131, 163], ["elevation", "OBSERVATION_MODIFIER", 46, 55], ["peripheral monocytes", "ANATOMY", 59, 79], ["immature morphology", "OBSERVATION_MODIFIER", 102, 121], ["enlarged", "OBSERVATION_MODIFIER", 131, 139], ["infiltrated spleens", "OBSERVATION", 144, 163], ["normal", "OBSERVATION", 182, 188]]], ["Also, numbers of white blood cells were increased in the WEHI-3 injection group and decreased in TS-treated group.", [["white blood cells", "ANATOMY", 17, 34], ["WEHI-3", "CHEMICAL", 57, 63], ["white blood cells", "CELL", 17, 34], ["WEHI-3", "GENE_OR_GENE_PRODUCT", 57, 63], ["white blood cells", "CELL_TYPE", 17, 34], ["white blood cells", "TEST", 17, 34], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["decreased", "OBSERVATION_MODIFIER", 84, 93]]], ["Our experiments indicated that spleen and liver size decreased, which then decreased the white blood cells in the TS-treated group.", [["spleen", "ANATOMY", 31, 37], ["liver", "ANATOMY", 42, 47], ["white blood cells", "ANATOMY", 89, 106], ["spleen", "ORGAN", 31, 37], ["liver", "ORGAN", 42, 47], ["blood cells", "CELL", 95, 106], ["TS", "SIMPLE_CHEMICAL", 114, 116], ["white blood cells", "CELL_TYPE", 89, 106], ["Our experiments", "TEST", 0, 15], ["spleen and liver size", "PROBLEM", 31, 52], ["the white blood cells", "PROBLEM", 85, 106], ["spleen", "ANATOMY", 31, 37], ["liver", "ANATOMY", 42, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["decreased", "OBSERVATION_MODIFIER", 53, 62], ["decreased", "OBSERVATION_MODIFIER", 75, 84]]], ["The recruitment of leukocytes toward stimuli is of great significance for the production of effective immune response.", [["leukocytes", "ANATOMY", 19, 29], ["leukocytes", "CELL", 19, 29], ["leukocytes", "CELL_TYPE", 19, 29], ["recruitment", "OBSERVATION_MODIFIER", 4, 15], ["leukocytes", "OBSERVATION", 19, 29]]], ["Recently, studies showed that leukocyte values were raised by increasing malignancy in cancer cells.43 Our previous literature suggests that TS exhibits anti-inflammatory potential in vitro and in vivo by regulating the immune system process and the physiological response to inflammatory stimuli.", [["leukocyte", "ANATOMY", 30, 39], ["cancer cells", "ANATOMY", 87, 99], ["immune system", "ANATOMY", 220, 233], ["malignancy", "DISEASE", 73, 83], ["cancer", "DISEASE", 87, 93], ["leukocyte", "CELL", 30, 39], ["cancer cells", "CELL", 87, 99], ["cancer cells", "CELL_TYPE", 87, 99], ["leukocyte values", "TEST", 30, 46], ["increasing malignancy in cancer cells", "PROBLEM", 62, 99], ["inflammatory stimuli", "TEST", 276, 296], ["leukocyte", "OBSERVATION", 30, 39], ["increasing", "OBSERVATION_MODIFIER", 62, 72], ["malignancy", "OBSERVATION", 73, 83], ["cancer cells", "OBSERVATION", 87, 99], ["anti-inflammatory", "OBSERVATION_MODIFIER", 153, 170], ["inflammatory stimuli", "OBSERVATION", 276, 296]]], ["The anti-inflammatory effect of TS involves suppression of LPS-induced production of TNF-\u03b1 and IL-1\u03b2 in the serum and organs of mice.44 In the present study, the TS-treated group had reduced levels of leukocytes, showing that TS promoted immune responses in BALB/c mice and exhibited antileukemia activity toward murine WEHI-3 cells.DiscussionNatural products, including plants, provide rich resources for anticancer drug discovery.", [["serum", "ANATOMY", 108, 113], ["organs", "ANATOMY", 118, 124], ["leukocytes", "ANATOMY", 201, 211], ["WEHI-3 cells", "ANATOMY", 320, 332], ["anticancer", "ANATOMY", 406, 416], ["LPS", "CHEMICAL", 59, 62], ["TS", "SIMPLE_CHEMICAL", 32, 34], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 85, 90], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 95, 100], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["organs", "ORGAN", 118, 124], ["mice", "ORGANISM", 128, 132], ["TS", "SIMPLE_CHEMICAL", 162, 164], ["leukocytes", "CELL", 201, 211], ["BALB/c mice", "ORGANISM", 258, 269], ["murine", "ORGANISM", 313, 319], ["WEHI-3 cells", "CELL", 320, 332], ["anticancer", "CANCER", 406, 416], ["TNF", "PROTEIN", 85, 88], ["IL-1\u03b2", "PROTEIN", 95, 100], ["leukocytes", "CELL_TYPE", 201, 211], ["murine WEHI-3 cells", "CELL_LINE", 313, 332], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 265, 269], ["murine", "SPECIES", 313, 319], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 265, 269], ["LPS", "PROBLEM", 59, 62], ["TNF", "TEST", 85, 88], ["IL", "TEST", 95, 97], ["the present study", "TEST", 139, 156], ["the TS", "TEST", 158, 164], ["reduced levels of leukocytes", "PROBLEM", 183, 211], ["BALB/c mice", "TEST", 258, 269], ["antileukemia activity", "PROBLEM", 284, 305], ["DiscussionNatural products", "TREATMENT", 333, 359], ["anticancer drug discovery", "TREATMENT", 406, 431], ["anti-inflammatory", "OBSERVATION_MODIFIER", 4, 21], ["leukocytes", "ANATOMY", 201, 211], ["antileukemia activity", "OBSERVATION", 284, 305]]], ["As the different components in a given herb may buffer toxic effects or offer synergistic activities, extracts or mixtures of these herbs may offer greater therapeutic or preventive activity in combination.45 In our previous study, a number of compounds, including gallic acid, methyl gallate, ethyl gallate, kaempferol, kaempferol-3-O-\u03b2-D-glucoside, quercetin, quercitrin, quercetin-3-O-\u03b2-D-glucoside, and rutin, were isolated from the leaves of TS, as verified by HPLC, with the analogous information reported in the literature.10 The total phenolic content of TS was estimated to be 130 \u00b1 26 mg gallic acid, equivalents/g of plant extracts.", [["extracts", "ANATOMY", 102, 110], ["leaves", "ANATOMY", 437, 443], ["extracts", "ANATOMY", 634, 642], ["gallic acid", "CHEMICAL", 265, 276], ["methyl gallate", "CHEMICAL", 278, 292], ["ethyl gallate", "CHEMICAL", 294, 307], ["kaempferol", "CHEMICAL", 309, 319], ["kaempferol-3-O-\u03b2-D-glucoside", "CHEMICAL", 321, 349], ["quercetin", "CHEMICAL", 351, 360], ["quercitrin", "CHEMICAL", 362, 372], ["quercetin-3-O-\u03b2-D-glucoside", "CHEMICAL", 374, 401], ["rutin", "CHEMICAL", 407, 412], ["gallic acid", "CHEMICAL", 598, 609], ["gallic acid", "CHEMICAL", 265, 276], ["methyl gallate", "CHEMICAL", 278, 292], ["ethyl gallate", "CHEMICAL", 294, 307], ["kaempferol", "CHEMICAL", 309, 319], ["kaempferol-3-O-\u03b2-D-glucoside", "CHEMICAL", 321, 349], ["quercetin", "CHEMICAL", 351, 360], ["quercitrin", "CHEMICAL", 362, 372], ["quercetin-3-O-\u03b2-D-glucoside", "CHEMICAL", 374, 401], ["rutin", "CHEMICAL", 407, 412], ["gallic acid", "CHEMICAL", 598, 609], ["extracts", "ORGANISM_SUBSTANCE", 102, 110], ["gallic acid", "SIMPLE_CHEMICAL", 265, 276], ["methyl gallate", "SIMPLE_CHEMICAL", 278, 292], ["ethyl gallate", "SIMPLE_CHEMICAL", 294, 307], ["kaempferol", "SIMPLE_CHEMICAL", 309, 319], ["kaempferol-3-O-\u03b2-D-glucoside", "SIMPLE_CHEMICAL", 321, 349], ["quercetin", "SIMPLE_CHEMICAL", 351, 360], ["quercitrin", "SIMPLE_CHEMICAL", 362, 372], ["quercetin-3-O-\u03b2-D-glucoside", "SIMPLE_CHEMICAL", 374, 401], ["rutin", "SIMPLE_CHEMICAL", 407, 412], ["gallic acid", "SIMPLE_CHEMICAL", 598, 609], ["extracts", "ORGANISM_SUBSTANCE", 634, 642], ["herb", "TREATMENT", 39, 43], ["toxic effects", "PROBLEM", 55, 68], ["synergistic activities", "TREATMENT", 78, 100], ["these herbs", "TREATMENT", 126, 137], ["gallic acid", "TREATMENT", 265, 276], ["methyl gallate", "TREATMENT", 278, 292], ["ethyl gallate", "TREATMENT", 294, 307], ["kaempferol", "TREATMENT", 309, 319], ["kaempferol", "TREATMENT", 321, 331], ["glucoside", "TREATMENT", 340, 349], ["quercetin", "TREATMENT", 351, 360], ["quercitrin", "TREATMENT", 362, 372], ["quercetin", "TREATMENT", 374, 383], ["D-glucoside", "TREATMENT", 390, 401], ["rutin", "TREATMENT", 407, 412], ["gallic acid", "TEST", 598, 609], ["plant extracts", "TREATMENT", 628, 642]]], ["The yield of gallic acid, the natural phenolic component purified from TS, was approximately 10%.8 Although it remains unclear which of the components of TS are active compounds, polyphenols have received increasing attention recently because of some interesting new findings regarding their biological activities.", [["gallic acid", "CHEMICAL", 13, 24], ["polyphenols", "CHEMICAL", 179, 190], ["gallic acid", "CHEMICAL", 13, 24], ["polyphenols", "CHEMICAL", 179, 190], ["gallic acid", "SIMPLE_CHEMICAL", 13, 24], ["TS", "SIMPLE_CHEMICAL", 154, 156], ["polyphenols", "SIMPLE_CHEMICAL", 179, 190], ["gallic acid", "TREATMENT", 13, 24], ["polyphenols", "TREATMENT", 179, 190], ["increasing attention", "TREATMENT", 205, 225], ["gallic acid", "OBSERVATION", 13, 24], ["natural", "OBSERVATION_MODIFIER", 30, 37], ["phenolic component", "OBSERVATION", 38, 56], ["active", "OBSERVATION_MODIFIER", 161, 167]]], ["Of these compounds, it has been demonstrated that gallic acid possesses antioxidant and anticancer activities.16 Gallic acid and its structurally related compounds are some of the main phenolic components of both black and green tea, and red wine.", [["anticancer", "ANATOMY", 88, 98], ["tea", "ANATOMY", 229, 232], ["gallic acid", "CHEMICAL", 50, 61], ["Gallic acid", "CHEMICAL", 113, 124], ["green tea", "CHEMICAL", 223, 232], ["gallic acid", "CHEMICAL", 50, 61], ["Gallic acid", "CHEMICAL", 113, 124], ["gallic acid", "SIMPLE_CHEMICAL", 50, 61], ["anticancer", "CANCER", 88, 98], ["Gallic acid", "SIMPLE_CHEMICAL", 113, 124], ["tea", "ORGANISM_SUBDIVISION", 229, 232], ["tea", "SPECIES", 229, 232], ["green tea", "SPECIES", 223, 232], ["red wine", "SPECIES", 238, 246], ["gallic acid possesses antioxidant", "TREATMENT", 50, 83], ["anticancer activities", "TREATMENT", 88, 109], ["Gallic acid", "TEST", 113, 124], ["its structurally related compounds", "PROBLEM", 129, 163], ["gallic acid", "OBSERVATION", 50, 61], ["Gallic acid", "OBSERVATION_MODIFIER", 113, 124], ["compounds", "OBSERVATION_MODIFIER", 154, 163], ["main", "OBSERVATION_MODIFIER", 180, 184], ["phenolic components", "OBSERVATION", 185, 204], ["both", "OBSERVATION_MODIFIER", 208, 212], ["black", "OBSERVATION_MODIFIER", 213, 218], ["green tea", "OBSERVATION", 223, 232]]], ["Studies have found that gallic acid induces apoptosis in cancer cells (such as HL-60RG, Hela, dRLh-84, PLC/PRF/5 and KB cells) with higher sensitivity than normal analogs (such as rat primary cultured hepatocytes, macrophages, endothelial cells and fibroblasts).46 Some studies have shown that gallic acid causes inactivating phosphorylation of CDC25A/CDC25C- CDC2, leading to cell cycle arrest, and apoptosis induction in human prostate carcinoma DU 145 cells.47 In the current work, TS exhibited antileukemic potential that might be due to the presence of flavonoids and polyphenolics (gallic acids) in it.", [["cancer cells", "ANATOMY", 57, 69], ["HL-60RG", "ANATOMY", 79, 86], ["Hela", "ANATOMY", 88, 92], ["dRLh-84", "ANATOMY", 94, 101], ["PLC/PRF/5", "ANATOMY", 103, 112], ["KB cells", "ANATOMY", 117, 125], ["hepatocytes", "ANATOMY", 201, 212], ["macrophages", "ANATOMY", 214, 225], ["endothelial cells", "ANATOMY", 227, 244], ["fibroblasts", "ANATOMY", 249, 260], ["cell", "ANATOMY", 377, 381], ["prostate carcinoma DU 145 cells", "ANATOMY", 429, 460], ["gallic acid", "CHEMICAL", 24, 35], ["cancer", "DISEASE", 57, 63], ["gallic acid", "CHEMICAL", 294, 305], ["prostate carcinoma", "DISEASE", 429, 447], ["gallic acids", "CHEMICAL", 588, 600], ["gallic acid", "CHEMICAL", 24, 35], ["gallic acid", "CHEMICAL", 294, 305], ["flavonoids", "CHEMICAL", 558, 568], ["polyphenolics", "CHEMICAL", 573, 586], ["gallic acids", "CHEMICAL", 588, 600], ["gallic acid", "SIMPLE_CHEMICAL", 24, 35], ["cancer cells", "CELL", 57, 69], ["HL-60RG", "CELL", 79, 86], ["Hela", "CELL", 88, 92], ["dRLh-84", "CELL", 94, 101], ["PLC", "GENE_OR_GENE_PRODUCT", 103, 106], ["KB cells", "CELL", 117, 125], ["rat", "ORGANISM", 180, 183], ["hepatocytes", "CELL", 201, 212], ["macrophages", "CELL", 214, 225], ["endothelial cells", "CELL", 227, 244], ["fibroblasts", "CELL", 249, 260], ["gallic acid", "SIMPLE_CHEMICAL", 294, 305], ["CDC25A", "GENE_OR_GENE_PRODUCT", 345, 351], ["CDC25C", "GENE_OR_GENE_PRODUCT", 352, 358], ["CDC2", "GENE_OR_GENE_PRODUCT", 360, 364], ["cell", "CELL", 377, 381], ["human", "ORGANISM", 423, 428], ["prostate carcinoma DU 145 cells", "CELL", 429, 460], ["TS", "SIMPLE_CHEMICAL", 485, 487], ["flavonoids", "SIMPLE_CHEMICAL", 558, 568], ["polyphenolics", "SIMPLE_CHEMICAL", 573, 586], ["gallic acids", "SIMPLE_CHEMICAL", 588, 600], ["cancer cells", "CELL_TYPE", 57, 69], ["HL-60RG, Hela, dRLh-84, PLC/PRF/5", "CELL_LINE", 79, 112], ["KB cells", "CELL_LINE", 117, 125], ["rat primary cultured hepatocytes", "CELL_LINE", 180, 212], ["macrophages", "CELL_TYPE", 214, 225], ["endothelial cells", "CELL_TYPE", 227, 244], ["fibroblasts", "CELL_TYPE", 249, 260], ["CDC25A", "PROTEIN", 345, 351], ["CDC25C", "PROTEIN", 352, 358], ["CDC2", "PROTEIN", 360, 364], ["human prostate carcinoma DU 145 cells", "CELL_LINE", 423, 460], ["rat", "SPECIES", 180, 183], ["human", "SPECIES", 423, 428], ["rat", "SPECIES", 180, 183], ["human", "SPECIES", 423, 428], ["Studies", "TEST", 0, 7], ["gallic acid", "TEST", 24, 35], ["apoptosis in cancer cells", "PROBLEM", 44, 69], ["HL", "TEST", 79, 81], ["Hela", "TEST", 88, 92], ["dRLh", "TEST", 94, 98], ["PLC/PRF/5 and KB cells", "TEST", 103, 125], ["higher sensitivity than normal analogs", "PROBLEM", 132, 170], ["macrophages", "PROBLEM", 214, 225], ["fibroblasts", "PROBLEM", 249, 260], ["Some studies", "TEST", 265, 277], ["gallic acid", "PROBLEM", 294, 305], ["CDC25A", "PROBLEM", 345, 351], ["CDC25C- CDC2", "TREATMENT", 352, 364], ["cell cycle arrest", "PROBLEM", 377, 394], ["apoptosis induction", "TREATMENT", 400, 419], ["human prostate carcinoma", "PROBLEM", 423, 447], ["flavonoids", "PROBLEM", 558, 568], ["polyphenolics (gallic acids", "TREATMENT", 573, 600], ["gallic acid", "OBSERVATION", 24, 35], ["cancer cells", "OBSERVATION", 57, 69], ["hepatocytes", "ANATOMY", 201, 212], ["macrophages", "ANATOMY", 214, 225], ["endothelial cells", "OBSERVATION", 227, 244], ["gallic acid", "OBSERVATION", 294, 305], ["cell cycle arrest", "OBSERVATION", 377, 394], ["prostate", "ANATOMY", 429, 437], ["carcinoma", "OBSERVATION", 438, 447], ["145 cells", "OBSERVATION", 451, 460], ["might be due to", "UNCERTAINTY", 526, 541], ["flavonoids", "OBSERVATION", 558, 568]]], ["However, further isolation, structural characterization of active constituents is necessary to extrapolate the mechanism of action.ConclusionTaken together, our results confirm the potential of Toona sinensis as an agent of chemotherapeutic in murine myelocytic leukemia WEHI-3 cells in vitro and in vivo.", [["myelocytic leukemia WEHI-3 cells", "ANATOMY", 251, 283], ["murine myelocytic leukemia", "DISEASE", 244, 270], ["Toona sinensis", "ORGANISM", 194, 208], ["murine", "ORGANISM", 244, 250], ["myelocytic leukemia WEHI-3 cells", "CELL", 251, 283], ["murine myelocytic leukemia WEHI-3 cells", "CELL_LINE", 244, 283], ["Toona sinensis", "SPECIES", 194, 208], ["murine", "SPECIES", 244, 250], ["Toona sinensis", "SPECIES", 194, 208], ["further isolation", "TREATMENT", 9, 26], ["structural characterization", "TEST", 28, 55], ["active constituents", "PROBLEM", 59, 78], ["Toona sinensis", "PROBLEM", 194, 208], ["chemotherapeutic in murine myelocytic leukemia WEHI", "TREATMENT", 224, 275], ["active", "OBSERVATION_MODIFIER", 59, 65], ["murine myelocytic leukemia WEHI", "OBSERVATION", 244, 275]]], ["These findings also sustain our contention that T. sinensis may possess anticancer properties potentially valuable for application in food and drug products.", [["anticancer", "ANATOMY", 72, 82], ["T. sinensis", "ORGANISM", 48, 59], ["anticancer", "CANCER", 72, 82], ["T. sinensis", "SPECIES", 48, 59], ["T. sinensis", "SPECIES", 48, 59], ["T. sinensis", "PROBLEM", 48, 59], ["application in food", "TREATMENT", 119, 138], ["drug products", "TREATMENT", 143, 156]]], ["However, further in vivo studies using animal models are necessary to elaborate and exploit this nascent promise.", [["further in vivo studies", "TEST", 9, 32], ["animal models", "TREATMENT", 39, 52]]]], "PMC7112510": [["IntroductionPorcine reproductive and respiratory syndrome (PRRS), characterized by severe reproductive failure in sows, and respiratory distress in piglets and growing pigs, is now considered one of the most important diseases in countries with intensive swine industries (Rossow, 1998).", [["respiratory", "ANATOMY", 124, 135], ["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["PRRS", "DISEASE", 59, 63], ["reproductive failure", "DISEASE", 90, 110], ["respiratory distress", "DISEASE", 124, 144], ["piglets", "ORGANISM", 148, 155], ["pigs", "ORGANISM", 168, 172], ["piglets", "SPECIES", 148, 155], ["pigs", "SPECIES", 168, 172], ["PRRS", "SPECIES", 59, 63], ["pigs", "SPECIES", 168, 172], ["swine", "SPECIES", 255, 260], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome", "PROBLEM", 37, 57], ["severe reproductive failure", "PROBLEM", 83, 110], ["respiratory distress", "PROBLEM", 124, 144], ["respiratory syndrome", "OBSERVATION", 37, 57], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["reproductive", "OBSERVATION_MODIFIER", 90, 102], ["failure", "OBSERVATION", 103, 110], ["respiratory distress", "OBSERVATION", 124, 144], ["diseases", "OBSERVATION", 218, 226]]], ["The causative agent, PRRS virus (PRRSV), is a positive-strand RNA virus belonging to the family Arteriviridae (Meulenberg, 2000).", [["PRRS virus", "DISEASE", 21, 31], ["PRRS virus", "ORGANISM", 21, 31], ["PRRSV", "ORGANISM", 33, 38], ["PRRS virus", "SPECIES", 21, 31], ["PRRS virus", "SPECIES", 21, 31], ["PRRSV", "SPECIES", 33, 38], ["The causative agent", "PROBLEM", 0, 19], ["PRRS virus", "PROBLEM", 21, 31], ["a positive-strand RNA virus", "PROBLEM", 44, 71]]], ["Accumulating evidences have revealed that PRRSV appears to develop a defensive mechanism to evade the antiviral activities of interferon (IFN): It suppresses production of type I IFN (IFN-\u03b1/\u03b2) in infected MARC-145 cells and alveolar macrophages (Miller et al., 2004, Murtaugh et al., 2002); Furthermore, it diminishes IFN-\u03b1/\u03b2 production induced by infection with transmissible gastroenteritis coronavirus (TGEV) or transfection with double-strand RNA (dsRNA) (Albina et al., 1998, Miller et al., 2004).", [["MARC-145 cells", "ANATOMY", 205, 219], ["alveolar macrophages", "ANATOMY", 224, 244], ["infection", "DISEASE", 348, 357], ["transmissible gastroenteritis coronavirus", "DISEASE", 363, 404], ["PRRSV", "ORGANISM", 42, 47], ["interferon", "GENE_OR_GENE_PRODUCT", 126, 136], ["IFN", "GENE_OR_GENE_PRODUCT", 138, 141], ["type I IFN", "GENE_OR_GENE_PRODUCT", 172, 182], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 184, 189], ["\u03b2", "GENE_OR_GENE_PRODUCT", 190, 191], ["MARC-145 cells", "CELL", 205, 219], ["alveolar macrophages", "CELL", 224, 244], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 318, 323], ["\u03b2", "GENE_OR_GENE_PRODUCT", 324, 325], ["transmissible gastroenteritis coronavirus", "ORGANISM", 363, 404], ["TGEV", "ORGANISM", 406, 410], ["interferon", "PROTEIN", 126, 136], ["IFN", "PROTEIN", 138, 141], ["type I IFN", "PROTEIN", 172, 182], ["IFN", "PROTEIN", 184, 187], ["\u03b1", "PROTEIN", 188, 189], ["\u03b2", "PROTEIN", 190, 191], ["MARC-145 cells", "CELL_LINE", 205, 219], ["alveolar macrophages", "CELL_TYPE", 224, 244], ["IFN", "PROTEIN", 318, 321], ["\u03b1", "PROTEIN", 322, 323], ["\u03b2", "PROTEIN", 324, 325], ["transmissible gastroenteritis coronavirus", "SPECIES", 363, 404], ["PRRSV", "SPECIES", 42, 47], ["MARC-145", "SPECIES", 205, 213], ["transmissible gastroenteritis coronavirus", "SPECIES", 363, 404], ["TGEV", "SPECIES", 406, 410], ["PRRSV", "PROBLEM", 42, 47], ["a defensive mechanism", "PROBLEM", 67, 88], ["interferon (IFN)", "TREATMENT", 126, 142], ["type I IFN", "PROBLEM", 172, 182], ["IFN", "TEST", 184, 187], ["alveolar macrophages", "PROBLEM", 224, 244], ["IFN", "TEST", 318, 321], ["\u03b2 production", "PROBLEM", 324, 336], ["infection", "PROBLEM", 348, 357], ["transmissible gastroenteritis coronavirus (TGEV", "PROBLEM", 363, 410], ["double-strand RNA (dsRNA", "TREATMENT", 433, 457], ["PRRSV", "OBSERVATION", 42, 47], ["alveolar macrophages", "ANATOMY", 224, 244], ["infection", "OBSERVATION", 348, 357]]], ["However, the mechanisms used by PRRSV to suppress the production of type I IFN remain unclear.IntroductionSecretion of type I IFN (IFN-\u03b1/\u03b2) is a key step in the innate immune response to viral infection (Kawai and Akira, 2006, Takaoka and Yanai, 2006).", [["viral infection", "DISEASE", 187, 202], ["PRRSV", "ORGANISM", 32, 37], ["type I IFN", "GENE_OR_GENE_PRODUCT", 68, 78], ["type I IFN", "GENE_OR_GENE_PRODUCT", 119, 129], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 131, 136], ["\u03b2", "GENE_OR_GENE_PRODUCT", 137, 138], ["type I IFN", "PROTEIN", 68, 78], ["type I IFN", "PROTEIN", 119, 129], ["IFN", "PROTEIN", 131, 134], ["\u03b1", "PROTEIN", 135, 136], ["\u03b2", "PROTEIN", 137, 138], ["PRRSV", "SPECIES", 32, 37], ["PRRSV", "TREATMENT", 32, 37], ["type I IFN", "PROBLEM", 68, 78], ["IntroductionSecretion", "TEST", 94, 115], ["type I IFN", "PROBLEM", 119, 129], ["IFN", "TEST", 131, 134], ["viral infection", "PROBLEM", 187, 202], ["viral infection", "OBSERVATION", 187, 202]]], ["PRRSV is a single-stranded RNA virus, whose genome is duplicated into dsRNA during replication.", [["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["a single-stranded RNA virus", "PROBLEM", 9, 36], ["RNA virus", "OBSERVATION", 27, 36], ["dsRNA", "OBSERVATION_MODIFIER", 70, 75]]], ["The common intermediate dsRNA can trigger a cascade of cellular events, leading to secretion of type I IFN.", [["cellular", "ANATOMY", 55, 63], ["cellular", "CELL", 55, 63], ["type I IFN", "GENE_OR_GENE_PRODUCT", 96, 106], ["type I IFN", "PROTEIN", 96, 106], ["cellular events", "PROBLEM", 55, 70], ["secretion of type I IFN", "PROBLEM", 83, 106], ["common", "ANATOMY", 4, 10], ["intermediate dsRNA", "OBSERVATION", 11, 29]]], ["Initially, the pathogen-associated molecular pattern in dsRNA is recognized by multiple pattern recognition receptors (PRRs), including Toll-like receptor 3 (TLR3) and cytoplasmic RNA helicase, such as retinoic acid-inducible protein I (RIG-I) or melanoma differentiation-associated gene 5 (MDA5) (Yoneyama et al., 2004).", [["cytoplasmic", "ANATOMY", 168, 179], ["melanoma", "ANATOMY", 247, 255], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 88, 117], ["PRRs", "GENE_OR_GENE_PRODUCT", 119, 123], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 136, 156], ["TLR3", "GENE_OR_GENE_PRODUCT", 158, 162], ["cytoplasmic", "ORGANISM_SUBSTANCE", 168, 179], ["retinoic acid-inducible protein I", "GENE_OR_GENE_PRODUCT", 202, 235], ["RIG-I", "GENE_OR_GENE_PRODUCT", 237, 242], ["melanoma differentiation-associated gene 5", "GENE_OR_GENE_PRODUCT", 247, 289], ["MDA5", "GENE_OR_GENE_PRODUCT", 291, 295], ["pattern recognition receptors", "PROTEIN", 88, 117], ["PRRs", "PROTEIN", 119, 123], ["Toll-like receptor 3", "PROTEIN", 136, 156], ["TLR3", "PROTEIN", 158, 162], ["cytoplasmic RNA helicase", "PROTEIN", 168, 192], ["retinoic acid-inducible protein I", "PROTEIN", 202, 235], ["RIG-I", "PROTEIN", 237, 242], ["melanoma differentiation-associated gene 5", "DNA", 247, 289], ["MDA5", "DNA", 291, 295], ["the pathogen", "PROBLEM", 11, 23], ["molecular pattern in dsRNA", "PROBLEM", 35, 61], ["Toll-like receptor 3 (TLR3)", "TREATMENT", 136, 163], ["cytoplasmic RNA helicase", "TREATMENT", 168, 192], ["retinoic acid-inducible protein I", "TEST", 202, 235], ["melanoma differentiation", "PROBLEM", 247, 271], ["molecular pattern", "OBSERVATION", 35, 52], ["dsRNA", "OBSERVATION", 56, 61], ["melanoma", "OBSERVATION", 247, 255]]], ["TLR3 can detect either extracellular dsRNA or dsRNA within vesicles.", [["extracellular", "ANATOMY", 23, 36], ["vesicles", "ANATOMY", 59, 67], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 36], ["vesicles", "CELLULAR_COMPONENT", 59, 67], ["TLR3", "PROTEIN", 0, 4], ["TLR3", "TREATMENT", 0, 4], ["extracellular dsRNA or dsRNA within vesicles", "PROBLEM", 23, 67], ["extracellular", "OBSERVATION_MODIFIER", 23, 36], ["dsRNA", "OBSERVATION", 37, 42], ["dsRNA", "OBSERVATION", 46, 51]]], ["Activation of TLR3 by dsRNA then leads to the recruitment of the adaptor molecule TRIF through MyD88-independent pathway (Fitzgerald et al., 2003).", [["TLR3", "GENE_OR_GENE_PRODUCT", 14, 18], ["TRIF", "GENE_OR_GENE_PRODUCT", 82, 86], ["MyD88", "GENE_OR_GENE_PRODUCT", 95, 100], ["TLR3", "PROTEIN", 14, 18], ["adaptor molecule", "PROTEIN", 65, 81], ["TRIF", "PROTEIN", 82, 86], ["MyD88", "PROTEIN", 95, 100], ["Activation of TLR3 by dsRNA", "TREATMENT", 0, 27], ["the adaptor molecule TRIF", "TREATMENT", 61, 86]]], ["Alternatively, RIG-I or MDA5 serves as intracellular dsRNA receptors via DexD/H-box helicase domains.", [["intracellular", "ANATOMY", 39, 52], ["RIG-I", "GENE_OR_GENE_PRODUCT", 15, 20], ["MDA5", "GENE_OR_GENE_PRODUCT", 24, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["DexD", "GENE_OR_GENE_PRODUCT", 73, 77], ["RIG-I", "PROTEIN", 15, 20], ["MDA5", "PROTEIN", 24, 28], ["intracellular dsRNA receptors", "PROTEIN", 39, 68], ["DexD/H-box helicase domains", "PROTEIN", 73, 100], ["intracellular dsRNA receptors", "TREATMENT", 39, 68], ["DexD/H-box helicase domains", "TREATMENT", 73, 100]]], ["Caspase recruitment domains (CARDs) of RIG-I or MDA5 interact with the counterpart domains of IFN-\u03b2 promoter stimulator 1 (IPS-1, also known as MAVS/VISA/Cardif) (Kawai et al., 2005).", [["Caspase", "GENE_OR_GENE_PRODUCT", 0, 7], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["MDA5", "GENE_OR_GENE_PRODUCT", 48, 52], ["IFN-\u03b2 promoter stimulator 1", "GENE_OR_GENE_PRODUCT", 94, 121], ["IPS-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["MAVS", "GENE_OR_GENE_PRODUCT", 144, 148], ["Caspase recruitment domains", "PROTEIN", 0, 27], ["CARDs", "PROTEIN", 29, 34], ["RIG-I", "PROTEIN", 39, 44], ["MDA5", "PROTEIN", 48, 52], ["IFN-\u03b2 promoter stimulator 1", "DNA", 94, 121], ["IPS-1", "DNA", 123, 128], ["MAVS", "PROTEIN", 144, 148], ["VISA", "DNA", 149, 153], ["Cardif", "DNA", 154, 160], ["Caspase recruitment domains", "TREATMENT", 0, 27], ["IFN-\u03b2 promoter stimulator", "TREATMENT", 94, 119]]], ["Despite utilizing the different adaptors, both pathways converge to activate the two downstream kinases, Tank-binding kinase 1 (TBK1) and inhibitor of \u03baB kinase \u025b (IKK\u025b), resulting in the phosphorylation and activation of transcription factors, including IFN regulatory factor 3 (IRF3), NF-\u03baB, and AP-1 (Fitzgerald et al., 2003).", [["Tank-binding kinase 1", "GENE_OR_GENE_PRODUCT", 105, 126], ["TBK1", "GENE_OR_GENE_PRODUCT", 128, 132], ["inhibitor of \u03baB kinase \u025b", "GENE_OR_GENE_PRODUCT", 138, 162], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 164, 168], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 255, 278], ["IRF3", "GENE_OR_GENE_PRODUCT", 280, 284], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 287, 292], ["AP-1", "GENE_OR_GENE_PRODUCT", 298, 302], ["downstream kinases", "PROTEIN", 85, 103], ["Tank-binding kinase 1", "PROTEIN", 105, 126], ["TBK1", "PROTEIN", 128, 132], ["\u03baB kinase \u025b", "PROTEIN", 151, 162], ["IKK\u025b", "PROTEIN", 164, 168], ["transcription factors", "PROTEIN", 222, 243], ["IFN regulatory factor 3", "PROTEIN", 255, 278], ["IRF3", "PROTEIN", 280, 284], ["NF-\u03baB", "PROTEIN", 287, 292], ["AP", "PROTEIN", 298, 300], ["the different adaptors", "TREATMENT", 18, 40], ["Tank-binding kinase", "TREATMENT", 105, 124], ["inhibitor", "TREATMENT", 138, 147], ["transcription factors", "PROBLEM", 222, 243], ["IFN regulatory factor", "TEST", 255, 276], ["IRF3", "TEST", 280, 284], ["NF", "TEST", 287, 289], ["AP", "TEST", 298, 300]]], ["The coordinate activation of these transcription factors results in the formation of a transcriptionally competent enhanceosome that induces type I IFN production and downstream inflammatory cytokines (Thanos and Maniatis, 1995).IntroductionIn order to combat the antiviral effects of IFN-\u03b1/\u03b2, many viruses, such as influenza A virus, Hepatitis C virus, and Ebola virus, have evolved distinct strategies to inhibit IFN signaling pathways for their survival (Cardenas et al., 2006, Cheng et al., 2006, Talon et al., 2000).", [["enhanceosome", "ANATOMY", 115, 127], ["influenza A", "DISEASE", 316, 327], ["Hepatitis C virus", "DISEASE", 335, 352], ["Ebola virus", "DISEASE", 358, 369], ["enhanceosome", "CANCER", 115, 127], ["type I IFN", "GENE_OR_GENE_PRODUCT", 141, 151], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 285, 290], ["\u03b2", "GENE_OR_GENE_PRODUCT", 291, 292], ["influenza A virus", "ORGANISM", 316, 333], ["Hepatitis C virus", "ORGANISM", 335, 352], ["Ebola virus", "ORGANISM", 358, 369], ["IFN", "GENE_OR_GENE_PRODUCT", 415, 418], ["transcription factors", "PROTEIN", 35, 56], ["enhanceosome", "PROTEIN", 115, 127], ["type I IFN", "PROTEIN", 141, 151], ["inflammatory cytokines", "PROTEIN", 178, 200], ["IFN", "PROTEIN", 285, 288], ["\u03b1", "PROTEIN", 289, 290], ["\u03b2", "PROTEIN", 291, 292], ["IFN", "PROTEIN", 415, 418], ["influenza A virus", "SPECIES", 316, 333], ["Hepatitis C virus", "SPECIES", 335, 352], ["Ebola virus", "SPECIES", 358, 369], ["influenza A virus", "SPECIES", 316, 333], ["Hepatitis C virus", "SPECIES", 335, 352], ["Ebola virus", "SPECIES", 358, 369], ["these transcription factors", "PROBLEM", 29, 56], ["type I IFN production", "PROBLEM", 141, 162], ["downstream inflammatory cytokines", "PROBLEM", 167, 200], ["IntroductionIn", "TREATMENT", 229, 243], ["the antiviral effects", "TREATMENT", 260, 281], ["IFN", "TEST", 285, 288], ["\u03b2", "PROBLEM", 291, 292], ["many viruses", "PROBLEM", 294, 306], ["influenza A virus", "PROBLEM", 316, 333], ["Hepatitis C virus", "PROBLEM", 335, 352], ["Ebola virus", "PROBLEM", 358, 369], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190], ["viruses", "OBSERVATION", 299, 306]]], ["In the present study, we investigated the mechanisms used by PRRSV to inhibit IFN-\u03b2 production in MARC-145 cells.", [["MARC-145 cells", "ANATOMY", 98, 112], ["PRRSV", "ORGANISM", 61, 66], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["MARC-145 cells", "CELL", 98, 112], ["IFN", "PROTEIN", 78, 81], ["\u03b2", "PROTEIN", 82, 83], ["MARC-145 cells", "CELL_LINE", 98, 112], ["PRRSV", "SPECIES", 61, 66], ["MARC-145", "SPECIES", 98, 106], ["the present study", "TEST", 3, 20], ["PRRSV", "PROBLEM", 61, 66], ["IFN", "TEST", 78, 81]]], ["Our results showed that PRRSV infection prevented IFN-\u03b2 expression in MARC-145 cells by inactivating IPS-1, thereby interrupting the dsRNA-signaling pathway.Virus and cells ::: Materials and methodsPRRSV strain CH-1a, the first field isolate in China, was kindly provided by Dr. Guangzhi Tong (Harbin Veterinary Research Institute, Harbin, China).", [["MARC-145 cells", "ANATOMY", 70, 84], ["cells", "ANATOMY", 167, 172], ["PRRSV infection", "DISEASE", 24, 39], ["CH-1a", "CHEMICAL", 211, 216], ["PRRSV", "ORGANISM", 24, 29], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 50, 55], ["MARC-145 cells", "CELL", 70, 84], ["IPS-1", "GENE_OR_GENE_PRODUCT", 101, 106], ["dsRNA", "GENE_OR_GENE_PRODUCT", 133, 138], ["Virus", "ORGANISM", 157, 162], ["cells", "CELL", 167, 172], ["PRRSV strain CH-1a", "ORGANISM", 198, 216], ["IFN", "PROTEIN", 50, 53], ["\u03b2", "PROTEIN", 54, 55], ["MARC-145 cells", "CELL_LINE", 70, 84], ["IPS-1", "PROTEIN", 101, 106], ["PRRSV", "SPECIES", 24, 29], ["MARC-145", "SPECIES", 70, 78], ["PRRSV strain CH-1a", "SPECIES", 198, 216], ["PRRSV infection", "PROBLEM", 24, 39], ["IFN", "PROBLEM", 50, 53], ["the dsRNA", "TREATMENT", 129, 138], ["PRRSV infection", "OBSERVATION", 24, 39]]], ["MARC-145 cell was cultured and maintained in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% heated-inactivated fetal bovine serum (FBS), 0.25 \u03bcg/ml fungizone, 100 U/ml penicillin, 10 \u03bcg/ml streptomycin sulfate, and 5 \u03bcg/ml gentamicin and then held at 37 \u00b0C in a humidified 5% CO2 incubator.Plasmids ::: Materials and methodsThe plasmids pNF-\u03baB-Luc and pAP-1-Luc were from Stratagene.", [["MARC-145 cell", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 126, 144], ["FBS", "ANATOMY", 146, 149], ["plasmids", "ANATOMY", 343, 351], ["MARC-145", "CHEMICAL", 0, 8], ["fungizone", "CHEMICAL", 163, 172], ["penicillin", "CHEMICAL", 183, 193], ["streptomycin", "CHEMICAL", 204, 216], ["gentamicin", "CHEMICAL", 238, 248], ["CO2", "CHEMICAL", 291, 294], ["fungizone", "CHEMICAL", 163, 172], ["penicillin", "CHEMICAL", 183, 193], ["streptomycin sulfate", "CHEMICAL", 204, 224], ["gentamicin", "CHEMICAL", 238, 248], ["CO2", "CHEMICAL", 291, 294], ["MARC-145 cell", "CELL", 0, 13], ["bovine", "ORGANISM", 132, 138], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["FBS", "ORGANISM_SUBSTANCE", 146, 149], ["fungizone", "SIMPLE_CHEMICAL", 163, 172], ["penicillin", "SIMPLE_CHEMICAL", 183, 193], ["streptomycin sulfate", "SIMPLE_CHEMICAL", 204, 224], ["gentamicin", "SIMPLE_CHEMICAL", 238, 248], ["CO2", "SIMPLE_CHEMICAL", 291, 294], ["pNF-\u03baB-Luc", "GENE_OR_GENE_PRODUCT", 352, 362], ["pAP-1", "GENE_OR_GENE_PRODUCT", 367, 372], ["Luc", "GENE_OR_GENE_PRODUCT", 373, 376], ["MARC-145 cell", "CELL_LINE", 0, 13], ["plasmids", "DNA", 343, 351], ["pNF", "DNA", 352, 355], ["\u03baB", "DNA", 356, 358], ["Luc", "DNA", 359, 362], ["pAP", "DNA", 367, 370], ["1", "DNA", 371, 372], ["Luc", "DNA", 373, 376], ["bovine", "SPECIES", 132, 138], ["bovine", "SPECIES", 132, 138], ["Dulbecco's Modified Eagle medium (DMEM", "TREATMENT", 45, 83], ["inactivated fetal bovine serum (FBS", "TREATMENT", 114, 149], ["fungizone", "TREATMENT", 163, 172], ["penicillin", "TREATMENT", 183, 193], ["streptomycin sulfate", "TREATMENT", 204, 224], ["gentamicin", "TREATMENT", 238, 248], ["a humidified 5% CO2 incubator", "TREATMENT", 275, 304], ["The plasmids pNF", "TEST", 339, 355], ["pAP", "TEST", 367, 370], ["Stratagene", "TREATMENT", 387, 397], ["145 cell", "OBSERVATION_MODIFIER", 5, 13]]], ["Human IPS-1 gene was cloned from Hela cells by RT-PCR using the specific primer pair (5\u2032-ATTAGATCTATGCCGTTTGCTGAAGACAAG-3\u2032 and 5\u2032-TCTAAGCTTCTAGTGCAGACGCCGCCGGTA-3\u2032) and was ligated into pCMV-Tag2B (Stratagene) to generate IPS-1 expression construct.", [["Hela cells", "ANATOMY", 33, 43], ["Human", "ORGANISM", 0, 5], ["IPS-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["Hela cells", "CELL", 33, 43], ["pCMV-Tag2B", "GENE_OR_GENE_PRODUCT", 186, 196], ["IPS-1", "GENE_OR_GENE_PRODUCT", 222, 227], ["Human IPS-1 gene", "DNA", 0, 16], ["Hela cells", "CELL_LINE", 33, 43], ["pCMV", "DNA", 186, 190], ["Tag2B", "DNA", 191, 196], ["Stratagene", "DNA", 198, 208], ["IPS-1 expression construct", "DNA", 222, 248], ["Human", "SPECIES", 0, 5], ["Human IPS-1", "SPECIES", 0, 11], ["Human IPS", "TREATMENT", 0, 9], ["Hela cells", "TREATMENT", 33, 43], ["RT", "TEST", 47, 49], ["PCR", "TEST", 50, 53], ["ATTAGATCTATGCCGTTTGCTGAAGACAAG", "TEST", 89, 119], ["TCTAAGCTTCTAGTGCAGACGCCGCCGGTA", "TEST", 130, 160], ["IPS", "TEST", 222, 225]]], ["Human IRF3 and IRF3(5D) were amplified by PCR with pIRF3-GFP and pIRF3(5D)-GFP (Chang et al., 2006) as templates separately, kindly provided by Dr. Yi-Ling Lin (National Defense Medical Center, Taipei, Taiwan, China), and were ligated into pCMV-Tag2B to generate Flag-tagged expression constructs.", [["Human", "ORGANISM", 0, 5], ["IRF3", "GENE_OR_GENE_PRODUCT", 6, 10], ["IRF3", "GENE_OR_GENE_PRODUCT", 15, 19], ["5D", "GENE_OR_GENE_PRODUCT", 20, 22], ["pIRF3-GFP", "GENE_OR_GENE_PRODUCT", 51, 60], ["pIRF3(5D)-GFP", "GENE_OR_GENE_PRODUCT", 65, 78], ["pCMV", "GENE_OR_GENE_PRODUCT", 240, 244], ["Tag2B", "GENE_OR_GENE_PRODUCT", 245, 250], ["Flag", "GENE_OR_GENE_PRODUCT", 263, 267], ["Human IRF3", "PROTEIN", 0, 10], ["IRF3", "PROTEIN", 15, 19], ["5D", "PROTEIN", 20, 22], ["pIRF3-GFP and pIRF3(5D)-GFP", "DNA", 51, 78], ["pCMV", "DNA", 240, 244], ["Tag2B", "DNA", 245, 250], ["Flag-tagged expression constructs", "DNA", 263, 296], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human IRF3", "TREATMENT", 0, 10], ["IRF3(5D)", "TREATMENT", 15, 23], ["pIRF3", "TEST", 51, 56]]], ["The expression plasmids for wild-type RIG-I (pEF-Flag-RIG-I), its constitutively active mutant (pEF-Flag-RIG-IN) and p125-Luc (IFN-\u03b2-Luc) were gifts of T. Fujita (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) (Yoneyama et al., 2004).", [["plasmids", "ANATOMY", 15, 23], ["RIG-I", "GENE_OR_GENE_PRODUCT", 38, 43], ["pEF-Flag-RIG-I", "GENE_OR_GENE_PRODUCT", 45, 59], ["pEF-Flag-RIG-IN", "GENE_OR_GENE_PRODUCT", 96, 111], ["p125-Luc", "GENE_OR_GENE_PRODUCT", 117, 125], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 127, 136], ["expression plasmids", "DNA", 4, 23], ["wild-type RIG-I", "PROTEIN", 28, 43], ["pEF", "PROTEIN", 45, 48], ["Flag", "PROTEIN", 49, 53], ["RIG", "PROTEIN", 54, 57], ["I", "PROTEIN", 58, 59], ["constitutively active mutant", "PROTEIN", 66, 94], ["pEF", "PROTEIN", 96, 99], ["Flag", "PROTEIN", 100, 104], ["RIG", "PROTEIN", 105, 108], ["IN", "PROTEIN", 109, 111], ["p125", "PROTEIN", 117, 121], ["Luc", "PROTEIN", 122, 125], ["IFN", "PROTEIN", 127, 130], ["\u03b2-Luc", "PROTEIN", 131, 136], ["The expression plasmids", "TREATMENT", 0, 23], ["wild", "TEST", 28, 32], ["pEF", "TEST", 45, 48], ["p125", "TEST", 117, 121], ["IFN", "TEST", 127, 130]]], ["The pcDNA3.1-TBK1, pcDNA3.1-IKK\u025b, and pEF-Bos-Flag-TRIF expression plasmids were gifts of K. Fitzgerald (University of Massachusetts Medical School, Worcester, MA) (Fitzgerald et al., 2003).", [["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 4, 12], ["TBK1", "GENE_OR_GENE_PRODUCT", 13, 17], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 19, 25], ["1-IKK\u025b", "GENE_OR_GENE_PRODUCT", 26, 32], ["pEF-Bos-Flag-TRIF", "GENE_OR_GENE_PRODUCT", 38, 55], ["pcDNA3.1", "DNA", 4, 12], ["TBK1", "PROTEIN", 13, 17], ["pcDNA3", "DNA", 19, 25], ["1-IKK\u025b, and pEF-Bos-Flag-TRIF expression plasmids", "DNA", 26, 75], ["TBK1", "PROBLEM", 13, 17], ["pcDNA3", "PROBLEM", 19, 25], ["IKK\u025b", "TEST", 28, 32], ["pEF", "TEST", 38, 41], ["TRIF expression plasmids", "TREATMENT", 51, 75], ["TBK1", "OBSERVATION", 13, 17]]], ["(PRDIII-I)4-Luc was kindly provided by S. Ludwig (Heinrich Heine University, D\u00fcsseldorf, Germany) (Ehrhardt et al., 2004).RNA extraction and semi-quantitative RT-PCR for IFN-\u03b2 mRNA ::: Materials and methodsTotal cellular RNA was extracted from MARC-145 cells by using TRIzol (Invitrogen), and treated with DNase I (Promega) according to the manufacturer's instructions.", [["cellular", "ANATOMY", 212, 220], ["MARC-145 cells", "ANATOMY", 244, 258], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 170, 175], ["cellular", "CELL", 212, 220], ["MARC-145 cells", "CELL", 244, 258], ["TRIzol", "ORGANISM", 268, 274], ["DNase I", "GENE_OR_GENE_PRODUCT", 306, 313], ["Promega", "ORGANISM", 315, 322], ["IFN-\u03b2 mRNA", "RNA", 170, 180], ["cellular RNA", "RNA", 212, 224], ["MARC-145 cells", "CELL_LINE", 244, 258], ["DNase I", "PROTEIN", 306, 313], ["MARC-145", "SPECIES", 244, 252], ["RNA extraction", "TEST", 122, 136], ["semi-quantitative RT-PCR", "TEST", 141, 165], ["Total cellular RNA", "PROBLEM", 206, 224], ["TRIzol (Invitrogen", "TREATMENT", 268, 286], ["DNase I (Promega)", "TREATMENT", 306, 323], ["cellular RNA", "OBSERVATION", 212, 224], ["145 cells", "OBSERVATION_MODIFIER", 249, 258]]], ["Then, RNA was reverse-transcribed into cDNA by using Superscript RNaseH reverse transcriptase (Invitrogen).", [["RNaseH reverse transcriptase", "GENE_OR_GENE_PRODUCT", 65, 93], ["cDNA", "DNA", 39, 43], ["Superscript RNaseH reverse transcriptase", "PROTEIN", 53, 93]]], ["The generated cDNA was amplified by semi-quantitative PCR using primers for IFN-\u03b2 (5\u2032-GATTCATCTAGCACTGGCTGG-3\u2032/5\u2032-CTTCAGGTAATGCAGAATCC-3\u2032) and for GAPDH (5\u2032-ACCACAGTCCATGCCATCAC-3\u2032/5\u2032-TCCACCACCCTGTTGCTGTA-3\u2032).Transfection and reporter assay ::: Materials and methodsTransient transfection was performed by using Lipofectamine 2000 (Invitrogen).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["GAPDH", "GENE_OR_GENE_PRODUCT", 147, 152], ["cDNA", "DNA", 14, 18], ["IFN", "PROTEIN", 76, 79], ["GAPDH", "PROTEIN", 147, 152], ["semi-quantitative PCR", "TEST", 36, 57], ["primers", "TEST", 64, 71], ["IFN", "TEST", 76, 79], ["\u03b2", "TEST", 80, 81], ["GATTCATCTAGCACTGGCTGG", "TEST", 86, 107], ["GAPDH", "TEST", 147, 152], ["ACCACAGTCCATGCCATCAC", "TEST", 157, 177], ["Transient transfection", "PROBLEM", 266, 288], ["Lipofectamine", "TREATMENT", 312, 325]]], ["MARC-145 cells were seeded in 24-well plates at a density of 2\u20134 \u00d7 105 cells per well.", [["MARC-145 cells", "ANATOMY", 0, 14], ["cells", "ANATOMY", 71, 76], ["MARC-145", "CHEMICAL", 0, 8], ["MARC-145 cells", "CELL", 0, 14], ["cells", "CELL", 71, 76], ["MARC-145 cells", "CELL_LINE", 0, 14], ["2\u20134 \u00d7 105 cells", "CELL_LINE", 61, 76], ["145 cells", "OBSERVATION_MODIFIER", 5, 14]]], ["When cells were grown to 70\u201380% confluency, cells were cotransfected with 100 ng of luciferase reporter plasmid (p125-Luc for IFN-\u03b2, (PRDIII-I)4-Luc for IRF3, pNF-\u03baB-Luc for NF-\u03baB, and pAP-1-Luc for AP-1, respectively), 100 ng of the Renilla luciferase construct phRL-TK (Promega) which was served as an internal control, and 400 ng of the indicated expression plasmid.", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 44, 49], ["plasmid", "ANATOMY", 361, 368], ["cells", "CELL", 5, 10], ["cells", "CELL", 44, 49], ["luciferase", "GENE_OR_GENE_PRODUCT", 84, 94], ["p125-Luc", "GENE_OR_GENE_PRODUCT", 113, 121], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 126, 131], ["PRDIII-I", "GENE_OR_GENE_PRODUCT", 134, 142], ["Luc", "GENE_OR_GENE_PRODUCT", 145, 148], ["IRF3", "GENE_OR_GENE_PRODUCT", 153, 157], ["pNF-\u03baB", "GENE_OR_GENE_PRODUCT", 159, 165], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 174, 179], ["pAP-1", "GENE_OR_GENE_PRODUCT", 185, 190], ["AP-1", "GENE_OR_GENE_PRODUCT", 199, 203], ["luciferase", "GENE_OR_GENE_PRODUCT", 242, 252], ["phRL", "GENE_OR_GENE_PRODUCT", 263, 267], ["Promega", "ORGANISM", 272, 279], ["luciferase reporter plasmid", "DNA", 84, 111], ["p125", "DNA", 113, 117], ["Luc for IFN-\u03b2, (PRDIII-I)4", "DNA", 118, 144], ["Luc", "DNA", 145, 148], ["IRF3", "PROTEIN", 153, 157], ["pNF", "DNA", 159, 162], ["\u03baB", "DNA", 163, 165], ["Luc", "DNA", 166, 169], ["NF-\u03baB", "DNA", 174, 179], ["pAP", "DNA", 185, 188], ["1", "DNA", 189, 190], ["Luc", "DNA", 191, 194], ["AP-1", "DNA", 199, 203], ["Renilla luciferase construct phRL-TK", "DNA", 234, 270], ["expression plasmid", "DNA", 350, 368], ["cells", "TEST", 44, 49], ["luciferase reporter plasmid", "TEST", 84, 111], ["p125", "TEST", 113, 117], ["IFN", "TEST", 126, 129], ["IRF3", "TEST", 153, 157], ["pNF", "TEST", 159, 162], ["NF", "TEST", 174, 176], ["B", "TEST", 178, 179], ["pAP", "TEST", 185, 188], ["AP", "TEST", 199, 201], ["the Renilla luciferase", "TEST", 230, 252], ["phRL", "TEST", 263, 267], ["an internal control", "TREATMENT", 301, 320], ["expression plasmid", "TREATMENT", 350, 368]]], ["Twenty-four hours later, cells were transfected with or without poly(IC) (1.0 \u03bcg).", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["cells", "PROBLEM", 25, 30]]], ["Luciferase activities were measured 12 h after poly(IC) transfection.", [["Luciferase activities", "TEST", 0, 21], ["poly(IC) transfection", "TREATMENT", 47, 68]]], ["In selected experiments, cells were infected or mock-infected with PRRSV before cotransfection of reporter plasmid and expression plasmid.", [["cells", "ANATOMY", 25, 30], ["plasmid", "ANATOMY", 107, 114], ["plasmid", "ANATOMY", 130, 137], ["cells", "CELL", 25, 30], ["PRRSV", "ORGANISM", 67, 72], ["reporter plasmid", "DNA", 98, 114], ["expression plasmid", "DNA", 119, 137], ["PRRSV", "SPECIES", 67, 72], ["PRRSV", "TREATMENT", 67, 72], ["reporter plasmid", "TREATMENT", 98, 114], ["expression plasmid", "TREATMENT", 119, 137]]], ["In all experiments, cell extracts were prepared by triple freeze\u2013thaw cycles and luciferase activity was measured using a dual-luciferase assay system (Promega) and a luminometer (Turner BioSystems, Inc. Sunnyvale, CA).", [["cell extracts", "ANATOMY", 20, 33], ["cell extracts", "ORGANISM_SUBSTANCE", 20, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 81, 91], ["luciferase", "GENE_OR_GENE_PRODUCT", 127, 137], ["luciferase", "PROTEIN", 81, 91], ["cell extracts", "TREATMENT", 20, 33], ["triple freeze\u2013thaw cycles", "TREATMENT", 51, 76], ["luciferase activity", "TEST", 81, 100], ["a dual-luciferase assay system", "TREATMENT", 120, 150], ["a luminometer (Turner BioSystems", "TREATMENT", 165, 197]]], ["Data represent relative firefly luciferase activity normalized to Renilla luciferase activity.IRF3 nuclear translocation assay ::: Materials and methodsMARC-145 cells were grown to confluency in six-well plates.", [["nuclear", "ANATOMY", 99, 106], ["methodsMARC-145 cells", "ANATOMY", 145, 166], ["luciferase", "GENE_OR_GENE_PRODUCT", 32, 42], ["Renilla", "GENE_OR_GENE_PRODUCT", 66, 73], ["luciferase", "GENE_OR_GENE_PRODUCT", 74, 84], ["IRF3", "GENE_OR_GENE_PRODUCT", 94, 98], ["methodsMARC-145 cells", "CELL", 145, 166], ["luciferase", "PROTEIN", 32, 42], ["luciferase", "PROTEIN", 74, 84], ["IRF3", "PROTEIN", 94, 98], ["methodsMARC-145 cells", "CELL_LINE", 145, 166], ["relative firefly luciferase activity", "PROBLEM", 15, 51], ["IRF3 nuclear translocation assay", "TEST", 94, 126], ["Materials", "TEST", 131, 140], ["methodsMARC-145 cells", "TREATMENT", 145, 166], ["firefly luciferase", "OBSERVATION", 24, 42], ["145 cells", "OBSERVATION_MODIFIER", 157, 166], ["confluency", "OBSERVATION_MODIFIER", 181, 191]]], ["After transfection with 2.0 \u03bcg of IRF3-GFP fusion expression construct per well, cells were mock-infected or infected with PRRSV at a 0.1 multiplicity of infection (MOI).", [["cells", "ANATOMY", 81, 86], ["infection", "DISEASE", 154, 163], ["IRF3", "GENE_OR_GENE_PRODUCT", 34, 38], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 81, 86], ["PRRSV", "ORGANISM", 123, 128], ["IRF3", "PROTEIN", 34, 38], ["GFP fusion expression construct", "DNA", 39, 70], ["PRRSV", "SPECIES", 123, 128], ["transfection", "TEST", 6, 18], ["IRF3-GFP fusion expression construct", "TREATMENT", 34, 70], ["PRRSV", "PROBLEM", 123, 128], ["infection", "PROBLEM", 154, 163], ["infection", "OBSERVATION", 154, 163]]], ["Twelve hours postinfection, cells were transfected with 2.0 \u03bcg of poly(IC) or left untransfected.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 66, 74], ["poly(IC)", "TREATMENT", 66, 74], ["left", "ANATOMY_MODIFIER", 78, 82], ["untransfected", "OBSERVATION", 83, 96]]], ["Twelve hours later, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and stained with 4\u2032,6-diamidino-2-phenylindole-dihydrochloride (DAPI) (Invitrogen) to detect nuclei.", [["cells", "ANATOMY", 20, 25], ["nuclei", "ANATOMY", 194, 200], ["Triton X-100", "CHEMICAL", 87, 99], ["4\u2032,6-diamidino-2-phenylindole-dihydrochloride", "CHEMICAL", 118, 163], ["DAPI", "CHEMICAL", 165, 169], ["paraformaldehyde", "CHEMICAL", 45, 61], ["4\u2032,6-diamidino-2-phenylindole-dihydrochloride", "CHEMICAL", 118, 163], ["DAPI", "CHEMICAL", 165, 169], ["cells", "CELL", 20, 25], ["paraformaldehyde", "SIMPLE_CHEMICAL", 45, 61], ["Triton X-100", "SIMPLE_CHEMICAL", 87, 99], ["4\u2032,6-diamidino-2-phenylindole-dihydrochloride", "SIMPLE_CHEMICAL", 118, 163], ["DAPI", "SIMPLE_CHEMICAL", 165, 169], ["Invitrogen", "SIMPLE_CHEMICAL", 172, 182], ["nuclei", "CELLULAR_COMPONENT", 194, 200], ["cells", "TEST", 20, 25], ["4% paraformaldehyde", "TREATMENT", 42, 61], ["diamidino", "TREATMENT", 123, 132], ["phenylindole", "TREATMENT", 135, 147], ["dihydrochloride", "TREATMENT", 148, 163], ["nuclei", "ANATOMY", 194, 200]]], ["Fluorescence was examined by using a Zeiss LSM 510 Meta confocal microscope.Statistical analysis ::: Materials and methodsStudent's t-test was used to determine statistical significance and P-values of <0.05 were considered statistically significant.PRRSV infection fails to activate IFN-\u03b2 and interrupts poly(IC)-mediated IFN-\u03b2 induction ::: ResultPrevious work has showed that PRRSV infection cannot induce IFN-\u03b2 expression, as revealed by real-time RT-PCR and IFN-\u03b2 bioassasy (Miller et al., 2004, Murtaugh et al., 2002).", [["PRRSV infection", "DISEASE", 250, 265], ["PRRSV infection", "DISEASE", 379, 394], ["PRRSV", "ORGANISM", 250, 255], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 284, 289], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 305, 313], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 323, 328], ["PRRSV", "ORGANISM", 379, 384], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 409, 414], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 463, 468], ["IFN", "PROTEIN", 284, 287], ["\u03b2", "PROTEIN", 288, 289], ["IFN", "PROTEIN", 323, 326], ["\u03b2", "PROTEIN", 327, 328], ["IFN", "PROTEIN", 409, 412], ["\u03b2", "PROTEIN", 413, 414], ["IFN", "PROTEIN", 463, 466], ["PRRSV", "SPECIES", 250, 255], ["PRRSV", "SPECIES", 250, 255], ["PRRSV", "SPECIES", 379, 384], ["methodsStudent's t-test", "TEST", 115, 138], ["P-values", "TEST", 190, 198], ["PRRSV infection", "PROBLEM", 250, 265], ["IFN", "TEST", 284, 287], ["PRRSV infection", "PROBLEM", 379, 394], ["IFN", "TEST", 409, 412], ["PCR", "TEST", 455, 458], ["IFN", "TEST", 463, 466], ["infection", "OBSERVATION", 256, 265], ["PRRSV infection", "OBSERVATION", 379, 394]]], ["In this study, we used IFN-\u03b2 promoter luciferase reporter system, a sensitive method used extensively in studying IFN signaling pathway, to analyze IFN-\u03b2 expression after PRRSV infection.", [["PRRSV infection", "DISEASE", 171, 186], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 23, 28], ["luciferase", "GENE_OR_GENE_PRODUCT", 38, 48], ["IFN", "GENE_OR_GENE_PRODUCT", 114, 117], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 148, 153], ["PRRSV", "ORGANISM", 171, 176], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 114, 117], ["IFN", "PROTEIN", 148, 151], ["\u03b2", "PROTEIN", 152, 153], ["PRRSV", "SPECIES", 171, 176], ["this study", "TEST", 3, 13], ["IFN", "TREATMENT", 23, 26], ["PRRSV infection", "PROBLEM", 171, 186], ["infection", "OBSERVATION", 177, 186]]], ["MARC-145 cells were cotransfected with p125-Luc and phRL-TK, followed by mock-infected or infected with PRRSV at different MOIs (1.0 and 0.1).", [["MARC-145 cells", "ANATOMY", 0, 14], ["MARC-145 cells", "CELL", 0, 14], ["p125", "GENE_OR_GENE_PRODUCT", 39, 43], ["Luc", "GENE_OR_GENE_PRODUCT", 44, 47], ["phRL-TK", "GENE_OR_GENE_PRODUCT", 52, 59], ["PRRSV", "ORGANISM", 104, 109], ["MARC-145 cells", "CELL_LINE", 0, 14], ["p125-Luc and phRL-TK", "DNA", 39, 59], ["PRRSV", "SPECIES", 104, 109], ["p125", "TEST", 39, 43], ["phRL", "TEST", 52, 56], ["PRRSV", "PROBLEM", 104, 109], ["145 cells", "OBSERVATION_MODIFIER", 5, 14], ["TK", "ANATOMY", 57, 59], ["infected", "OBSERVATION", 90, 98]]], ["Transfection with poly(IC) was used as positive control to test whether MARC-145 can recognize dsRNA to activate IFN-\u03b2 promoter activity.", [["poly", "CHEMICAL", 18, 22], ["MARC-145", "CHEMICAL", 72, 80], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 18, 26], ["MARC-145", "GENE_OR_GENE_PRODUCT", 72, 80], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 113, 118], ["MARC", "PROTEIN", 72, 76], ["IFN", "PROTEIN", 113, 116], ["\u03b2 promoter", "DNA", 117, 127], ["Transfection with poly(IC)", "TREATMENT", 0, 26]]], ["As shown in Fig. 1A, IFN-\u03b2 promoter-driven luciferase activity was barely detectable in PRRSV-infected cells in comparison to a strong reporter signal in cells transfected with poly(IC), indicating that PRRSV infection failed to activate IFN-\u03b2 promoter activity.", [["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 154, 159], ["PRRSV infection", "DISEASE", 203, 218], ["1A", "GENE_OR_GENE_PRODUCT", 17, 19], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 21, 26], ["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["PRRSV", "ORGANISM", 88, 93], ["cells", "CELL", 103, 108], ["cells", "CELL", 154, 159], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 177, 185], ["PRRSV", "ORGANISM", 203, 208], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 238, 243], ["IFN-\u03b2 promoter", "DNA", 21, 35], ["luciferase", "PROTEIN", 43, 53], ["PRRSV-infected cells", "CELL_LINE", 88, 108], ["IFN", "PROTEIN", 238, 241], ["\u03b2 promoter", "DNA", 242, 252], ["PRRSV", "SPECIES", 88, 93], ["PRRSV", "SPECIES", 203, 208], ["IFN-\u03b2 promoter", "TREATMENT", 21, 35], ["infected cells", "PROBLEM", 94, 108], ["a strong reporter signal in cells", "PROBLEM", 126, 159], ["poly(IC)", "TREATMENT", 177, 185], ["PRRSV infection", "PROBLEM", 203, 218], ["Fig", "OBSERVATION", 12, 15], ["infected cells", "OBSERVATION", 94, 108], ["PRRSV infection", "OBSERVATION", 203, 218]]], ["To support this result, the expression of IFN-\u03b2 mRNA was analyzed by semi-quantitative RT-PCR at different time points after PRRSV infection.", [["PRRSV infection", "DISEASE", 125, 140], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 42, 47], ["PRRSV", "ORGANISM", 125, 130], ["IFN-\u03b2 mRNA", "RNA", 42, 52], ["PRRSV", "SPECIES", 125, 130], ["IFN", "PROBLEM", 42, 45], ["PCR", "TEST", 90, 93], ["PRRSV infection", "PROBLEM", 125, 140], ["infection", "OBSERVATION", 131, 140]]], ["There was no significant change in the level of IFN-\u03b2 mRNA expression in the cell extracts at the times indicated after PRRSV infection (Fig. 1B).", [["cell extracts", "ANATOMY", 77, 90], ["PRRSV infection", "DISEASE", 120, 135], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["cell extracts", "ORGANISM_SUBSTANCE", 77, 90], ["PRRSV", "ORGANISM", 120, 125], ["IFN-\u03b2 mRNA", "RNA", 48, 58], ["PRRSV", "SPECIES", 120, 125], ["significant change", "PROBLEM", 13, 31], ["IFN", "TREATMENT", 48, 51], ["the cell extracts", "TREATMENT", 73, 90], ["PRRSV infection", "PROBLEM", 120, 135], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["change", "OBSERVATION", 25, 31], ["infection", "OBSERVATION", 126, 135]]], ["Consistent with the result of IFN-\u03b2 promoter-driven luciferase reporter assay, an increased level of IFN-\u03b2 mRNA expression was observed in cells transfected with poly(IC).PRRSV infection fails to activate IFN-\u03b2 and interrupts poly(IC)-mediated IFN-\u03b2 induction ::: ResultIn order to examine whether PRRSV inhibits dsRNA-induced IFN-\u03b2 promoter activity, mock- and PRRSV-infected MARC-145 cells were transfected with poly(IC) and IFN-\u03b2 promoter activity was analyzed.", [["cells", "ANATOMY", 139, 144], ["MARC-145 cells", "ANATOMY", 377, 391], ["PRRSV infection", "DISEASE", 171, 186], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 30, 35], ["luciferase", "GENE_OR_GENE_PRODUCT", 52, 62], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 101, 106], ["cells", "CELL", 139, 144], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 162, 170], ["PRRSV", "ORGANISM", 171, 176], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 205, 210], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 226, 234], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 244, 249], ["PRRSV", "ORGANISM", 298, 303], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 327, 332], ["PRRSV", "ORGANISM", 362, 367], ["MARC-145 cells", "CELL", 377, 391], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 414, 422], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 427, 432], ["IFN-\u03b2 promoter", "DNA", 30, 44], ["luciferase", "PROTEIN", 52, 62], ["IFN-\u03b2 mRNA", "RNA", 101, 111], ["IFN", "PROTEIN", 205, 208], ["\u03b2", "PROTEIN", 209, 210], ["IFN", "PROTEIN", 244, 247], ["\u03b2", "PROTEIN", 248, 249], ["IFN", "PROTEIN", 327, 330], ["\u03b2 promoter", "DNA", 331, 341], ["MARC-145 cells", "CELL_LINE", 377, 391], ["IFN", "PROTEIN", 427, 430], ["PRRSV", "SPECIES", 171, 176], ["PRRSV", "SPECIES", 171, 176], ["PRRSV", "SPECIES", 298, 303], ["PRRSV", "SPECIES", 362, 367], ["MARC-145", "SPECIES", 377, 385], ["IFN-\u03b2 promoter", "TREATMENT", 30, 44], ["luciferase reporter assay", "TEST", 52, 77], ["an increased level of IFN", "PROBLEM", 79, 104], ["mRNA expression", "PROBLEM", 107, 122], ["poly(IC)", "TREATMENT", 162, 170], ["PRRSV infection", "PROBLEM", 171, 186], ["IFN", "TEST", 205, 208], ["PRRSV", "PROBLEM", 298, 303], ["dsRNA", "TEST", 313, 318], ["IFN", "TEST", 327, 330], ["mock", "TEST", 352, 356], ["PRRSV", "PROBLEM", 362, 367], ["poly(IC)", "TREATMENT", 414, 422], ["IFN-\u03b2 promoter activity", "TREATMENT", 427, 450], ["infection", "OBSERVATION", 177, 186]]], ["As shown in Fig. 2, the IFN-\u03b2 promoter was activated 30- to 40-fold when mock-infected cells were transfected with poly(IC), whereas the activation induced by poly(IC) transfection was significantly inhibited in PRRSV-infected cells (Fig. 2).", [["cells", "ANATOMY", 87, 92], ["cells", "ANATOMY", 227, 232], ["poly(IC", "CHEMICAL", 159, 166], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 24, 29], ["cells", "CELL", 87, 92], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 115, 123], ["PRRSV", "ORGANISM", 212, 217], ["cells", "CELL", 227, 232], ["IFN-\u03b2 promoter", "DNA", 24, 38], ["PRRSV-infected cells", "CELL_LINE", 212, 232], ["PRRSV", "SPECIES", 212, 217], ["the IFN-\u03b2 promoter", "TREATMENT", 20, 38], ["infected cells", "PROBLEM", 78, 92], ["poly(IC)", "TREATMENT", 115, 123], ["poly(IC) transfection", "TREATMENT", 159, 180], ["Fig", "OBSERVATION", 12, 15], ["infected cells", "OBSERVATION", 218, 232]]], ["This result was consistent with previous observation that PRRSV infection abolished dsRNA-triggered IFN-\u03b2 expression (Miller et al., 2004).PRRSV activates NF-\u03baB and AP-1, but inhibits dsRNA-induced activation of IRF3 ::: ResultIFN-\u03b2 transcription requires the activation of transcription factors NF-\u03baB, IRF3, and AP-1 and their subsequent binding to the IFN-\u03b2 enhancer (Thanos and Maniatis, 1995).", [["PRRSV infection", "DISEASE", 58, 73], ["PRRSV", "ORGANISM", 58, 63], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 100, 105], ["PRRSV", "ORGANISM", 139, 144], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["AP-1", "GENE_OR_GENE_PRODUCT", 165, 169], ["IRF3", "GENE_OR_GENE_PRODUCT", 212, 216], ["ResultIFN-\u03b2", "GENE_OR_GENE_PRODUCT", 221, 232], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 296, 301], ["IRF3", "GENE_OR_GENE_PRODUCT", 303, 307], ["AP-1", "GENE_OR_GENE_PRODUCT", 313, 317], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 354, 359], ["IFN", "PROTEIN", 100, 103], ["\u03b2", "PROTEIN", 104, 105], ["NF-\u03baB", "PROTEIN", 155, 160], ["AP", "PROTEIN", 165, 167], ["IRF3", "PROTEIN", 212, 216], ["ResultIFN", "PROTEIN", 221, 230], ["\u03b2", "PROTEIN", 231, 232], ["transcription factors", "PROTEIN", 274, 295], ["NF-\u03baB", "PROTEIN", 296, 301], ["IRF3", "PROTEIN", 303, 307], ["AP-1", "PROTEIN", 313, 317], ["IFN-\u03b2 enhancer", "DNA", 354, 368], ["PRRSV", "SPECIES", 58, 63], ["PRRSV", "SPECIES", 139, 144], ["PRRSV infection", "PROBLEM", 58, 73], ["dsRNA", "PROBLEM", 84, 89], ["PRRSV activates NF", "TEST", 139, 157], ["dsRNA", "PROBLEM", 184, 189], ["transcription factors", "TEST", 274, 295], ["NF", "TEST", 296, 298], ["IRF3", "TEST", 303, 307], ["AP", "TEST", 313, 315], ["consistent with", "UNCERTAINTY", 16, 31], ["infection", "OBSERVATION", 64, 73]]], ["In order to identify the transcription factor which is associated with the suppression of IFN-\u03b2 promoter after PRRSV infection, we measured the activation of NF-\u03baB, IRF3 and AP-1 after PRRSV infection.", [["PRRSV infection", "DISEASE", 111, 126], ["PRRSV infection", "DISEASE", 185, 200], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["PRRSV", "ORGANISM", 111, 116], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 158, 163], ["IRF3", "GENE_OR_GENE_PRODUCT", 165, 169], ["AP-1", "GENE_OR_GENE_PRODUCT", 174, 178], ["PRRSV", "ORGANISM", 185, 190], ["transcription factor", "PROTEIN", 25, 45], ["IFN-\u03b2 promoter", "DNA", 90, 104], ["NF-\u03baB", "PROTEIN", 158, 163], ["IRF3", "PROTEIN", 165, 169], ["AP", "PROTEIN", 174, 176], ["PRRSV", "SPECIES", 111, 116], ["PRRSV", "SPECIES", 185, 190], ["the transcription factor", "PROBLEM", 21, 45], ["IFN-\u03b2 promoter", "TREATMENT", 90, 104], ["PRRSV infection", "PROBLEM", 111, 126], ["NF", "TEST", 158, 160], ["AP", "TEST", 174, 176], ["PRRSV infection", "PROBLEM", 185, 200], ["infection", "OBSERVATION", 191, 200]]], ["As shown in Fig. 3A, PRRSV infection alone elevated NF-\u03baB-dependent reporter gene expression, as previously reported (Lee and Kleiboeker, 2005).", [["PRRSV infection", "DISEASE", 21, 36], ["3A", "GENE_OR_GENE_PRODUCT", 17, 19], ["PRRSV", "ORGANISM", 21, 26], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["NF-\u03baB", "PROTEIN", 52, 57], ["reporter gene", "DNA", 68, 81], ["PRRSV", "SPECIES", 21, 26], ["PRRSV infection", "PROBLEM", 21, 36], ["elevated NF", "PROBLEM", 43, 54], ["Fig", "OBSERVATION", 12, 15], ["PRRSV", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 27, 36], ["gene expression", "OBSERVATION", 77, 92]]], ["Similarly, PRRSV infection alone also increased AP-1-dependent reporter gene expression (Fig. 3B).", [["PRRSV infection", "DISEASE", 11, 26], ["PRRSV", "ORGANISM", 11, 16], ["AP-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["AP", "PROTEIN", 48, 50], ["reporter gene", "DNA", 63, 76], ["PRRSV", "SPECIES", 11, 16], ["PRRSV infection", "PROBLEM", 11, 26], ["PRRSV", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["However, PRRSV did not alter IRF3-dependent reporter gene expression (Fig. 3C).", [["PRRSV", "ORGANISM", 9, 14], ["IRF3", "GENE_OR_GENE_PRODUCT", 29, 33], ["IRF3", "PROTEIN", 29, 33], ["reporter gene", "DNA", 44, 57], ["PRRSV", "SPECIES", 9, 14], ["PRRSV", "PROBLEM", 9, 14]]], ["Again, PRRSV abrogated poly(IC)-induced expression of IRF3-dependent reporter gene.", [["poly(IC", "CHEMICAL", 23, 30], ["PRRSV", "ORGANISM", 7, 12], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 23, 31], ["IRF3", "GENE_OR_GENE_PRODUCT", 54, 58], ["IRF3-dependent reporter gene", "DNA", 54, 82], ["PRRSV", "SPECIES", 7, 12], ["IRF3", "OBSERVATION", 54, 58]]], ["Taken together, PRRSV infection activated NF-\u03baB and AP-1, but did not changed IRF3 transcriptional activity.", [["infection", "DISEASE", 22, 31], ["PRRSV", "ORGANISM", 16, 21], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 42, 47], ["AP-1", "GENE_OR_GENE_PRODUCT", 52, 56], ["IRF3", "GENE_OR_GENE_PRODUCT", 78, 82], ["NF-\u03baB", "PROTEIN", 42, 47], ["AP", "PROTEIN", 52, 54], ["IRF3", "PROTEIN", 78, 82], ["PRRSV", "SPECIES", 16, 21], ["PRRSV infection", "PROBLEM", 16, 31], ["NF", "TEST", 42, 44], ["AP", "TEST", 52, 54], ["infection", "OBSERVATION", 22, 31], ["IRF3", "OBSERVATION", 78, 82], ["transcriptional activity", "OBSERVATION", 83, 107]]], ["In addition, PRRSV nullified dsRNA-induced expression of IRF3-dependent reporter gene.", [["PRRSV", "ORGANISM", 13, 18], ["IRF3", "GENE_OR_GENE_PRODUCT", 57, 61], ["IRF3-dependent reporter gene", "DNA", 57, 85], ["PRRSV", "SPECIES", 13, 18], ["PRRSV nullified dsRNA", "TREATMENT", 13, 34]]], ["This observation suggests that PRRSV suppresses IFN-\u03b2 transcription by interfering with IRF3 activity.PRRSV activates NF-\u03baB and AP-1, but inhibits dsRNA-induced activation of IRF3 ::: ResultIRF3, a cytoplasmic protein, migrates to the nucleus and binds to the PRDIII and PRDI sites of IFN-\u03b2 promoter to initiate IFN-\u03b2 transcription upon viral infection (Fitzgerald et al., 2003).", [["cytoplasmic", "ANATOMY", 198, 209], ["nucleus", "ANATOMY", 235, 242], ["viral infection", "DISEASE", 337, 352], ["PRRSV", "ORGANISM", 31, 36], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["IRF3", "GENE_OR_GENE_PRODUCT", 88, 92], ["PRRSV", "ORGANISM", 102, 107], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 118, 123], ["AP-1", "GENE_OR_GENE_PRODUCT", 128, 132], ["IRF3", "GENE_OR_GENE_PRODUCT", 175, 179], ["ResultIRF3", "GENE_OR_GENE_PRODUCT", 184, 194], ["cytoplasmic", "ORGANISM_SUBSTANCE", 198, 209], ["nucleus", "CELLULAR_COMPONENT", 235, 242], ["PRDIII", "GENE_OR_GENE_PRODUCT", 260, 266], ["PRDI", "GENE_OR_GENE_PRODUCT", 271, 275], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 285, 290], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 312, 317], ["IFN", "PROTEIN", 48, 51], ["\u03b2", "PROTEIN", 52, 53], ["IRF3", "PROTEIN", 88, 92], ["NF-\u03baB", "PROTEIN", 118, 123], ["AP", "PROTEIN", 128, 130], ["IRF3", "PROTEIN", 175, 179], ["ResultIRF3", "PROTEIN", 184, 194], ["cytoplasmic protein", "PROTEIN", 198, 217], ["PRDIII and PRDI sites", "DNA", 260, 281], ["IFN-\u03b2 promoter", "DNA", 285, 299], ["IFN", "PROTEIN", 312, 315], ["\u03b2", "PROTEIN", 316, 317], ["PRRSV", "SPECIES", 31, 36], ["PRRSV", "SPECIES", 102, 107], ["This observation", "TEST", 0, 16], ["PRRSV", "PROBLEM", 31, 36], ["PRRSV activates NF", "TEST", 102, 120], ["AP", "TEST", 128, 130], ["a cytoplasmic protein", "PROBLEM", 196, 217], ["IFN-\u03b2 promoter", "TREATMENT", 285, 299], ["IFN", "TREATMENT", 312, 315], ["viral infection", "PROBLEM", 337, 352], ["IRF3 activity", "OBSERVATION", 88, 101], ["cytoplasmic protein", "OBSERVATION", 198, 217], ["nucleus", "ANATOMY", 235, 242], ["viral infection", "OBSERVATION", 337, 352]]], ["To determine whether PRRSV prevents IRF3 migration from the cytoplasm to the nucleus, MARC-145 cells were transiently transfected with IRF3-GFP fusion expression construct and the subcellular localization of the fusion protein was analyzed using confocal microscopy.", [["cytoplasm", "ANATOMY", 60, 69], ["nucleus", "ANATOMY", 77, 84], ["MARC-145 cells", "ANATOMY", 86, 100], ["subcellular", "ANATOMY", 180, 191], ["PRRSV", "ORGANISM", 21, 26], ["IRF3", "GENE_OR_GENE_PRODUCT", 36, 40], ["cytoplasm", "ORGANISM_SUBSTANCE", 60, 69], ["nucleus", "CELLULAR_COMPONENT", 77, 84], ["MARC-145 cells", "CELL", 86, 100], ["IRF3", "GENE_OR_GENE_PRODUCT", 135, 139], ["GFP", "GENE_OR_GENE_PRODUCT", 140, 143], ["IRF3", "PROTEIN", 36, 40], ["MARC-145 cells", "CELL_LINE", 86, 100], ["IRF3", "PROTEIN", 135, 139], ["GFP fusion expression construct", "DNA", 140, 171], ["fusion protein", "PROTEIN", 212, 226], ["PRRSV", "SPECIES", 21, 26], ["PRRSV", "PROBLEM", 21, 26], ["IRF3 migration", "PROBLEM", 36, 50], ["IRF3-GFP fusion expression construct", "TREATMENT", 135, 171], ["the fusion protein", "TEST", 208, 226], ["confocal microscopy", "TEST", 246, 265], ["IRF3 migration", "OBSERVATION", 36, 50], ["nucleus", "ANATOMY", 77, 84]]], ["As shown in Fig. 4A, IRF3-GFP was located exclusively in the cytoplasm in mock-infected MARC-145 cells, but it rapidly translocated to the nucleus when those cells were transfected with poly(IC) (Fig. 4B).", [["cytoplasm", "ANATOMY", 61, 70], ["MARC-145 cells", "ANATOMY", 88, 102], ["nucleus", "ANATOMY", 139, 146], ["cells", "ANATOMY", 158, 163], ["4A", "GENE_OR_GENE_PRODUCT", 17, 19], ["IRF3", "GENE_OR_GENE_PRODUCT", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["cytoplasm", "ORGANISM_SUBSTANCE", 61, 70], ["MARC-145 cells", "CELL", 88, 102], ["nucleus", "CELLULAR_COMPONENT", 139, 146], ["cells", "CELL", 158, 163], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 186, 194], ["IRF3", "PROTEIN", 21, 25], ["GFP", "PROTEIN", 26, 29], ["MARC-145 cells", "CELL_LINE", 88, 102], ["MARC-145", "SPECIES", 88, 96], ["IRF3-GFP", "TEST", 21, 29], ["poly(IC", "TREATMENT", 186, 193], ["Fig", "OBSERVATION", 12, 15], ["infected MARC", "OBSERVATION", 79, 92], ["145 cells", "OBSERVATION_MODIFIER", 93, 102], ["nucleus", "ANATOMY_MODIFIER", 139, 146]]], ["In contrast, nuclear IRF3-GFP translocation did not occur in PRRSV-infected cells (Fig. 4C).", [["nuclear", "ANATOMY", 13, 20], ["cells", "ANATOMY", 76, 81], ["nuclear", "CELLULAR_COMPONENT", 13, 20], ["IRF3", "GENE_OR_GENE_PRODUCT", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["PRRSV", "ORGANISM", 61, 66], ["cells", "CELL", 76, 81], ["IRF3", "PROTEIN", 21, 25], ["GFP", "PROTEIN", 26, 29], ["PRRSV-infected cells", "CELL_TYPE", 61, 81], ["PRRSV", "SPECIES", 61, 66], ["nuclear IRF3", "TEST", 13, 25], ["GFP translocation", "PROBLEM", 26, 43], ["IRF3", "OBSERVATION", 21, 25], ["infected cells", "OBSERVATION", 67, 81]]], ["Moreover, PRRSV prevented the nuclear translocation of IRF3-GFP induced by poly(IC) (Fig. 4D).PRRSV interrupts the dsRNA-signaling pathway upstream of IRF3 ::: ResultTo pinpoint the target PRRSV acted upon to block the intracellular dsRNA-mediated signaling pathway, we first investigated whether PRRSV inhibits the activity of IRF3 directly.", [["nuclear", "ANATOMY", 30, 37], ["intracellular", "ANATOMY", 219, 232], ["PRRSV", "ORGANISM", 10, 15], ["nuclear", "CELLULAR_COMPONENT", 30, 37], ["IRF3", "GENE_OR_GENE_PRODUCT", 55, 59], ["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["PRRSV", "ORGANISM", 94, 99], ["IRF3", "GENE_OR_GENE_PRODUCT", 151, 155], ["PRRSV", "ORGANISM", 189, 194], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 219, 232], ["PRRSV", "ORGANISM", 297, 302], ["IRF3", "GENE_OR_GENE_PRODUCT", 328, 332], ["IRF3", "PROTEIN", 55, 59], ["GFP", "PROTEIN", 60, 63], ["IRF3", "PROTEIN", 151, 155], ["IRF3", "PROTEIN", 328, 332], ["PRRSV", "SPECIES", 10, 15], ["PRRSV", "SPECIES", 94, 99], ["PRRSV", "SPECIES", 189, 194], ["PRRSV", "SPECIES", 297, 302], ["PRRSV", "PROBLEM", 10, 15], ["PRRSV", "PROBLEM", 94, 99], ["the intracellular dsRNA", "TREATMENT", 215, 238], ["PRRSV", "PROBLEM", 297, 302]]], ["As shown in Fig. 5A, transfection of wild-type IRF3 activated the IFN-\u03b2 promoter 4.5- and 4.3-fold in mock- and PRRSV-infected MARC-145 cells, respectively, suggesting that PRRSV infection did not directly inhibit the activity of IRF3.", [["MARC-145 cells", "ANATOMY", 127, 141], ["PRRSV infection", "DISEASE", 173, 188], ["IRF3", "GENE_OR_GENE_PRODUCT", 47, 51], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 66, 71], ["PRRSV", "ORGANISM", 112, 117], ["MARC-145 cells", "CELL", 127, 141], ["PRRSV", "ORGANISM", 173, 178], ["IRF3", "GENE_OR_GENE_PRODUCT", 230, 234], ["IRF3", "PROTEIN", 47, 51], ["IFN-\u03b2 promoter", "DNA", 66, 80], ["MARC-145 cells", "CELL_LINE", 127, 141], ["IRF3", "PROTEIN", 230, 234], ["PRRSV", "SPECIES", 112, 117], ["MARC-145", "SPECIES", 127, 135], ["PRRSV", "SPECIES", 173, 178], ["the IFN", "TEST", 62, 69], ["promoter", "TEST", 72, 80], ["PRRSV", "PROBLEM", 112, 117], ["PRRSV infection", "PROBLEM", 173, 188], ["145 cells", "OBSERVATION_MODIFIER", 132, 141], ["PRRSV infection", "OBSERVATION", 173, 188]]], ["Similarly, transfection of IRF3(5D), a constitutively active mutant of IRF3, also increased IFN-\u03b2 promoter activity comparably in mock-infected and PRRSV-infected cells (Fig. 5A), at a much higher level, i.e., 20- and 19-fold, respectively.", [["cells", "ANATOMY", 163, 168], ["IRF3(5D)", "GENE_OR_GENE_PRODUCT", 27, 35], ["IRF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 92, 97], ["PRRSV", "ORGANISM", 148, 153], ["cells", "CELL", 163, 168], ["Fig. 5A", "CELL", 170, 177], ["IRF3(5D)", "PROTEIN", 27, 35], ["IRF3", "PROTEIN", 71, 75], ["IFN", "PROTEIN", 92, 95], ["PRRSV-infected cells", "CELL_TYPE", 148, 168], ["PRRSV", "SPECIES", 148, 153], ["IRF3", "PROBLEM", 27, 31], ["a constitutively active mutant of IRF3", "PROBLEM", 37, 75], ["increased IFN", "PROBLEM", 82, 95], ["infected and PRRSV-infected cells", "PROBLEM", 135, 168], ["IRF3", "OBSERVATION", 27, 31], ["active", "OBSERVATION_MODIFIER", 54, 60], ["IRF3", "OBSERVATION", 71, 75], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["infected", "OBSERVATION_MODIFIER", 135, 143], ["infected cells", "OBSERVATION", 154, 168]]], ["These results suggested that signaling components downstream of IRF3 were intact in the PRRSV-infected cells.PRRSV interrupts the dsRNA-signaling pathway upstream of IRF3 ::: ResultWe then investigated whether PRRSV infection diminished dsRNA-triggered IFN-\u03b2 promoter activity in cells overexpressing IRF3 or IRF3(5D).", [["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 280, 285], ["PRRSV infection", "DISEASE", 210, 225], ["IRF3", "GENE_OR_GENE_PRODUCT", 64, 68], ["PRRSV", "ORGANISM", 88, 93], ["cells", "CELL", 103, 108], ["PRRSV", "ORGANISM", 109, 114], ["IRF3", "GENE_OR_GENE_PRODUCT", 166, 170], ["PRRSV", "ORGANISM", 210, 215], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 253, 258], ["cells", "CELL", 280, 285], ["IRF3", "GENE_OR_GENE_PRODUCT", 301, 305], ["IRF3", "GENE_OR_GENE_PRODUCT", 309, 313], ["IRF3", "PROTEIN", 64, 68], ["PRRSV-infected cells", "CELL_TYPE", 88, 108], ["IRF3", "PROTEIN", 166, 170], ["IFN", "PROTEIN", 253, 256], ["\u03b2 promoter", "DNA", 257, 267], ["IRF3", "PROTEIN", 301, 305], ["IRF3(5D)", "PROTEIN", 309, 317], ["PRRSV", "SPECIES", 88, 93], ["PRRSV", "SPECIES", 109, 114], ["PRRSV", "SPECIES", 210, 215], ["signaling components downstream of IRF3", "PROBLEM", 29, 68], ["PRRSV", "PROBLEM", 109, 114], ["PRRSV infection diminished dsRNA", "PROBLEM", 210, 242], ["IFN", "PROBLEM", 253, 256], ["components", "OBSERVATION_MODIFIER", 39, 49], ["downstream", "OBSERVATION_MODIFIER", 50, 60], ["IRF3", "OBSERVATION_MODIFIER", 64, 68], ["intact", "OBSERVATION_MODIFIER", 74, 80], ["infected cells", "OBSERVATION", 94, 108], ["infection", "OBSERVATION", 216, 225]]], ["As shown in Fig. 5A, poly(IC) transfection further enhanced IFN-\u03b2 promoter activity in the mock-infected cells transfected with wild-type or constitutively active IRF3.", [["cells", "ANATOMY", 105, 110], ["5A, poly(IC", "CHEMICAL", 17, 28], ["poly(IC", "SIMPLE_CHEMICAL", 21, 28], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 60, 65], ["cells", "CELL", 105, 110], ["IRF3", "GENE_OR_GENE_PRODUCT", 163, 167], ["IFN", "PROTEIN", 60, 63], ["\u03b2 promoter", "DNA", 64, 74], ["mock-infected cells", "CELL_LINE", 91, 110], ["IRF3", "PROTEIN", 163, 167], ["poly(IC) transfection further enhanced IFN", "TREATMENT", 21, 63], ["infected cells", "PROBLEM", 96, 110], ["active", "OBSERVATION_MODIFIER", 156, 162], ["IRF3", "OBSERVATION", 163, 167]]], ["This enhancement, however, was significantly inhibited by PRRSV infection performed prior to poly(IC) transfection.", [["PRRSV infection", "DISEASE", 58, 73], ["poly", "CHEMICAL", 93, 97], ["PRRSV", "ORGANISM", 58, 63], ["PRRSV", "SPECIES", 58, 63], ["PRRSV infection", "PROBLEM", 58, 73], ["poly(IC) transfection", "TREATMENT", 93, 114], ["enhancement", "OBSERVATION_MODIFIER", 5, 16], ["infection", "OBSERVATION", 64, 73]]], ["It appeared that PRRSV repressed dsRNA-mediated signal transduction at the steps upstream of IRF3 proteins in the pathway leading to IFN-\u03b2 production.PRRSV impedes the dsRNA-signaling pathway upstream of TBK1/IKK\u025b ::: ResultTBK1 and IKK\u025b are two related I\u03baB kinase homologs upstream of IRF3, and are essential components for IRF3 activation (Fitzgerald et al., 2003).", [["PRRSV", "ORGANISM", 17, 22], ["dsRNA", "GENE_OR_GENE_PRODUCT", 33, 38], ["IRF3", "GENE_OR_GENE_PRODUCT", 93, 97], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 133, 138], ["PRRSV", "ORGANISM", 150, 155], ["TBK1", "GENE_OR_GENE_PRODUCT", 204, 208], ["IKK", "GENE_OR_GENE_PRODUCT", 209, 212], ["ResultTBK1", "GENE_OR_GENE_PRODUCT", 218, 228], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 233, 237], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 254, 264], ["IRF3", "GENE_OR_GENE_PRODUCT", 286, 290], ["IRF3", "GENE_OR_GENE_PRODUCT", 325, 329], ["IRF3 proteins", "PROTEIN", 93, 106], ["IFN", "PROTEIN", 133, 136], ["\u03b2", "PROTEIN", 137, 138], ["TBK1", "PROTEIN", 204, 208], ["IKK\u025b", "PROTEIN", 209, 213], ["ResultTBK1", "PROTEIN", 218, 228], ["IKK\u025b", "PROTEIN", 233, 237], ["I\u03baB kinase homologs", "PROTEIN", 254, 273], ["IRF3", "PROTEIN", 286, 290], ["IRF3", "PROTEIN", 325, 329], ["PRRSV", "SPECIES", 17, 22], ["PRRSV", "SPECIES", 150, 155], ["PRRSV repressed dsRNA", "PROBLEM", 17, 38], ["IRF3 proteins", "PROBLEM", 93, 106], ["IFN", "PROBLEM", 133, 136], ["TBK1", "TEST", 204, 208], ["ResultTBK1", "TEST", 218, 228], ["IKK", "TEST", 233, 236], ["IRF3", "PROBLEM", 286, 290], ["IRF3 activation", "PROBLEM", 325, 340], ["PRRSV", "OBSERVATION", 17, 22], ["IRF3 proteins", "OBSERVATION", 93, 106], ["dsRNA", "OBSERVATION", 168, 173], ["IRF3", "OBSERVATION", 286, 290]]], ["In order to further analyze the step at which PRRSV interfered with the activation of IRF3, we next investigated whether PRRSV is able to inhibit the activity of the kinases responsible for IRF3 activation.", [["PRRSV", "ORGANISM", 46, 51], ["IRF3", "GENE_OR_GENE_PRODUCT", 86, 90], ["PRRSV", "ORGANISM", 121, 126], ["IRF3", "GENE_OR_GENE_PRODUCT", 190, 194], ["IRF3", "PROTEIN", 86, 90], ["kinases", "PROTEIN", 166, 173], ["IRF3", "PROTEIN", 190, 194], ["PRRSV", "SPECIES", 46, 51], ["PRRSV", "SPECIES", 121, 126], ["IRF3", "TREATMENT", 86, 90], ["PRRSV", "PROBLEM", 121, 126], ["IRF3 activation", "PROBLEM", 190, 205]]], ["Mock-infected and PRRSV-infected cells were cotransfected with a plasmid for expression of IKK\u025b or TBK1 and the IFN-\u03b2 promoter luciferase reporter plasmid, and IFN-\u03b2 promoter activity was examined with or without transfection of poly(IC).", [["cells", "ANATOMY", 33, 38], ["plasmid", "ANATOMY", 65, 72], ["PRRSV", "ORGANISM", 18, 23], ["cells", "CELL", 33, 38], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 91, 95], ["TBK1", "GENE_OR_GENE_PRODUCT", 99, 103], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 112, 117], ["luciferase", "GENE_OR_GENE_PRODUCT", 127, 137], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 160, 165], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 229, 237], ["IKK\u025b", "PROTEIN", 91, 95], ["TBK1", "PROTEIN", 99, 103], ["IFN-\u03b2 promoter luciferase reporter plasmid", "DNA", 112, 154], ["IFN-\u03b2 promoter", "DNA", 160, 174], ["PRRSV", "SPECIES", 18, 23], ["PRRSV", "SPECIES", 18, 23], ["PRRSV", "PROBLEM", 18, 23], ["infected cells", "PROBLEM", 24, 38], ["a plasmid", "TREATMENT", 63, 72], ["IKK", "TEST", 91, 94], ["TBK1", "PROBLEM", 99, 103], ["the IFN", "TREATMENT", 108, 115], ["\u03b2 promoter luciferase reporter plasmid", "TREATMENT", 116, 154], ["IFN", "TREATMENT", 160, 163], ["transfection of poly(IC)", "TREATMENT", 213, 237], ["infected", "OBSERVATION", 5, 13], ["infected cells", "OBSERVATION", 24, 38]]], ["Similar to IRF3, each of the individual kinases activated IFN-\u03b2 promoter in both the mock- and PRRSV-infected cells (Fig. 5B), suggesting that the signaling pathway downstream of TBK1/IKK\u025b was still intact in the PRRSV-infected cells.", [["cells", "ANATOMY", 110, 115], ["cells", "ANATOMY", 228, 233], ["IRF3", "GENE_OR_GENE_PRODUCT", 11, 15], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["PRRSV", "ORGANISM", 95, 100], ["cells", "CELL", 110, 115], ["Fig. 5B", "CELL", 117, 124], ["TBK1", "GENE_OR_GENE_PRODUCT", 179, 183], ["IKK", "GENE_OR_GENE_PRODUCT", 184, 187], ["\u025b", "GENE_OR_GENE_PRODUCT", 187, 188], ["PRRSV", "ORGANISM", 213, 218], ["cells", "CELL", 228, 233], ["IRF3", "PROTEIN", 11, 15], ["IFN-\u03b2 promoter", "DNA", 58, 72], ["infected cells", "CELL_TYPE", 101, 115], ["TBK1", "PROTEIN", 179, 183], ["IKK\u025b", "PROTEIN", 184, 188], ["PRRSV-infected cells", "CELL_TYPE", 213, 233], ["PRRSV", "SPECIES", 95, 100], ["PRRSV", "SPECIES", 213, 218], ["IFN-\u03b2 promoter", "TREATMENT", 58, 72], ["infected cells", "PROBLEM", 101, 115], ["TBK1/IKK\u025b", "TEST", 179, 188], ["IRF3", "OBSERVATION", 11, 15], ["infected cells", "OBSERVATION", 101, 115], ["infected cells", "OBSERVATION", 219, 233]]], ["However, PRRSV significantly inhibited poly(IC)-induced IFN-\u03b2 promoter activation in cells cotransfected with TBK1 or IKK\u025b expression constructs (Fig. 5B).", [["cells", "ANATOMY", 85, 90], ["poly(IC", "CHEMICAL", 39, 46], ["poly(IC)", "CHEMICAL", 39, 47], ["PRRSV", "ORGANISM", 9, 14], ["poly(IC)", "SIMPLE_CHEMICAL", 39, 47], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 56, 61], ["cells", "CELL", 85, 90], ["TBK1", "GENE_OR_GENE_PRODUCT", 110, 114], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 118, 122], ["IFN", "PROTEIN", 56, 59], ["\u03b2 promoter", "DNA", 60, 70], ["TBK1", "PROTEIN", 110, 114], ["IKK\u025b expression constructs", "DNA", 118, 144], ["PRRSV", "SPECIES", 9, 14], ["PRRSV", "PROBLEM", 9, 14], ["IFN-\u03b2 promoter activation in cells cotransfected", "TREATMENT", 56, 104], ["TBK1", "PROBLEM", 110, 114], ["IKK\u025b expression constructs", "TREATMENT", 118, 144]]], ["Results here raised a possibility that PRRSV interfered with targets upstream of the kinases TBK1 and IKK\u025b in the dsRNA-signaling pathway.PRRSV obstructs the IPS-1-mediated IFN-\u03b2 induction ::: ResultTwo distinct signaling pathways, RIG-I and TLR3, have been identified to mediate dsRNA responses.", [["PRRSV", "ORGANISM", 39, 44], ["TBK1", "GENE_OR_GENE_PRODUCT", 93, 97], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 102, 106], ["dsRNA", "GENE_OR_GENE_PRODUCT", 114, 119], ["PRRSV", "ORGANISM", 138, 143], ["IPS-1", "GENE_OR_GENE_PRODUCT", 158, 163], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 173, 178], ["RIG-I", "GENE_OR_GENE_PRODUCT", 232, 237], ["TLR3", "GENE_OR_GENE_PRODUCT", 242, 246], ["kinases", "PROTEIN", 85, 92], ["TBK1", "PROTEIN", 93, 97], ["IKK\u025b", "PROTEIN", 102, 106], ["IFN", "PROTEIN", 173, 176], ["\u03b2", "PROTEIN", 177, 178], ["RIG-I", "PROTEIN", 232, 237], ["TLR3", "PROTEIN", 242, 246], ["PRRSV", "SPECIES", 138, 143], ["PRRSV", "SPECIES", 39, 44], ["PRRSV", "SPECIES", 138, 143], ["PRRSV", "PROBLEM", 39, 44], ["the kinases TBK1", "TEST", 81, 97], ["IKK", "TEST", 102, 105], ["PRRSV obstructs the IPS", "PROBLEM", 138, 161], ["distinct signaling pathways", "PROBLEM", 203, 230], ["kinases TBK1", "OBSERVATION", 85, 97], ["dsRNA", "ANATOMY", 114, 119], ["distinct", "OBSERVATION_MODIFIER", 203, 211], ["signaling pathways", "OBSERVATION", 212, 230]]], ["Both TBK1 and IKK\u025b are components of the pathways (Yamamoto et al., 2002, Yoneyama et al., 2004).", [["TBK1", "GENE_OR_GENE_PRODUCT", 5, 9], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 14, 18], ["TBK1", "PROTEIN", 5, 9], ["IKK\u025b", "PROTEIN", 14, 18], ["TBK1", "OBSERVATION", 5, 9], ["IKK", "OBSERVATION_MODIFIER", 14, 17]]], ["IPS-1, an element lying upstream of TBK1 and IKK\u025b in the RIG-I signaling pathway, is essential for IFN production.", [["IPS-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TBK1", "GENE_OR_GENE_PRODUCT", 36, 40], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 45, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 57, 62], ["IFN", "GENE_OR_GENE_PRODUCT", 99, 102], ["IPS-1", "DNA", 0, 5], ["TBK1", "PROTEIN", 36, 40], ["IKK\u025b", "PROTEIN", 45, 49], ["IFN", "PROTEIN", 99, 102], ["IPS", "TEST", 0, 3], ["TBK1", "PROBLEM", 36, 40], ["IKK", "TEST", 45, 48], ["IFN production", "PROBLEM", 99, 113], ["TBK1", "OBSERVATION", 36, 40], ["essential for", "UNCERTAINTY", 85, 98]]], ["It is likely that PRRSV inhibits IFN-\u03b2 production by suppressing IPS-1.", [["PRRSV", "ORGANISM", 18, 23], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["IPS-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["IFN", "PROTEIN", 33, 36], ["\u03b2", "PROTEIN", 37, 38], ["IPS", "PROTEIN", 65, 68], ["PRRSV", "SPECIES", 18, 23], ["PRRSV", "PROBLEM", 18, 23], ["likely that", "UNCERTAINTY", 6, 17], ["PRRSV", "OBSERVATION", 18, 23]]], ["Hence, an IPS-1 expression plasmid and the IFN-\u03b2 promoter luciferase reporter plasmid were cotransfected into mock-infected or PRRSV-infected MARC-145 cells.", [["MARC-145 cells", "ANATOMY", 142, 156], ["IPS-1", "GENE_OR_GENE_PRODUCT", 10, 15], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 43, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 58, 68], ["PRRSV", "ORGANISM", 127, 132], ["MARC-145 cells", "CELL", 142, 156], ["IPS-1 expression plasmid", "DNA", 10, 34], ["IFN-\u03b2 promoter luciferase reporter plasmid", "DNA", 43, 85], ["MARC-145 cells", "CELL_LINE", 142, 156], ["PRRSV", "SPECIES", 127, 132], ["PRRSV", "SPECIES", 127, 132], ["MARC-145", "SPECIES", 142, 150], ["an IPS", "TEST", 7, 13], ["1 expression plasmid", "TREATMENT", 14, 34], ["the IFN-\u03b2 promoter luciferase reporter plasmid", "TREATMENT", 39, 85], ["PRRSV", "PROBLEM", 127, 132]]], ["In sharp contrast to the effects of IRF3, TBK1, and IKK\u025b transfections (Fig. 5), overexpression of IPS-1 diminished IFN-\u03b2 promoter activity (5.9-fold) in PRRSV-infected cells compared with mock-infected cells (23.6-fold) (Fig. 6A).", [["cells", "ANATOMY", 169, 174], ["cells", "ANATOMY", 203, 208], ["PRRSV-infected", "DISEASE", 154, 168], ["IRF3", "GENE_OR_GENE_PRODUCT", 36, 40], ["TBK1", "GENE_OR_GENE_PRODUCT", 42, 46], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 52, 56], ["IPS-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 121], ["PRRSV", "ORGANISM", 154, 159], ["cells", "CELL", 169, 174], ["cells", "CELL", 203, 208], ["IRF3", "PROTEIN", 36, 40], ["TBK1", "PROTEIN", 42, 46], ["IKK\u025b", "PROTEIN", 52, 56], ["IPS", "PROTEIN", 99, 102], ["IFN-\u03b2 promoter", "DNA", 116, 130], ["PRRSV-infected cells", "CELL_TYPE", 154, 174], ["mock-infected cells", "CELL_TYPE", 189, 208], ["PRRSV", "SPECIES", 154, 159], ["IRF3", "PROBLEM", 36, 40], ["TBK1", "TEST", 42, 46], ["IPS", "TEST", 99, 102], ["diminished IFN", "PROBLEM", 105, 119], ["promoter activity", "TEST", 122, 139], ["PRRSV", "PROBLEM", 154, 159], ["infected cells", "PROBLEM", 160, 174], ["mock", "TEST", 189, 193], ["infected cells", "PROBLEM", 194, 208], ["IRF3", "OBSERVATION", 36, 40], ["infected cells", "OBSERVATION", 160, 174], ["infected cells", "OBSERVATION", 194, 208]]], ["When those cells transfected with poly(IC), IFN-\u03b2 promoter activation was only seen in the mock-infected cells.", [["cells", "ANATOMY", 11, 16], ["cells", "ANATOMY", 105, 110], ["cells", "CELL", 11, 16], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 34, 42], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["cells", "CELL", 105, 110], ["IFN", "PROTEIN", 44, 47], ["mock-infected cells", "CELL_LINE", 91, 110], ["poly(IC)", "TREATMENT", 34, 42], ["IFN-\u03b2 promoter activation", "TREATMENT", 44, 69], ["infected cells", "PROBLEM", 96, 110], ["infected cells", "OBSERVATION", 96, 110]]], ["These results provided evidence that PRRSV suppressed IPS-1 specific induction of IFN-\u03b2 production.", [["PRRSV", "ORGANISM", 37, 42], ["IPS-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 82, 87], ["IPS", "PROTEIN", 54, 57], ["IFN", "PROTEIN", 82, 85], ["\u03b2", "PROTEIN", 86, 87], ["PRRSV", "SPECIES", 37, 42], ["PRRSV suppressed IPS", "TREATMENT", 37, 57], ["IFN", "PROBLEM", 82, 85]]], ["It is highly likely that IPS-1 is the target protein PRRSV acted upon to annihilate the dsRNA-induced IFN-\u03b2 production.PRRSV blocks RIG-I-mediated IFN-\u03b2 induction ::: ResultIPS-1 is an adaptor molecule of RIG-I to induce IFN-\u03b2 production in dsRNA-signaling pathway.", [["IPS-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRRSV", "ORGANISM", 53, 58], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 102, 107], ["PRRSV", "ORGANISM", 119, 124], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 132, 138], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 147, 152], ["ResultIPS-1", "GENE_OR_GENE_PRODUCT", 167, 178], ["RIG-I", "GENE_OR_GENE_PRODUCT", 205, 210], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 221, 226], ["dsRNA", "GENE_OR_GENE_PRODUCT", 241, 246], ["IPS", "PROTEIN", 25, 28], ["IFN", "PROTEIN", 102, 105], ["\u03b2", "PROTEIN", 106, 107], ["IFN", "PROTEIN", 147, 150], ["\u03b2", "PROTEIN", 151, 152], ["ResultIPS", "PROTEIN", 167, 176], ["RIG-I", "PROTEIN", 205, 210], ["IFN", "PROTEIN", 221, 224], ["\u03b2", "PROTEIN", 225, 226], ["PRRSV", "SPECIES", 53, 58], ["PRRSV", "SPECIES", 119, 124], ["IPS", "TEST", 25, 28], ["the target protein PRRSV", "TREATMENT", 34, 58], ["the dsRNA", "PROBLEM", 84, 93], ["IFN", "PROBLEM", 102, 105], ["ResultIPS", "TEST", 167, 176], ["IFN", "PROBLEM", 221, 224], ["highly likely", "UNCERTAINTY", 6, 19]]], ["If IPS-1 is the target for inactivation by PRRSV, the ability of RIG-I to induce IFN-\u03b2 promoter activity in PRRSV-infected cells should also be reduced.", [["cells", "ANATOMY", 123, 128], ["IPS-1", "GENE_OR_GENE_PRODUCT", 3, 8], ["PRRSV", "ORGANISM", 43, 48], ["RIG-I", "GENE_OR_GENE_PRODUCT", 65, 70], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 86], ["PRRSV", "ORGANISM", 108, 113], ["cells", "CELL", 123, 128], ["IPS-1", "DNA", 3, 8], ["RIG-I", "PROTEIN", 65, 70], ["IFN-\u03b2 promoter", "DNA", 81, 95], ["PRRSV-infected cells", "CELL_TYPE", 108, 128], ["PRRSV", "SPECIES", 43, 48], ["PRRSV", "SPECIES", 108, 113], ["IPS", "TEST", 3, 6], ["IFN", "PROBLEM", 81, 84], ["PRRSV", "PROBLEM", 108, 113], ["infected cells", "PROBLEM", 114, 128], ["infected cells", "OBSERVATION", 114, 128], ["reduced", "OBSERVATION_MODIFIER", 144, 151]]], ["To confirm this hypothesis, mock-infected and PRRSV-infected MARC-145 cells were cotransfected with a wild-type RIG-I expression vector and the IFN-\u03b2 promoter luciferase reporter plasmid.", [["MARC-145 cells", "ANATOMY", 61, 75], ["PRRSV", "ORGANISM", 46, 51], ["MARC-145 cells", "CELL", 61, 75], ["RIG-I", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 144, 149], ["luciferase", "GENE_OR_GENE_PRODUCT", 159, 169], ["MARC-145 cells", "CELL_LINE", 61, 75], ["wild-type RIG-I expression vector", "DNA", 102, 135], ["IFN-\u03b2 promoter luciferase reporter plasmid", "DNA", 144, 186], ["PRRSV", "SPECIES", 46, 51], ["PRRSV", "SPECIES", 46, 51], ["MARC-145", "SPECIES", 61, 69], ["this hypothesis", "PROBLEM", 11, 26], ["infected", "PROBLEM", 33, 41], ["PRRSV", "PROBLEM", 46, 51], ["a wild-type RIG-I expression vector", "TREATMENT", 100, 135], ["the IFN-\u03b2 promoter luciferase reporter plasmid", "TREATMENT", 140, 186]]], ["As shown in Fig. 6B, the RIG-I expression did not induce IFN-\u03b2 promoter activity in PRRSV-infected cells, whereas it did induce a 3.6-fold increase in mock-infected cells.", [["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 165, 170], ["RIG-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 57, 62], ["PRRSV", "ORGANISM", 84, 89], ["cells", "CELL", 99, 104], ["cells", "CELL", 165, 170], ["RIG", "PROTEIN", 25, 28], ["IFN", "PROTEIN", 57, 60], ["PRRSV-infected cells", "CELL_TYPE", 84, 104], ["mock-infected cells", "CELL_TYPE", 151, 170], ["PRRSV", "SPECIES", 84, 89], ["IFN", "PROBLEM", 57, 60], ["infected cells", "PROBLEM", 90, 104], ["infected cells", "PROBLEM", 156, 170], ["infected cells", "OBSERVATION", 90, 104], ["infected cells", "OBSERVATION", 156, 170]]], ["Similarly, transfection of a constitutively active mutant of RIG-I (RIG-IN) also increased IFN-\u03b2 promoter activity comparably in mock-infected cells, however RIG-IN expression did not enhance IFN-\u03b2 promoter activity in PRRSV-infected cells (Fig. 6B).", [["cells", "ANATOMY", 143, 148], ["cells", "ANATOMY", 234, 239], ["RIG-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 68, 74], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 91, 96], ["cells", "CELL", 143, 148], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 158, 164], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 192, 197], ["PRRSV", "ORGANISM", 219, 224], ["cells", "CELL", 234, 239], ["RIG-I", "PROTEIN", 61, 66], ["RIG", "PROTEIN", 68, 71], ["IFN", "PROTEIN", 91, 94], ["\u03b2 promoter", "DNA", 95, 105], ["RIG", "PROTEIN", 158, 161], ["IFN", "PROTEIN", 192, 195], ["\u03b2 promoter", "DNA", 196, 206], ["PRRSV-infected cells", "CELL_TYPE", 219, 239], ["PRRSV", "SPECIES", 219, 224], ["increased IFN", "PROBLEM", 81, 94], ["infected cells", "PROBLEM", 134, 148], ["RIG", "TEST", 158, 161], ["IFN", "TEST", 192, 195], ["infected cells", "PROBLEM", 225, 239], ["active", "OBSERVATION_MODIFIER", 44, 50], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["infected cells", "OBSERVATION", 134, 148], ["infected cells", "OBSERVATION", 225, 239]]], ["Furthermore, poly(IC) elevated IFN-\u03b2 promoter activity only in the mock-infected cells.", [["cells", "ANATOMY", 81, 86], ["poly", "CHEMICAL", 13, 17], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 13, 21], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["cells", "CELL", 81, 86], ["IFN", "PROTEIN", 31, 34], ["mock-infected cells", "CELL_TYPE", 67, 86], ["poly(IC) elevated IFN", "PROBLEM", 13, 34], ["promoter activity", "PROBLEM", 37, 54], ["infected cells", "PROBLEM", 72, 86], ["infected cells", "OBSERVATION", 72, 86]]], ["These results provided additional evidence to the hypothesis that IPS-1 was the target protein of PRRSV suppression.PRRSV infection partially reduces TRIF-mediated IFN-\u03b2 induction and IRF3 activation ::: ResultIn order to investigate whether PRRSV also impairs the TLR3 pathway-associated TRIF-mediated induction of IFN-\u03b2 and IRF3 activation, MARC-145 cells were cotransfected with a TRIF expression plasmid and IFN-\u03b2 promoter luciferase reporter plasmid or a luciferase reporter plasmid containing repeated IRF3 binding sites (PRDIII-I).", [["MARC-145 cells", "ANATOMY", 343, 357], ["PRRSV infection", "DISEASE", 116, 131], ["IPS-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["PRRSV", "ORGANISM", 98, 103], ["PRRSV", "ORGANISM", 116, 121], ["TRIF", "GENE_OR_GENE_PRODUCT", 150, 154], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 164, 169], ["IRF3", "GENE_OR_GENE_PRODUCT", 184, 188], ["PRRSV", "ORGANISM", 242, 247], ["TLR3", "GENE_OR_GENE_PRODUCT", 265, 269], ["TRIF", "GENE_OR_GENE_PRODUCT", 289, 293], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 316, 321], ["IRF3", "GENE_OR_GENE_PRODUCT", 326, 330], ["MARC-145 cells", "CELL", 343, 357], ["TRIF", "GENE_OR_GENE_PRODUCT", 384, 388], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 412, 417], ["luciferase", "GENE_OR_GENE_PRODUCT", 427, 437], ["luciferase", "GENE_OR_GENE_PRODUCT", 460, 470], ["IRF3", "GENE_OR_GENE_PRODUCT", 508, 512], ["PRDIII-I", "GENE_OR_GENE_PRODUCT", 528, 536], ["IPS", "PROTEIN", 66, 69], ["TRIF", "PROTEIN", 150, 154], ["IFN", "PROTEIN", 164, 167], ["\u03b2", "PROTEIN", 168, 169], ["IRF3", "PROTEIN", 184, 188], ["TLR3", "PROTEIN", 265, 269], ["TRIF", "PROTEIN", 289, 293], ["IFN", "PROTEIN", 316, 319], ["IRF3", "PROTEIN", 326, 330], ["MARC-145 cells", "CELL_LINE", 343, 357], ["TRIF expression plasmid", "DNA", 384, 407], ["IFN-\u03b2 promoter luciferase reporter plasmid", "DNA", 412, 454], ["luciferase reporter plasmid", "DNA", 460, 487], ["IRF3 binding sites", "DNA", 508, 526], ["PRDIII-I", "DNA", 528, 536], ["PRRSV", "SPECIES", 116, 121], ["PRRSV", "SPECIES", 98, 103], ["PRRSV", "SPECIES", 116, 121], ["PRRSV", "SPECIES", 242, 247], ["IPS", "TEST", 66, 69], ["PRRSV suppression", "TREATMENT", 98, 115], ["PRRSV infection", "PROBLEM", 116, 131], ["PRRSV", "PROBLEM", 242, 247], ["IFN", "TREATMENT", 316, 319], ["IRF3 activation", "PROBLEM", 326, 341], ["a TRIF expression plasmid", "TREATMENT", 382, 407], ["IFN-\u03b2 promoter luciferase reporter plasmid", "TREATMENT", 412, 454], ["a luciferase reporter plasmid", "TREATMENT", 458, 487], ["repeated IRF3 binding sites", "PROBLEM", 499, 526], ["PRRSV suppression", "OBSERVATION", 98, 115], ["infection", "OBSERVATION", 122, 131]]], ["As shown in Fig. 7, overexpression of TRIF significantly increased production of both IFN-\u03b2 promoter-specific and IRF3-specific luciferase.", [["TRIF", "GENE_OR_GENE_PRODUCT", 38, 42], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["IRF3", "GENE_OR_GENE_PRODUCT", 114, 118], ["luciferase", "GENE_OR_GENE_PRODUCT", 128, 138], ["TRIF", "PROTEIN", 38, 42], ["IFN-\u03b2 promoter", "DNA", 86, 100], ["IRF3", "PROTEIN", 114, 118], ["luciferase", "PROTEIN", 128, 138], ["TRIF", "PROBLEM", 38, 42], ["Fig", "OBSERVATION", 12, 15], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["production", "OBSERVATION_MODIFIER", 67, 77]]], ["These increases were only partially reversed (30%) by PRRSV infection.", [["PRRSV infection", "DISEASE", 54, 69], ["PRRSV", "ORGANISM", 54, 59], ["PRRSV", "SPECIES", 54, 59], ["PRRSV infection", "PROBLEM", 54, 69], ["infection", "OBSERVATION", 60, 69]]], ["This was quite different from its inhibition in the RIG-I pathway where PRRSV significantly abolished IPS-1-specific and RIG-I-specific activations.DiscussionInnate immunity is the first line defense against invading pathogens.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 52, 57], ["PRRSV", "ORGANISM", 72, 77], ["IPS-1", "GENE_OR_GENE_PRODUCT", 102, 107], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 121, 127], ["RIG", "PROTEIN", 52, 55], ["IPS", "PROTEIN", 102, 105], ["PRRSV", "SPECIES", 72, 77], ["PRRSV", "PROBLEM", 72, 77], ["IPS", "TEST", 102, 105], ["invading pathogens", "PROBLEM", 208, 226]]], ["Previous studies have demonstrated that PRRSV infection results in low type I IFN levels (Albina et al., 1998, Miller et al., 2004), which is normally produced rapidly in direct response to virus replication in infected cells, suggesting that PRRSV evolves a strategy to interfere with the type I IFN signaling pathway, and subsequently to evade the innate immune response.", [["cells", "ANATOMY", 220, 225], ["PRRSV infection", "DISEASE", 40, 55], ["PRRSV", "ORGANISM", 40, 45], ["type I IFN", "GENE_OR_GENE_PRODUCT", 71, 81], ["cells", "CELL", 220, 225], ["PRRSV", "ORGANISM", 243, 248], ["type I IFN", "GENE_OR_GENE_PRODUCT", 290, 300], ["IFN", "PROTEIN", 78, 81], ["infected cells", "CELL_TYPE", 211, 225], ["IFN", "PROTEIN", 297, 300], ["PRRSV", "SPECIES", 40, 45], ["PRRSV", "SPECIES", 243, 248], ["Previous studies", "TEST", 0, 16], ["PRRSV infection", "PROBLEM", 40, 55], ["low type I IFN levels", "PROBLEM", 67, 88], ["Miller et al.", "TEST", 111, 124], ["virus replication in infected cells", "PROBLEM", 190, 225], ["PRRSV", "PROBLEM", 243, 248], ["PRRSV", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55], ["low type", "OBSERVATION_MODIFIER", 67, 75], ["infected cells", "OBSERVATION", 211, 225]]], ["Like other RNA viruses, PRRSV replication has an obligatory requirement for the generation of dsRNA, which is a potent inducer of type I IFN.", [["PRRSV", "ORGANISM", 24, 29], ["type I IFN", "GENE_OR_GENE_PRODUCT", 130, 140], ["type I IFN", "PROTEIN", 130, 140], ["PRRSV", "SPECIES", 24, 29], ["other RNA viruses", "PROBLEM", 5, 22], ["PRRSV replication", "TREATMENT", 24, 41], ["an obligatory requirement", "PROBLEM", 46, 71], ["the generation of dsRNA", "PROBLEM", 76, 99], ["RNA viruses", "OBSERVATION", 11, 22], ["PRRSV replication", "OBSERVATION", 24, 41], ["dsRNA", "OBSERVATION", 94, 99]]], ["In this study, we attempted to elucidate the potential mechanisms used by PRRSV to prevent dsRNA-induced transcription of IFN-\u03b2, thereby antagonizing the innate immune response.DiscussionInitiation of IFN synthesis typically involves binding of specific transcription factors, which collectively comprise the transcriptional enhanceasome, to the positive regulatory domains in the IFN-\u03b2 gene promoter.", [["IFN", "CHEMICAL", 201, 204], ["PRRSV", "ORGANISM", 74, 79], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["IFN", "GENE_OR_GENE_PRODUCT", 201, 204], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 381, 386], ["IFN", "PROTEIN", 122, 125], ["\u03b2", "PROTEIN", 126, 127], ["IFN", "PROTEIN", 201, 204], ["transcription factors", "PROTEIN", 254, 275], ["transcriptional enhanceasome", "PROTEIN", 309, 337], ["positive regulatory domains", "DNA", 346, 373], ["IFN-\u03b2 gene promoter", "DNA", 381, 400], ["PRRSV", "SPECIES", 74, 79], ["this study", "TEST", 3, 13], ["PRRSV", "TREATMENT", 74, 79], ["dsRNA", "PROBLEM", 91, 96], ["IFN", "TREATMENT", 122, 125], ["IFN synthesis", "PROBLEM", 201, 214], ["specific transcription factors", "PROBLEM", 245, 275]]], ["These transcription factors include NF-\u03baB, AP-1, and members of the IFN regulatory factors (IRF) family, such as IRF3 (Thanos and Maniatis, 1995).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["AP-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["IFN regulatory factors", "GENE_OR_GENE_PRODUCT", 68, 90], ["IRF", "GENE_OR_GENE_PRODUCT", 92, 95], ["IRF3", "GENE_OR_GENE_PRODUCT", 113, 117], ["transcription factors", "PROTEIN", 6, 27], ["NF-\u03baB", "PROTEIN", 36, 41], ["AP-1", "PROTEIN", 43, 47], ["IFN regulatory factors (IRF) family", "PROTEIN", 68, 103], ["IRF3", "PROTEIN", 113, 117]]], ["Using plasmid constructs with the individual binding sites of these transcription factors linked to luciferase reporter genes, we showed that transcription factor NF-\u03baB and AP-1 were activated by PRRSV infection, whereas the activity of transcription factor IRF3 was significantly inhibited (Fig. 3), indicating that inhibition of IFN-\u03b2 transcription by PRRSV occurs through a mechanism involving IRF3 activity.", [["PRRSV infection", "DISEASE", 196, 211], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["AP-1", "GENE_OR_GENE_PRODUCT", 173, 177], ["PRRSV", "ORGANISM", 196, 201], ["IRF3", "GENE_OR_GENE_PRODUCT", 258, 262], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 331, 336], ["PRRSV", "ORGANISM", 354, 359], ["IRF3", "GENE_OR_GENE_PRODUCT", 397, 401], ["plasmid constructs", "DNA", 6, 24], ["transcription factors", "PROTEIN", 68, 89], ["luciferase reporter genes", "DNA", 100, 125], ["transcription factor", "PROTEIN", 142, 162], ["NF-\u03baB", "PROTEIN", 163, 168], ["AP-1", "PROTEIN", 173, 177], ["transcription factor", "PROTEIN", 237, 257], ["IRF3", "PROTEIN", 258, 262], ["IFN", "PROTEIN", 331, 334], ["\u03b2", "PROTEIN", 335, 336], ["IRF3", "PROTEIN", 397, 401], ["PRRSV", "SPECIES", 196, 201], ["PRRSV", "SPECIES", 354, 359], ["plasmid constructs", "TREATMENT", 6, 24], ["luciferase reporter genes", "TEST", 100, 125], ["transcription factor NF", "TEST", 142, 165], ["AP", "TEST", 173, 175], ["PRRSV infection", "PROBLEM", 196, 211], ["transcription factor IRF3", "TEST", 237, 262], ["IFN-\u03b2 transcription", "TREATMENT", 331, 350], ["infection", "OBSERVATION", 202, 211], ["IRF3 activity", "OBSERVATION", 397, 410]]], ["Many viruses interact with IRF3 directly to inactivate IRF3 function, thereby suppressing IFN-\u03b2 transcription.", [["IRF3", "GENE_OR_GENE_PRODUCT", 27, 31], ["IRF3", "GENE_OR_GENE_PRODUCT", 55, 59], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["IRF3", "PROTEIN", 27, 31], ["IRF3", "PROTEIN", 55, 59], ["IFN", "PROTEIN", 90, 93], ["\u03b2", "PROTEIN", 94, 95], ["viruses", "OBSERVATION", 5, 12]]], ["For example, rotavirus NSP1 and human papillomavirus E6 bind directly to IRF3 (Barro and Patton, 2005, Ronco et al., 1998).", [["rotavirus NSP1", "ORGANISM", 13, 27], ["human papillomavirus E6", "ORGANISM", 32, 55], ["IRF3", "GENE_OR_GENE_PRODUCT", 73, 77], ["rotavirus NSP1", "PROTEIN", 13, 27], ["human papillomavirus E6", "PROTEIN", 32, 55], ["IRF3", "PROTEIN", 73, 77], ["rotavirus", "SPECIES", 13, 22], ["human", "SPECIES", 32, 37], ["papillomavirus", "SPECIES", 38, 52], ["rotavirus", "SPECIES", 13, 22], ["human papillomavirus E6", "SPECIES", 32, 55], ["rotavirus NSP1", "TREATMENT", 13, 27]]], ["PRRSV, however, appeared to employ different mechanisms.", [["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5]]], ["It did not inhibit IRF3-induced expression of the IFN-\u03b2 reporter gene with wtIRF3 or IRF3(5D) in this study.", [["IRF3", "GENE_OR_GENE_PRODUCT", 19, 23], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 50, 55], ["wtIRF3", "GENE_OR_GENE_PRODUCT", 75, 81], ["IRF3", "GENE_OR_GENE_PRODUCT", 85, 89], ["IRF3", "PROTEIN", 19, 23], ["IFN-\u03b2 reporter gene", "DNA", 50, 69], ["wtIRF3", "PROTEIN", 75, 81], ["IRF3", "PROTEIN", 85, 89], ["IRF3", "PROBLEM", 19, 23], ["IRF3", "PROBLEM", 85, 89], ["this study", "TEST", 97, 107], ["IRF3", "OBSERVATION", 19, 23]]], ["TBK1 and IKK\u025b are elements upstream of IRF3 in the signaling pathway.", [["TBK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 9, 13], ["IRF3", "GENE_OR_GENE_PRODUCT", 39, 43], ["TBK1", "PROTEIN", 0, 4], ["IKK\u025b", "PROTEIN", 9, 13], ["IRF3", "PROTEIN", 39, 43], ["TBK1", "PROBLEM", 0, 4], ["IRF3", "PROBLEM", 39, 43], ["IRF3", "OBSERVATION", 39, 43]]], ["PRRSV infection did not alter IRF3 activity in cells overexpressing TBK1 or IKK\u025b.", [["cells", "ANATOMY", 47, 52], ["PRRSV infection", "DISEASE", 0, 15], ["PRRSV", "ORGANISM", 0, 5], ["IRF3", "GENE_OR_GENE_PRODUCT", 30, 34], ["cells", "CELL", 47, 52], ["TBK1", "GENE_OR_GENE_PRODUCT", 68, 72], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 76, 80], ["IRF3", "PROTEIN", 30, 34], ["TBK1", "PROTEIN", 68, 72], ["IKK\u025b", "PROTEIN", 76, 80], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV infection", "PROBLEM", 0, 15], ["TBK1", "PROBLEM", 68, 72], ["infection", "OBSERVATION", 6, 15]]], ["In addition, comparable IFN-\u03b2 promoter activities were obtained in cells overexpressing IRF3, IRF3(5D), TBK1, and IKK\u025b in mock- or PRRSV-infected cells.", [["cells", "ANATOMY", 67, 72], ["cells", "ANATOMY", 146, 151], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 24, 29], ["cells", "CELL", 67, 72], ["IRF3", "GENE_OR_GENE_PRODUCT", 88, 92], ["IRF3(5D", "GENE_OR_GENE_PRODUCT", 94, 101], ["TBK1", "GENE_OR_GENE_PRODUCT", 104, 108], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 114, 118], ["PRRSV", "ORGANISM", 131, 136], ["cells", "CELL", 146, 151], ["IFN", "PROTEIN", 24, 27], ["IRF3", "PROTEIN", 88, 92], ["IRF3", "PROTEIN", 94, 98], ["5D", "PROTEIN", 99, 101], ["TBK1", "PROTEIN", 104, 108], ["IKK\u025b", "PROTEIN", 114, 118], ["mock- or PRRSV-infected cells", "CELL_LINE", 122, 151], ["PRRSV", "SPECIES", 131, 136], ["TBK1", "TEST", 104, 108], ["IKK", "TEST", 114, 117], ["PRRSV", "PROBLEM", 131, 136], ["infected cells", "PROBLEM", 137, 151], ["infected cells", "OBSERVATION", 137, 151]]], ["Poly(IC)-induced IFN-\u03b2 reporter gene expression, however, was significantly decreased in PRRSV-infected cells.", [["cells", "ANATOMY", 104, 109], ["Poly", "CHEMICAL", 0, 4], ["IC", "CHEMICAL", 5, 7], ["PRRSV-infected", "DISEASE", 89, 103], ["Poly(IC)", "CHEMICAL", 0, 8], ["Poly(IC)", "SIMPLE_CHEMICAL", 0, 8], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 17, 22], ["PRRSV", "ORGANISM", 89, 94], ["cells", "CELL", 104, 109], ["IFN", "PROTEIN", 17, 20], ["PRRSV", "SPECIES", 89, 94], ["Poly(IC)", "TREATMENT", 0, 8], ["PRRSV-infected cells", "PROBLEM", 89, 109], ["decreased", "OBSERVATION_MODIFIER", 76, 85], ["infected cells", "OBSERVATION", 95, 109]]], ["Generally, poly(IC) is sensed by host's pattern recognition receptors, such as RIG-I and TLR3.", [["poly", "CHEMICAL", 11, 15], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 11, 19], ["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["TLR3", "GENE_OR_GENE_PRODUCT", 89, 93], ["pattern recognition receptors", "PROTEIN", 40, 69], ["RIG-I", "PROTEIN", 79, 84], ["TLR3", "PROTEIN", 89, 93], ["TLR3", "ANATOMY", 89, 93]]], ["The latter then recruit the corresponding adaptor molecule to relay the signal to TBK1 and IKK\u025b.", [["TBK1", "GENE_OR_GENE_PRODUCT", 82, 86], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 91, 95], ["adaptor molecule", "PROTEIN", 42, 58], ["TBK1", "PROTEIN", 82, 86], ["IKK\u025b", "PROTEIN", 91, 95]]], ["PRRSV significantly dampened IFN-\u03b2 reporter gene expression stimulated by poly(IC) in cells overexpressing TBK1/IKK\u025b.", [["cells", "ANATOMY", 86, 91], ["PRRSV", "ORGANISM", 0, 5], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 29, 34], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 74, 82], ["cells", "CELL", 86, 91], ["TBK1", "GENE_OR_GENE_PRODUCT", 107, 111], ["IKK", "GENE_OR_GENE_PRODUCT", 112, 115], ["\u025b", "GENE_OR_GENE_PRODUCT", 115, 116], ["IFN", "PROTEIN", 29, 32], ["\u03b2 reporter gene", "DNA", 33, 48], ["TBK1", "PROTEIN", 107, 111], ["IKK\u025b", "PROTEIN", 112, 116], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5]]], ["Based on these observations, we reasoned that PRRSV did not interact with IRF3 and even did not interfere with TBK1/IKK\u025b kinases directly, and that the target of PRRSV interaction existed upstream of IRF3 and TBK1/IKK\u025b in the signaling pathway.DiscussionThe IKK-related kinases TBK1 and IKK\u025b are the common signaling molecules in RIG-I and TLR3 signaling pathways.", [["PRRSV", "ORGANISM", 46, 51], ["IRF3", "GENE_OR_GENE_PRODUCT", 74, 78], ["TBK1", "GENE_OR_GENE_PRODUCT", 111, 115], ["IKK\u025b kinases", "GENE_OR_GENE_PRODUCT", 116, 128], ["PRRSV", "ORGANISM", 162, 167], ["IRF3", "GENE_OR_GENE_PRODUCT", 200, 204], ["TBK1", "GENE_OR_GENE_PRODUCT", 209, 213], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 214, 218], ["IKK", "GENE_OR_GENE_PRODUCT", 258, 261], ["TBK1", "GENE_OR_GENE_PRODUCT", 278, 282], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 287, 291], ["RIG-I", "GENE_OR_GENE_PRODUCT", 330, 335], ["TLR3", "GENE_OR_GENE_PRODUCT", 340, 344], ["IRF3", "PROTEIN", 74, 78], ["TBK1", "PROTEIN", 111, 115], ["IKK", "PROTEIN", 116, 119], ["\u025b kinases", "PROTEIN", 119, 128], ["IRF3", "PROTEIN", 200, 204], ["TBK1", "PROTEIN", 209, 213], ["IKK\u025b", "PROTEIN", 214, 218], ["IKK-related kinases", "PROTEIN", 258, 277], ["TBK1", "PROTEIN", 278, 282], ["IKK\u025b", "PROTEIN", 287, 291], ["signaling molecules", "PROTEIN", 307, 326], ["TLR3", "PROTEIN", 340, 344], ["PRRSV", "SPECIES", 46, 51], ["PRRSV", "SPECIES", 162, 167], ["PRRSV", "PROBLEM", 46, 51], ["IRF3", "TREATMENT", 74, 78], ["TBK1", "TEST", 111, 115], ["PRRSV interaction", "PROBLEM", 162, 179], ["IRF3", "PROBLEM", 200, 204], ["The IKK", "TEST", 254, 261], ["kinases TBK1", "TEST", 270, 282], ["IKK", "TEST", 287, 290]]], ["The RIG-I pathway is considered to play an essential role in the sensing of incoming virus infection and directly relay regulatory signals to the host antiviral response, which was confirmed with the generation of RIG-I-deficient mice (Kato et al., 2005).", [["infection", "DISEASE", 91, 100], ["RIG-I", "GENE_OR_GENE_PRODUCT", 4, 9], ["RIG-I", "GENE_OR_GENE_PRODUCT", 214, 219], ["mice", "ORGANISM", 230, 234], ["RIG", "PROTEIN", 4, 7], ["RIG-I", "PROTEIN", 214, 219], ["mice", "SPECIES", 230, 234], ["mice", "SPECIES", 230, 234], ["incoming virus infection", "PROBLEM", 76, 100]]], ["In this study, IFN-\u03b2 production induced by overexpression of RIG-I, the dsRNA-sensing protein, is significantly inhibited by PRRSV, suggesting that PRRSV may target RIG-I directly or a component of the signaling pathway downstream of RIG-I and upstream of TBK1/IKK\u025b.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 15, 20], ["RIG-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["PRRSV", "ORGANISM", 125, 130], ["PRRSV", "ORGANISM", 148, 153], ["RIG-I", "GENE_OR_GENE_PRODUCT", 165, 170], ["RIG-I", "GENE_OR_GENE_PRODUCT", 234, 239], ["TBK1", "GENE_OR_GENE_PRODUCT", 256, 260], ["IKK", "GENE_OR_GENE_PRODUCT", 261, 264], ["\u025b", "GENE_OR_GENE_PRODUCT", 264, 265], ["IFN", "PROTEIN", 15, 18], ["\u03b2", "PROTEIN", 19, 20], ["RIG-I", "PROTEIN", 61, 66], ["dsRNA-sensing protein", "PROTEIN", 72, 93], ["RIG-I", "PROTEIN", 165, 170], ["RIG-I", "DNA", 234, 239], ["TBK1", "PROTEIN", 256, 260], ["IKK\u025b", "PROTEIN", 261, 265], ["PRRSV", "SPECIES", 125, 130], ["PRRSV", "SPECIES", 148, 153], ["this study", "TEST", 3, 13], ["the dsRNA-sensing protein", "PROBLEM", 68, 93], ["PRRSV", "PROBLEM", 125, 130], ["PRRSV", "PROBLEM", 148, 153], ["TBK1", "PROBLEM", 256, 260], ["TBK1", "OBSERVATION", 256, 260], ["IKK\u025b", "OBSERVATION", 261, 265]]], ["To identify the target which PRRSV interacts with, we focused on the IPS-1 molecule, a component between RIG-I and TBK1/IKK\u025b in the signaling pathway.", [["PRRSV", "ORGANISM", 29, 34], ["IPS-1", "GENE_OR_GENE_PRODUCT", 69, 74], ["RIG-I", "GENE_OR_GENE_PRODUCT", 105, 110], ["TBK1", "GENE_OR_GENE_PRODUCT", 115, 119], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 120, 124], ["IPS-1 molecule", "PROTEIN", 69, 83], ["RIG-I", "PROTEIN", 105, 110], ["TBK1", "PROTEIN", 115, 119], ["IKK\u025b", "PROTEIN", 120, 124], ["PRRSV", "SPECIES", 29, 34], ["TBK1", "PROBLEM", 115, 119]]], ["We showed here that IPS-1-induced IFN-\u03b2 production was blocked in PRRSV-infected cells (Fig. 6) whereas elements downstream of IPS-1 remained intact.", [["cells", "ANATOMY", 81, 86], ["IPS-1", "CHEMICAL", 20, 25], ["IPS-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 34, 39], ["PRRSV", "ORGANISM", 66, 71], ["cells", "CELL", 81, 86], ["IPS-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["IFN", "PROTEIN", 34, 37], ["\u03b2", "PROTEIN", 38, 39], ["PRRSV-infected cells", "CELL_LINE", 66, 86], ["IPS-1", "DNA", 127, 132], ["PRRSV", "SPECIES", 66, 71], ["IPS", "TEST", 20, 23], ["IFN", "PROBLEM", 34, 37], ["\u03b2 production", "PROBLEM", 38, 50], ["blocked", "PROBLEM", 55, 62], ["PRRSV", "PROBLEM", 66, 71], ["infected cells", "PROBLEM", 72, 86], ["IPS", "TEST", 127, 130], ["infected cells", "OBSERVATION", 72, 86], ["IPS", "ANATOMY", 127, 130], ["intact", "OBSERVATION", 142, 148]]], ["Collectively, these observations strongly suggest that IPS-1 is the target with which PRRSV interfered to suppress dsRNA-initiated production of IFN-\u03b2.DiscussionTLR3 can also recognize dsRNA and transmit signals to activate IRF3 and NF-\u03baB, eventually leading to IFN-\u03b2 induction (Fitzgerald et al., 2003).", [["IPS-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["PRRSV", "ORGANISM", 86, 91], ["DiscussionTLR3", "GENE_OR_GENE_PRODUCT", 151, 165], ["IRF3", "GENE_OR_GENE_PRODUCT", 224, 228], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 233, 238], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 262, 267], ["IPS", "PROTEIN", 55, 58], ["IFN", "PROTEIN", 145, 148], ["DiscussionTLR3", "PROTEIN", 151, 165], ["IRF3", "PROTEIN", 224, 228], ["NF-\u03baB", "PROTEIN", 233, 238], ["IFN", "PROTEIN", 262, 265], ["\u03b2", "PROTEIN", 266, 267], ["PRRSV", "SPECIES", 86, 91], ["dsRNA", "PROBLEM", 115, 120], ["IFN", "TREATMENT", 145, 148], ["dsRNA", "PROBLEM", 185, 190], ["IFN", "TREATMENT", 262, 265]]], ["In this study, we showed that PRRSV also inhibited IFN-\u03b2 promoter activities by interfering with TRIF, the adaptor molecule of TLR3.", [["PRRSV", "ORGANISM", 30, 35], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["TRIF", "GENE_OR_GENE_PRODUCT", 97, 101], ["TLR3", "GENE_OR_GENE_PRODUCT", 127, 131], ["IFN", "PROTEIN", 51, 54], ["TRIF", "PROTEIN", 97, 101], ["adaptor molecule", "PROTEIN", 107, 123], ["TLR3", "PROTEIN", 127, 131], ["PRRSV", "SPECIES", 30, 35], ["this study", "TEST", 3, 13], ["PRRSV", "PROBLEM", 30, 35], ["IFN", "TREATMENT", 51, 54], ["TRIF", "TREATMENT", 97, 101], ["the adaptor molecule of TLR3", "TREATMENT", 103, 131]]], ["However, TRIF-stimulated expression was only partially diminished by PRRSV.", [["TRIF", "GENE_OR_GENE_PRODUCT", 9, 13], ["PRRSV", "ORGANISM", 69, 74], ["TRIF", "PROTEIN", 9, 13], ["PRRSV", "SPECIES", 69, 74], ["diminished", "OBSERVATION", 55, 65]]], ["Taken together, PRRSV mainly interfered with the RIG-I signaling pathway which in turn suppressed IFN-\u03b2 production and the subsequent innate immune response.DiscussionInhibition of dsRNA-induced transcriptional activation of IFN-\u03b2 guarantees that no antiviral activities by IFN-stimulated genes are induced in already infected cells as well as in surrounding noninfected cells (Fensterl et al., 2005).", [["cells", "ANATOMY", 327, 332], ["cells", "ANATOMY", 371, 376], ["PRRSV", "ORGANISM", 16, 21], ["RIG-I", "GENE_OR_GENE_PRODUCT", 49, 54], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 98, 103], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 225, 230], ["IFN", "GENE_OR_GENE_PRODUCT", 274, 277], ["cells", "CELL", 327, 332], ["cells", "CELL", 371, 376], ["RIG-I", "PROTEIN", 49, 54], ["IFN", "PROTEIN", 98, 101], ["\u03b2", "PROTEIN", 102, 103], ["IFN", "PROTEIN", 225, 228], ["\u03b2", "PROTEIN", 229, 230], ["IFN-stimulated genes", "DNA", 274, 294], ["infected cells", "CELL_TYPE", 318, 332], ["noninfected cells", "CELL_TYPE", 359, 376], ["PRRSV", "SPECIES", 16, 21], ["dsRNA", "TREATMENT", 181, 186], ["IFN-\u03b2 guarantees", "TREATMENT", 225, 241], ["antiviral activities", "TREATMENT", 250, 270], ["already infected cells", "PROBLEM", 310, 332], ["infected cells", "OBSERVATION", 318, 332]]], ["This explains why PRRSV is capable of establishing persistent infection and persisting in some animals for months (Allende et al., 2000, Wills et al., 2003).", [["infection", "DISEASE", 62, 71], ["PRRSV", "ORGANISM", 18, 23], ["PRRSV", "SPECIES", 18, 23], ["PRRSV", "PROBLEM", 18, 23], ["persistent infection", "PROBLEM", 51, 71], ["persistent", "OBSERVATION_MODIFIER", 51, 61], ["infection", "OBSERVATION", 62, 71], ["persisting", "OBSERVATION_MODIFIER", 76, 86]]], ["In addition to direct antiviral activities, the type I IFN also serves as an important link between the innate and adaptive immune responses through multiple mechanisms (Biron, 1998, Meier et al., 2004).", [["type I IFN", "GENE_OR_GENE_PRODUCT", 48, 58], ["type I IFN", "PROTEIN", 48, 58], ["direct antiviral activities", "TREATMENT", 15, 42]]], ["PRRSV induces tardy and week neutralizing antibodies and IFN-\u03b3 production, resulting in delayed viral clearance (Lopez and Osorio, 2004, Murtaugh et al., 2002, Royaee et al., 2004).", [["PRRSV", "ORGANISM", 0, 5], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 57, 62], ["tardy and week neutralizing antibodies", "PROTEIN", 14, 52], ["IFN", "PROTEIN", 57, 60], ["\u03b3", "PROTEIN", 61, 62], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["neutralizing antibodies", "TEST", 29, 52], ["IFN", "PROBLEM", 57, 60], ["delayed viral clearance", "PROBLEM", 88, 111], ["viral clearance", "OBSERVATION", 96, 111]]], ["Consistent with previous studies that PRRSV infection results in inadequate induction of type I interferon (IFN-\u03b1/\u03b2) (Albina et al., 1998, Miller et al., 2004), results in this study clearly showed that PRRSV infection interfered with RIG-I and TLR3 signaling pathway to inhibit IFN-\u03b2 promoter activity.", [["PRRSV infection", "DISEASE", 38, 53], ["PRRSV infection", "DISEASE", 203, 218], ["PRRSV", "ORGANISM", 38, 43], ["type I interferon", "GENE_OR_GENE_PRODUCT", 89, 106], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 108, 113], ["\u03b2", "GENE_OR_GENE_PRODUCT", 114, 115], ["PRRSV", "ORGANISM", 203, 208], ["RIG-I", "GENE_OR_GENE_PRODUCT", 235, 240], ["TLR3", "GENE_OR_GENE_PRODUCT", 245, 249], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 279, 284], ["type I interferon", "PROTEIN", 89, 106], ["IFN", "PROTEIN", 108, 111], ["\u03b1", "PROTEIN", 112, 113], ["\u03b2", "PROTEIN", 114, 115], ["TLR3", "PROTEIN", 245, 249], ["IFN", "PROTEIN", 279, 282], ["\u03b2 promoter", "DNA", 283, 293], ["PRRSV", "SPECIES", 38, 43], ["PRRSV", "SPECIES", 203, 208], ["previous studies", "TEST", 16, 32], ["PRRSV infection", "PROBLEM", 38, 53], ["type I interferon", "TREATMENT", 89, 106], ["IFN", "TEST", 108, 111], ["this study", "TEST", 172, 182], ["PRRSV infection", "PROBLEM", 203, 218], ["RIG-I and TLR3 signaling pathway", "TREATMENT", 235, 267], ["IFN", "TREATMENT", 279, 282], ["PRRSV infection", "OBSERVATION", 203, 218]]], ["This inhibition results in poor innate immune responses, which in turn, to affect the ensuing adaptive immune responses critically, including delayed IFN-\u03b3 and neutralizing antibody production, ultimately leading to viremia and establishment of persistent infection (Murtaugh et al., 2002, Overend et al., 2007).DiscussionIn conclusion, we showed that PRRSV primarily interfered with the RIG-I signaling pathway via inactivation of IPS-1 adapter molecule, thereby preventing the nuclear translocation of IRF3.", [["nuclear", "ANATOMY", 479, 486], ["viremia", "DISEASE", 216, 223], ["infection", "DISEASE", 256, 265], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 150, 155], ["PRRSV", "ORGANISM", 352, 357], ["RIG-I", "GENE_OR_GENE_PRODUCT", 388, 393], ["IPS-1", "GENE_OR_GENE_PRODUCT", 432, 437], ["nuclear", "CELLULAR_COMPONENT", 479, 486], ["IRF3", "GENE_OR_GENE_PRODUCT", 504, 508], ["IFN", "PROTEIN", 150, 153], ["RIG-I", "PROTEIN", 388, 393], ["IPS-1 adapter molecule", "PROTEIN", 432, 454], ["IRF3", "PROTEIN", 504, 508], ["PRRSV", "SPECIES", 352, 357], ["delayed IFN", "PROBLEM", 142, 153], ["neutralizing antibody production", "PROBLEM", 160, 192], ["viremia", "PROBLEM", 216, 223], ["persistent infection", "PROBLEM", 245, 265], ["PRRSV", "PROBLEM", 352, 357], ["IPS", "TEST", 432, 435], ["IRF3", "PROBLEM", 504, 508], ["viremia", "OBSERVATION", 216, 223], ["persistent", "OBSERVATION_MODIFIER", 245, 255], ["infection", "OBSERVATION", 256, 265], ["IRF3", "OBSERVATION", 504, 508]]], ["As a result, viral induction of IFN-\u03b2 production was interrupted.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN", "PROTEIN", 32, 35], ["\u03b2", "PROTEIN", 36, 37], ["viral induction", "TREATMENT", 13, 28], ["IFN", "PROBLEM", 32, 35]]], ["By doing so, PRRSV may get an opportunity to evade the innate immune response.", [["PRRSV", "ORGANISM", 13, 18], ["PRRSV", "SPECIES", 13, 18]]], ["Certainly, apart from RIG-I and TLR3 signaling pathways, PRRSV may also use other pathways, such as PKR, to evade the innate immune response.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 22, 27], ["TLR3", "GENE_OR_GENE_PRODUCT", 32, 36], ["PRRSV", "ORGANISM", 57, 62], ["PKR", "GENE_OR_GENE_PRODUCT", 100, 103], ["TLR3", "PROTEIN", 32, 36], ["PKR", "PROTEIN", 100, 103], ["PRRSV", "SPECIES", 57, 62], ["PRRSV", "PROBLEM", 57, 62], ["PKR", "TEST", 100, 103]]], ["Understanding of those mechanisms would help accelerate development of improved vaccines or better methods to control PRRSV infection more effectively.", [["PRRSV infection", "DISEASE", 118, 133], ["PRRSV", "ORGANISM", 118, 123], ["PRRSV", "SPECIES", 118, 123], ["PRRSV", "SPECIES", 118, 123], ["improved vaccines", "TREATMENT", 71, 88], ["PRRSV infection", "PROBLEM", 118, 133], ["infection", "OBSERVATION", 124, 133]]]], "PMC7405818": [["IntroductionIn today's rapidly evolving clinical landscape, the increasing utilization and value of wide field fundus photography cannot be understated.", [["fundus", "MULTI-TISSUE_STRUCTURE", 111, 117], ["wide field fundus photography", "TEST", 100, 129], ["increasing", "OBSERVATION_MODIFIER", 64, 74]]], ["For example, a 2013 New Zealand survey reported that 82.6% of optometry practices had fundus photography capabilities.1 In light of the COVID-19 pandemic, fundus photography's potential role as an essential screening tool for eyecare providers is unprecedented, as telemedicine with wide field fundus photography is increasingly being implemented in ophthalmology and optometry private and institutional practices.", [["fundus", "ANATOMY", 86, 92], ["fundus", "ANATOMY", 155, 161], ["fundus", "MULTI-TISSUE_STRUCTURE", 86, 92], ["fundus", "MULTI-TISSUE_STRUCTURE", 155, 161], ["fundus", "MULTI-TISSUE_STRUCTURE", 294, 300], ["New Zealand survey", "TEST", 20, 38], ["optometry practices", "TEST", 62, 81], ["fundus photography capabilities", "TEST", 86, 117], ["the COVID", "TEST", 132, 141], ["fundus photography", "TEST", 155, 173], ["wide field fundus photography", "TEST", 283, 312]]], ["Here we present two cases reflecting the unlikely but possible risk of seizures in patients undergoing flash fundus photography.", [["fundus", "ANATOMY", 109, 115], ["seizures", "DISEASE", 71, 79], ["patients", "ORGANISM", 83, 91], ["fundus", "MULTI-TISSUE_STRUCTURE", 109, 115], ["patients", "SPECIES", 83, 91], ["seizures", "PROBLEM", 71, 79], ["flash fundus photography", "TEST", 103, 127], ["unlikely but possible", "UNCERTAINTY", 41, 62], ["seizures", "OBSERVATION", 71, 79]]], ["We suggest that appropriate screening for patients may be of benefit as wide field fundus photography continues to develop into a vital and ever more popular diagnostic tool.Case one ::: FindingsA 68-year-old woman with history of seizures on 800mg of tegretol presented for routine follow up.", [["fundus", "ANATOMY", 83, 89], ["seizures", "DISEASE", 231, 239], ["tegretol", "CHEMICAL", 252, 260], ["tegretol", "CHEMICAL", 252, 260], ["patients", "ORGANISM", 42, 50], ["fundus", "MULTI-TISSUE_STRUCTURE", 83, 89], ["woman", "ORGANISM", 209, 214], ["tegretol", "SIMPLE_CHEMICAL", 252, 260], ["patients", "SPECIES", 42, 50], ["woman", "SPECIES", 209, 214], ["appropriate screening", "TEST", 16, 37], ["wide field fundus photography", "TEST", 72, 101], ["seizures", "PROBLEM", 231, 239], ["tegretol", "TREATMENT", 252, 260], ["seizures", "OBSERVATION", 231, 239]]], ["She had a history of pars plana vitrectomy for visually significant asteroid hyalosis, and had undergone Optos wide field imaging (Optos, Dunfermline, United Kingdom) in the past without complication.", [["hyalosis", "DISEASE", 77, 85], ["pars plana vitrectomy", "TREATMENT", 21, 42], ["visually significant asteroid hyalosis", "PROBLEM", 47, 85], ["Optos wide field imaging", "TEST", 105, 129], ["complication", "PROBLEM", 187, 199], ["plana", "ANATOMY", 26, 31], ["vitrectomy", "OBSERVATION", 32, 42], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["asteroid hyalosis", "OBSERVATION", 68, 85]]], ["Immediately after the initial Optos fundus photography camera flash, she felt an impending seizure starting with movements in her right arm.", [["right arm", "ANATOMY", 130, 139], ["seizure", "DISEASE", 91, 98], ["fundus", "MULTI-TISSUE_STRUCTURE", 36, 42], ["arm", "ORGANISM_SUBDIVISION", 136, 139], ["the initial Optos fundus photography", "TEST", 18, 54], ["an impending seizure", "PROBLEM", 78, 98], ["seizure", "OBSERVATION", 91, 98], ["right", "ANATOMY_MODIFIER", 130, 135], ["arm", "ANATOMY", 136, 139]]], ["She received 1mg of diazepam and was cushioned in a dark room with pillows and supervision.", [["diazepam", "CHEMICAL", 20, 28], ["diazepam", "CHEMICAL", 20, 28], ["diazepam", "SIMPLE_CHEMICAL", 20, 28], ["diazepam", "TREATMENT", 20, 28], ["pillows", "TREATMENT", 67, 74]]], ["Despite these measures, she experienced an impressive clonic seizure that lasted several minutes before resolving without sequalae.Case two ::: FindingsA 72-year-old gentleman presented as a new patient for evaluation of possible retinal vein occlusion.", [["retinal vein", "ANATOMY", 230, 242], ["seizure", "DISEASE", 61, 68], ["retinal vein occlusion", "DISEASE", 230, 252], ["gentleman", "ORGANISM", 166, 175], ["patient", "ORGANISM", 195, 202], ["retinal vein", "MULTI-TISSUE_STRUCTURE", 230, 242], ["patient", "SPECIES", 195, 202], ["an impressive clonic seizure", "PROBLEM", 40, 68], ["sequalae", "PROBLEM", 122, 130], ["evaluation", "TEST", 207, 217], ["retinal vein occlusion", "PROBLEM", 230, 252], ["impressive", "OBSERVATION_MODIFIER", 43, 53], ["clonic", "OBSERVATION_MODIFIER", 54, 60], ["seizure", "OBSERVATION", 61, 68], ["possible", "UNCERTAINTY", 221, 229], ["retinal vein", "ANATOMY", 230, 242], ["occlusion", "OBSERVATION", 243, 252]]], ["Again, immediately following Optos fundus imaging he experienced an atonic seizure with slurred speech and poor motor control.", [["seizure", "DISEASE", 75, 82], ["fundus", "MULTI-TISSUE_STRUCTURE", 35, 41], ["Optos fundus imaging", "TEST", 29, 49], ["an atonic seizure", "PROBLEM", 65, 82], ["slurred speech", "PROBLEM", 88, 102], ["poor motor control", "PROBLEM", 107, 125], ["atonic", "OBSERVATION_MODIFIER", 68, 74], ["seizure", "OBSERVATION", 75, 82]]], ["The patient did not lose consciousness, but the seizure lasted about 15 seconds before he was able to communicate.", [["seizure", "DISEASE", 48, 55], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["consciousness", "PROBLEM", 25, 38], ["the seizure", "PROBLEM", 44, 55]]], ["Upon recovery, he reported history of a similar seizure 30 years prior after seeing flashing lights.", [["seizure", "DISEASE", 48, 55], ["a similar seizure", "PROBLEM", 38, 55]]], ["No medication was given, and additional imaging was deferred.DiscussionPhotic or pattern induced seizures were first described in 1885 by Gowers, who reported a girl who would seize when entering bright sunlight.2 In the era of television, the popular children's show \u201cPok\u00e9mon\u201d aired an episode on December 16, 1997 that infamously caused photic induced seizures in \u2265560 children in Tokyo, Japan due to a 4 second sequence of flashing red and blue screens.", [["seizures", "DISEASE", 97, 105], ["seizures", "DISEASE", 354, 362], ["children", "ORGANISM", 252, 260], ["children", "ORGANISM", 371, 379], ["girl", "SPECIES", 161, 165], ["children", "SPECIES", 252, 260], ["children", "SPECIES", 371, 379], ["medication", "TREATMENT", 3, 13], ["additional imaging", "TEST", 29, 47], ["seizures", "PROBLEM", 97, 105], ["photic induced seizures", "PROBLEM", 339, 362], ["flashing red and blue screens", "PROBLEM", 426, 455]]], ["Large population studies conducted by the Royal Air Force and Danish Air Force suggest that the incidence of photosensitivity\u2014paroxysmal electroencephalogram (EEG) responses to flashing lights\u2014ranges from 0.35% to 2.4%.2 More prone to photosensitive EEG responses, children have a higher incidence of photosensitivity\u2014around 8% according to some studies.2 The incidence of true photic induced seizures (versus photosensitivity) is closer to 1.1/100,000 in the overall population, but 5.7/100,000 for ages 7\u201319 years according to studies in Great Britain.2 Risk factors for photosensitivity include younger age and female sex.DiscussionA review of photic induced seizures includes the following high-risk characteristics of photic stimuli: high-contrast, binocular exposure, diffuse light, red-colored flicker, flash cycles between 15 and 25 cycles per second.", [["photosensitivity", "DISEASE", 109, 125], ["photosensitivity", "DISEASE", 301, 317], ["seizures", "DISEASE", 393, 401], ["photosensitivity", "DISEASE", 410, 426], ["photosensitivity", "DISEASE", 573, 589], ["seizures", "DISEASE", 662, 670], ["children", "ORGANISM", 265, 273], ["children", "SPECIES", 265, 273], ["Large population studies", "TEST", 0, 24], ["photosensitivity", "PROBLEM", 109, 125], ["paroxysmal electroencephalogram", "TEST", 126, 157], ["EEG", "TEST", 159, 162], ["flashing lights\u2014ranges", "TEST", 177, 199], ["photosensitivity\u2014", "TREATMENT", 301, 318], ["some studies", "TEST", 341, 353], ["true photic induced seizures", "PROBLEM", 373, 401], ["photosensitivity", "PROBLEM", 410, 426], ["photosensitivity", "PROBLEM", 573, 589], ["photic induced seizures", "PROBLEM", 647, 670], ["photic stimuli", "TEST", 723, 737], ["high-contrast", "PROBLEM", 739, 752], ["binocular exposure", "PROBLEM", 754, 772], ["diffuse light, red-colored flicker", "PROBLEM", 774, 808], ["flash cycles", "TEST", 810, 822], ["population", "OBSERVATION", 6, 16], ["Air Force", "OBSERVATION", 48, 57], ["true", "OBSERVATION_MODIFIER", 373, 377], ["photic induced seizures", "OBSERVATION", 378, 401], ["diffuse", "OBSERVATION_MODIFIER", 774, 781]]], ["Rarely, patients will respond to single bright flashes, as in the above cases.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["single bright flashes", "PROBLEM", 33, 54]]], ["To our knowledge, there are no peer-reviewed reports of fundus camera flashes causing seizures.", [["fundus", "ANATOMY", 56, 62], ["seizures", "DISEASE", 86, 94], ["fundus", "MULTI-TISSUE_STRUCTURE", 56, 62], ["fundus camera flashes", "PROBLEM", 56, 77], ["seizures", "PROBLEM", 86, 94], ["no", "UNCERTAINTY", 28, 30]]], ["The Food and Drug Administration's online adverse event reporting system has a single report of adverse reaction to the Optos fundus camera flash in a patient with history of epilepsy.3 The Optos and Zeiss Clarus (Carl Zeiss AG, Oberkochen, Germany) wide field fundus camera user manuals both include an epilepsy warning that patients with epilepsy may be sensitive to flashes of light.4,5 Interestingly, conventional imaging with Topcon fundus photography does not include an epilepsy warning,6 highlighting the potential importance of different technologies used in image acquisition.", [["epilepsy", "DISEASE", 175, 183], ["epilepsy", "DISEASE", 304, 312], ["epilepsy", "DISEASE", 340, 348], ["epilepsy", "DISEASE", 477, 485], ["fundus", "MULTI-TISSUE_STRUCTURE", 126, 132], ["patient", "ORGANISM", 151, 158], ["fundus", "MULTI-TISSUE_STRUCTURE", 261, 267], ["patients", "ORGANISM", 326, 334], ["fundus", "MULTI-TISSUE_STRUCTURE", 438, 444], ["patient", "SPECIES", 151, 158], ["patients", "SPECIES", 326, 334], ["Drug Administration", "TREATMENT", 13, 32], ["adverse reaction", "PROBLEM", 96, 112], ["epilepsy", "PROBLEM", 175, 183], ["an epilepsy", "PROBLEM", 301, 312], ["epilepsy", "PROBLEM", 340, 348], ["conventional imaging", "TEST", 405, 425], ["Topcon fundus photography", "TEST", 431, 456], ["an epilepsy warning", "PROBLEM", 474, 493], ["image acquisition", "TEST", 568, 585], ["epilepsy", "OBSERVATION", 175, 183], ["epilepsy", "OBSERVATION", 304, 312], ["epilepsy", "OBSERVATION", 477, 485]]], ["For example, the Optos is a confocal scanning laser ophthalmoscope whereas the Zeiss Clarus is a broad line fundus imaging ophthalmoscope.", [["Zeiss Clarus", "DNA", 79, 91], ["a confocal scanning laser ophthalmoscope", "TEST", 26, 66], ["a broad line fundus imaging ophthalmoscope", "TEST", 95, 137], ["broad line", "OBSERVATION", 97, 107]]], ["The relationship between light intensity and photic-induced seizures is poorly understood; it is generally believed that the likelihood of photoconvulsive response increases with higher light intensities (Table 1).7 In our experience, hundreds of thousands of fundus photographs have been taken at our practice over the past 25 years with conventional non-wide field Topcon and Zeiss cameras without a seizure instance.", [["fundus", "ANATOMY", 260, 266], ["seizures", "DISEASE", 60, 68], ["seizure", "DISEASE", 402, 409], ["fundus", "MULTI-TISSUE_STRUCTURE", 260, 266], ["light intensity and photic-induced seizures", "PROBLEM", 25, 68], ["photoconvulsive response", "PROBLEM", 139, 163], ["fundus photographs", "TEST", 260, 278], ["a seizure instance", "PROBLEM", 400, 418], ["light intensity", "OBSERVATION_MODIFIER", 25, 40], ["light intensities", "OBSERVATION_MODIFIER", 186, 203]]], ["In contrast, the two aforementioned seizure instances occurred out of thousands of Optos photographs taken over the past five years.", [["seizure", "DISEASE", 36, 43], ["the two aforementioned seizure instances", "PROBLEM", 13, 53], ["seizure", "OBSERVATION", 36, 43]]], ["Although the Optos and Zeiss Clarus wide field fundus cameras include an epilepsy warning, our case series is limited in that it does not establish causality between fundus photography flash and seizures.Strategies to mitigate riskGiven the omnipresence of wide field photography in eyecare, we recommend screening guidelines to mitigate the risk of photic induced seizures.", [["fundus", "ANATOMY", 166, 172], ["epilepsy", "DISEASE", 73, 81], ["seizures", "DISEASE", 195, 203], ["seizures", "DISEASE", 365, 373], ["fundus", "MULTI-TISSUE_STRUCTURE", 47, 53], ["fundus", "MULTI-TISSUE_STRUCTURE", 166, 172], ["an epilepsy", "PROBLEM", 70, 81], ["fundus photography flash", "TEST", 166, 190], ["seizures", "PROBLEM", 195, 203], ["wide field photography", "TEST", 257, 279], ["screening guidelines", "TREATMENT", 305, 325], ["photic induced seizures", "PROBLEM", 350, 373], ["epilepsy", "OBSERVATION", 73, 81]]], ["Screening questions should include history of seizures or epilepsy, with younger age and female proclivity to photosensitivity in mind.", [["seizures", "DISEASE", 46, 54], ["epilepsy", "DISEASE", 58, 66], ["photosensitivity", "DISEASE", 110, 126], ["seizures", "PROBLEM", 46, 54], ["epilepsy", "PROBLEM", 58, 66]]], ["However, it is important to note that most patients presenting with photosensitive seizures have no prior history.", [["seizures", "DISEASE", 83, 91], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["photosensitive seizures", "PROBLEM", 68, 91]]], ["In a review of video game induced seizures, 27 of 35 patients did not have a history of epilepsy.2 If fundus photography is absolutely necessary in a high-risk patient, we recommend that a physician be available during imaging.", [["fundus", "ANATOMY", 102, 108], ["seizures", "DISEASE", 34, 42], ["epilepsy", "DISEASE", 88, 96], ["patients", "ORGANISM", 53, 61], ["fundus", "MULTI-TISSUE_STRUCTURE", 102, 108], ["patient", "ORGANISM", 160, 167], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 160, 167], ["seizures", "PROBLEM", 34, 42], ["epilepsy", "PROBLEM", 88, 96], ["fundus photography", "TEST", 102, 120], ["imaging", "TEST", 219, 226], ["epilepsy", "OBSERVATION", 88, 96]]], ["Additionally, settings such as flash intensity may be manually decreased.", [["flash intensity", "PROBLEM", 31, 46], ["decreased", "OBSERVATION_MODIFIER", 63, 72]]], ["Patients may cover the contralateral eye with their hand or with a patch to reduce binocular exposure to the flash.", [["eye", "ANATOMY", 37, 40], ["hand", "ANATOMY", 52, 56], ["Patients", "ORGANISM", 0, 8], ["eye", "ORGAN", 37, 40], ["hand", "ORGANISM_SUBDIVISION", 52, 56], ["Patients", "SPECIES", 0, 8], ["a patch", "TREATMENT", 65, 72], ["binocular exposure", "PROBLEM", 83, 101], ["the flash", "PROBLEM", 105, 114], ["contralateral", "ANATOMY_MODIFIER", 23, 36], ["eye", "ANATOMY", 37, 40]]], ["If patients experience a seizure after exposure to fundus camera flash, gently ease them onto the ground and turn them on their side with a soft cushion under their head.", [["fundus", "ANATOMY", 51, 57], ["head", "ANATOMY", 165, 169], ["seizure", "DISEASE", 25, 32], ["patients", "ORGANISM", 3, 11], ["fundus", "MULTI-TISSUE_STRUCTURE", 51, 57], ["head", "ORGANISM_SUBDIVISION", 165, 169], ["patients", "SPECIES", 3, 11], ["a seizure", "PROBLEM", 23, 32], ["fundus camera flash", "PROBLEM", 51, 70], ["a soft cushion", "TREATMENT", 138, 152], ["head", "ANATOMY", 165, 169]]], ["Ensure that the ground is clear and hazard free.", [["clear", "OBSERVATION", 26, 31], ["free", "OBSERVATION_MODIFIER", 43, 47]]], ["If the patient has a tie or clothing around the neck, loosen the clothing article to make it easier for the patient to breath.", [["neck", "ANATOMY", 48, 52], ["patient", "ORGANISM", 7, 14], ["neck", "ORGANISM_SUBDIVISION", 48, 52], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 108, 115], ["a tie or clothing around the neck", "PROBLEM", 19, 52], ["neck", "ANATOMY", 48, 52]]], ["Do not try to place anything in the patient's mouth.", [["mouth", "ANATOMY", 46, 51], ["patient", "ORGANISM", 36, 43], ["mouth", "ORGANISM_SUBDIVISION", 46, 51], ["patient", "SPECIES", 36, 43], ["mouth", "ANATOMY", 46, 51]]], ["Lastly, time the seizure.", [["seizure", "DISEASE", 17, 24], ["the seizure", "PROBLEM", 13, 24]]], ["If the seizure lasts for longer than 5 minutes, call 911.", [["seizure", "DISEASE", 7, 14], ["the seizure", "PROBLEM", 3, 14]]], ["After resolution of the seizure, we recommend patients consider alternative transportation if they drove themselves to the appointment.ConclusionIn summary, we present two patients who experienced an episode of photic-induced seizures from wide field color fundus photography.", [["fundus", "ANATOMY", 257, 263], ["seizure", "DISEASE", 24, 31], ["seizures", "DISEASE", 226, 234], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 172, 180], ["fundus", "MULTI-TISSUE_STRUCTURE", 257, 263], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 172, 180], ["the seizure", "PROBLEM", 20, 31], ["photic-induced seizures", "PROBLEM", 211, 234], ["wide field color fundus photography", "TEST", 240, 275]]], ["Research into the different technologies of image acquisition may reveal additional strategies to reduce risk.", [["image acquisition", "TEST", 44, 61]]], ["Given the ubiquity of wide field photography, especially amidst the rising era of telemedicine in the COVID19 pandemic, we recommend all patients undergo brief screening for history of seizures prior to exposure to the camera flash.Patient consentConsent to publish the case report was not obtained.", [["seizures", "DISEASE", 185, 193], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["Patient", "SPECIES", 232, 239], ["wide field photography", "TEST", 22, 44], ["brief screening", "TEST", 154, 169], ["seizures", "PROBLEM", 185, 193], ["the camera flash", "PROBLEM", 215, 231]]], ["This report does not contain any personal information that could lead to the identification of the patient.FundingCalifornia Retina Research Foundation.AuthorshipAll authors attest that they meet the current ICMJE criteria for Authorship.Declaration of competing interestThe authors have no relevant financial disclosures.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["California Retina", "OBSERVATION", 114, 131], ["no", "UNCERTAINTY", 288, 290]]]], "PMC7176270": [["Gehrie reports clinical trial support from Cerus (Concord, California) and Terumo BCT (Tokyo, Japan), and is on the speaker\u2019s bureau for Grifols Diagnostics (Barcelona, Spain).", [["clinical trial support", "TREATMENT", 15, 37], ["Terumo BCT", "TREATMENT", 75, 85]]], ["Dr. Frank has served on scientific advisory boards for Baxter (Deerfield, Illinois), Haemonetics (Boston, Massachusetts), and Medtronic (Minneapolis, Minnesota).", [["Medtronic", "ANATOMY", 126, 135]]]], "PMC7127076": [["IntroductionAngiotensin-converting enzyme (ACE, EC 3.4.15.1), also known as dipeptidyl carboxypeptidase, is well studied in the animal kingdom.", [["IntroductionAngiotensin", "CHEMICAL", 0, 23], ["IntroductionAngiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 0, 41], ["dipeptidyl carboxypeptidase", "GENE_OR_GENE_PRODUCT", 76, 103], ["IntroductionAngiotensin-converting enzyme", "PROTEIN", 0, 41], ["ACE", "PROTEIN", 43, 46], ["dipeptidyl carboxypeptidase", "PROTEIN", 76, 103], ["IntroductionAngiotensin", "TREATMENT", 0, 23], ["converting enzyme", "TEST", 24, 41], ["ACE", "TEST", 43, 46], ["EC", "TEST", 48, 50], ["dipeptidyl carboxypeptidase", "TREATMENT", 76, 103]]], ["The mammalian ACE is best known for its role in the renin\u2013angiotensin system, which is involved in the regulation of blood pressure homeostasis (Bernstein et al., 2013).", [["blood", "ANATOMY", 117, 122], ["ACE", "GENE_OR_GENE_PRODUCT", 14, 17], ["renin\u2013angiotensin", "GENE_OR_GENE_PRODUCT", 52, 69], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["mammalian ACE", "PROTEIN", 4, 17], ["The mammalian ACE", "TREATMENT", 0, 17], ["blood pressure homeostasis", "TREATMENT", 117, 143], ["mammalian ACE", "OBSERVATION", 4, 17]]], ["Angiotensin I is converted to the vasoconstrictor angiotensin II by ACE through the cleavage of a C-terminal dipeptide of angiotensin I. Apart from this, ACE takes part in thermoregulation (Schwimmer et al., 2004), hematopoiesis (Hubert et al., 2006), and immune responses (Bernstein et al., 2013).", [["Angiotensin I", "CHEMICAL", 0, 13], ["angiotensin II", "CHEMICAL", 50, 64], ["angiotensin", "CHEMICAL", 122, 133], ["C", "CHEMICAL", 98, 99], ["Angiotensin I", "GENE_OR_GENE_PRODUCT", 0, 13], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 50, 64], ["ACE", "GENE_OR_GENE_PRODUCT", 68, 71], ["angiotensin I.", "GENE_OR_GENE_PRODUCT", 122, 136], ["ACE", "GENE_OR_GENE_PRODUCT", 154, 157], ["Angiotensin I", "PROTEIN", 0, 13], ["ACE", "PROTEIN", 154, 157], ["the vasoconstrictor angiotensin II", "TREATMENT", 30, 64], ["ACE", "TREATMENT", 68, 71], ["a C-terminal dipeptide of angiotensin I.", "TREATMENT", 96, 136], ["ACE", "TREATMENT", 154, 157], ["hematopoiesis", "PROBLEM", 215, 228], ["hematopoiesis", "ANATOMY", 215, 228]]], ["The mammalian ACE has two distinct isoforms, i.e., a double-domain somatic form and a single-domain testicular form (Bernstein et al., 2013).IntroductionInsects have an open circulatory hemolymph system that is considered to lack all components of the renin\u2013angiotensin system except ACE homologs (Fournier et al., 2012).", [["testicular", "ANATOMY", 100, 110], ["ACE", "GENE_OR_GENE_PRODUCT", 14, 17], ["testicular", "ORGAN", 100, 110], ["renin\u2013angiotensin", "GENE_OR_GENE_PRODUCT", 252, 269], ["ACE", "GENE_OR_GENE_PRODUCT", 284, 287], ["mammalian ACE", "PROTEIN", 4, 17], ["double-domain somatic form", "PROTEIN", 53, 79], ["renin\u2013angiotensin", "PROTEIN", 252, 269], ["ACE homologs", "PROTEIN", 284, 296], ["IntroductionInsects", "TREATMENT", 141, 160], ["an open circulatory hemolymph system", "TREATMENT", 166, 202], ["the renin\u2013angiotensin system", "TREATMENT", 248, 276], ["ACE homologs", "TREATMENT", 284, 296], ["testicular", "ANATOMY", 100, 110], ["circulatory hemolymph system", "OBSERVATION", 174, 202]]], ["Insect ACE only has one isoform, which resembles the testicular form of the mammalian ACE (Lemeire et al., 2008).", [["testicular", "ANATOMY", 53, 63], ["ACE", "GENE_OR_GENE_PRODUCT", 7, 10], ["testicular", "ORGAN", 53, 63], ["ACE", "GENE_OR_GENE_PRODUCT", 86, 89], ["ACE", "PROTEIN", 7, 10], ["testicular", "ANATOMY", 53, 63]]], ["The biological functions of ACEs in insects are diversified.", [["ACEs", "GENE_OR_GENE_PRODUCT", 28, 32], ["ACEs", "PROTEIN", 28, 32]]], ["They are involved in larval growth and development (Isaac et al., 2007), metabolic inactivation and biosynthesis of neuropeptides (Isaac et al., 2009), digestion (Lemeire et al., 2008), regulation of male and female fecundity (Isaac et al., 1999; Ekbote et al., 2003; Sun et al., 2018), modulation of insect-plant interactions as effector proteins (Wang et al., 2015), and immune response (Aguilar et al., 2005; Macours et al., 2003; Duressa and Huybrechts, 2016).", [["effector proteins", "PROTEIN", 330, 347], ["biosynthesis of neuropeptides", "TREATMENT", 100, 129]]], ["Regarding the roles of ACE in the innate immune system of insects, upregulation of ACE transcripts was observed in defense against both gram-negative and gram-positive bacteria but not against fungal infection in Locusta migratoria and Anopheles gambiae (Aguilar et al., 2005; Macours et al., 2003; Duressa and Huybrechts, 2016).Introduction", [["fungal infection", "DISEASE", 193, 209], ["ACE", "GENE_OR_GENE_PRODUCT", 23, 26], ["immune system", "ANATOMICAL_SYSTEM", 41, 54], ["ACE", "GENE_OR_GENE_PRODUCT", 83, 86], ["Locusta migratoria", "ORGANISM", 213, 231], ["Anopheles gambiae", "ORGANISM", 236, 253], ["ACE", "PROTEIN", 23, 26], ["ACE transcripts", "RNA", 83, 98], ["Locusta migratoria", "SPECIES", 213, 231], ["Anopheles gambiae", "SPECIES", 236, 253], ["Locusta migratoria", "SPECIES", 213, 231], ["Anopheles gambiae", "SPECIES", 236, 253], ["ACE", "TREATMENT", 23, 26], ["ACE transcripts", "TREATMENT", 83, 98], ["both gram", "TEST", 131, 140], ["gram-positive bacteria", "PROBLEM", 154, 176], ["fungal infection in Locusta migratoria", "PROBLEM", 193, 231], ["positive bacteria", "OBSERVATION_MODIFIER", 159, 176], ["not against", "UNCERTAINTY", 181, 192], ["fungal infection", "OBSERVATION", 193, 209]]]], "b08aff60bef5972aa0f4e33b60bcf53b9b9c8769": [["IntroductionThe lignocellulose component of the plant cell wall is composed of cellulose, hemicellulose, and lignin [1, 2] .", [["cell wall", "ANATOMY", 54, 63], ["cell wall", "MULTI-TISSUE_STRUCTURE", 54, 63], ["cellulose", "SIMPLE_CHEMICAL", 79, 88], ["hemicellulose", "SIMPLE_CHEMICAL", 90, 103], ["lignin [1, 2]", "SIMPLE_CHEMICAL", 109, 122], ["The lignocellulose component", "TREATMENT", 12, 40], ["the plant cell wall", "TREATMENT", 44, 63], ["plant cell", "OBSERVATION", 48, 58], ["wall", "ANATOMY_MODIFIER", 59, 63]]], ["Microbial degradation of lignocellulosic biomass in animal feed and food production, and softwood pulp bleaching in paper production is of increasing industrial significance [3e6] .", [["pulp", "ANATOMY", 98, 102], ["pulp", "TISSUE", 98, 102], ["Microbial degradation of lignocellulosic biomass", "PROBLEM", 0, 48], ["softwood pulp bleaching", "PROBLEM", 89, 112], ["increasing industrial significance", "PROBLEM", 139, 173], ["lignocellulosic biomass", "OBSERVATION", 25, 48], ["softwood pulp bleaching", "OBSERVATION", 89, 112], ["increasing", "OBSERVATION_MODIFIER", 139, 149]]], ["Hemicelluloses are either highly or partially acetylated, which strongly inhibits degradation by polysaccharide-hydrolyzing enzymes [6] .", [["Hemicelluloses", "SIMPLE_CHEMICAL", 0, 14], ["polysaccharide-hydrolyzing enzymes", "PROTEIN", 97, 131], ["Hemicelluloses", "PROBLEM", 0, 14], ["polysaccharide", "TEST", 97, 111], ["hydrolyzing enzymes", "TEST", 112, 131]]], ["However, the activity of major hemicellulose-hydrolyzing enzymes such as xylanases and mannanases can be enhanced by the enzymes acetylxylan esterase and acetyl esterase, which remove acetyl groups from hemicellulose [7, 8] .", [["mannanases", "CHEMICAL", 87, 97], ["acetyl", "CHEMICAL", 154, 160], ["acetyl", "CHEMICAL", 184, 190], ["acetylxylan", "CHEMICAL", 129, 140], ["acetyl", "CHEMICAL", 154, 160], ["acetyl", "CHEMICAL", 184, 190], ["hemicellulose", "SIMPLE_CHEMICAL", 31, 44], ["xylanases", "GENE_OR_GENE_PRODUCT", 73, 82], ["mannanases", "SIMPLE_CHEMICAL", 87, 97], ["acetylxylan esterase", "GENE_OR_GENE_PRODUCT", 129, 149], ["acetyl esterase", "GENE_OR_GENE_PRODUCT", 154, 169], ["acetyl groups", "SIMPLE_CHEMICAL", 184, 197], ["hemicellulose [7, 8]", "SIMPLE_CHEMICAL", 203, 223], ["major hemicellulose-hydrolyzing enzymes", "PROTEIN", 25, 64], ["xylanases", "PROTEIN", 73, 82], ["mannanases", "PROTEIN", 87, 97], ["enzymes", "PROTEIN", 121, 128], ["acetylxylan esterase", "PROTEIN", 129, 149], ["acetyl esterase", "PROTEIN", 154, 169], ["hydrolyzing enzymes", "TEST", 45, 64], ["xylanases", "PROBLEM", 73, 82], ["mannanases", "PROBLEM", 87, 97], ["the enzymes acetylxylan esterase", "TEST", 117, 149], ["acetyl esterase", "TEST", 154, 169], ["acetyl groups", "TREATMENT", 184, 197], ["hemicellulose", "TEST", 203, 216]]], ["Carbohydrate esterases (CE), which includes acetylxylan and acetyl esterase, are categorized into 16 families (CE1e16) within the CAZy database (http://www.cazy.org/Carbohydrate-Esterases.html) [9] .", [["acetyl", "CHEMICAL", 60, 66], ["Carbohydrate", "CHEMICAL", 0, 12], ["acetylxylan", "CHEMICAL", 44, 55], ["acetyl", "CHEMICAL", 60, 66], ["Carbohydrate esterases", "GENE_OR_GENE_PRODUCT", 0, 22], ["CE", "SIMPLE_CHEMICAL", 24, 26], ["acetylxylan", "SIMPLE_CHEMICAL", 44, 55], ["acetyl esterase", "GENE_OR_GENE_PRODUCT", 60, 75], ["Carbohydrate esterases", "PROTEIN", 0, 22], ["acetylxylan", "PROTEIN", 44, 55], ["acetyl esterase", "PROTEIN", 60, 75], ["Carbohydrate esterases", "TEST", 0, 22], ["acetylxylan and acetyl esterase", "TREATMENT", 44, 75]]], ["With the exception of CE4, most CE family enzymes contain an a/b-hydrolase fold and function as serine esterases via a catalytic triad [10e13] .IntroductionThe crystal structures of bacterial CE3 enzymes, which are acetylxylan esterases, have been reported for Clostridium thermocellum (CtCes3-1; PDB code 2vpt) [14] and Sinorhizobium meliloti (Sm23; PDB code 4tx1) [15] .", [["serine", "CHEMICAL", 96, 102], ["acetylxylan", "CHEMICAL", 215, 226], ["CE4", "GENE_OR_GENE_PRODUCT", 22, 25], ["serine", "AMINO_ACID", 96, 102], ["CE3", "GENE_OR_GENE_PRODUCT", 192, 195], ["acetylxylan esterases", "GENE_OR_GENE_PRODUCT", 215, 236], ["Clostridium thermocellum", "ORGANISM", 261, 285], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 287, 295], ["PDB code 2vpt) [14]", "GENE_OR_GENE_PRODUCT", 297, 316], ["Sinorhizobium meliloti", "ORGANISM", 321, 343], ["CE4", "PROTEIN", 22, 25], ["CE family enzymes", "PROTEIN", 32, 49], ["hydrolase", "PROTEIN", 65, 74], ["bacterial CE3 enzymes", "PROTEIN", 182, 203], ["acetylxylan esterases", "PROTEIN", 215, 236], ["Clostridium thermocellum", "SPECIES", 261, 285], ["Sinorhizobium meliloti", "SPECIES", 321, 343], ["Clostridium thermocellum", "SPECIES", 261, 285], ["Sinorhizobium meliloti", "SPECIES", 321, 343], ["an a/b-hydrolase fold", "TEST", 58, 79], ["serine esterases", "TEST", 96, 112], ["a catalytic triad", "TEST", 117, 134], ["bacterial CE3 enzymes", "TEST", 182, 203], ["acetylxylan esterases", "TREATMENT", 215, 236], ["Clostridium thermocellum", "PROBLEM", 261, 285], ["Sinorhizobium meliloti", "TREATMENT", 321, 343]]], ["We recently reported the crystal structure of a fungal CE3 acetyl esterase with a catalytic domain from Talaromyces cellulolyticus (TcAE206; PDB code 5b5s, previous PDB code 3x0h) [16] .", [["acetyl", "CHEMICAL", 59, 65], ["acetyl", "CHEMICAL", 59, 65], ["CE3 acetyl esterase", "GENE_OR_GENE_PRODUCT", 55, 74], ["Talaromyces cellulolyticus", "ORGANISM", 104, 130], ["fungal CE3 acetyl esterase", "PROTEIN", 48, 74], ["catalytic domain", "PROTEIN", 82, 98], ["Talaromyces cellulolyticus (TcAE206; PDB code 5b5s", "PROTEIN", 104, 154], ["Talaromyces cellulolyticus", "SPECIES", 104, 130], ["Talaromyces cellulolyticus", "SPECIES", 104, 130], ["a fungal CE3 acetyl esterase", "PROBLEM", 46, 74], ["a catalytic domain", "PROBLEM", 80, 98], ["Talaromyces cellulolyticus", "TREATMENT", 104, 130], ["fungal", "OBSERVATION_MODIFIER", 48, 54], ["acetyl esterase", "OBSERVATION", 59, 74]]], ["Even though the structure of TcAE206 is similar to that of other CE3 enzymes, its substrate specificity differs considerably.", [["TcAE206", "CHEMICAL", 29, 36], ["TcAE206", "CHEMICAL", 29, 36], ["TcAE206", "GENE_OR_GENE_PRODUCT", 29, 36], ["CE3 enzymes", "GENE_OR_GENE_PRODUCT", 65, 76], ["TcAE206", "PROTEIN", 29, 36], ["CE3 enzymes", "PROTEIN", 65, 76], ["other CE3 enzymes", "TEST", 59, 76]]], ["TcAE206 exhibits enzymatic activity against acetylated oligosaccharides but not acetylated xylans [16] .", [["TcAE206", "CHEMICAL", 0, 7], ["TcAE206", "CHEMICAL", 0, 7], ["acetylated xylans", "CHEMICAL", 80, 97], ["TcAE206", "SIMPLE_CHEMICAL", 0, 7], ["xylans [16]", "SIMPLE_CHEMICAL", 91, 102], ["acetylated oligosaccharides", "PROBLEM", 44, 71], ["acetylated xylans", "TREATMENT", 80, 97], ["enzymatic activity", "OBSERVATION", 17, 35]]], ["In contrast, CtCes3-1 shows enzymatic activity against acetylated xylans and oligosaccharides [14] The substrate specificity of Sm23 was omitted from this comparison because acetylated xylans and oligosaccharides were not used as substrates [15] .", [["Sm23", "CHEMICAL", 128, 132], ["xylans", "CHEMICAL", 66, 72], ["xylans", "CHEMICAL", 185, 191], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 13, 21], ["acetylated xylans", "SIMPLE_CHEMICAL", 55, 72], ["oligosaccharides [14]", "SIMPLE_CHEMICAL", 77, 98], ["Sm23", "SIMPLE_CHEMICAL", 128, 132], ["xylans", "SIMPLE_CHEMICAL", 185, 191], ["oligosaccharides", "SIMPLE_CHEMICAL", 196, 212], ["CtCes3", "PROTEIN", 13, 19], ["Sm23", "PROTEIN", 128, 132], ["CtCes3", "TEST", 13, 19], ["acetylated xylans", "TREATMENT", 55, 72], ["oligosaccharides", "TEST", 77, 93], ["The substrate specificity", "TEST", 99, 124], ["acetylated xylans", "TREATMENT", 174, 191], ["oligosaccharides", "TREATMENT", 196, 212]]], ["The manner in which the acetylated carbohydrate moiety binds has yet to be fully elucidated, however.", [["carbohydrate", "CHEMICAL", 35, 47], ["the acetylated carbohydrate moiety binds", "TREATMENT", 20, 60]]], ["Here, we report for the first time the substrate/product complex structure of a CE3 family enzyme and discuss the substrate-induced conformational change in the generally basic residue His182.IntroductionAbbreviation: TcAE206, the catalytic domain of acetylesterase from Talaromyces cellulolyticus; S10A, mutant of TcAE206 substituted serine 10 with alanine; CE, carbohydrate esterase; CtCes3-1, acetylxylan esterase from Clostridium thermocellum; Sm23, acetylxylan esterase from Sinorhizobium meliloti; RMSD, root mean square deviation.Protein expression and purificationAn expression vector (pS10A) for substituting TcAE206 Ser10 with an Ala residue was constructed by site-directed mutagenesis as described previously [16] .", [["alanine", "CHEMICAL", 350, 357], ["CE", "CHEMICAL", 359, 361], ["TcAE206", "CHEMICAL", 618, 625], ["His", "CHEMICAL", 185, 188], ["serine", "CHEMICAL", 335, 341], ["alanine", "CHEMICAL", 350, 357], ["carbohydrate", "CHEMICAL", 363, 375], ["acetylxylan", "CHEMICAL", 396, 407], ["TcAE206", "CHEMICAL", 618, 625], ["Ala", "CHEMICAL", 640, 643], ["CE3", "GENE_OR_GENE_PRODUCT", 80, 83], ["TcAE206", "GENE_OR_GENE_PRODUCT", 218, 225], ["acetylesterase", "GENE_OR_GENE_PRODUCT", 251, 265], ["Talaromyces cellulolyticus", "ORGANISM", 271, 297], ["S10A", "GENE_OR_GENE_PRODUCT", 299, 303], ["TcAE206 substituted serine 10", "GENE_OR_GENE_PRODUCT", 315, 344], ["alanine", "AMINO_ACID", 350, 357], ["CE", "SIMPLE_CHEMICAL", 359, 361], ["carbohydrate esterase", "GENE_OR_GENE_PRODUCT", 363, 384], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 386, 394], ["acetylxylan esterase", "GENE_OR_GENE_PRODUCT", 396, 416], ["Clostridium thermocellum", "ORGANISM", 422, 446], ["Sm23", "GENE_OR_GENE_PRODUCT", 448, 452], ["acetylxylan esterase", "GENE_OR_GENE_PRODUCT", 454, 474], ["Sinorhizobium meliloti", "ORGANISM", 480, 502], ["TcAE206 Ser10", "GENE_OR_GENE_PRODUCT", 618, 631], ["CE3 family enzyme", "PROTEIN", 80, 97], ["TcAE206", "PROTEIN", 218, 225], ["catalytic domain", "PROTEIN", 231, 247], ["acetylesterase", "PROTEIN", 251, 265], ["S10A", "PROTEIN", 299, 303], ["TcAE206", "PROTEIN", 315, 322], ["carbohydrate esterase", "PROTEIN", 363, 384], ["CtCes3-1, acetylxylan esterase", "PROTEIN", 386, 416], ["Clostridium thermocellum; Sm23, acetylxylan esterase", "PROTEIN", 422, 474], ["purificationAn expression vector", "DNA", 560, 592], ["pS10A", "DNA", 594, 599], ["TcAE206 Ser10", "PROTEIN", 618, 631], ["Talaromyces cellulolyticus", "SPECIES", 271, 297], ["Clostridium thermocellum", "SPECIES", 422, 446], ["Sinorhizobium meliloti", "SPECIES", 480, 502], ["Talaromyces cellulolyticus", "SPECIES", 271, 297], ["Clostridium thermocellum", "SPECIES", 422, 446], ["Sinorhizobium meliloti", "SPECIES", 480, 502], ["the substrate-induced conformational change", "PROBLEM", 110, 153], ["the catalytic domain of acetylesterase", "PROBLEM", 227, 265], ["Talaromyces cellulolyticus", "TEST", 271, 297], ["alanine", "TEST", 350, 357], ["CE", "TEST", 359, 361], ["carbohydrate esterase", "TEST", 363, 384], ["CtCes3", "TEST", 386, 392], ["acetylxylan esterase", "TEST", 396, 416], ["Clostridium thermocellum", "TEST", 422, 446], ["acetylxylan esterase", "TEST", 454, 474], ["root mean square deviation", "PROBLEM", 510, 536], ["Protein expression", "TEST", 537, 555], ["purificationAn expression vector", "TREATMENT", 560, 592], ["substituting TcAE206 Ser10", "TREATMENT", 605, 631], ["an Ala residue", "TREATMENT", 637, 651], ["root", "ANATOMY", 510, 514]]], ["Escherichia coli BL21 (DE3) harboring pS10A was cultivated and induced as described previously [16] .", [["Escherichia coli", "ORGANISM", 0, 16], ["BL21", "ORGANISM", 17, 21], ["DE3", "GENE_OR_GENE_PRODUCT", 23, 26], ["pS10A", "GENE_OR_GENE_PRODUCT", 38, 43], ["DE3", "PROTEIN", 23, 26], ["pS10A", "DNA", 38, 43], ["Escherichia coli BL21", "SPECIES", 0, 21], ["Escherichia coli BL21", "SPECIES", 0, 21], ["DE3", "SPECIES", 23, 26], ["Escherichia coli", "PROBLEM", 0, 16], ["harboring pS10A", "PROBLEM", 28, 43], ["coli BL21", "OBSERVATION", 12, 21]]], ["The cells were then harvested by centrifugation, dissolved in 20 mM Tris-HCl (pH 8.0) containing 50 mM NaCl, and stored at \u00c080 C. The cells were lysed by three cycles of freezing-thawing, and the resulting lysate was centrifuged (35,870 \u00c2 g for 20 min at 4 C); the resulting supernatant including mutant of TcAE206 (S10A) was loaded onto a HiTrap Q column (GE Healthcare, Buckinghamshire, UK) equilibrated with 20 mM Tris-HCl (pH 8.0) and eluted using a linear gradient of 0.0e1.0 M NaCl in the same buffer.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 134, 139], ["lysate", "ANATOMY", 206, 212], ["supernatant", "ANATOMY", 275, 286], ["Tris-HCl", "CHEMICAL", 68, 76], ["NaCl", "CHEMICAL", 103, 107], ["TcAE206", "CHEMICAL", 307, 314], ["Tris-HCl", "CHEMICAL", 417, 425], ["NaCl", "CHEMICAL", 483, 487], ["Tris-HCl", "CHEMICAL", 68, 76], ["NaCl", "CHEMICAL", 103, 107], ["Tris-HCl", "CHEMICAL", 417, 425], ["NaCl", "CHEMICAL", 483, 487], ["cells", "CELL", 4, 9], ["Tris-HCl", "SIMPLE_CHEMICAL", 68, 76], ["cells", "CELL", 134, 139], ["TcAE206", "SIMPLE_CHEMICAL", 307, 314], ["Tris-HCl", "SIMPLE_CHEMICAL", 417, 425], ["S10A", "PROTEIN", 316, 320], ["pH", "TEST", 78, 80], ["50 mM NaCl", "TREATMENT", 97, 107], ["freezing-thawing", "TREATMENT", 170, 186], ["a HiTrap Q column", "TREATMENT", 338, 355], ["pH", "TEST", 427, 429], ["a linear gradient", "TEST", 452, 469], ["NaCl", "TREATMENT", 483, 487]]], ["The collected active fractions were saturated with 1.0 M (NH 4 ) 2 SO 4 and then loaded onto a HiTrap PHE column (GE Healthcare) previously equilibrated with the same buffer containing 1.0 M (NH 4 ) 2 SO 4 .", [["PHE", "CHEMICAL", 102, 105], ["(NH 4 ) 2 SO 4", "CHEMICAL", 57, 71], ["(NH 4 ) 2 SO 4", "CHEMICAL", 191, 205], ["NH 4 ) 2 SO 4", "SIMPLE_CHEMICAL", 58, 71], ["The collected active fractions", "TREATMENT", 0, 30], ["a HiTrap PHE column (GE Healthcare)", "TREATMENT", 93, 128], ["the same buffer containing", "TREATMENT", 158, 184], ["active", "OBSERVATION_MODIFIER", 14, 20], ["fractions", "OBSERVATION_MODIFIER", 21, 30]]], ["The enzyme was eluted with a linear 1.0e0.0 M (NH 4 ) 2 SO 4 gradient.", [["(NH 4 ) 2 SO 4", "CHEMICAL", 46, 60], ["The enzyme", "TEST", 0, 10]]], ["The active fractions were pooled, concentrated, and loaded onto a Superdex 200 pg gel filtration column (GE Healthcare) equilibrated with 20 mM Tris-HCl (pH 8.0) containing 50 mM NaCl.", [["fractions", "ANATOMY", 11, 20], ["Tris-HCl", "CHEMICAL", 144, 152], ["NaCl", "CHEMICAL", 179, 183], ["Tris-HCl", "CHEMICAL", 144, 152], ["NaCl", "CHEMICAL", 179, 183], ["Tris-HCl", "SIMPLE_CHEMICAL", 144, 152], ["a Superdex 200 pg gel filtration column (GE Healthcare", "TREATMENT", 64, 118], ["20 mM Tris-HCl", "TREATMENT", 138, 152], ["pH", "TEST", 154, 156], ["50 mM NaCl", "TREATMENT", 173, 183], ["active", "OBSERVATION_MODIFIER", 4, 10], ["fractions", "OBSERVATION_MODIFIER", 11, 20]]], ["The protein concentration was determined by measuring the absorption at 280 nm.", [["The protein concentration", "TEST", 0, 25], ["protein concentration", "OBSERVATION", 4, 25]]], ["The protein was then concentrated to 12 mg mL \u00c01 in 20 mM Tris-HCl buffer (pH 8.0).Crystallization and X-ray diffraction analysisThe initial crystallization screening of S10A was performed using Crystal Screen HT (Hampton Research) at 20 C by the sittingdrop vapor diffusion method, in which a 0.5-mL volume of protein solution was mixed with an equal volume of reservoir solution.", [["Tris-HCl", "CHEMICAL", 58, 66], ["Tris-HCl", "CHEMICAL", 58, 66], ["Tris-HCl", "SIMPLE_CHEMICAL", 58, 66], ["S10A", "SIMPLE_CHEMICAL", 170, 174], ["pH", "TEST", 75, 77], ["Crystallization", "TEST", 83, 98], ["X-ray diffraction analysis", "TEST", 103, 129], ["The initial crystallization screening", "TEST", 129, 166], ["Crystal Screen", "TEST", 195, 209], ["a 0.5-mL volume of protein solution", "TREATMENT", 292, 327], ["an equal volume of reservoir solution", "TREATMENT", 343, 380]]], ["Small crystals were grown for 1 day in reagent No.", [["Small crystals", "PROBLEM", 0, 14], ["crystals", "OBSERVATION", 6, 14]]], ["G3, 0.1 M 2morpholinoethanesulfonic acid (MES) buffer (pH 6.5), 25% (v/v) polyethylene glycol monomethyl ester (PEGME) 550, and 10 mM ZnSO 4 .", [["0.1 M 2morpholinoethanesulfonic acid", "CHEMICAL", 4, 40], ["MES", "CHEMICAL", 42, 45], ["polyethylene glycol monomethyl ester", "CHEMICAL", 74, 110], ["PEGME", "CHEMICAL", 112, 117], ["2morpholinoethanesulfonic acid", "CHEMICAL", 10, 40], ["MES", "CHEMICAL", 42, 45], ["polyethylene glycol monomethyl ester", "CHEMICAL", 74, 110], ["PEGME", "CHEMICAL", 112, 117], ["ZnSO 4", "CHEMICAL", 134, 140], ["M 2morpholinoethanesulfonic acid", "SIMPLE_CHEMICAL", 8, 40], ["MES", "SIMPLE_CHEMICAL", 42, 45], ["polyethylene glycol monomethyl ester", "SIMPLE_CHEMICAL", 74, 110], ["PEGME", "SIMPLE_CHEMICAL", 112, 117], ["G3", "TEST", 0, 2], ["2morpholinoethanesulfonic acid (MES) buffer (pH", "TREATMENT", 10, 57], ["v/v) polyethylene glycol monomethyl ester (PEGME)", "TREATMENT", 69, 118]]], ["The crystallization conditions were optimized using the hanging-drop vapor diffusion method, in which a 2.0-mL volume of protein solution was mixed with an equal volume of reservoir solution.", [["the hanging-drop vapor diffusion method", "TREATMENT", 52, 91], ["a 2.0-mL volume of protein solution", "TREATMENT", 102, 137], ["an equal volume of reservoir solution", "TREATMENT", 153, 190]]], ["S10A, with 10 mM D-glucose pentaacetate (Sigma-Aldrich, St. Louis, MO, USA), was crystallized in 0.1 M MES buffer (pH 6.5), 15e20% (v/v) PEGME 550, and 10 mM ZnSO 4 for 3 days at 20 C. The resulting crystals were then soaked in reservoir solution containing 25% (v/v) polyethylene glycol 400 as a cryoprotectant.", [["S10A", "CHEMICAL", 0, 4], ["D-glucose pentaacetate", "CHEMICAL", 17, 39], ["ZnSO", "CHEMICAL", 158, 162], ["polyethylene glycol 400", "CHEMICAL", 268, 291], ["D-glucose pentaacetate", "CHEMICAL", 17, 39], ["ZnSO 4", "CHEMICAL", 158, 164], ["polyethylene glycol", "CHEMICAL", 268, 287], ["S10A", "SIMPLE_CHEMICAL", 0, 4], ["D-glucose pentaacetate", "SIMPLE_CHEMICAL", 17, 39], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 41, 54], ["St. Louis", "ORGANISM", 56, 65], ["polyethylene glycol 400", "SIMPLE_CHEMICAL", 268, 291], ["pH", "TEST", 115, 117], ["PEGME", "TREATMENT", 137, 142], ["10 mM ZnSO", "TREATMENT", 152, 162], ["The resulting crystals", "TREATMENT", 185, 207], ["reservoir solution", "TREATMENT", 228, 246], ["v/v) polyethylene glycol", "TREATMENT", 263, 287], ["a cryoprotectant", "TREATMENT", 295, 311]]], ["X-ray diffraction data for the S10Aeacetate ion crystals were collected at the beamline BL44XU at SPring-8 (Hyogo, Japan) using 0.9-\u00c5 wavelength radiation.", [["S10Aeacetate", "CHEMICAL", 31, 43], ["S10Aeacetate", "CHEMICAL", 31, 43], ["S10Aeacetate ion crystals", "SIMPLE_CHEMICAL", 31, 56], ["X-ray diffraction data", "TEST", 0, 22], ["the S10Aeacetate ion crystals", "PROBLEM", 27, 56], ["0.9-\u00c5 wavelength radiation", "TREATMENT", 128, 154]]], ["A total 180 of data were collected using a Rayonix MX300-HE CCD detector.", [["a Rayonix MX300", "TREATMENT", 41, 56]]], ["All data were processed to 1.40-\u00c5 resolution using HKL2000 (DENZO and SCALEPACK) [17] .Phasing, refinement, and structural analysisGeneral data handling was carried out using the CCP4 package [18] .", [["All data", "TEST", 0, 8], ["HKL2000 (DENZO and SCALEPACK)", "TREATMENT", 51, 80], ["structural analysis", "TEST", 112, 131], ["the CCP4 package", "TREATMENT", 175, 191]]], ["The initial model of the S10A mutant complexed with acetate ion was determined by molecular replacement using PHASER [19] with a search model of TcAE206 (PDB code 5b5s).", [["acetate", "CHEMICAL", 52, 59], ["acetate", "CHEMICAL", 52, 59], ["S10A", "GENE_OR_GENE_PRODUCT", 25, 29], ["acetate", "SIMPLE_CHEMICAL", 52, 59], ["TcAE206", "SIMPLE_CHEMICAL", 145, 152], ["S10A mutant", "PROTEIN", 25, 36], ["TcAE206", "PROTEIN", 145, 152], ["PDB code 5b5s", "PROTEIN", 154, 167], ["acetate ion", "TREATMENT", 52, 63]]], ["Water molecules were added using COOT, and model geometry was analyzed using RAMPAGE [22] .", [["COOT", "SIMPLE_CHEMICAL", 33, 37], ["Water molecules", "TREATMENT", 0, 15], ["COOT", "TREATMENT", 33, 37]]], ["Molecular graphics figures were created using PyMOL (http://pymol. sourceforge.net/) [23] .Overall structure of TcAE206_S10A complexed with acetate ionThe complex structure of S10Aeacetate ion was solved at 1.4-\u00c5 resolution.", [["TcAE206_", "CHEMICAL", 112, 120], ["acetate", "CHEMICAL", 140, 147], ["S10Aeacetate", "CHEMICAL", 176, 188], ["TcAE206_S10A", "CHEMICAL", 112, 124], ["acetate", "CHEMICAL", 140, 147], ["S10Aeacetate", "CHEMICAL", 176, 188], ["TcAE206_S10A", "SIMPLE_CHEMICAL", 112, 124], ["acetate ion", "SIMPLE_CHEMICAL", 140, 151], ["S10Aeacetate ion", "SIMPLE_CHEMICAL", 176, 192], ["TcAE206_S10A", "PROTEIN", 112, 124], ["PyMOL (http://pymol", "TREATMENT", 46, 65], ["acetate ion", "TREATMENT", 140, 151], ["S10Aeacetate ion", "TREATMENT", 176, 192], ["complex", "OBSERVATION_MODIFIER", 155, 162], ["structure", "OBSERVATION_MODIFIER", 163, 172]]], ["The prepared crystals belonged to space group P3 2 21, with unit cell a \u00bc b \u00bc 64.6 \u00c5 and c \u00bc 89.6 \u00c5.", [["cell", "ANATOMY", 65, 69], ["space group P3 2 21", "DNA", 34, 53], ["The prepared crystals", "TREATMENT", 0, 21], ["space group P3", "TEST", 34, 48], ["c", "TEST", 89, 90]]], ["The asymmetric unit consisted of one molecule with a solvent content of 49.4%, which corresponded to a Matthews coefficient of 2.43 \u00c5 3 Da \u00c01 [24] .", [["a solvent content", "TEST", 51, 68], ["asymmetric", "OBSERVATION_MODIFIER", 4, 14]]], ["Data collection and refinement statistics are shown in Table 1 .", [["Data collection", "TEST", 0, 15]]], ["The overall structure of S10A was constructed from Met1 to Ser207, with an acetate ion, solvent molecules, and metal ions.", [["acetate", "CHEMICAL", 75, 82], ["Ser207", "CHEMICAL", 59, 65], ["acetate", "CHEMICAL", 75, 82], ["S10A", "GENE_OR_GENE_PRODUCT", 25, 29], ["Met1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Ser207", "GENE_OR_GENE_PRODUCT", 59, 65], ["acetate", "SIMPLE_CHEMICAL", 75, 82], ["metal ions", "SIMPLE_CHEMICAL", 111, 121], ["S10A", "PROTEIN", 25, 29], ["an acetate ion, solvent molecules", "TREATMENT", 72, 105], ["metal ions", "TREATMENT", 111, 121], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["metal ions", "OBSERVATION", 111, 121]]], ["There was no major difference in overall structure between S10A and wild-type TcAE206 [16] , with the root mean square deviation (RMSD) of 0.4 \u00c5 over 207 Ca atoms.", [["Ca", "CHEMICAL", 154, 156], ["Ca", "CHEMICAL", 154, 156], ["S10A", "PROTEIN", 59, 63], ["major difference in overall structure between S10A", "PROBLEM", 13, 63], ["no", "UNCERTAINTY", 10, 12], ["major", "OBSERVATION_MODIFIER", 13, 18], ["difference", "OBSERVATION_MODIFIER", 19, 29], ["root", "ANATOMY_MODIFIER", 102, 106]]], ["Briefly, the structure of S10A formed an a/b-hydrolase fold and canonical SGNH-hydrolase superfamily fold comprising five central parallel b-strands and flanked by six a-helices, with a classic serine esterase catalytic triad (Ser-Asp-His).Overall structure of TcAE206_S10A complexed with acetate ionThe catalytic domain structure of TcAE206 is similar to the structures of CtCes3-1 (Z-score of 25.5 and RMSD of 2.0 \u00c5 over 192 Ca atoms) and Sm23 (Z-score of 19.8 and RMSD of 1.9 \u00c5 over 168 Ca atoms) [14e16].", [["TcAE206_", "CHEMICAL", 261, 269], ["acetate", "CHEMICAL", 289, 296], ["TcAE206", "CHEMICAL", 334, 341], ["Ca", "CHEMICAL", 427, 429], ["Ca", "CHEMICAL", 490, 492], ["serine", "CHEMICAL", 194, 200], ["His", "CHEMICAL", 235, 238], ["TcAE206_S10A", "CHEMICAL", 261, 273], ["acetate", "CHEMICAL", 289, 296], ["TcAE206", "CHEMICAL", 334, 341], ["Ca", "CHEMICAL", 427, 429], ["Ca", "CHEMICAL", 490, 492], ["S10A", "GENE_OR_GENE_PRODUCT", 26, 30], ["SGNH-hydrolase", "GENE_OR_GENE_PRODUCT", 74, 88], ["TcAE206_S10A", "SIMPLE_CHEMICAL", 261, 273], ["acetate", "SIMPLE_CHEMICAL", 289, 296], ["TcAE206", "SIMPLE_CHEMICAL", 334, 341], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 374, 382], ["S10A", "PROTEIN", 26, 30], ["SGNH", "PROTEIN", 74, 78], ["hydrolase superfamily", "PROTEIN", 79, 100], ["b-strands", "PROTEIN", 139, 148], ["a-helices", "PROTEIN", 168, 177], ["classic serine esterase catalytic triad", "PROTEIN", 186, 225], ["Ser-Asp", "PROTEIN", 227, 234], ["His", "PROTEIN", 235, 238], ["TcAE206_S10A", "PROTEIN", 261, 273], ["catalytic domain structure", "PROTEIN", 304, 330], ["TcAE206", "PROTEIN", 334, 341], ["CtCes3", "PROTEIN", 374, 380], ["an a/b-hydrolase fold", "PROBLEM", 38, 59], ["canonical SGNH", "TEST", 64, 78], ["hydrolase superfamily fold", "PROBLEM", 79, 105], ["a classic serine esterase catalytic triad", "PROBLEM", 184, 225], ["acetate", "TREATMENT", 289, 296], ["CtCes3", "TEST", 374, 380], ["Z-score", "TEST", 384, 391], ["RMSD", "TEST", 404, 408], ["Ca atoms", "TEST", 427, 435], ["Sm23", "TEST", 441, 445], ["Z-score", "TEST", 447, 454], ["RMSD", "TEST", 467, 471], ["central", "ANATOMY_MODIFIER", 122, 129]]], ["In addition, the major residues constituting the catalytic triad (Ser10, Asp180, and His182) and oxyanion hole (Ser10, Gly62, and Asn92) in the active site of TcAE206 are completely conserved in CtCes3-1 (Ser44, Asp205, His208, Gly95, and Asn124) and Sm23 (Ser10, Asp187, His190, Gly50, and Asn90) ( Supplementary Fig. S1 ).", [["Ser10", "CHEMICAL", 66, 71], ["Asp", "CHEMICAL", 73, 76], ["His", "CHEMICAL", 85, 88], ["Ser10", "CHEMICAL", 112, 117], ["Gly62", "CHEMICAL", 119, 124], ["Asn92", "CHEMICAL", 130, 135], ["Ser44", "CHEMICAL", 205, 210], ["Asp205", "CHEMICAL", 212, 218], ["His208", "CHEMICAL", 220, 226], ["Gly95", "CHEMICAL", 228, 233], ["Asn124", "CHEMICAL", 239, 245], ["Sm23", "CHEMICAL", 251, 255], ["Ser10", "CHEMICAL", 257, 262], ["Asp", "CHEMICAL", 264, 267], ["His", "CHEMICAL", 272, 275], ["Gly50", "CHEMICAL", 280, 285], ["Asn90", "CHEMICAL", 291, 296], ["Ser10", "GENE_OR_GENE_PRODUCT", 66, 71], ["Asp180", "AMINO_ACID", 73, 79], ["His182", "GENE_OR_GENE_PRODUCT", 85, 91], ["Ser10", "GENE_OR_GENE_PRODUCT", 112, 117], ["Gly62", "GENE_OR_GENE_PRODUCT", 119, 124], ["Asn92", "GENE_OR_GENE_PRODUCT", 130, 135], ["TcAE206", "GENE_OR_GENE_PRODUCT", 159, 166], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 195, 203], ["Ser44", "GENE_OR_GENE_PRODUCT", 205, 210], ["Asp205", "GENE_OR_GENE_PRODUCT", 212, 218], ["His208", "GENE_OR_GENE_PRODUCT", 220, 226], ["Gly95", "GENE_OR_GENE_PRODUCT", 228, 233], ["Asn124", "GENE_OR_GENE_PRODUCT", 239, 245], ["Sm23", "GENE_OR_GENE_PRODUCT", 251, 255], ["Ser10", "GENE_OR_GENE_PRODUCT", 257, 262], ["Asp187", "AMINO_ACID", 264, 270], ["His190", "GENE_OR_GENE_PRODUCT", 272, 278], ["Gly50", "GENE_OR_GENE_PRODUCT", 280, 285], ["Asn90", "GENE_OR_GENE_PRODUCT", 291, 296], ["catalytic triad", "PROTEIN", 49, 64], ["Ser10", "PROTEIN", 66, 71], ["His182", "PROTEIN", 85, 91], ["oxyanion hole", "PROTEIN", 97, 110], ["Ser10", "PROTEIN", 112, 117], ["Gly62", "PROTEIN", 119, 124], ["Asn92", "PROTEIN", 130, 135], ["TcAE206", "PROTEIN", 159, 166], ["CtCes3", "PROTEIN", 195, 201], ["Sm23", "PROTEIN", 251, 255], ["Asn90", "PROTEIN", 291, 296], ["the catalytic triad", "TEST", 45, 64], ["Asp", "TEST", 73, 76], ["oxyanion hole", "TREATMENT", 97, 110], ["CtCes3", "TEST", 195, 201], ["Asp205", "TEST", 212, 218], ["His208", "TEST", 220, 226], ["Sm23", "TEST", 251, 255], ["Ser10", "TEST", 257, 262], ["Asp", "TEST", 264, 267], ["His", "TEST", 272, 275], ["Gly50", "TEST", 280, 285], ["Asn90", "TEST", 291, 296], ["S1", "ANATOMY", 319, 321]]], ["The coordinates and structural factors for TcAE206_S10A were deposited in the Protein Data Bank under the accession code 5B5L.Metal-binding sitesSimilar to TcAE206 and CtCes3-1, a calcium ion that does not affect the enzymatic activity was observed the N-terminal end of the central b-strand (b2) in S10A (Fig. 1) [14, 16] .", [["Metal", "CHEMICAL", 126, 131], ["calcium", "CHEMICAL", 180, 187], ["TcAE206", "CHEMICAL", 156, 163], ["CtCes3-1", "CHEMICAL", 168, 176], ["calcium", "CHEMICAL", 180, 187], ["N", "CHEMICAL", 253, 254], ["TcAE206_S10A", "GENE_OR_GENE_PRODUCT", 43, 55], ["TcAE206", "SIMPLE_CHEMICAL", 156, 163], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 168, 176], ["calcium", "SIMPLE_CHEMICAL", 180, 187], ["structural factors", "PROTEIN", 20, 38], ["TcAE206_S10A", "PROTEIN", 43, 55], ["5B5L", "PROTEIN", 121, 125], ["CtCes3", "PROTEIN", 168, 174], ["N-terminal end", "PROTEIN", 253, 267], ["central b-strand", "PROTEIN", 275, 291], ["b2", "PROTEIN", 293, 295], ["TcAE206_S10A", "PROBLEM", 43, 55], ["Metal-binding sitesSimilar", "TEST", 126, 152], ["TcAE206", "TEST", 156, 163], ["CtCes3", "TEST", 168, 174], ["a calcium ion", "TEST", 178, 191], ["enzymatic activity", "OBSERVATION", 217, 235], ["central", "ANATOMY_MODIFIER", 275, 282], ["b-strand", "OBSERVATION", 283, 291]]], ["Interestingly, significant electron density coordinated in a distorted octahedral form with six coordination bonds was also observed: Asp56 (OD1 and OD2), three water molecules, and His98 (NE2) in crystallographic symmetry.", [["His98", "CHEMICAL", 182, 187], ["NE2", "CHEMICAL", 189, 192], ["Asp56", "CHEMICAL", 134, 139], ["OD2", "CHEMICAL", 149, 152], ["His98", "CHEMICAL", 182, 187], ["NE2", "CHEMICAL", 189, 192], ["electron", "SIMPLE_CHEMICAL", 27, 35], ["Asp56", "SIMPLE_CHEMICAL", 134, 139], ["OD1", "SIMPLE_CHEMICAL", 141, 144], ["His98", "SIMPLE_CHEMICAL", 182, 187], ["NE2", "SIMPLE_CHEMICAL", 189, 192], ["Asp56", "PROTEIN", 134, 139], ["OD1", "PROTEIN", 141, 144], ["OD2", "PROTEIN", 149, 152], ["water molecules", "PROTEIN", 161, 176], ["NE2", "PROTEIN", 189, 192], ["significant electron density coordinated", "PROBLEM", 15, 55], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["electron", "OBSERVATION_MODIFIER", 27, 35], ["density", "OBSERVATION", 36, 43]]], ["These features are not present in the structures of wildtype TcAE206, CtCes3-1, or Sm23 [14e16].", [["TcAE206", "GENE_OR_GENE_PRODUCT", 61, 68], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 70, 78], ["Sm23", "GENE_OR_GENE_PRODUCT", 83, 87], ["wildtype TcAE206", "PROTEIN", 52, 68], ["CtCes3", "PROTEIN", 70, 76], ["CtCes3", "TEST", 70, 76], ["not present", "UNCERTAINTY", 19, 30]]], ["We assigned a zinc ion to this electron density based on electron density size, shape, and coordination number, which is appropriate based on the presence of ZnSO 4 in the crystallization solution.", [["zinc", "CHEMICAL", 14, 18], ["ZnSO 4", "CHEMICAL", 158, 164], ["zinc", "CHEMICAL", 14, 18], ["ZnSO 4", "CHEMICAL", 158, 164], ["electron", "SIMPLE_CHEMICAL", 31, 39], ["electron", "SIMPLE_CHEMICAL", 57, 65], ["ZnSO 4", "SIMPLE_CHEMICAL", 158, 164], ["ZnSO 4", "PROTEIN", 158, 164], ["a zinc ion", "TREATMENT", 12, 22], ["ZnSO", "TREATMENT", 158, 162], ["the crystallization solution", "TREATMENT", 168, 196], ["electron density", "OBSERVATION_MODIFIER", 57, 73], ["size", "OBSERVATION_MODIFIER", 74, 78], ["shape", "OBSERVATION_MODIFIER", 80, 85], ["coordination", "OBSERVATION_MODIFIER", 91, 103], ["number", "OBSERVATION_MODIFIER", 104, 110]]], ["It is assumed that introduction of this zinc ion further strengthens the hydrogen bond network between neighboring molecules.", [["zinc", "CHEMICAL", 40, 44], ["zinc", "CHEMICAL", 40, 44], ["hydrogen", "CHEMICAL", 73, 81], ["zinc ion", "SIMPLE_CHEMICAL", 40, 48], ["this zinc ion", "TREATMENT", 35, 48], ["hydrogen bond", "OBSERVATION", 73, 86]]], ["Calcium and zinc ions are located sufficiently far from the active site that they are presumed to contribute to stabilization of the structure rather than catalytic activity.Surface environment of the active site entranceAlthough the key residues of the active site are completely conserved in TcAE206 and CtCes3-1, the substrate specificity of TcAE206 (S10A) differs from that of CtCes3-1 [14, 16] .", [["Calcium", "CHEMICAL", 0, 7], ["zinc", "CHEMICAL", 12, 16], ["Calcium", "CHEMICAL", 0, 7], ["zinc", "CHEMICAL", 12, 16], ["Calcium", "SIMPLE_CHEMICAL", 0, 7], ["zinc ions", "SIMPLE_CHEMICAL", 12, 21], ["TcAE206", "GENE_OR_GENE_PRODUCT", 294, 301], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 306, 314], ["TcAE206", "GENE_OR_GENE_PRODUCT", 345, 352], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 381, 389], ["TcAE206 and CtCes3-1", "DNA", 294, 314], ["TcAE206", "PROTEIN", 345, 352], ["S10A", "PROTEIN", 354, 358], ["CtCes3", "PROTEIN", 381, 387], ["Calcium and zinc ions", "TREATMENT", 0, 21], ["CtCes3", "TEST", 306, 312], ["CtCes3", "TEST", 381, 387], ["zinc ions", "OBSERVATION", 12, 21], ["active", "OBSERVATION_MODIFIER", 60, 66], ["site", "OBSERVATION", 67, 71], ["presumed to contribute to", "UNCERTAINTY", 86, 111], ["stabilization", "OBSERVATION", 112, 125], ["catalytic activity", "OBSERVATION", 155, 173], ["active", "OBSERVATION_MODIFIER", 201, 207], ["active", "OBSERVATION_MODIFIER", 254, 260]]], ["As mentioned in the \"Introduction\" section, Sm23 was omitted from this comparison because acetylated xylans (polysaccharides) and oligosaccharides were not used as substrates [15] .", [["xylans", "CHEMICAL", 101, 107], ["xylans", "CHEMICAL", 101, 107], ["Sm23", "GENE_OR_GENE_PRODUCT", 44, 48], ["xylans", "SIMPLE_CHEMICAL", 101, 107], ["polysaccharides", "SIMPLE_CHEMICAL", 109, 124], ["oligosaccharides", "SIMPLE_CHEMICAL", 130, 146], ["acetylated xylans (polysaccharides", "TREATMENT", 90, 124], ["oligosaccharides", "TREATMENT", 130, 146]]], ["Nucleophilic Ser10 (substituted with Ala in this study) and additional residues that form the oxyanion hole (Gly62 and Asn92) are located in the small cavity, and the catalytic triad residues Asp179 and His182 are also located near this region ( Fig. 2A) .", [["Ser10", "CHEMICAL", 13, 18], ["Ala", "CHEMICAL", 37, 40], ["Gly62", "CHEMICAL", 109, 114], ["Ser10", "CHEMICAL", 13, 18], ["Ala", "CHEMICAL", 37, 40], ["Gly62", "CHEMICAL", 109, 114], ["Asn92", "CHEMICAL", 119, 124], ["Asp179", "CHEMICAL", 192, 198], ["His", "CHEMICAL", 203, 206], ["Ser10", "SIMPLE_CHEMICAL", 13, 18], ["Ala", "AMINO_ACID", 37, 40], ["Gly62", "SIMPLE_CHEMICAL", 109, 114], ["Asn92", "AMINO_ACID", 119, 124], ["His182", "AMINO_ACID", 203, 209], ["catalytic triad residues", "PROTEIN", 167, 191], ["Fig. 2A", "PROTEIN", 246, 253], ["Nucleophilic Ser10", "TREATMENT", 0, 18], ["Ala", "TREATMENT", 37, 40], ["this study", "TEST", 44, 54], ["additional residues", "TREATMENT", 60, 79], ["the oxyanion hole (Gly62 and Asn92)", "TREATMENT", 90, 125], ["the catalytic triad residues Asp179", "PROBLEM", 163, 198], ["small cavity", "ANATOMY", 145, 157]]], ["The cavity is approximately 6.0 \u00c2 7.0 \u00c2 6.0 \u00c5 (vertical \u00c2 horizontal \u00c2 depth) in TcAE206 (S10A) and 6.5 \u00c2 7.0 \u00c2 10 \u00c5 in CtCes3-1.", [["CtCes3-1", "GENE_OR_GENE_PRODUCT", 120, 128], ["TcAE206", "PROTEIN", 81, 88], ["S10A", "PROTEIN", 90, 94], ["CtCes3", "PROTEIN", 120, 126], ["\u00c2", "TEST", 38, 39], ["\u00c5", "TEST", 44, 45], ["vertical \u00c2 horizontal \u00c2 depth", "TEST", 47, 76], ["TcAE206", "TEST", 81, 88], ["S10A", "TEST", 90, 94], ["\u00c2", "TEST", 104, 105], ["CtCes3", "TEST", 120, 126], ["cavity", "OBSERVATION_MODIFIER", 4, 10], ["approximately", "OBSERVATION_MODIFIER", 14, 27], ["6.0", "OBSERVATION_MODIFIER", 28, 31]]], ["Although the cavity in each enzyme has sufficient volume to accommodate an acetate group, the total cleft volume of S10A is substantially smaller than that of CtCes3-1: pocket volumes of approximately 140 \u00c5 3 (S10A) and 250 \u00c5 3 (CtCes3-1), respectively, as calculated using the CASTp server (http://cast.engr.uic.edu) [25] .", [["acetate", "CHEMICAL", 75, 82], ["acetate", "CHEMICAL", 75, 82], ["acetate", "SIMPLE_CHEMICAL", 75, 82], ["cleft", "ORGAN", 100, 105], ["S10A", "GENE_OR_GENE_PRODUCT", 116, 120], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 159, 167], ["S10A", "PROTEIN", 116, 120], ["CtCes3", "PROTEIN", 159, 165], ["the cavity in each enzyme", "TEST", 9, 34], ["an acetate group", "TREATMENT", 72, 88], ["the total cleft volume", "TEST", 90, 112], ["CtCes3", "TEST", 159, 165], ["pocket volumes", "TEST", 169, 183], ["CtCes3", "TEST", 229, 235], ["cavity", "OBSERVATION", 13, 19], ["sufficient volume", "OBSERVATION", 39, 56], ["total", "OBSERVATION_MODIFIER", 94, 99], ["cleft", "OBSERVATION_MODIFIER", 100, 105], ["volume", "OBSERVATION_MODIFIER", 106, 112], ["substantially", "OBSERVATION_MODIFIER", 124, 137], ["smaller", "OBSERVATION_MODIFIER", 138, 145], ["pocket", "OBSERVATION_MODIFIER", 169, 175], ["volumes", "OBSERVATION_MODIFIER", 176, 183]]], ["Correia et al. reported that the internal cavity of CtCes3-1 may be able to accommodate more bulky polysaccharide substrates [14] .", [["CtCes3-1", "GENE_OR_GENE_PRODUCT", 52, 60], ["CtCes3", "PROTEIN", 52, 58], ["more bulky polysaccharide substrates", "PROBLEM", 88, 124], ["internal cavity", "ANATOMY", 33, 48]]], ["Our complex structure supports their conclusion because our data provide an explanation as to why TcAE206 does not exhibit enzyme activity toward polysaccharide substrates.Surface environment of the active site entranceWe also compared electron potential maps for the areas around the hydrophobic pockets of S10A and CtCes3-1 (Fig. 2B ).", [["TcAE206", "CHEMICAL", 98, 105], ["TcAE206", "CHEMICAL", 98, 105], ["TcAE206", "SIMPLE_CHEMICAL", 98, 105], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 317, 325], ["S10A", "PROTEIN", 308, 312], ["CtCes3", "PROTEIN", 317, 323], ["Fig. 2B", "PROTEIN", 327, 334], ["polysaccharide substrates", "TREATMENT", 146, 171], ["S10A", "TEST", 308, 312], ["CtCes3", "TEST", 317, 323], ["active", "OBSERVATION_MODIFIER", 199, 205], ["hydrophobic pockets", "OBSERVATION", 285, 304]]], ["S10A forms a flat surface around the pocket, whereas protrusions on both sides of the active site pocket are apparent with CtCes3-1.", [["surface", "ANATOMY", 18, 25], ["S10A", "CHEMICAL", 0, 4], ["S10A", "GENE_OR_GENE_PRODUCT", 0, 4], ["flat surface", "CELLULAR_COMPONENT", 13, 25], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 123, 131], ["S10A", "PROTEIN", 0, 4], ["CtCes3", "PROTEIN", 123, 129], ["a flat surface around the pocket", "PROBLEM", 11, 43], ["CtCes3", "TEST", 123, 129], ["flat", "OBSERVATION_MODIFIER", 13, 17], ["surface", "OBSERVATION_MODIFIER", 18, 25], ["pocket", "OBSERVATION_MODIFIER", 37, 43], ["protrusions", "OBSERVATION_MODIFIER", 53, 64], ["both", "ANATOMY_MODIFIER", 68, 72], ["sides", "ANATOMY_MODIFIER", 73, 78], ["active", "OBSERVATION_MODIFIER", 86, 92], ["site", "OBSERVATION_MODIFIER", 93, 97], ["pocket", "OBSERVATION", 98, 104]]], ["The area around the pocket region of S10A is more hydrophobic than the area around the pocket of CtCes3-1; S10A has few charged residues in this area to interact with a carbohydrate moiety.", [["carbohydrate", "CHEMICAL", 169, 181], ["S10A", "GENE_OR_GENE_PRODUCT", 37, 41], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 97, 105], ["S10A", "GENE_OR_GENE_PRODUCT", 107, 111], ["S10A", "PROTEIN", 37, 41], ["CtCes3", "PROTEIN", 97, 103], ["S10A", "PROTEIN", 107, 111], ["CtCes3", "TEST", 97, 103], ["few charged residues", "PROBLEM", 116, 136], ["a carbohydrate moiety", "TREATMENT", 167, 188], ["area", "OBSERVATION_MODIFIER", 4, 8], ["pocket", "OBSERVATION_MODIFIER", 20, 26], ["more", "OBSERVATION_MODIFIER", 45, 49], ["hydrophobic", "OBSERVATION_MODIFIER", 50, 61], ["pocket", "OBSERVATION_MODIFIER", 87, 93], ["few", "OBSERVATION_MODIFIER", 116, 119], ["charged residues", "OBSERVATION", 120, 136]]], ["Therefore, in comparison with CtCes3-1, it appears to be less favorable for TcAE206 to bind long substrates (i.e., polysaccharides).Active site structure of the TcAE206 mutant (S10A)Prior to this study, in which we solved the structure of the mutant active site (TcAE206_S10A) complexed with an acetate ion (a product of D-glucose pentaacetate) (Fig. 3A) , no substrate/product structure of a CE3 family enzyme had been reported.", [["TcAE206", "CHEMICAL", 76, 83], ["acetate", "CHEMICAL", 295, 302], ["D-glucose pentaacetate", "CHEMICAL", 321, 343], ["TcAE206", "CHEMICAL", 76, 83], ["acetate", "CHEMICAL", 295, 302], ["D-glucose pentaacetate", "CHEMICAL", 321, 343], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 30, 38], ["TcAE206", "SIMPLE_CHEMICAL", 76, 83], ["TcAE206", "GENE_OR_GENE_PRODUCT", 161, 168], ["acetate", "SIMPLE_CHEMICAL", 295, 302], ["D-glucose pentaacetate", "SIMPLE_CHEMICAL", 321, 343], ["CE3", "GENE_OR_GENE_PRODUCT", 393, 396], ["CtCes3", "PROTEIN", 30, 36], ["TcAE206", "PROTEIN", 76, 83], ["TcAE206 mutant", "PROTEIN", 161, 175], ["S10A", "PROTEIN", 177, 181], ["mutant active site", "PROTEIN", 243, 261], ["TcAE206_S10A", "PROTEIN", 263, 275], ["CE3 family enzyme", "PROTEIN", 393, 410], ["this study", "TEST", 191, 201], ["an acetate ion", "TREATMENT", 292, 306], ["D-glucose pentaacetate", "TREATMENT", 321, 343], ["a CE3 family enzyme", "TEST", 391, 410], ["mutant", "OBSERVATION_MODIFIER", 243, 249], ["active", "OBSERVATION_MODIFIER", 250, 256], ["site", "OBSERVATION_MODIFIER", 257, 261]]], ["S10A assumes the SGNH-hydrolase superfamily structure; the key residues constituting the catalytic triad (Ser10Ala, Asp179, and His182) and oxyanion hole (Ser10Ala, Gly62, and Asn92) are completely conserved, as described above.", [["Asp", "CHEMICAL", 116, 119], ["His", "CHEMICAL", 128, 131], ["Gly62", "CHEMICAL", 165, 170], ["Asn92", "CHEMICAL", 176, 181], ["S10A", "GENE_OR_GENE_PRODUCT", 0, 4], ["SGNH-hydrolase", "GENE_OR_GENE_PRODUCT", 17, 31], ["Asp179", "AMINO_ACID", 116, 122], ["His182", "GENE_OR_GENE_PRODUCT", 128, 134], ["Ser10Ala", "GENE_OR_GENE_PRODUCT", 155, 163], ["Gly62", "GENE_OR_GENE_PRODUCT", 165, 170], ["Asn92", "GENE_OR_GENE_PRODUCT", 176, 181], ["S10A", "PROTEIN", 0, 4], ["SGNH-hydrolase superfamily structure", "PROTEIN", 17, 53], ["catalytic triad", "PROTEIN", 89, 104], ["Ser10Ala", "PROTEIN", 106, 114], ["His182", "PROTEIN", 128, 134], ["oxyanion hole", "PROTEIN", 140, 153], ["Ser10Ala", "PROTEIN", 155, 163], ["Gly62", "PROTEIN", 165, 170], ["Asn92", "PROTEIN", 176, 181], ["the SGNH-hydrolase superfamily structure", "PROBLEM", 13, 53], ["the catalytic triad", "TEST", 85, 104], ["Asp", "TEST", 116, 119], ["oxyanion hole", "TREATMENT", 140, 153]]], ["Some SGNH-hydrolases, such as coronavirus hemagglutinin-esterase (PDB code 3cl5) [26] , plateletactivating acetyl hydrolase (PDB code 1wab) [27] , and Neisseria meningitides peptidoglycan O-acetylesterase (PDB code 4k7j) [28] , reportedly form a complex with an acetate ion at a position equivalent to that in S10A.", [["acetyl", "CHEMICAL", 107, 113], ["acetate", "CHEMICAL", 262, 269], ["acetyl", "CHEMICAL", 107, 113], ["O", "CHEMICAL", 188, 189], ["acetate", "CHEMICAL", 262, 269], ["SGNH-hydrolases", "GENE_OR_GENE_PRODUCT", 5, 20], ["coronavirus hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 30, 64], ["PDB code 3cl5", "GENE_OR_GENE_PRODUCT", 66, 79], ["plateletactivating acetyl hydrolase", "GENE_OR_GENE_PRODUCT", 88, 123], ["PDB code 1wab", "GENE_OR_GENE_PRODUCT", 125, 138], ["Neisseria meningitides peptidoglycan O-acetylesterase", "SIMPLE_CHEMICAL", 151, 204], ["acetate", "SIMPLE_CHEMICAL", 262, 269], ["SGNH-hydrolases", "PROTEIN", 5, 20], ["coronavirus hemagglutinin", "PROTEIN", 30, 55], ["esterase", "PROTEIN", 56, 64], ["PDB", "PROTEIN", 66, 69], ["3cl5", "PROTEIN", 75, 79], ["plateletactivating acetyl hydrolase", "PROTEIN", 88, 123], ["PDB code 1wab", "PROTEIN", 125, 138], ["Neisseria meningitides peptidoglycan O-acetylesterase", "PROTEIN", 151, 204], ["PDB", "PROTEIN", 206, 209], ["S10A", "PROTEIN", 310, 314], ["coronavirus hemagglutinin", "SPECIES", 30, 55], ["Neisseria meningitides", "SPECIES", 151, 173], ["Neisseria meningitides", "SPECIES", 151, 173], ["Some SGNH", "TEST", 0, 9], ["hydrolases", "PROBLEM", 10, 20], ["coronavirus hemagglutinin-esterase", "PROBLEM", 30, 64], ["plateletactivating acetyl hydrolase", "TREATMENT", 88, 123], ["Neisseria", "TEST", 151, 160], ["an acetate ion", "TREATMENT", 259, 273]]], ["Therefore, the acetate ion in S10A is considered to be located in the correct position for catalytic activity [26e28].", [["acetate", "CHEMICAL", 15, 22], ["S10A", "CHEMICAL", 30, 34], ["acetate", "CHEMICAL", 15, 22], ["acetate", "SIMPLE_CHEMICAL", 15, 22], ["S10A", "SIMPLE_CHEMICAL", 30, 34], ["the acetate ion in S10A", "TREATMENT", 11, 34]]], ["The acetate ion (O) in S10A forms three hydrogen bonds: Fig. 1 .", [["acetate", "CHEMICAL", 4, 11], ["S10A", "CHEMICAL", 23, 27], ["acetate", "CHEMICAL", 4, 11], ["O", "CHEMICAL", 17, 18], ["hydrogen", "CHEMICAL", 40, 48], ["acetate", "SIMPLE_CHEMICAL", 4, 11], ["S10A", "SIMPLE_CHEMICAL", 23, 27], ["The acetate ion", "TREATMENT", 0, 15], ["hydrogen bonds", "OBSERVATION", 40, 54]]], ["Surface metal ionebinding site in S10A.", [["Surface metal ionebinding site", "DNA", 0, 30], ["S10A", "PROTEIN", 34, 38], ["Surface metal ionebinding site", "TREATMENT", 0, 30], ["metal ionebinding", "OBSERVATION", 8, 25]]], ["2Fo\u00c0Fc electron density map surrounding the metal ionebinding site in S10A are contoured at the 1.0-s level in gray color.", [["metal ionebinding site", "DNA", 44, 66], ["S10A", "DNA", 70, 74], ["2Fo\u00c0Fc electron density map", "TREATMENT", 0, 27], ["the metal ionebinding site", "TREATMENT", 40, 66], ["gray color", "TEST", 111, 121], ["density", "OBSERVATION", 16, 23], ["metal", "OBSERVATION_MODIFIER", 44, 49], ["ionebinding site", "OBSERVATION", 50, 66], ["contoured", "OBSERVATION_MODIFIER", 79, 88]]], ["The residues of S10A are shown as a green-stick model, and oxygen and nitrogen atoms are shown in red and blue, respectively.", [["oxygen", "CHEMICAL", 59, 65], ["nitrogen", "CHEMICAL", 70, 78], ["oxygen", "CHEMICAL", 59, 65], ["nitrogen", "CHEMICAL", 70, 78], ["S10A", "GENE_OR_GENE_PRODUCT", 16, 20], ["oxygen", "SIMPLE_CHEMICAL", 59, 65], ["nitrogen atoms", "SIMPLE_CHEMICAL", 70, 84], ["S10A", "PROTEIN", 16, 20], ["The residues of S10A", "PROBLEM", 0, 20], ["a green-stick model", "TREATMENT", 34, 53], ["oxygen and nitrogen atoms", "TREATMENT", 59, 84], ["nitrogen atoms", "OBSERVATION", 70, 84]]], ["Ca 2\u00fe and Zn 2\u00fe ions are shown as green-and orange-sphere models, respectively.", [["Ca", "CHEMICAL", 0, 2], ["Zn", "CHEMICAL", 10, 12], ["Ca 2\u00fe and Zn 2\u00fe", "CHEMICAL", 0, 15], ["Ca 2\u00fe", "SIMPLE_CHEMICAL", 0, 5], ["Zn 2\u00fe ions", "SIMPLE_CHEMICAL", 10, 20], ["Ca", "TEST", 0, 2], ["Zn 2\u00fe ions", "TEST", 10, 20]]], ["His98 in the crystal symmetric subunit is shown in marine color and labeled in red.", [["His98", "CHEMICAL", 0, 5], ["His98", "GENE_OR_GENE_PRODUCT", 0, 5], ["His98", "PROTEIN", 0, 5], ["crystal symmetric subunit", "PROTEIN", 13, 38], ["symmetric", "OBSERVATION_MODIFIER", 21, 30], ["subunit", "OBSERVATION_MODIFIER", 31, 38], ["marine color", "OBSERVATION", 51, 63], ["red", "OBSERVATION", 79, 82]]], ["Hydrogen bonds are shown as dashed lines.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["lines", "CELL", 35, 40], ["dashed lines", "CELL_LINE", 28, 40], ["Hydrogen bonds", "PROBLEM", 0, 14], ["dashed lines", "OBSERVATION", 28, 40]]], ["(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) with the side chain of Asn92 (ND), the main chain amide of Ala10, and Gly62, at distances of 2.8, 2.9, and 2.9 \u00c5, respectively (Fig. 3A) .", [["Asn92", "CHEMICAL", 154, 159], ["Asn92", "CHEMICAL", 154, 159], ["amide", "CHEMICAL", 181, 186], ["Ala10", "CHEMICAL", 190, 195], ["Gly62", "CHEMICAL", 201, 206], ["Asn92", "GENE_OR_GENE_PRODUCT", 154, 159], ["Ala10", "GENE_OR_GENE_PRODUCT", 190, 195], ["Gly62", "AMINO_ACID", 201, 206], ["Asn92", "PROTEIN", 154, 159], ["ND", "PROTEIN", 161, 163], ["Ala10", "PROTEIN", 190, 195], ["Gly62", "PROTEIN", 201, 206], ["main", "ANATOMY_MODIFIER", 170, 174]]], ["These three hydrogen bonds have been observed in other SGNHhydrolases as well [26e28] .", [["hydrogen", "CHEMICAL", 12, 20], ["SGNHhydrolases", "GENE_OR_GENE_PRODUCT", 55, 69], ["SGNHhydrolases", "PROTEIN", 55, 69], ["These three hydrogen bonds", "PROBLEM", 0, 26], ["hydrogen bonds", "OBSERVATION", 12, 26]]], ["The acetate ion is thought to stabilize the oxyanion hole by forming hydrogen bonds.", [["acetate", "CHEMICAL", 4, 11], ["acetate", "CHEMICAL", 4, 11], ["hydrogen", "CHEMICAL", 69, 77], ["acetate", "SIMPLE_CHEMICAL", 4, 11], ["The acetate ion", "TREATMENT", 0, 15], ["the oxyanion hole", "TREATMENT", 40, 57], ["oxyanion hole", "OBSERVATION", 44, 57], ["hydrogen bonds", "OBSERVATION", 69, 83]]], ["Interestingly, the position of the acetate ion is normally occupied by a water molecule, essentially stabilizing the formation of the oxyanion hole in TcAE206 (Fig. 3B ) and CtCes3-1 (Fig. 3C) .Active site structure of the TcAE206 mutant (S10A)Moreover, the oxygen atom (OXT) of the acetate ion forms hydrogen bonds with the side chain of His182 (NE2) and two water molecules (W1 and W2), at distances of 2.5, 2.6, and 2.7 \u00c5, respectively (Fig. 3A) .", [["acetate", "CHEMICAL", 35, 42], ["oxygen", "CHEMICAL", 258, 264], ["OXT", "CHEMICAL", 271, 274], ["acetate", "CHEMICAL", 283, 290], ["His182", "CHEMICAL", 339, 345], ["NE2", "CHEMICAL", 347, 350], ["acetate", "CHEMICAL", 35, 42], ["CtCes3-1", "CHEMICAL", 174, 182], ["oxygen", "CHEMICAL", 258, 264], ["acetate", "CHEMICAL", 283, 290], ["hydrogen", "CHEMICAL", 301, 309], ["His182", "CHEMICAL", 339, 345], ["NE2", "CHEMICAL", 347, 350], ["acetate", "SIMPLE_CHEMICAL", 35, 42], ["TcAE206", "SIMPLE_CHEMICAL", 151, 158], ["CtCes3-1", "GENE_OR_GENE_PRODUCT", 174, 182], ["TcAE206", "GENE_OR_GENE_PRODUCT", 223, 230], ["oxygen atom", "SIMPLE_CHEMICAL", 258, 269], ["OXT", "SIMPLE_CHEMICAL", 271, 274], ["acetate ion", "SIMPLE_CHEMICAL", 283, 294], ["hydrogen bonds", "SIMPLE_CHEMICAL", 301, 315], ["His182", "SIMPLE_CHEMICAL", 339, 345], ["NE2", "SIMPLE_CHEMICAL", 347, 350], ["TcAE206 mutant", "PROTEIN", 223, 237], ["S10A", "PROTEIN", 239, 243], ["NE2", "PROTEIN", 347, 350], ["W1", "PROTEIN", 377, 379], ["W2", "PROTEIN", 384, 386], ["the acetate ion", "TREATMENT", 31, 46], ["the oxyanion hole", "TREATMENT", 130, 147], ["CtCes3", "TEST", 174, 180], ["the oxygen atom", "TREATMENT", 254, 269], ["the acetate ion forms hydrogen bonds", "TREATMENT", 279, 315], ["the side chain", "TEST", 321, 335], ["position", "OBSERVATION_MODIFIER", 19, 27], ["oxyanion hole", "OBSERVATION", 134, 147]]], ["Water molecules corresponding to W1 and W2 were not observed in TcAE206, however, both water molecules were far away from the generally basic residue His182 to play as the hydrolytic water; W1 and W2 were located 3.9 and 3.8 \u00c5 away from His182 (NE2), respectively.Active site structure of the TcAE206 mutant (S10A)Although the nucleophilic Ser was substituted with an Ala residue in TcAE206, the structures of the main chain and its neighboring residues were similar to those of TcAE206 (Fig. 3B) .", [["TcAE206", "CHEMICAL", 64, 71], ["His182", "CHEMICAL", 150, 156], ["Ser", "CHEMICAL", 340, 343], ["Ala", "CHEMICAL", 368, 371], ["TcAE206", "CHEMICAL", 383, 390], ["TcAE206", "CHEMICAL", 64, 71], ["His", "CHEMICAL", 150, 153], ["His182", "CHEMICAL", 237, 243], ["Ser", "CHEMICAL", 340, 343], ["Ala", "CHEMICAL", 368, 371], ["TcAE206", "CHEMICAL", 383, 390], ["TcAE206", "CHEMICAL", 479, 486], ["TcAE206", "SIMPLE_CHEMICAL", 64, 71], ["TcAE206", "GENE_OR_GENE_PRODUCT", 293, 300], ["Ser", "AMINO_ACID", 340, 343], ["Ala", "AMINO_ACID", 368, 371], ["TcAE206", "SIMPLE_CHEMICAL", 383, 390], ["W1", "PROTEIN", 33, 35], ["W2", "PROTEIN", 40, 42], ["TcAE206", "PROTEIN", 64, 71], ["W1", "PROTEIN", 190, 192], ["W2", "PROTEIN", 197, 199], ["NE2", "PROTEIN", 245, 248], ["TcAE206 mutant", "PROTEIN", 293, 307], ["S10A", "PROTEIN", 309, 313], ["TcAE206", "PROTEIN", 479, 486], ["Water molecules", "PROBLEM", 0, 15], ["an Ala residue", "PROBLEM", 365, 379], ["Ala residue", "OBSERVATION", 368, 379], ["main", "OBSERVATION_MODIFIER", 414, 418], ["chain", "OBSERVATION_MODIFIER", 419, 424], ["neighboring residues", "OBSERVATION", 433, 453]]], ["In contrast, the main chains of Gly62 and Asp179 and the side chain of Asn92 (ND) are slightly close to the acetate ion.", [["Gly62", "CHEMICAL", 32, 37], ["Asp179", "CHEMICAL", 42, 48], ["Asn92", "CHEMICAL", 71, 76], ["acetate", "CHEMICAL", 108, 115], ["Gly62", "CHEMICAL", 32, 37], ["Asp179", "CHEMICAL", 42, 48], ["Asn92", "CHEMICAL", 71, 76], ["acetate", "CHEMICAL", 108, 115], ["Gly62", "GENE_OR_GENE_PRODUCT", 32, 37], ["Asp179", "AMINO_ACID", 42, 48], ["Asn92", "SIMPLE_CHEMICAL", 71, 76], ["acetate", "SIMPLE_CHEMICAL", 108, 115], ["Gly62", "PROTEIN", 32, 37], ["Asp179", "PROTEIN", 42, 48], ["side chain", "PROTEIN", 57, 67], ["ND", "PROTEIN", 78, 80], ["Gly62", "TEST", 32, 37], ["Asp179", "TEST", 42, 48], ["Asn92 (ND)", "TREATMENT", 71, 81], ["the acetate ion", "TREATMENT", 104, 119], ["main", "OBSERVATION_MODIFIER", 17, 21], ["chains", "OBSERVATION_MODIFIER", 22, 28], ["slightly", "OBSERVATION_MODIFIER", 86, 94]]], ["In addition, His182 (NE2) moves 0.8 \u00c5 further toward the center of the active site (acetate ion) than does His182 (NE2) of TcAE206 (Fig. 3B) .", [["His182", "CHEMICAL", 13, 19], ["NE2", "CHEMICAL", 21, 24], ["acetate", "CHEMICAL", 84, 91], ["His182", "CHEMICAL", 107, 113], ["His182", "CHEMICAL", 13, 19], ["NE2", "CHEMICAL", 21, 24], ["acetate", "CHEMICAL", 84, 91], ["His182", "CHEMICAL", 107, 113], ["NE2", "CHEMICAL", 115, 118], ["TcAE206", "CHEMICAL", 123, 130], ["His182", "SIMPLE_CHEMICAL", 13, 19], ["acetate", "SIMPLE_CHEMICAL", 84, 91], ["His182", "SIMPLE_CHEMICAL", 107, 113], ["NE2", "SIMPLE_CHEMICAL", 115, 118], ["TcAE206", "SIMPLE_CHEMICAL", 123, 130], ["His182 (NE2)", "PROTEIN", 13, 25], ["NE2", "PROTEIN", 115, 118], ["TcAE206", "PROTEIN", 123, 130], ["active", "OBSERVATION", 71, 77]]], ["The His residue is thought to play a key role in the catalytic activity of serine esterases, as described below.", [["His", "CHEMICAL", 4, 7], ["serine", "CHEMICAL", 75, 81], ["serine", "AMINO_ACID", 75, 81], ["esterases", "GENE_OR_GENE_PRODUCT", 82, 91], ["serine esterases", "PROTEIN", 75, 91], ["serine esterases", "TEST", 75, 91]]], ["In the absence of substrate, Ser10 forms a hydrogen bond with His182 (Fig. 4, step 1 ).", [["Ser10", "CHEMICAL", 29, 34], ["Ser10", "CHEMICAL", 29, 34], ["hydrogen", "CHEMICAL", 43, 51], ["His", "CHEMICAL", 62, 65], ["Ser10", "SIMPLE_CHEMICAL", 29, 34], ["Ser10", "PROTEIN", 29, 34], ["a hydrogen bond", "TEST", 41, 56]]], ["In the presence of substrate, the nucleophilic Ser is deprotonated by the generally basic His residue in cooperation with the generally acidic Asp and then attacks the carbonyl carbon of the substrate (Fig. 4, step 2 and 3).", [["Asp", "CHEMICAL", 143, 146], ["carbonyl carbon", "CHEMICAL", 168, 183], ["Ser", "CHEMICAL", 47, 50], ["His", "CHEMICAL", 90, 93], ["Asp", "CHEMICAL", 143, 146], ["carbonyl carbon", "CHEMICAL", 168, 183], ["Ser", "AMINO_ACID", 47, 50], ["Asp", "AMINO_ACID", 143, 146], ["His residue", "PROBLEM", 90, 101], ["the generally acidic Asp", "PROBLEM", 122, 146], ["the carbonyl carbon", "TREATMENT", 164, 183]]], ["The resulting tetrahedral intermediate rapidly breaks down to a covalent acyl-enzyme (Sereacetyl group) and alcohol moiety (Fig. 4, step 4) .", [["Sereacetyl", "CHEMICAL", 86, 96], ["alcohol", "CHEMICAL", 108, 115], ["acyl", "CHEMICAL", 73, 77], ["Sereacetyl", "CHEMICAL", 86, 96], ["alcohol", "CHEMICAL", 108, 115], ["Sereacetyl", "SIMPLE_CHEMICAL", 86, 96], ["alcohol moiety", "SIMPLE_CHEMICAL", 108, 122], ["a covalent acyl-enzyme (Sereacetyl group)", "TREATMENT", 62, 103], ["alcohol moiety", "TREATMENT", 108, 122], ["tetrahedral", "OBSERVATION_MODIFIER", 14, 25], ["intermediate", "OBSERVATION_MODIFIER", 26, 38], ["rapidly breaks", "OBSERVATION", 39, 53]]], ["By releasing the alcohol moiety, a space is made for the hydrolytic water molecule.", [["alcohol", "CHEMICAL", 17, 24], ["alcohol", "CHEMICAL", 17, 24], ["alcohol", "SIMPLE_CHEMICAL", 17, 24], ["hydrolytic water molecule", "PROTEIN", 57, 82], ["the hydrolytic water molecule", "TREATMENT", 53, 82]]], ["The hydrolytic water molecule is also deprotonated by the His residue, and the resulting hydroxyl anion attacks the acyl-enzyme (Fig. 4, step 5 and 6) , thereby returning the Ser residue to a protonated state so that it is ready for the next reaction ( Fig. 4 step 1) .", [["hydroxyl", "CHEMICAL", 89, 97], ["acyl", "CHEMICAL", 116, 120], ["His", "CHEMICAL", 58, 61], ["hydroxyl", "CHEMICAL", 89, 97], ["acyl", "CHEMICAL", 116, 120], ["Ser", "CHEMICAL", 175, 178], ["hydroxyl anion", "SIMPLE_CHEMICAL", 89, 103], ["acyl-enzyme", "PROTEIN", 116, 127], ["The hydrolytic water molecule", "PROBLEM", 0, 29], ["the His residue", "PROBLEM", 54, 69], ["the resulting hydroxyl anion attacks", "PROBLEM", 75, 111], ["the next reaction", "PROBLEM", 233, 250], ["hydrolytic", "OBSERVATION_MODIFIER", 4, 14], ["water molecule", "OBSERVATION", 15, 29]]], ["Our data suggest that the His residue should move toward the center of the active site to facilitate these two deprotonation steps.Active site structure of the TcAE206 mutant (S10A)In conclusion, our complex structure does not provide sufficient detail to fully elucidate the interaction between the carbohydrate Fig. 3 .", [["His", "CHEMICAL", 26, 29], ["carbohydrate", "CHEMICAL", 300, 312], ["TcAE206", "GENE_OR_GENE_PRODUCT", 160, 167], ["TcAE206 mutant", "PROTEIN", 160, 174], ["S10A", "PROTEIN", 176, 180], ["carbohydrate Fig.", "PROTEIN", 300, 317], ["Our data", "TEST", 0, 8], ["the His residue", "PROBLEM", 22, 37], ["active", "OBSERVATION", 75, 81]]], ["Active site structure of CE3 acetyl esterases.", [["acetyl", "CHEMICAL", 29, 35], ["CE3 acetyl", "CHEMICAL", 25, 35], ["CE3 acetyl esterases", "GENE_OR_GENE_PRODUCT", 25, 45], ["CE3 acetyl esterases", "PROTEIN", 25, 45], ["CE3 acetyl esterases", "PROBLEM", 25, 45], ["acetyl esterases", "OBSERVATION", 29, 45]]], ["(A) Stereo view of the active site of S10A (green-stick model) complexed with an acetate ion (yellow-stick model).", [["acetate", "CHEMICAL", 81, 88], ["acetate", "CHEMICAL", 81, 88], ["acetate", "SIMPLE_CHEMICAL", 81, 88], ["S10A", "PROTEIN", 38, 42], ["an acetate ion (yellow-stick model", "TREATMENT", 78, 112]]], ["Water molecules (W1 and W2; red spheres) were illustrated using the PyMol program.", [["W1", "PROTEIN", 17, 19], ["W2", "PROTEIN", 24, 26], ["Water molecules", "PROBLEM", 0, 15], ["the PyMol program", "TREATMENT", 64, 81]]], ["(B) TcAE206 (cyan-stick model) superimposed on the S10A structure.", [["TcAE206", "CHEMICAL", 4, 11], ["(B) TcAE206", "CHEMICAL", 0, 11], ["S10A structure", "PROTEIN", 51, 65], ["cyan-stick model", "TEST", 13, 29]]], ["The water molecule in TcAE206 is shown as a blue-sphere model.", [["TcAE206", "CHEMICAL", 22, 29], ["TcAE206", "CHEMICAL", 22, 29], ["TcAE206", "SIMPLE_CHEMICAL", 22, 29], ["TcAE206", "PROTEIN", 22, 29], ["a blue-sphere model", "TREATMENT", 42, 61], ["water molecule", "OBSERVATION", 4, 18]]], ["(C) CtCes3-1 (gray-stick model) is superimposed on the S10A structure.", [["CtCes3-1", "GENE_OR_GENE_PRODUCT", 4, 12], ["S10A", "GENE_OR_GENE_PRODUCT", 55, 59], ["S10A structure", "PROTEIN", 55, 69], ["CtCes3", "TEST", 4, 10], ["gray-stick model", "TEST", 14, 30]]], ["The three water molecules in CtCes3-1 are shown as blue-sphere models.", [["CtCes3-1", "GENE_OR_GENE_PRODUCT", 29, 37], ["CtCes3", "PROTEIN", 29, 35], ["CtCes3", "TEST", 29, 35], ["sphere models", "OBSERVATION", 56, 69]]], ["Scheme of the catalytic reaction of fungal carbohydrate family 3 enzymes.", [["carbohydrate", "CHEMICAL", 43, 55], ["carbohydrate family 3", "GENE_OR_GENE_PRODUCT", 43, 64], ["fungal carbohydrate family 3 enzymes", "PROTEIN", 36, 72], ["the catalytic reaction", "PROBLEM", 10, 32]]], ["R indicates the carbohydrate moiety of the substrate. moieties and amino acids.", [["amino acids", "CHEMICAL", 67, 78], ["carbohydrate", "CHEMICAL", 16, 28], ["amino acids", "CHEMICAL", 67, 78], ["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["amino acids", "AMINO_ACID", 67, 78], ["amino acids", "TREATMENT", 67, 78], ["carbohydrate moiety", "OBSERVATION", 16, 35]]], ["Experiments designed to solve the complex structure of TcAE206 are currently ongoing, with the goal of elucidating the detailed catalytic mechanism of TcAE206 and the structural basis of its specificity for acetylated carbohydrate substrates.PDB accession numberThe coordinates and structural features of TcAE206_S10A complexed with an acetate ion were deposited in the Protein Data Bank under accession code 5B5L.", [["TcAE206", "CHEMICAL", 55, 62], ["TcAE206", "CHEMICAL", 151, 158], ["acetate", "CHEMICAL", 336, 343], ["TcAE206", "CHEMICAL", 55, 62], ["TcAE206", "CHEMICAL", 151, 158], ["carbohydrate", "CHEMICAL", 218, 230], ["acetate", "CHEMICAL", 336, 343], ["TcAE206", "SIMPLE_CHEMICAL", 55, 62], ["TcAE206", "SIMPLE_CHEMICAL", 151, 158], ["TcAE206_S10A", "GENE_OR_GENE_PRODUCT", 305, 317], ["acetate", "SIMPLE_CHEMICAL", 336, 343], ["TcAE206_S10A", "PROTEIN", 305, 317], ["acetylated carbohydrate substrates", "TREATMENT", 207, 241], ["an acetate ion", "TREATMENT", 333, 347]]]], "89ec194732e513702a5ec1539e1941140c476068": [["IntroductionNowadays, there is a renewed interest in medicinal plants because of the potentially important sources of bioactive substance that may be very important in the field of medicine.", [["medicinal plants", "TREATMENT", 53, 69], ["bioactive substance", "TREATMENT", 118, 137]]], ["Essential oils (EOs) are volatile, natural, complex compounds isolated from natural plant materials (flowers, buds, seeds, leaves, root, and stem).", [["Essential oils", "ANATOMY", 0, 14], ["flowers", "ANATOMY", 101, 108], ["buds", "ANATOMY", 110, 114], ["seeds", "ANATOMY", 116, 121], ["leaves", "ANATOMY", 123, 129], ["root", "ANATOMY", 131, 135], ["stem", "ANATOMY", 141, 145], ["EOs", "CHEMICAL", 16, 19], ["EOs", "SIMPLE_CHEMICAL", 16, 19], ["flowers", "ORGANISM_SUBDIVISION", 101, 108], ["buds", "ORGANISM_SUBDIVISION", 110, 114], ["seeds", "ORGANISM_SUBDIVISION", 116, 121], ["leaves", "ORGANISM_SUBDIVISION", 123, 129], ["root", "TISSUE", 131, 135], ["stem", "TISSUE", 141, 145], ["complex compounds", "PROBLEM", 44, 61], ["natural plant materials", "TREATMENT", 76, 99], ["oils", "OBSERVATION_MODIFIER", 10, 14], ["EOs", "OBSERVATION_MODIFIER", 16, 19], ["volatile", "OBSERVATION_MODIFIER", 25, 33], ["complex", "OBSERVATION_MODIFIER", 44, 51], ["compounds", "OBSERVATION_MODIFIER", 52, 61], ["root", "OBSERVATION_MODIFIER", 131, 135], ["stem", "ANATOMY", 141, 145]]], ["EOs have a broad spectrum of biological activities, such as anti-microbial [1] [2] [3] , antiviral [4] and anti-inflammatory effects [5] .", [["EOs", "SIMPLE_CHEMICAL", 0, 3], ["anti-microbial [1] [2] [3]", "SIMPLE_CHEMICAL", 60, 86], ["antiviral [4]", "SIMPLE_CHEMICAL", 89, 102], ["EOs", "TEST", 0, 3], ["biological activities", "TREATMENT", 29, 50], ["anti-microbial [", "TREATMENT", 60, 76], ["antiviral [4", "TREATMENT", 89, 101], ["anti-inflammatory effects", "TREATMENT", 107, 132]]], ["Houttuynia cordata Thunb.", [["Houttuynia cordata", "ORGANISM", 0, 18], ["Houttuynia cordata", "SPECIES", 0, 18], ["Houttuynia cordata", "SPECIES", 0, 18], ["cordata Thunb", "OBSERVATION", 11, 24]]], ["(H. cordata) injection, in which EO is the main active compound, is widely used to treat respiratory infections, conjunctivitis, keratitis, H. cordata injection was recognized as the formula for the prevention of Severe Acute Respiratory Syndrome (SARS) by the Health Ministry of China during the outbreak of the SARS epidemic [6] .", [["respiratory", "ANATOMY", 89, 100], ["EO", "CHEMICAL", 33, 35], ["respiratory infections", "DISEASE", 89, 111], ["conjunctivitis", "DISEASE", 113, 127], ["keratitis", "DISEASE", 129, 138], ["Acute Respiratory Syndrome", "DISEASE", 220, 246], ["SARS", "DISEASE", 248, 252], ["SARS", "DISEASE", 313, 317], ["H. cordata", "ORGANISM", 1, 11], ["EO", "SIMPLE_CHEMICAL", 33, 35], ["H. cordata", "ORGANISM", 140, 150], ["H. cordata", "SPECIES", 1, 11], ["H. cordata", "SPECIES", 140, 150], ["H. cordata", "SPECIES", 1, 11], ["H. cordata", "SPECIES", 140, 150], ["H. cordata) injection", "TREATMENT", 1, 22], ["respiratory infections", "PROBLEM", 89, 111], ["conjunctivitis", "PROBLEM", 113, 127], ["keratitis", "PROBLEM", 129, 138], ["H. cordata injection", "TREATMENT", 140, 160], ["Severe Acute Respiratory Syndrome", "PROBLEM", 213, 246], ["main", "OBSERVATION_MODIFIER", 43, 47], ["active", "OBSERVATION_MODIFIER", 48, 54], ["compound", "OBSERVATION", 55, 63], ["respiratory", "ANATOMY", 89, 100], ["infections", "OBSERVATION", 101, 111], ["conjunctivitis", "OBSERVATION", 113, 127], ["keratitis", "OBSERVATION", 129, 138], ["Severe", "OBSERVATION_MODIFIER", 213, 219], ["Acute", "OBSERVATION_MODIFIER", 220, 225], ["Respiratory Syndrome", "OBSERVATION", 226, 246]]], ["However, the H. cordata injection was suspended for its severe adverse drug reactions (ADR), such as breathing problems, high fever, rash, anaphylactic shock, and even sudden death by the China Food and Drug Administration (CFDA) in 2006.IntroductionGenerally, H. cordata essential oil (HEO) is extracted from fresh H. cordata using hydrodistillation extraction and then dissolved in Tween 80 solution to prepare the H. cordata injection [7] [8] [9] [10] .", [["adverse drug reactions", "DISEASE", 63, 85], ["ADR", "DISEASE", 87, 90], ["breathing problems", "DISEASE", 101, 119], ["fever", "DISEASE", 126, 131], ["rash", "DISEASE", 133, 137], ["anaphylactic shock", "DISEASE", 139, 157], ["sudden death", "DISEASE", 168, 180], ["HEO", "CHEMICAL", 287, 290], ["Tween 80", "CHEMICAL", 384, 392], ["H. cordata", "ORGANISM", 13, 23], ["H. cordata", "ORGANISM", 261, 271], ["oil", "ORGANISM_SUBSTANCE", 282, 285], ["HEO", "SIMPLE_CHEMICAL", 287, 290], ["H. cordata", "ORGANISM", 316, 326], ["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 438, 454], ["H. cordata", "SPECIES", 13, 23], ["H. cordata", "SPECIES", 261, 271], ["H. cordata", "SPECIES", 316, 326], ["H. cordata", "SPECIES", 13, 23], ["H. cordata", "SPECIES", 261, 271], ["H. cordata", "SPECIES", 316, 326], ["H. cordata", "SPECIES", 417, 427], ["the H. cordata injection", "TREATMENT", 9, 33], ["its severe adverse drug reactions", "PROBLEM", 52, 85], ["breathing problems", "PROBLEM", 101, 119], ["high fever", "PROBLEM", 121, 131], ["rash", "PROBLEM", 133, 137], ["anaphylactic shock", "PROBLEM", 139, 157], ["sudden death", "PROBLEM", 168, 180], ["hydrodistillation extraction", "TREATMENT", 333, 361], ["the H. cordata injection", "TREATMENT", 413, 437], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["anaphylactic shock", "OBSERVATION", 139, 157]]], ["The volatile compounds include houttuynin (3-oxododecanal, Hou, Figure 1 ), 2-undecanone, pinene, camphene, myrcene, limonene, and so on, among which Hou is the main active compound [11] .", [["houttuynin", "CHEMICAL", 31, 41], ["3-oxododecanal, Hou, Figure 1 ), 2-undecanone", "CHEMICAL", 43, 88], ["pinene", "CHEMICAL", 90, 96], ["camphene", "CHEMICAL", 98, 106], ["myrcene", "CHEMICAL", 108, 115], ["limonene", "CHEMICAL", 117, 125], ["houttuynin", "CHEMICAL", 31, 41], ["3-oxododecanal", "CHEMICAL", 43, 57], ["Hou", "CHEMICAL", 59, 62], ["2-undecanone", "CHEMICAL", 76, 88], ["pinene", "CHEMICAL", 90, 96], ["camphene", "CHEMICAL", 98, 106], ["myrcene", "CHEMICAL", 108, 115], ["limonene", "CHEMICAL", 117, 125], ["houttuynin", "SIMPLE_CHEMICAL", 31, 41], ["3-oxododecanal", "SIMPLE_CHEMICAL", 43, 57], ["Hou, Figure 1 ), 2-undecanone", "SIMPLE_CHEMICAL", 59, 88], ["pinene", "SIMPLE_CHEMICAL", 90, 96], ["camphene", "SIMPLE_CHEMICAL", 98, 106], ["myrcene", "SIMPLE_CHEMICAL", 108, 115], ["limonene", "SIMPLE_CHEMICAL", 117, 125], ["undecanone", "TREATMENT", 78, 88], ["pinene", "TREATMENT", 90, 96], ["camphene", "TREATMENT", 98, 106], ["myrcene", "TREATMENT", 108, 115], ["limonene", "TREATMENT", 117, 125], ["volatile compounds", "OBSERVATION", 4, 22]]], ["Studies that investigated the relationship between ADR and Hou content showed that Hou is easily destroyed (oxidation, polymerization, or condensation reaction) by the high temperature during the hydrodistillation extraction due to its poor stability [13, 14] .", [["ADR", "CHEMICAL", 51, 54], ["ADR", "SIMPLE_CHEMICAL", 51, 54], ["Studies", "TEST", 0, 7], ["polymerization", "PROBLEM", 119, 133], ["condensation reaction", "PROBLEM", 138, 159], ["the high temperature", "PROBLEM", 164, 184], ["the hydrodistillation extraction", "TREATMENT", 192, 224], ["high temperature", "OBSERVATION_MODIFIER", 168, 184]]], ["In addition, our group found that degradation products of Hou showed serious acute toxicity, which would induce ADR.", [["Hou", "CHEMICAL", 58, 61], ["toxicity", "DISEASE", 83, 91], ["ADR", "CHEMICAL", 112, 115], ["serious acute toxicity", "PROBLEM", 69, 91], ["ADR", "PROBLEM", 112, 115], ["serious", "OBSERVATION_MODIFIER", 69, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["toxicity", "OBSERVATION", 83, 91]]], ["H. cordata injection can also cause hemolysis, which may result from impurities of HEO or Tween 80 in the formulation [15, 16] .", [["hemolysis", "DISEASE", 36, 45], ["HEO", "CHEMICAL", 83, 86], ["Tween 80", "CHEMICAL", 90, 98], ["HEO", "CHEMICAL", 83, 86], ["Tween 80", "CHEMICAL", 90, 98], ["H. cordata", "ORGANISM", 0, 10], ["HEO", "SIMPLE_CHEMICAL", 83, 86], ["Tween 80", "SIMPLE_CHEMICAL", 90, 98], ["H. cordata", "SPECIES", 0, 10], ["H. cordata", "SPECIES", 0, 10], ["H. cordata injection", "TREATMENT", 0, 20], ["hemolysis", "PROBLEM", 36, 45]]], ["Additonally, impurities (vegetable proteins, peptide polysaccharides, and tannins) in HEO may stimulate the immune system to produce ADR-like allergic reactions [15] .", [["immune system", "ANATOMY", 108, 121], ["peptide polysaccharides, and tannins", "CHEMICAL", 45, 81], ["HEO", "CHEMICAL", 86, 89], ["ADR", "CHEMICAL", 133, 136], ["allergic reactions", "DISEASE", 142, 160], ["vegetable", "ORGANISM_SUBDIVISION", 25, 34], ["peptide polysaccharides", "SIMPLE_CHEMICAL", 45, 68], ["tannins", "SIMPLE_CHEMICAL", 74, 81], ["HEO", "SIMPLE_CHEMICAL", 86, 89], ["ADR", "SIMPLE_CHEMICAL", 133, 136], ["impurities (vegetable proteins", "PROBLEM", 13, 43], ["peptide polysaccharides", "TREATMENT", 45, 68], ["tannins", "TREATMENT", 74, 81], ["ADR", "PROBLEM", 133, 136], ["allergic reactions", "PROBLEM", 142, 160]]], ["Therefore, a facile and comprehensive approach to avoid the occurrence of ADR is urgently needed.", [["ADR", "CHEMICAL", 74, 77], ["ADR", "SIMPLE_CHEMICAL", 74, 77], ["a facile and comprehensive approach", "TREATMENT", 11, 46], ["ADR", "PROBLEM", 74, 77]]], ["Xue et al. reported that solvent extraction performed at room temperature is highly efficient to extract Hou-riched HEO [17] .", [["HEO", "CHEMICAL", 116, 119], ["solvent extraction", "TREATMENT", 25, 43]]], ["Compared to the hydrodistillation extraction, the mild solvent extraction condition can avoid the destruction of Hou.", [["the hydrodistillation extraction", "TREATMENT", 12, 44], ["the mild solvent extraction condition", "TREATMENT", 46, 83], ["the destruction of Hou", "PROBLEM", 94, 116], ["mild", "OBSERVATION_MODIFIER", 50, 54], ["solvent extraction", "OBSERVATION", 55, 73]]], ["However, they did not study the safety and activity of the extract.", [["extract", "ANATOMY", 59, 66]]], ["In addition, impurities in the extract were not removed, which were not conducive to the safety of the product.", [["extract", "ANATOMY", 31, 38], ["impurities", "OBSERVATION_MODIFIER", 13, 23]]], ["Therefore, purification is especially needed to remove impurities and further improve the safety and activity.", [["purification", "TREATMENT", 11, 23]]], ["However, to our knowledge, there is no study reported on purification of essential oil from H. cordata.", [["oil", "ANATOMY", 83, 86], ["oil", "ORGANISM_SUBSTANCE", 83, 86], ["H. cordata", "ORGANISM", 92, 102], ["H. cordata", "SPECIES", 92, 102], ["H. cordata", "SPECIES", 92, 102], ["study", "TEST", 39, 44]]], ["Generally, liquid-liquid extraction [18] , fractionation [19] , and silica gel column chromatography [20] are used for purification of natural products.", [["silica gel", "CHEMICAL", 68, 78], ["silica", "SIMPLE_CHEMICAL", 68, 74], ["liquid-liquid extraction", "TREATMENT", 11, 35], ["fractionation", "TEST", 43, 56], ["silica gel column chromatography", "TEST", 68, 100], ["natural products", "TREATMENT", 135, 151], ["natural products", "OBSERVATION", 135, 151]]], ["Unfortunately, these extraction procedures are inefficient, costly, time and solvent consuming, and labor intensive [21] .", [["these extraction procedures", "TREATMENT", 15, 42]]], ["In addition, it is very difficult to enrich the essential oil due to its extremely low polarity and stability.", [["oil", "ANATOMY", 58, 61], ["oil", "ORGANISM_SUBSTANCE", 58, 61], ["low polarity", "OBSERVATION_MODIFIER", 83, 95], ["stability", "OBSERVATION_MODIFIER", 100, 109]]], ["Comparatively, macroporous resins (MRs) have unique advantageous adsorption properties due to the ideal pore structure and various surface functional groups available on these resins [22, 23] .", [["pore", "ANATOMY", 104, 108], ["surface", "ANATOMY", 131, 138], ["macroporous resins", "TREATMENT", 15, 33], ["unique advantageous adsorption properties", "TREATMENT", 45, 86], ["the ideal pore structure", "PROBLEM", 94, 118], ["these resins", "TEST", 170, 182], ["macroporous resins", "OBSERVATION", 15, 33]]], ["They are durable nonpolar, middle-polar, and polar macroporous polymers and have been successfully applied for the separation of flavonoids [24, 25] , saponins [26, 27] and alkaloids [28] from traditional Chinese medicine or herbs.", [["flavonoids [24, 25] , saponins [26, 27] and alkaloids [28]", "CHEMICAL", 129, 187], ["flavonoids", "CHEMICAL", 129, 139], ["24, 25] , saponins [26, 27] and alkaloids", "CHEMICAL", 141, 182], ["flavonoids", "SIMPLE_CHEMICAL", 129, 139], ["24, 25]", "SIMPLE_CHEMICAL", 141, 148], ["saponins [26, 27]", "SIMPLE_CHEMICAL", 151, 168], ["alkaloids [28]", "SIMPLE_CHEMICAL", 173, 187], ["polar macroporous polymers", "TREATMENT", 45, 71], ["flavonoids", "TEST", 129, 139], ["saponins", "TEST", 151, 159], ["alkaloids", "TEST", 173, 182], ["traditional Chinese medicine", "TREATMENT", 193, 221], ["herbs", "TREATMENT", 225, 230], ["durable", "OBSERVATION_MODIFIER", 9, 16], ["nonpolar", "OBSERVATION_MODIFIER", 17, 25], ["middle", "ANATOMY_MODIFIER", 27, 33], ["polar", "ANATOMY_MODIFIER", 34, 39], ["polar", "ANATOMY_MODIFIER", 45, 50], ["macroporous polymers", "OBSERVATION", 51, 71]]], ["Moreover, MRs are relatively low-cost and easily regenerated, which is especially important for industrial applications.IntroductionIntravenous microemulsions (MEs) are biodegradable, biocompatible, physically stable, easy to scale up, and cost effective [29] .", [["Intravenous", "ANATOMY", 132, 143], ["Intravenous microemulsions", "SIMPLE_CHEMICAL", 132, 158], ["MRs", "TEST", 10, 13], ["IntroductionIntravenous microemulsions", "TREATMENT", 120, 158], ["stable", "OBSERVATION_MODIFIER", 210, 216]]], ["Most importantly, the good solubility in oil and lipophilicity of HEO make it possible to be encapsulated in the inner oil phase of MEs, thereby improving its stability and safety.", [["oil", "ANATOMY", 41, 44], ["inner oil", "ANATOMY", 113, 122], ["HEO", "CHEMICAL", 66, 69], ["HEO", "CHEMICAL", 66, 69], ["oil", "ORGANISM_SUBSTANCE", 41, 44], ["HEO", "SIMPLE_CHEMICAL", 66, 69], ["MEs", "SIMPLE_CHEMICAL", 132, 135], ["good", "OBSERVATION_MODIFIER", 22, 26], ["solubility", "OBSERVATION_MODIFIER", 27, 37]]], ["This study aimed to develop a safe and highly active HEO preparation through purification by MR followed by ME encapsulation.", [["HEO", "SIMPLE_CHEMICAL", 53, 56], ["MR", "PROTEIN", 93, 95], ["This study", "TEST", 0, 10], ["MR", "TEST", 93, 95]]], ["In addition, safety evaluation tests and in vitro antiviral tests were performed with different extracts and preparations.", [["extracts", "ANATOMY", 96, 104], ["extracts", "ORGANISM_SUBSTANCE", 96, 104], ["safety evaluation tests", "TEST", 13, 36], ["vitro antiviral tests", "TEST", 44, 65]]], ["We hope that this study will be helpful for future antiviral therapies and infectious diseases.", [["infectious diseases", "DISEASE", 75, 94], ["this study", "TEST", 13, 23], ["future antiviral therapies", "TREATMENT", 44, 70], ["infectious diseases", "PROBLEM", 75, 94]]], ["Xue et al. reported that solvent extraction performed at room temperature is highly efficient to extract Hou-riched HEO [17] .", [["HEO", "CHEMICAL", 116, 119], ["solvent extraction", "TREATMENT", 25, 43]]], ["Compared to the hydrodistillation extraction, the mild solvent extraction condition can avoid the destruction of Hou.", [["the hydrodistillation extraction", "TREATMENT", 12, 44], ["the mild solvent extraction condition", "TREATMENT", 46, 83], ["the destruction of Hou", "PROBLEM", 94, 116], ["mild", "OBSERVATION_MODIFIER", 50, 54], ["solvent extraction", "OBSERVATION", 55, 73]]], ["However, they did not study the safety and activity of the extract.", [["extract", "ANATOMY", 59, 66]]], ["In addition, impurities in the extract were not removed, which were not conducive to the safety of the product.", [["extract", "ANATOMY", 31, 38], ["impurities", "OBSERVATION_MODIFIER", 13, 23]]], ["Therefore, purification is especially needed to remove impurities and further improve the safety and activity.", [["purification", "TREATMENT", 11, 23]]], ["However, to our knowledge, there is no study reported on purification of essential oil from H. cordata.", [["oil", "ANATOMY", 83, 86], ["oil", "ORGANISM_SUBSTANCE", 83, 86], ["H. cordata", "ORGANISM", 92, 102], ["H. cordata", "SPECIES", 92, 102], ["H. cordata", "SPECIES", 92, 102], ["study", "TEST", 39, 44]]], ["Generally, liquid-liquid extraction [18] , fractionation [19] , and silica gel column chromatography [20] are used for purification of natural products.", [["silica gel", "CHEMICAL", 68, 78], ["silica", "SIMPLE_CHEMICAL", 68, 74], ["liquid-liquid extraction", "TREATMENT", 11, 35], ["fractionation", "TEST", 43, 56], ["silica gel column chromatography", "TEST", 68, 100], ["natural products", "TREATMENT", 135, 151], ["natural products", "OBSERVATION", 135, 151]]], ["Unfortunately, these extraction procedures are inefficient, costly, time and solvent consuming, and labor intensive [21] .", [["these extraction procedures", "TREATMENT", 15, 42]]], ["In addition, it is very difficult to enrich the essential oil due to its extremely low polarity and stability.", [["oil", "ANATOMY", 58, 61], ["oil", "ORGANISM_SUBSTANCE", 58, 61], ["low polarity", "OBSERVATION_MODIFIER", 83, 95], ["stability", "OBSERVATION_MODIFIER", 100, 109]]], ["Comparatively, macroporous resins (MRs) have unique advantageous adsorption properties due to the ideal pore structure and various surface functional groups available on these resins [22, 23] .", [["pore", "ANATOMY", 104, 108], ["surface", "ANATOMY", 131, 138], ["macroporous resins", "TREATMENT", 15, 33], ["unique advantageous adsorption properties", "TREATMENT", 45, 86], ["the ideal pore structure", "PROBLEM", 94, 118], ["these resins", "TEST", 170, 182], ["macroporous resins", "OBSERVATION", 15, 33]]], ["They are durable nonpolar, middle-polar, and polar macroporous polymers and have been successfully applied for the separation of flavonoids [24, 25] , saponins [26, 27] and alkaloids [28] from traditional Chinese medicine or herbs.", [["flavonoids [24, 25] , saponins [26, 27] and alkaloids [28]", "CHEMICAL", 129, 187], ["flavonoids", "CHEMICAL", 129, 139], ["24, 25] , saponins [26, 27] and alkaloids", "CHEMICAL", 141, 182], ["flavonoids", "SIMPLE_CHEMICAL", 129, 139], ["24, 25]", "SIMPLE_CHEMICAL", 141, 148], ["saponins [26, 27]", "SIMPLE_CHEMICAL", 151, 168], ["alkaloids [28]", "SIMPLE_CHEMICAL", 173, 187], ["polar macroporous polymers", "TREATMENT", 45, 71], ["flavonoids", "TEST", 129, 139], ["saponins", "TEST", 151, 159], ["alkaloids", "TEST", 173, 182], ["traditional Chinese medicine", "TREATMENT", 193, 221], ["herbs", "TREATMENT", 225, 230], ["durable", "OBSERVATION_MODIFIER", 9, 16], ["nonpolar", "OBSERVATION_MODIFIER", 17, 25], ["middle", "ANATOMY_MODIFIER", 27, 33], ["polar", "ANATOMY_MODIFIER", 34, 39], ["polar", "ANATOMY_MODIFIER", 45, 50], ["macroporous polymers", "OBSERVATION", 51, 71]]], ["Moreover, MRs are relatively low-cost and easily regenerated, which is especially important for industrial applications.IntroductionIntravenous microemulsions (MEs) are biodegradable, biocompatible, physically stable, easy to scale up, and cost effective [29] .", [["Intravenous", "ANATOMY", 132, 143], ["Intravenous microemulsions", "SIMPLE_CHEMICAL", 132, 158], ["MRs", "TEST", 10, 13], ["IntroductionIntravenous microemulsions", "TREATMENT", 120, 158], ["stable", "OBSERVATION_MODIFIER", 210, 216]]], ["Most importantly, the good solubility in oil and lipophilicity of HEO make it possible to be encapsulated in the inner oil phase of MEs, thereby improving its stability and safety.", [["oil", "ANATOMY", 41, 44], ["inner oil", "ANATOMY", 113, 122], ["HEO", "CHEMICAL", 66, 69], ["HEO", "CHEMICAL", 66, 69], ["oil", "ORGANISM_SUBSTANCE", 41, 44], ["HEO", "SIMPLE_CHEMICAL", 66, 69], ["MEs", "SIMPLE_CHEMICAL", 132, 135], ["good", "OBSERVATION_MODIFIER", 22, 26], ["solubility", "OBSERVATION_MODIFIER", 27, 37]]], ["This study aimed to develop a safe and highly active HEO preparation through purification by MR followed by ME encapsulation.", [["HEO", "SIMPLE_CHEMICAL", 53, 56], ["MR", "PROTEIN", 93, 95], ["This study", "TEST", 0, 10], ["MR", "TEST", 93, 95]]], ["In addition, safety evaluation tests and in vitro antiviral tests were performed with different extracts and preparations.", [["extracts", "ANATOMY", 96, 104], ["extracts", "ORGANISM_SUBSTANCE", 96, 104], ["safety evaluation tests", "TEST", 13, 36], ["vitro antiviral tests", "TEST", 44, 65]]], ["We hope that this study will be helpful for future antiviral therapies and infectious diseases.Solvent Extraction of Crude HEOThe extraction ratio of HEO was affected by many factors, such as solvent polarity, extraction time, root length, and solid-liquid ratio.", [["root", "ANATOMY", 227, 231], ["infectious diseases", "DISEASE", 75, 94], ["HEO", "CHEMICAL", 150, 153], ["HEO", "CHEMICAL", 150, 153], ["HEOThe", "SIMPLE_CHEMICAL", 123, 129], ["HEO", "SIMPLE_CHEMICAL", 150, 153], ["this study", "TEST", 13, 23], ["future antiviral therapies", "TREATMENT", 44, 70], ["infectious diseases", "PROBLEM", 75, 94], ["Solvent Extraction", "TREATMENT", 95, 113], ["Crude HEOThe extraction", "TREATMENT", 117, 140], ["root length", "TEST", 227, 238]]], ["Among them, the solvent is the main factor that determines the composition of extracts.", [["extracts", "ANATOMY", 78, 86], ["extracts", "ORGANISM_SUBSTANCE", 78, 86]]], ["In order to obtain HEO with high Hou content and narrow down the range of extraction parameters, optimization of solvents with different polarity were optimized before orthogonal tests.", [["HEO", "SIMPLE_CHEMICAL", 19, 22], ["HEO", "TEST", 19, 22], ["extraction parameters", "TEST", 74, 95], ["optimization of solvents", "TREATMENT", 97, 121], ["orthogonal tests", "TEST", 168, 184], ["narrow", "OBSERVATION_MODIFIER", 49, 55]]], ["Here, solvents including non-polar petroleum ether (boiling range of 60-90 \u2022 C), medium polar ethyl acetate, and polar 95% ethanol were chosen for extraction using the Hou content as the index.", [["non-polar petroleum ether", "CHEMICAL", 25, 50], ["ethyl acetate", "CHEMICAL", 94, 107], ["ethanol", "CHEMICAL", 123, 130], ["petroleum ether", "CHEMICAL", 35, 50], ["ethyl acetate", "CHEMICAL", 94, 107], ["ethanol", "CHEMICAL", 123, 130], ["non-polar petroleum ether", "SIMPLE_CHEMICAL", 25, 50], ["polar ethyl acetate", "SIMPLE_CHEMICAL", 88, 107], ["ethanol", "SIMPLE_CHEMICAL", 123, 130], ["non-polar petroleum ether", "TREATMENT", 25, 50], ["medium polar ethyl acetate", "TREATMENT", 81, 107], ["polar 95% ethanol", "TREATMENT", 113, 130], ["extraction", "TREATMENT", 147, 157]]], ["Results showed that ethyl acetate had the highest Hou extract efficiency.", [["ethyl acetate", "CHEMICAL", 20, 33], ["ethyl acetate", "CHEMICAL", 20, 33], ["ethyl acetate", "SIMPLE_CHEMICAL", 20, 33], ["ethyl acetate", "TREATMENT", 20, 33], ["extract efficiency", "OBSERVATION", 54, 72]]], ["Therefore, ethyl acetate was used as the solvent for the extraction.Solvent Extraction of Crude HEOTo further optimize the extraction conditions, L9 (3) 4 orthogonal tests were employed and the experimental design was shown in Tables 1 and 2 .", [["ethyl acetate", "CHEMICAL", 11, 24], ["ethyl acetate", "CHEMICAL", 11, 24], ["ethyl acetate", "SIMPLE_CHEMICAL", 11, 24], ["ethyl acetate", "TREATMENT", 11, 24], ["the extraction", "TREATMENT", 53, 67], ["Solvent Extraction", "TREATMENT", 68, 86], ["the extraction conditions", "TREATMENT", 119, 144], ["4 orthogonal tests", "TEST", 153, 171]]], ["Table 1 showed the levels of each factor which would affect the extraction ratio of HEO.", [["HEO", "CHEMICAL", 84, 87], ["HEO", "CHEMICAL", 84, 87], ["HEO", "SIMPLE_CHEMICAL", 84, 87]]], ["In Table 2 , k i was the mean extraction ratio of the corresponding level of each factor and R was the range of the k i of each factor [30, 31] .", [["the mean extraction ratio", "TEST", 21, 46]]], ["The parameter of k i was used for judging the optimal level of each factor while R was used for judging the effect of the factors.", [["k i", "TREATMENT", 17, 20]]], ["The results indicated that the optimized extraction condition was A2 (factor A level 2)/B3/C3/D2 and the effect of the factors was D > A > B > C. Therefore, sufficient extraction solvents with proper polarity could easily infiltrate to the herbs thereby improve the extraction efficiency.", [["D", "SIMPLE_CHEMICAL", 131, 132], ["A2", "PROTEIN", 66, 68], ["B3", "PROTEIN", 88, 90], ["C3", "PROTEIN", 91, 93], ["D2", "PROTEIN", 94, 96], ["the optimized extraction condition", "TEST", 27, 61], ["B3/C3/D2", "PROBLEM", 88, 96], ["sufficient extraction solvents", "TREATMENT", 157, 187], ["easily infiltrate", "PROBLEM", 215, 232], ["the herbs", "TREATMENT", 236, 245], ["the extraction efficiency", "TREATMENT", 262, 287], ["infiltrate", "OBSERVATION", 222, 232], ["extraction efficiency", "OBSERVATION", 266, 287]]], ["Additionally, ultrasonic time could improve the extraction efficiency and feasible extraction time and root length were beneficial for the penetration of solvent.", [["root", "ANATOMY", 103, 107], ["root", "ORGAN", 103, 107], ["ultrasonic time", "TEST", 14, 29], ["the extraction efficiency", "TREATMENT", 44, 69], ["feasible extraction", "TREATMENT", 74, 93], ["the penetration of solvent", "TREATMENT", 135, 161]]], ["Overall, the optimized extraction condition was as follows: the ultrasonic time was 20 min (A2), the extraction time was three days (B3), the H. cordata root length was 1.0 cm (C3), and the solid-liquid ratio was 1/1.5 (kg/L, D2).", [["root", "ANATOMY", 153, 157], ["H. cordata", "SPECIES", 142, 152], ["H. cordata", "SPECIES", 142, 152], ["the H. cordata root length", "TEST", 138, 164], ["the solid-liquid ratio", "TEST", 186, 208], ["cordata root", "ANATOMY", 145, 157], ["length", "OBSERVATION_MODIFIER", 158, 164], ["1.0 cm", "OBSERVATION_MODIFIER", 169, 175]]], ["Using the optimized extraction condition, the HEO extraction ratio was 0.171% (wt %) and the Hou content in the extract was 8.80% (wt %) based on the GC analysis.", [["extract", "ANATOMY", 112, 119], ["HEO", "SIMPLE_CHEMICAL", 46, 49], ["the HEO extraction ratio", "TEST", 42, 66], ["wt", "TEST", 79, 81], ["the Hou content", "TEST", 89, 104], ["the GC analysis", "TEST", 146, 161]]], ["Moreover, the extract was treated by alcohol sinking and n-hexane extraction to prepare the crude HEO (Hou 15.0%) for MR purification.", [["extract", "ANATOMY", 14, 21], ["alcohol", "CHEMICAL", 37, 44], ["n-hexane", "CHEMICAL", 57, 65], ["HEO", "CHEMICAL", 98, 101], ["alcohol", "CHEMICAL", 37, 44], ["n-hexane", "CHEMICAL", 57, 65], ["alcohol", "SIMPLE_CHEMICAL", 37, 44], ["n-hexane", "SIMPLE_CHEMICAL", 57, 65], ["HEO", "SIMPLE_CHEMICAL", 98, 101], ["MR", "PROTEIN", 118, 120], ["n-hexane extraction", "TREATMENT", 57, 76], ["MR purification", "TREATMENT", 118, 133]]], ["Note: k i = \u2211 i 3 : the mean extraction ratio of the corresponding level of each factor; R = max{k i } \u2212 min{k i }: the range of the k i of each factor.Optimization of MR TypesMRs were selected in accordance with the structures and polarities of the adsorbed substances and resins [32] .", [["MR", "PROTEIN", 168, 170], ["k i", "TEST", 6, 9], ["the mean extraction ratio", "TEST", 20, 45], ["each factor", "TEST", 76, 87], ["MR TypesMRs", "TEST", 168, 179]]], ["As shown in Figure 1 , Hou contains a non-polarity long aliphatic chain and a mid-polarity carbonyl structure, which indicating a weak polarity.", [["carbonyl", "CHEMICAL", 91, 99], ["carbonyl", "CHEMICAL", 91, 99], ["non-polarity long aliphatic chain", "PROTEIN", 38, 71], ["mid-polarity carbonyl structure", "PROTEIN", 78, 109], ["a non-polarity long aliphatic chain", "PROBLEM", 36, 71], ["a mid-polarity carbonyl structure", "PROBLEM", 76, 109], ["a weak polarity", "PROBLEM", 128, 143], ["aliphatic chain", "OBSERVATION", 56, 71], ["carbonyl structure", "OBSERVATION", 91, 109], ["weak", "OBSERVATION_MODIFIER", 130, 134], ["polarity", "OBSERVATION_MODIFIER", 135, 143]]], ["Here, four types of MRs ranging from non-polar to mid-polar were screened for the adsorption and desorption tests.", [["MRs", "TEST", 20, 23], ["the adsorption and desorption tests", "TEST", 78, 113]]], ["Their absorption capacities, desorption capacities and desorption ratios are shown in Figure 2 .", [["Their absorption capacities", "PROBLEM", 0, 27], ["desorption capacities", "TEST", 29, 50], ["desorption ratios", "TEST", 55, 72]]], ["Results showed that all of the tested MRs had similar and high adsorption capacities (>10 mg/g).", [["MRs", "SIMPLE_CHEMICAL", 38, 41], ["the tested MRs", "TEST", 27, 41], ["high adsorption capacities", "PROBLEM", 58, 84]]], ["HPD100 had the highest adsorption capacity of 11.16 mg/g owing to its relative high surface area.", [["surface area", "ANATOMY", 84, 96], ["HPD100", "CHEMICAL", 0, 6], ["HPD100", "SIMPLE_CHEMICAL", 0, 6], ["high", "OBSERVATION_MODIFIER", 79, 83], ["surface", "OBSERVATION_MODIFIER", 84, 91]]], ["As for desorption ratios, D101 resin showed the highest desorption ratio (74.9%) and was significantly higher than AB-8 and HPD100.", [["D101", "SIMPLE_CHEMICAL", 26, 30], ["HPD100", "SIMPLE_CHEMICAL", 124, 130], ["desorption ratios", "TEST", 7, 24], ["D101 resin", "TREATMENT", 26, 36], ["the highest desorption ratio", "TEST", 44, 72], ["AB", "TEST", 115, 117], ["HPD100", "TEST", 124, 130]]], ["This could be explained by the appropriate polarity of D101 and its larger pore diameters [33] .", [["pore", "ANATOMY", 75, 79], ["D101", "SIMPLE_CHEMICAL", 55, 59], ["larger", "OBSERVATION_MODIFIER", 68, 74], ["pore", "OBSERVATION_MODIFIER", 75, 79], ["diameters", "OBSERVATION_MODIFIER", 80, 89]]], ["Considering the adsorption capacities and its corresponding desorption ratios, D101 was selected as the optimal resin for further purification.Optimization of MR TypesMRs were selected in accordance with the structures and polarities of the adsorbed substances and resins [32] .", [["D101", "CHEMICAL", 79, 83], ["D101", "CHEMICAL", 79, 83], ["D101", "SIMPLE_CHEMICAL", 79, 83], ["MR", "PROTEIN", 159, 161], ["the adsorption capacities", "PROBLEM", 12, 37], ["D101", "TREATMENT", 79, 83], ["further purification", "TREATMENT", 122, 142], ["MR TypesMRs", "TEST", 159, 170]]], ["As shown in Figure 1 , Hou contains a non-polarity long aliphatic chain and a mid-polarity carbonyl structure, which indicating a weak polarity.", [["carbonyl", "CHEMICAL", 91, 99], ["carbonyl", "CHEMICAL", 91, 99], ["non-polarity long aliphatic chain", "PROTEIN", 38, 71], ["mid-polarity carbonyl structure", "PROTEIN", 78, 109], ["a non-polarity long aliphatic chain", "PROBLEM", 36, 71], ["a mid-polarity carbonyl structure", "PROBLEM", 76, 109], ["a weak polarity", "PROBLEM", 128, 143], ["aliphatic chain", "OBSERVATION", 56, 71], ["carbonyl structure", "OBSERVATION", 91, 109], ["weak", "OBSERVATION_MODIFIER", 130, 134], ["polarity", "OBSERVATION_MODIFIER", 135, 143]]], ["Here, four types of MRs ranging from non-polar to mid-polar were screened for the adsorption and desorption tests.", [["MRs", "TEST", 20, 23], ["the adsorption and desorption tests", "TEST", 78, 113]]], ["Their absorption capacities, desorption capacities and desorption ratios are shown in Figure 2 .", [["Their absorption capacities", "PROBLEM", 0, 27], ["desorption capacities", "TEST", 29, 50], ["desorption ratios", "TEST", 55, 72]]], ["Results showed that all of the tested MRs had similar and high adsorption capacities (>10 mg/g).", [["MRs", "SIMPLE_CHEMICAL", 38, 41], ["the tested MRs", "TEST", 27, 41], ["high adsorption capacities", "PROBLEM", 58, 84]]], ["HPD100 had the highest adsorption capacity of 11.16 mg/g owing to its relative high surface area.", [["surface area", "ANATOMY", 84, 96], ["HPD100", "CHEMICAL", 0, 6], ["HPD100", "SIMPLE_CHEMICAL", 0, 6], ["high", "OBSERVATION_MODIFIER", 79, 83], ["surface", "OBSERVATION_MODIFIER", 84, 91]]], ["As for desorption ratios, D101 resin showed the highest desorption ratio (74.9%) and was significantly higher than AB-8 and HPD100.", [["D101", "SIMPLE_CHEMICAL", 26, 30], ["HPD100", "SIMPLE_CHEMICAL", 124, 130], ["desorption ratios", "TEST", 7, 24], ["D101 resin", "TREATMENT", 26, 36], ["the highest desorption ratio", "TEST", 44, 72], ["AB", "TEST", 115, 117], ["HPD100", "TEST", 124, 130]]], ["This could be explained by the appropriate polarity of D101 and its larger pore diameters [33] .", [["pore", "ANATOMY", 75, 79], ["D101", "SIMPLE_CHEMICAL", 55, 59], ["larger", "OBSERVATION_MODIFIER", 68, 74], ["pore", "OBSERVATION_MODIFIER", 75, 79], ["diameters", "OBSERVATION_MODIFIER", 80, 89]]], ["Considering the adsorption capacities and its corresponding desorption ratios, D101 was selected as the optimal resin for further purification.Optimization of the Adsorption TimeAdsorption time is an important factor affecting the adsorption ratio of Hou on D101.", [["D101", "CHEMICAL", 79, 83], ["D101", "CHEMICAL", 79, 83], ["D101", "SIMPLE_CHEMICAL", 79, 83], ["the adsorption capacities", "PROBLEM", 12, 37], ["D101", "TREATMENT", 79, 83], ["further purification", "TREATMENT", 122, 142], ["the Adsorption TimeAdsorption time", "TREATMENT", 159, 193], ["D101", "TREATMENT", 258, 262]]], ["The adsorption kinetic curve is one of the important characteristics that define the adsorption efficiency.", [["The adsorption kinetic curve", "TEST", 0, 28], ["the adsorption efficiency", "PROBLEM", 81, 106], ["adsorption efficiency", "OBSERVATION", 85, 106]]], ["As shown in Figure 3A , the adsorption ratio of Hou on D101 increases rapidly in the first 30 min and then increases slowly and finally reaches the equilibrium after 3 h.", [["D101", "CHEMICAL", 55, 59], ["D101", "SIMPLE_CHEMICAL", 55, 59], ["D101", "TREATMENT", 55, 59]]], ["The fast adsorption process of D101 resin in the first 30 min was due to the high diffusivity of Hou into macropores of the resin and the slow adsorption process 30 min later was because of its high transfer resistance into macropores.", [["D101 resin", "CHEMICAL", 31, 41], ["D101 resin", "SIMPLE_CHEMICAL", 31, 41], ["The fast adsorption process of D101 resin", "TREATMENT", 0, 41], ["the resin", "TREATMENT", 120, 129], ["the slow adsorption process", "TREATMENT", 134, 161], ["its high transfer resistance into macropores", "PROBLEM", 190, 234]]], ["The result indicated that Hou exhibited a fast adsorption feature on D101 resin and 3 h was appropriate as the adsorption time.Optimization for the Concentration of the Ethanol SolutionEthanol with low cost and nontoxic is usually used as the desorbent.", [["Ethanol", "CHEMICAL", 169, 176], ["Ethanol", "CHEMICAL", 169, 176], ["D101", "SIMPLE_CHEMICAL", 69, 73], ["Ethanol SolutionEthanol", "SIMPLE_CHEMICAL", 169, 192], ["D101 resin", "TREATMENT", 69, 79], ["the Ethanol SolutionEthanol", "TREATMENT", 165, 192], ["low cost and nontoxic", "TREATMENT", 198, 219]]], ["Here, different concentrations of ethanol-water solutions (60:40, 70:30, 80:20, 90:10, and 95:5 (v/v)) were used to establish the proper desorption conditions.", [["ethanol", "CHEMICAL", 34, 41], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["ethanol-water solutions", "TREATMENT", 34, 57]]], ["As shown in Figure 3B , the desorption ratio is the highest when the ethanol concentration was 90%.", [["ethanol", "CHEMICAL", 69, 76], ["ethanol", "CHEMICAL", 69, 76], ["ethanol", "SIMPLE_CHEMICAL", 69, 76], ["the desorption ratio", "TEST", 24, 44], ["the ethanol concentration", "TREATMENT", 65, 90]]], ["Thus, ethanol-water (90:10, v/v) solution was selected as the appropriate desorption solution and used in the following dynamic desorption experiments.Optimization of the Adsorption TimeAdsorption time is an important factor affecting the adsorption ratio of Hou on D101.", [["ethanol", "CHEMICAL", 6, 13], ["ethanol", "CHEMICAL", 6, 13], ["ethanol", "SIMPLE_CHEMICAL", 6, 13], ["ethanol-water", "TREATMENT", 6, 19], ["v/v) solution", "TREATMENT", 28, 41], ["the appropriate desorption solution", "TREATMENT", 58, 93], ["the Adsorption TimeAdsorption time", "TREATMENT", 167, 201], ["D101", "TREATMENT", 266, 270]]], ["The adsorption kinetic curve is one of the important characteristics that define the adsorption efficiency.", [["The adsorption kinetic curve", "TEST", 0, 28], ["the adsorption efficiency", "PROBLEM", 81, 106], ["adsorption efficiency", "OBSERVATION", 85, 106]]], ["As shown in Figure 3A , the adsorption ratio of Hou on D101 increases rapidly in the first 30 min and then increases slowly and finally reaches the equilibrium after 3 h.", [["D101", "CHEMICAL", 55, 59], ["D101", "SIMPLE_CHEMICAL", 55, 59], ["D101", "TREATMENT", 55, 59]]], ["The fast adsorption process of D101 resin in the first 30 min was due to the high diffusivity of Hou into macropores of the resin and the slow adsorption process 30 min later was because of its high transfer resistance into macropores.", [["D101 resin", "CHEMICAL", 31, 41], ["D101 resin", "SIMPLE_CHEMICAL", 31, 41], ["The fast adsorption process of D101 resin", "TREATMENT", 0, 41], ["the resin", "TREATMENT", 120, 129], ["the slow adsorption process", "TREATMENT", 134, 161], ["its high transfer resistance into macropores", "PROBLEM", 190, 234]]], ["The result indicated that Hou exhibited a fast adsorption feature on D101 resin and 3 h was appropriate as the adsorption time.Optimization for the Concentration of the Ethanol SolutionEthanol with low cost and nontoxic is usually used as the desorbent.", [["Ethanol", "CHEMICAL", 169, 176], ["Ethanol", "CHEMICAL", 169, 176], ["D101", "SIMPLE_CHEMICAL", 69, 73], ["Ethanol SolutionEthanol", "SIMPLE_CHEMICAL", 169, 192], ["D101 resin", "TREATMENT", 69, 79], ["the Ethanol SolutionEthanol", "TREATMENT", 165, 192], ["low cost and nontoxic", "TREATMENT", 198, 219]]], ["Here, different concentrations of ethanol-water solutions (60:40, 70:30, 80:20, 90:10, and 95:5 (v/v)) were used to establish the proper desorption conditions.", [["ethanol", "CHEMICAL", 34, 41], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["ethanol-water solutions", "TREATMENT", 34, 57]]], ["As shown in Figure 3B , the desorption ratio is the highest when the ethanol concentration was 90%.", [["ethanol", "CHEMICAL", 69, 76], ["ethanol", "CHEMICAL", 69, 76], ["ethanol", "SIMPLE_CHEMICAL", 69, 76], ["the desorption ratio", "TEST", 24, 44], ["the ethanol concentration", "TREATMENT", 65, 90]]], ["Thus, ethanol-water (90:10, v/v) solution was selected as the appropriate desorption solution and used in the following dynamic desorption experiments.Optimization for Breakthrough VolumeThe breakthrough volume is important in solid phase extraction because it represents the sample mount that can be adsorbed on resin without loss of analytes during the loading process [34] .", [["ethanol", "CHEMICAL", 6, 13], ["ethanol", "CHEMICAL", 6, 13], ["ethanol", "SIMPLE_CHEMICAL", 6, 13], ["ethanol-water", "TREATMENT", 6, 19], ["v/v) solution", "TREATMENT", 28, 41], ["the appropriate desorption solution", "TREATMENT", 58, 93], ["Breakthrough Volume", "TREATMENT", 168, 187], ["The breakthrough volume", "PROBLEM", 187, 210], ["solid phase extraction", "TREATMENT", 227, 249], ["loss of analytes", "PROBLEM", 327, 343], ["breakthrough", "OBSERVATION_MODIFIER", 191, 203], ["volume", "OBSERVATION", 204, 210], ["solid phase", "OBSERVATION_MODIFIER", 227, 238]]], ["Generally, 10% ratio of the exit to the inlet solute concentration is defined as the breakthrough point.", [["the inlet solute concentration", "TREATMENT", 36, 66]]], ["When the adsorption reaches the breakthrough point, the adsorption effect decreases, even disappears, and the analytes leak from the resin [35] .", [["the analytes leak", "PROBLEM", 106, 123]]], ["The dynamic breakthrough curve on D101 resin was obtained according to the volume of loading sample and the Hou concentration of the leak solution.", [["The dynamic breakthrough curve", "TEST", 0, 30], ["D101 resin", "TREATMENT", 34, 44], ["the leak solution", "TREATMENT", 129, 146], ["leak", "OBSERVATION", 133, 137]]], ["As shown in Figure 3C , the Hou concentration in the exit solute was very low before 7 bed volume (BV) at the sample flow rate of 6 BV/h, which suggested that Hou was almost completely absorbed by D101 resin.", [["sample", "ANATOMY", 110, 116], ["BV", "ORGANISM_SUBSTANCE", 99, 101], ["the Hou concentration", "TREATMENT", 24, 45], ["the sample flow rate", "TEST", 106, 126], ["D101 resin", "TREATMENT", 197, 207]]], ["Subsequently, the Hou concentration increased rapidly in the leak solution until it reacheed a steady plateau at 14 BV.", [["BV", "ORGANISM_SUBSTANCE", 116, 118], ["the Hou concentration", "TREATMENT", 14, 35], ["the leak solution", "TREATMENT", 57, 74], ["leak", "OBSERVATION", 61, 65]]], ["The result indicated that the breakthrough volume of Hou on D101 resin was approximately 7 BV.", [["BV", "ORGANISM_SUBSTANCE", 91, 93], ["D101 resin", "TREATMENT", 60, 70]]], ["Therefore, 7 BV of sample solution (Hou concentration: 0.225 mg/mL) was determined as the saturated adsorption volume for dynamic adsorption on D101 resin.Optimization for the Eluent VolumeBefore Hou desorption, 2 BV of distilled water and 5 BV of ethanol-water (30:70, v/v) were used to flush the resin to remove the high polar components and impurities.", [["BV", "ANATOMY", 13, 15], ["sample", "ANATOMY", 19, 25], ["Hou", "CHEMICAL", 36, 39], ["ethanol", "CHEMICAL", 248, 255], ["ethanol", "CHEMICAL", 248, 255], ["BV", "ORGANISM_SUBSTANCE", 13, 15], ["D101 resin", "SIMPLE_CHEMICAL", 144, 154], ["BV", "ORGANISM_SUBSTANCE", 214, 216], ["BV", "ORGANISM_SUBSTANCE", 242, 244], ["ethanol", "SIMPLE_CHEMICAL", 248, 255], ["7 BV of sample solution (Hou concentration", "TREATMENT", 11, 53], ["the saturated adsorption volume", "TREATMENT", 86, 117], ["dynamic adsorption on D101 resin", "TREATMENT", 122, 154], ["the Eluent VolumeBefore Hou desorption", "TREATMENT", 172, 210], ["distilled water", "TREATMENT", 220, 235], ["ethanol-water", "TREATMENT", 248, 261], ["v/v)", "TREATMENT", 270, 274], ["the resin", "TREATMENT", 294, 303], ["the high polar components", "TREATMENT", 314, 339], ["high polar", "OBSERVATION_MODIFIER", 318, 328]]], ["Subsequently, ethanol-water (90:10, v/v) was used as the desorption solution and the dynamic desorption curve was obtained according to the eluent volume of ethanol-water (90:10, v/v) and the Hou concentration of the eluent.", [["ethanol", "CHEMICAL", 14, 21], ["ethanol", "CHEMICAL", 157, 164], ["ethanol", "CHEMICAL", 14, 21], ["ethanol", "CHEMICAL", 157, 164], ["ethanol", "SIMPLE_CHEMICAL", 14, 21], ["ethanol", "SIMPLE_CHEMICAL", 157, 164], ["ethanol-water", "TREATMENT", 14, 27], ["v/v)", "TREATMENT", 36, 40], ["the desorption solution", "TREATMENT", 53, 76], ["the dynamic desorption curve", "TEST", 81, 109]]], ["As shown in Figure 3D , the dynamic desorption curve was sharp and narrow with no trailing peak, which indicated that Hou was completely desorbed from D101 resin and enriched in approximately 3 BV of the eluent.", [["BV", "ORGANISM_SUBSTANCE", 194, 196], ["the dynamic desorption curve", "TEST", 24, 52], ["trailing peak", "PROBLEM", 82, 95], ["D101 resin", "TREATMENT", 151, 161], ["narrow", "OBSERVATION_MODIFIER", 67, 73]]], ["After removing the solvent, pure HEO was obtained.Optimization for the Eluent VolumeAccording to the above results, the optimal purification conditions were confirmed as follows: D101 resin was used to adsorb 7 BV of sample solution (Hou 0.225 mg/mL) for 3 h at a flow rate ofOptimization for Breakthrough VolumeThe breakthrough volume is important in solid phase extraction because it represents the sample mount that can be adsorbed on resin without loss of analytes during the loading process [34] .", [["sample", "ANATOMY", 217, 223], ["HEO", "CHEMICAL", 33, 36], ["HEO", "CHEMICAL", 33, 36], ["HEO", "SIMPLE_CHEMICAL", 33, 36], ["D101 resin", "SIMPLE_CHEMICAL", 179, 189], ["the solvent", "TREATMENT", 15, 26], ["the optimal purification conditions", "TEST", 116, 151], ["D101 resin", "TREATMENT", 179, 189], ["a flow rate ofOptimization", "TREATMENT", 262, 288], ["Breakthrough Volume", "TREATMENT", 293, 312], ["The breakthrough volume", "PROBLEM", 312, 335], ["solid phase extraction", "TREATMENT", 352, 374], ["loss of analytes", "PROBLEM", 452, 468], ["breakthrough", "OBSERVATION_MODIFIER", 316, 328], ["volume", "OBSERVATION", 329, 335], ["solid phase", "OBSERVATION_MODIFIER", 352, 363]]], ["Generally, 10% ratio of the exit to the inlet solute concentration is defined as the breakthrough point.", [["the inlet solute concentration", "TREATMENT", 36, 66]]], ["When the adsorption reaches the breakthrough point, the adsorption effect decreases, even disappears, and the analytes leak from the resin [35] .", [["the analytes leak", "PROBLEM", 106, 123]]], ["The dynamic breakthrough curve on D101 resin was obtained according to the volume of loading sample and the Hou concentration of the leak solution.", [["The dynamic breakthrough curve", "TEST", 0, 30], ["D101 resin", "TREATMENT", 34, 44], ["the leak solution", "TREATMENT", 129, 146], ["leak", "OBSERVATION", 133, 137]]], ["As shown in Figure 3C , the Hou concentration in the exit solute was very low before 7 bed volume (BV) at the sample flow rate of 6 BV/h, which suggested that Hou was almost completely absorbed by D101 resin.", [["sample", "ANATOMY", 110, 116], ["BV", "ORGANISM_SUBSTANCE", 99, 101], ["the Hou concentration", "TREATMENT", 24, 45], ["the sample flow rate", "TEST", 106, 126], ["D101 resin", "TREATMENT", 197, 207]]], ["Subsequently, the Hou concentration increased rapidly in the leak solution until it reacheed a steady plateau at 14 BV.", [["BV", "ORGANISM_SUBSTANCE", 116, 118], ["the Hou concentration", "TREATMENT", 14, 35], ["the leak solution", "TREATMENT", 57, 74], ["leak", "OBSERVATION", 61, 65]]], ["The result indicated that the breakthrough volume of Hou on D101 resin was approximately 7 BV.", [["BV", "ORGANISM_SUBSTANCE", 91, 93], ["D101 resin", "TREATMENT", 60, 70]]], ["Therefore, 7 BV of sample solution (Hou concentration: 0.225 mg/mL) was determined as the saturated adsorption volume for dynamic adsorption on D101 resin.Optimization for the Eluent VolumeBefore Hou desorption, 2 BV of distilled water and 5 BV of ethanol-water (30:70, v/v) were used to flush the resin to remove the high polar components and impurities.", [["BV", "ANATOMY", 13, 15], ["sample", "ANATOMY", 19, 25], ["Hou", "CHEMICAL", 36, 39], ["ethanol", "CHEMICAL", 248, 255], ["ethanol", "CHEMICAL", 248, 255], ["BV", "ORGANISM_SUBSTANCE", 13, 15], ["D101 resin", "SIMPLE_CHEMICAL", 144, 154], ["BV", "ORGANISM_SUBSTANCE", 214, 216], ["BV", "ORGANISM_SUBSTANCE", 242, 244], ["ethanol", "SIMPLE_CHEMICAL", 248, 255], ["7 BV of sample solution (Hou concentration", "TREATMENT", 11, 53], ["the saturated adsorption volume", "TREATMENT", 86, 117], ["dynamic adsorption on D101 resin", "TREATMENT", 122, 154], ["the Eluent VolumeBefore Hou desorption", "TREATMENT", 172, 210], ["distilled water", "TREATMENT", 220, 235], ["ethanol-water", "TREATMENT", 248, 261], ["v/v)", "TREATMENT", 270, 274], ["the resin", "TREATMENT", 294, 303], ["the high polar components", "TREATMENT", 314, 339], ["high polar", "OBSERVATION_MODIFIER", 318, 328]]], ["Subsequently, ethanol-water (90:10, v/v) was used as the desorption solution and the dynamic desorption curve was obtained according to the eluent volume of ethanol-water (90:10, v/v) and the Hou concentration of the eluent.", [["ethanol", "CHEMICAL", 14, 21], ["ethanol", "CHEMICAL", 157, 164], ["ethanol", "CHEMICAL", 14, 21], ["ethanol", "CHEMICAL", 157, 164], ["ethanol", "SIMPLE_CHEMICAL", 14, 21], ["ethanol", "SIMPLE_CHEMICAL", 157, 164], ["ethanol-water", "TREATMENT", 14, 27], ["v/v)", "TREATMENT", 36, 40], ["the desorption solution", "TREATMENT", 53, 76], ["the dynamic desorption curve", "TEST", 81, 109]]], ["As shown in Figure 3D , the dynamic desorption curve was sharp and narrow with no trailing peak, which indicated that Hou was completely desorbed from D101 resin and enriched in approximately 3 BV of the eluent.", [["BV", "ORGANISM_SUBSTANCE", 194, 196], ["the dynamic desorption curve", "TEST", 24, 52], ["trailing peak", "PROBLEM", 82, 95], ["D101 resin", "TREATMENT", 151, 161], ["narrow", "OBSERVATION_MODIFIER", 67, 73]]], ["After removing the solvent, pure HEO was obtained.Optimization for the Eluent VolumeAccording to the above results, the optimal purification conditions were confirmed as follows: D101 resin was used to adsorb 7 BV of sample solution (Hou 0.225 mg/mL) for 3 h at a flow rate of 6 BV/h.", [["sample", "ANATOMY", 217, 223], ["HEO", "CHEMICAL", 33, 36], ["HEO", "CHEMICAL", 33, 36], ["HEO", "SIMPLE_CHEMICAL", 33, 36], ["D101 resin", "SIMPLE_CHEMICAL", 179, 189], ["the solvent", "TREATMENT", 15, 26], ["the optimal purification conditions", "TEST", 116, 151], ["D101 resin", "TREATMENT", 179, 189], ["a flow rate", "TEST", 262, 273]]], ["Then, 2 BV of deionized water and 5 BV of 30% ethanol were used to remove the high polar components and impurities.", [["BV", "ANATOMY", 8, 10], ["ethanol", "CHEMICAL", 46, 53], ["ethanol", "CHEMICAL", 46, 53], ["BV", "ORGANISM_SUBSTANCE", 8, 10], ["BV", "ORGANISM_SUBSTANCE", 36, 38], ["ethanol", "SIMPLE_CHEMICAL", 46, 53], ["deionized water", "TREATMENT", 14, 29], ["5 BV of 30% ethanol", "TREATMENT", 34, 53], ["high polar", "OBSERVATION_MODIFIER", 78, 88]]], ["At last, 5 BV of 90% ethanol was used for Hou desorption at a flow rate of 6 BV/h.Analysis of ExtractQualitative analysis was measured by both GC-MS and GC.", [["BV", "ANATOMY", 11, 13], ["ethanol", "CHEMICAL", 21, 28], ["ethanol", "CHEMICAL", 21, 28], ["BV", "ORGANISM_SUBSTANCE", 11, 13], ["ethanol", "SIMPLE_CHEMICAL", 21, 28], ["a flow rate", "TEST", 60, 71], ["ExtractQualitative analysis", "TEST", 94, 121], ["GC", "TEST", 153, 155]]], ["Then, hydrodistillation extracted HEO (HEHEO), crude HEO and pure HEO were further analyzed by GC.", [["HEO", "CHEMICAL", 34, 37], ["HEO", "CHEMICAL", 34, 37], ["HEO", "CHEMICAL", 66, 69], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["HEHEO", "SIMPLE_CHEMICAL", 39, 44], ["HEO", "SIMPLE_CHEMICAL", 53, 56], ["HEO", "SIMPLE_CHEMICAL", 66, 69], ["hydrodistillation", "TREATMENT", 6, 23], ["crude HEO and pure HEO", "TREATMENT", 47, 69]]], ["The GC chromatograms and corresponding results were shown in Figure 4 and Table 3 , respectively.", [["The GC chromatograms", "TEST", 0, 20]]], ["For the hydrodistillation extracted HEHEO (Figure 4A) , it was mainly composed of \u03b1-pinene (10.24%), bicycle [3.1.0] hexane (30.87%), \u03b2-myrcene (12.60%) and 2-undecanone (22.63%).", [["HEHEO", "CHEMICAL", 36, 41], ["\u03b1-pinene", "CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "CHEMICAL", 101, 123], ["\u03b2-myrcene", "CHEMICAL", 134, 143], ["2-undecanone", "CHEMICAL", 157, 169], ["HEHEO", "CHEMICAL", 36, 41], ["\u03b1-pinene", "CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "CHEMICAL", 101, 123], ["\u03b2-myrcene", "CHEMICAL", 134, 143], ["2-undecanone", "CHEMICAL", 157, 169], ["HEHEO", "SIMPLE_CHEMICAL", 36, 41], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "SIMPLE_CHEMICAL", 101, 123], ["\u03b2-myrcene", "SIMPLE_CHEMICAL", 134, 143], ["2-undecanone", "SIMPLE_CHEMICAL", 157, 169], ["the hydrodistillation", "TEST", 4, 25], ["bicycle", "TEST", 101, 108], ["hexane", "TEST", 117, 123], ["\u03b2-myrcene", "TREATMENT", 134, 143], ["undecanone", "TREATMENT", 159, 169], ["hydrodistillation", "OBSERVATION", 8, 25]]], ["2-undecanone was the oxidative product of Hou, however, the percentage of Hou was only 1.95% in HEHEO.", [["2-undecanone", "CHEMICAL", 0, 12], ["HEHEO", "CHEMICAL", 96, 101], ["2-undecanone", "CHEMICAL", 0, 12], ["2-undecanone", "SIMPLE_CHEMICAL", 0, 12], ["HEHEO", "SIMPLE_CHEMICAL", 96, 101]]], ["For the extracts prepared by solvent extraction, the Hou percentage was 80.88% and 84.94% for crude HEO ( Figure 4B ) and pure HEO ( Figure 4C ), respectively.", [["extracts", "ANATOMY", 8, 16], ["HEO", "CHEMICAL", 100, 103], ["extracts", "ORGANISM_SUBSTANCE", 8, 16], ["HEO", "SIMPLE_CHEMICAL", 100, 103], ["the Hou percentage", "TEST", 49, 67], ["crude HEO", "TEST", 94, 103]]], ["Contrastively, the percentage of 2-undecanone was less than 2%.", [["2-undecanone", "CHEMICAL", 33, 45], ["2-undecanone", "CHEMICAL", 33, 45], ["2-undecanone", "SIMPLE_CHEMICAL", 33, 45], ["percentage", "OBSERVATION_MODIFIER", 19, 29]]], ["It could be speculated that most of Hou was oxidized into 2-undecanone by the high temperature during the hydrodistillation extraction.", [["Hou", "CHEMICAL", 36, 39], ["2-undecanone", "CHEMICAL", 58, 70], ["2-undecanone", "CHEMICAL", 58, 70], ["2-undecanone", "SIMPLE_CHEMICAL", 58, 70], ["the high temperature", "PROBLEM", 74, 94], ["the hydrodistillation extraction", "TREATMENT", 102, 134], ["high temperature", "OBSERVATION_MODIFIER", 78, 94], ["hydrodistillation", "OBSERVATION", 106, 123]]], ["Therefore, the solvent extraction used in this study had much higher efficiency than hydrodistillation extraction due to its mild extraction conditions and suitable solvent.Analysis of Extract6 BV/h.", [["Extract6 BV", "PROTEIN", 185, 196], ["the solvent extraction", "TREATMENT", 11, 33], ["this study", "TEST", 42, 52], ["hydrodistillation extraction", "TREATMENT", 85, 113], ["its mild extraction conditions", "PROBLEM", 121, 151], ["suitable solvent", "TREATMENT", 156, 172], ["Analysis", "TEST", 173, 181], ["Extract6", "TEST", 185, 193], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["extraction", "OBSERVATION", 130, 140]]], ["Then, 2 BV of deionized water and 5 BV of 30% ethanol were used to remove the high polar components and impurities.", [["BV", "ANATOMY", 8, 10], ["ethanol", "CHEMICAL", 46, 53], ["ethanol", "CHEMICAL", 46, 53], ["BV", "ORGANISM_SUBSTANCE", 8, 10], ["BV", "ORGANISM_SUBSTANCE", 36, 38], ["ethanol", "SIMPLE_CHEMICAL", 46, 53], ["deionized water", "TREATMENT", 14, 29], ["5 BV of 30% ethanol", "TREATMENT", 34, 53], ["high polar", "OBSERVATION_MODIFIER", 78, 88]]], ["At last, 5 BV of 90% ethanol was used for Hou desorption at a flow rate of 6 BV/h.Analysis of ExtractQualitative analysis was measured by both GC-MS and GC.", [["BV", "ANATOMY", 11, 13], ["ethanol", "CHEMICAL", 21, 28], ["ethanol", "CHEMICAL", 21, 28], ["BV", "ORGANISM_SUBSTANCE", 11, 13], ["ethanol", "SIMPLE_CHEMICAL", 21, 28], ["a flow rate", "TEST", 60, 71], ["ExtractQualitative analysis", "TEST", 94, 121], ["GC", "TEST", 153, 155]]], ["Then, hydrodistillation extracted HEO (HEHEO), crude HEO and pure HEO were further analyzed by GC.", [["HEO", "CHEMICAL", 34, 37], ["HEO", "CHEMICAL", 34, 37], ["HEO", "CHEMICAL", 66, 69], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["HEHEO", "SIMPLE_CHEMICAL", 39, 44], ["HEO", "SIMPLE_CHEMICAL", 53, 56], ["HEO", "SIMPLE_CHEMICAL", 66, 69], ["hydrodistillation", "TREATMENT", 6, 23], ["crude HEO and pure HEO", "TREATMENT", 47, 69]]], ["The GC chromatograms and corresponding results were shown in Figure 4 and Table 3 , respectively.", [["The GC chromatograms", "TEST", 0, 20]]], ["For the hydrodistillation extracted HEHEO (Figure 4A) , it was mainly composed of \u03b1-pinene (10.24%), bicycle [3.1.0] hexane (30.87%), \u03b2-myrcene (12.60%) and 2-undecanone (22.63%).", [["HEHEO", "CHEMICAL", 36, 41], ["\u03b1-pinene", "CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "CHEMICAL", 101, 123], ["\u03b2-myrcene", "CHEMICAL", 134, 143], ["2-undecanone", "CHEMICAL", 157, 169], ["HEHEO", "CHEMICAL", 36, 41], ["\u03b1-pinene", "CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "CHEMICAL", 101, 123], ["\u03b2-myrcene", "CHEMICAL", 134, 143], ["2-undecanone", "CHEMICAL", 157, 169], ["HEHEO", "SIMPLE_CHEMICAL", 36, 41], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 82, 90], ["bicycle [3.1.0] hexane", "SIMPLE_CHEMICAL", 101, 123], ["\u03b2-myrcene", "SIMPLE_CHEMICAL", 134, 143], ["2-undecanone", "SIMPLE_CHEMICAL", 157, 169], ["the hydrodistillation", "TEST", 4, 25], ["bicycle", "TEST", 101, 108], ["hexane", "TEST", 117, 123], ["\u03b2-myrcene", "TREATMENT", 134, 143], ["undecanone", "TREATMENT", 159, 169], ["hydrodistillation", "OBSERVATION", 8, 25]]], ["2-undecanone was the oxidative product of Hou, however, the percentage of Hou was only 1.95% in HEHEO.", [["2-undecanone", "CHEMICAL", 0, 12], ["HEHEO", "CHEMICAL", 96, 101], ["2-undecanone", "CHEMICAL", 0, 12], ["2-undecanone", "SIMPLE_CHEMICAL", 0, 12], ["HEHEO", "SIMPLE_CHEMICAL", 96, 101]]], ["For the extracts prepared by solvent extraction, the Hou percentage was 80.88% and 84.94% for crude HEO ( Figure 4B ) and pure HEO ( Figure 4C ), respectively.", [["extracts", "ANATOMY", 8, 16], ["HEO", "CHEMICAL", 100, 103], ["extracts", "ORGANISM_SUBSTANCE", 8, 16], ["HEO", "SIMPLE_CHEMICAL", 100, 103], ["the Hou percentage", "TEST", 49, 67], ["crude HEO", "TEST", 94, 103]]], ["Contrastively, the percentage of 2-undecanone was less than 2%.", [["2-undecanone", "CHEMICAL", 33, 45], ["2-undecanone", "CHEMICAL", 33, 45], ["2-undecanone", "SIMPLE_CHEMICAL", 33, 45], ["percentage", "OBSERVATION_MODIFIER", 19, 29]]], ["It could be speculated that most of Hou was oxidized into 2-undecanone by the high temperature during the hydrodistillation extraction.", [["Hou", "CHEMICAL", 36, 39], ["2-undecanone", "CHEMICAL", 58, 70], ["2-undecanone", "CHEMICAL", 58, 70], ["2-undecanone", "SIMPLE_CHEMICAL", 58, 70], ["the high temperature", "PROBLEM", 74, 94], ["the hydrodistillation extraction", "TREATMENT", 102, 134], ["high temperature", "OBSERVATION_MODIFIER", 78, 94], ["hydrodistillation", "OBSERVATION", 106, 123]]], ["Therefore, the solvent extraction used in this study had much higher efficiency than hydrodistillation extraction due to its mild extraction conditions and suitable solvent.", [["the solvent extraction", "TREATMENT", 11, 33], ["this study", "TEST", 42, 52], ["hydrodistillation extraction", "TREATMENT", 85, 113], ["its mild extraction conditions", "PROBLEM", 121, 151], ["suitable solvent", "TREATMENT", 156, 172], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["extraction", "OBSERVATION", 130, 140]]], ["To correctly determine the Hou content, the standard curve method was used.", [["the standard curve method", "TREATMENT", 40, 65]]], ["Through calculation, the content of Hou was increased from 15.0% to 43.4% with the recovery of 58.4% after purification by D101 resin.", [["D101 resin", "TREATMENT", 123, 133]]], ["Meanwhile, validation experiments revealed that the average Hou content in pure HEO was 44.3% \u00b1 2.01%, which showed a great potential for industrial applications.", [["HEO", "CHEMICAL", 80, 83], ["HEO", "CHEMICAL", 80, 83], ["HEO", "SIMPLE_CHEMICAL", 80, 83], ["validation experiments", "TEST", 11, 33], ["industrial applications", "TREATMENT", 138, 161]]], ["Additionally, it was easy to find out that the pure HEO ( Figure 5B ) had a deep red color and transparent appearance after purification by D101 MR. Furthermore, it had a characteristic fishy odor and better liquidity, which represented a nice quality.", [["HEO", "CHEMICAL", 52, 55], ["a deep red color", "PROBLEM", 74, 90], ["a characteristic fishy odor", "PROBLEM", 169, 196], ["deep red color", "OBSERVATION", 76, 90], ["characteristic", "OBSERVATION_MODIFIER", 171, 185], ["fishy", "OBSERVATION_MODIFIER", 186, 191], ["odor", "OBSERVATION", 192, 196], ["better liquidity", "OBSERVATION_MODIFIER", 201, 217]]], ["Based on the above findings, it could be concluded that the method of solvent extraction following D101 purification to prepare Hou-riched HEO was highly efficient and could be further applied to large-scale preparation.", [["HEO", "CHEMICAL", 139, 142], ["D101", "SIMPLE_CHEMICAL", 99, 103], ["HEO", "SIMPLE_CHEMICAL", 139, 142], ["solvent extraction", "TREATMENT", 70, 88], ["D101 purification", "TREATMENT", 99, 116], ["Hou-riched HEO", "TREATMENT", 128, 142], ["large-scale preparation", "TREATMENT", 196, 219]]], ["To correctly determine the Hou content, the standard curve method was used.", [["the standard curve method", "TREATMENT", 40, 65]]], ["Through calculation, the content of Hou was increased from 15.0% to 43.4% with the recovery of 58.4% after purification by D101 resin.", [["D101 resin", "TREATMENT", 123, 133]]], ["Meanwhile, validation experiments revealed that the average Hou content in pure HEO was 44.3% \u00b1 2.01%, which showed a great potential for industrial applications.", [["HEO", "CHEMICAL", 80, 83], ["HEO", "CHEMICAL", 80, 83], ["HEO", "SIMPLE_CHEMICAL", 80, 83], ["validation experiments", "TEST", 11, 33], ["industrial applications", "TREATMENT", 138, 161]]], ["Additionally, it was easy to find out that the pure HEO ( Figure 5B ) had a deep red color and transparent appearance after purification by D101 MR. Furthermore, it had a characteristic fishy odor and better liquidity, which represented a nice quality.", [["HEO", "CHEMICAL", 52, 55], ["a deep red color", "PROBLEM", 74, 90], ["a characteristic fishy odor", "PROBLEM", 169, 196], ["deep red color", "OBSERVATION", 76, 90], ["characteristic", "OBSERVATION_MODIFIER", 171, 185], ["fishy", "OBSERVATION_MODIFIER", 186, 191], ["odor", "OBSERVATION", 192, 196], ["better liquidity", "OBSERVATION_MODIFIER", 201, 217]]], ["Based on the above findings, it could be concluded that the method of solvent extraction following D101 purification to prepare Hou-riched HEO was highly efficient and could be further applied to large-scale preparation.Characterization of HMETo further improve the safety and activities of HEO, HME (pure HEO: 2 mg/mL) was prepared and characterized.", [["HEO", "CHEMICAL", 139, 142], ["HEO", "CHEMICAL", 291, 294], ["HME", "CHEMICAL", 296, 299], ["HEO", "CHEMICAL", 306, 309], ["HEO", "CHEMICAL", 306, 309], ["D101", "SIMPLE_CHEMICAL", 99, 103], ["HEO", "SIMPLE_CHEMICAL", 139, 142], ["HMETo", "SIMPLE_CHEMICAL", 240, 245], ["HEO", "SIMPLE_CHEMICAL", 291, 294], ["HME", "SIMPLE_CHEMICAL", 296, 299], ["HEO", "SIMPLE_CHEMICAL", 306, 309], ["solvent extraction", "TREATMENT", 70, 88], ["D101 purification", "TREATMENT", 99, 116], ["Hou-riched HEO", "TREATMENT", 128, 142], ["large-scale preparation", "TREATMENT", 196, 219]]], ["As shown in Figure 6 , the prepared HME was a white milky liquid with a uniform appearance and no floating oil.", [["oil", "ANATOMY", 107, 110], ["HME", "CANCER", 36, 39], ["oil", "ORGANISM_SUBSTANCE", 107, 110], ["a white milky liquid", "PROBLEM", 44, 64], ["floating oil", "PROBLEM", 98, 110], ["no", "UNCERTAINTY", 95, 97], ["floating oil", "OBSERVATION", 98, 110]]], ["The average particle size ( Figure 6 ) and polydispersity index (PI) of HME were 179.1 nm and 0.126, respectively.", [["particle", "ANATOMY", 12, 20], ["Figure", "TEST", 28, 34], ["polydispersity index", "TEST", 43, 63], ["average", "OBSERVATION_MODIFIER", 4, 11], ["particle", "OBSERVATION_MODIFIER", 12, 20], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["HME had a high negative zeta potential of \u221237.51 mV with a high encapsulation rate of 94.7%.", [["a high encapsulation rate", "TEST", 57, 82]]], ["These results indicated that pure HEO was successfully encapsulated into ME and HME had excellent potential for industrial-scale production.Characterization of HMETo further improve the safety and activities of HEO, HME (pure HEO: 2 mg/mL) was prepared and characterized.", [["HEO", "CHEMICAL", 34, 37], ["ME", "CHEMICAL", 73, 75], ["HEO", "CHEMICAL", 211, 214], ["HME", "CHEMICAL", 216, 219], ["HEO", "CHEMICAL", 226, 229], ["HEO", "CHEMICAL", 34, 37], ["HEO", "CHEMICAL", 226, 229], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["ME", "SIMPLE_CHEMICAL", 73, 75], ["HMETo", "SIMPLE_CHEMICAL", 160, 165], ["HEO", "SIMPLE_CHEMICAL", 211, 214], ["HME", "SIMPLE_CHEMICAL", 216, 219], ["HEO", "SIMPLE_CHEMICAL", 226, 229]]], ["As shown in Figure 6 , the prepared HME was a white milky liquid with a uniform appearance and no floating oil.", [["oil", "ANATOMY", 107, 110], ["HME", "CANCER", 36, 39], ["oil", "ORGANISM_SUBSTANCE", 107, 110], ["a white milky liquid", "PROBLEM", 44, 64], ["floating oil", "PROBLEM", 98, 110], ["no", "UNCERTAINTY", 95, 97], ["floating oil", "OBSERVATION", 98, 110]]], ["The average particle size ( Figure 6 ) and polydispersity index (PI) of HME were 179.1 nm and 0.126, respectively.", [["particle", "ANATOMY", 12, 20], ["Figure", "TEST", 28, 34], ["polydispersity index", "TEST", 43, 63], ["average", "OBSERVATION_MODIFIER", 4, 11], ["particle", "OBSERVATION_MODIFIER", 12, 20], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["HME had a high negative zeta potential of \u221237.51 mV with a high encapsulation rate of 94.7%.", [["a high encapsulation rate", "TEST", 57, 82]]], ["These results indicated that pure HEO was successfully encapsulated into ME and HME had excellent potential for industrial-scale production.", [["HEO", "CHEMICAL", 34, 37], ["ME", "CHEMICAL", 73, 75], ["HEO", "CHEMICAL", 34, 37], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["ME", "SIMPLE_CHEMICAL", 73, 75]]], ["Photo of HME and its particle size distribution determined by the PSS NICOMP Particle Size System.In Vitro Hemolysis TestsIt is reported that H. cordata injection could cause hemolysis due to the impurities of HEO or Tween 80 in the formulation [15, 16] .", [["Hemolysis", "DISEASE", 107, 116], ["hemolysis", "DISEASE", 175, 184], ["HEO", "CHEMICAL", 210, 213], ["Tween 80", "CHEMICAL", 217, 225], ["HEO", "CHEMICAL", 210, 213], ["Tween 80", "CHEMICAL", 217, 225], ["H. cordata", "ORGANISM", 142, 152], ["HEO", "SIMPLE_CHEMICAL", 210, 213], ["Tween 80", "SIMPLE_CHEMICAL", 217, 225], ["H. cordata", "SPECIES", 142, 152], ["H. cordata", "SPECIES", 142, 152], ["Photo of HME", "TREATMENT", 0, 12], ["Vitro Hemolysis Tests", "TEST", 101, 122], ["H. cordata injection", "TREATMENT", 142, 162], ["hemolysis", "PROBLEM", 175, 184], ["particle", "OBSERVATION_MODIFIER", 21, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["Size", "OBSERVATION_MODIFIER", 86, 90], ["Hemolysis", "OBSERVATION", 107, 116]]], ["In vitro hemolysis tests were carried out to compare the hemolytic effect of different extracts.", [["extracts", "ANATOMY", 87, 95], ["hemolysis", "DISEASE", 9, 18], ["hemolytic", "DISEASE", 57, 66], ["extracts", "ORGANISM_SUBSTANCE", 87, 95], ["vitro hemolysis tests", "TEST", 3, 24], ["the hemolytic effect of different extracts", "PROBLEM", 53, 95], ["hemolysis", "OBSERVATION", 9, 18], ["hemolytic", "OBSERVATION", 57, 66]]], ["As shown in Table 4 , HEHEO had serious hemolytic effect and Tween 80 solution (2.5%) showed weak hemolysis, suggesting that HEHEO was toxic to erythrocyte.", [["erythrocyte", "ANATOMY", 144, 155], ["HEHEO", "CHEMICAL", 22, 27], ["hemolytic", "DISEASE", 40, 49], ["Tween 80", "CHEMICAL", 61, 69], ["hemolysis", "DISEASE", 98, 107], ["HEHEO", "CHEMICAL", 125, 130], ["Tween 80", "CHEMICAL", 61, 69], ["HEHEO", "CHEMICAL", 125, 130], ["HEHEO", "SIMPLE_CHEMICAL", 22, 27], ["Tween 80", "SIMPLE_CHEMICAL", 61, 69], ["HEHEO", "SIMPLE_CHEMICAL", 125, 130], ["erythrocyte", "CELL", 144, 155], ["serious hemolytic effect", "PROBLEM", 32, 56], ["Tween 80 solution", "TREATMENT", 61, 78], ["weak hemolysis", "PROBLEM", 93, 107], ["toxic to erythrocyte", "PROBLEM", 135, 155], ["hemolysis", "OBSERVATION", 98, 107]]], ["Compared with the crude HEO, pure HEO exhibited weak hemolysis that may result from Tween 80 in the solution, suggesting a reduced toxicity to erythrocyte after purification by D101.", [["erythrocyte", "ANATOMY", 143, 154], ["HEO", "CHEMICAL", 24, 27], ["HEO", "CHEMICAL", 34, 37], ["hemolysis", "DISEASE", 53, 62], ["Tween 80", "CHEMICAL", 84, 92], ["toxicity", "DISEASE", 131, 139], ["Tween 80", "CHEMICAL", 84, 92], ["HEO", "SIMPLE_CHEMICAL", 24, 27], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["Tween 80", "SIMPLE_CHEMICAL", 84, 92], ["erythrocyte", "CELL", 143, 154], ["D101", "SIMPLE_CHEMICAL", 177, 181], ["the crude HEO", "TEST", 14, 27], ["weak hemolysis", "PROBLEM", 48, 62], ["a reduced toxicity", "PROBLEM", 121, 139], ["erythrocyte after purification", "TREATMENT", 143, 173], ["weak", "OBSERVATION_MODIFIER", 48, 52], ["hemolysis", "OBSERVATION", 53, 62], ["reduced", "OBSERVATION_MODIFIER", 123, 130], ["toxicity", "OBSERVATION", 131, 139]]], ["However, the HME, which was prepared by encapsulation of pure HEO in ME, showed no hemolysis or agglutination.", [["HEO", "CHEMICAL", 62, 65], ["hemolysis", "DISEASE", 83, 92], ["HEO", "SIMPLE_CHEMICAL", 62, 65], ["hemolysis", "PROBLEM", 83, 92], ["agglutination", "PROBLEM", 96, 109], ["no", "UNCERTAINTY", 80, 82], ["hemolysis", "OBSERVATION", 83, 92], ["agglutination", "OBSERVATION", 96, 109]]], ["This indicated that MEs could further improve the safety of pure HEO.", [["HEO", "CHEMICAL", 65, 68], ["HEO", "CHEMICAL", 65, 68], ["MEs", "SIMPLE_CHEMICAL", 20, 23], ["HEO", "SIMPLE_CHEMICAL", 65, 68], ["MEs", "PROBLEM", 20, 23]]], ["Considering the high encapsulation rate of HME (94.7%), it could be speculated that pure HEO was fully encapsulated in the inner oil phase by the biodegradable and biocompatible shell. which could avoid the contact of HEO with erythrocyte and thus avoided hemolysis.", [["inner oil", "ANATOMY", 123, 132], ["erythrocyte", "ANATOMY", 227, 238], ["HEO", "CHEMICAL", 89, 92], ["hemolysis", "DISEASE", 256, 265], ["HEO", "CHEMICAL", 89, 92], ["HEO", "SIMPLE_CHEMICAL", 89, 92], ["HEO", "SIMPLE_CHEMICAL", 218, 221], ["erythrocyte", "CELL", 227, 238], ["the biodegradable and biocompatible shell", "TREATMENT", 142, 183], ["erythrocyte", "TREATMENT", 227, 238], ["hemolysis", "PROBLEM", 256, 265], ["high", "OBSERVATION_MODIFIER", 16, 20], ["encapsulation", "OBSERVATION_MODIFIER", 21, 34], ["inner", "OBSERVATION_MODIFIER", 123, 128], ["oil phase", "OBSERVATION", 129, 138], ["biocompatible shell", "OBSERVATION", 164, 183], ["hemolysis", "OBSERVATION", 256, 265]]], ["Furthermore, the tests indicated that hemolysis induced by HEHEO was one of the important reasons for ADR.", [["hemolysis", "DISEASE", 38, 47], ["HEHEO", "CHEMICAL", 59, 64], ["ADR", "CHEMICAL", 102, 105], ["ADR", "SIMPLE_CHEMICAL", 102, 105], ["the tests", "TEST", 13, 22], ["hemolysis", "PROBLEM", 38, 47], ["ADR", "PROBLEM", 102, 105], ["hemolysis", "OBSERVATION", 38, 47]]], ["Over all, HEHEO could induce hemolysis, MR purification could reduce hemolysis, and MEs could avoid hemolysis effectively.In Vitro Hemolysis TestsIt is reported that H. cordata injection could cause hemolysis due to the impurities of HEO or Tween 80 in the formulation [15, 16] .", [["HEHEO", "CHEMICAL", 10, 15], ["hemolysis", "DISEASE", 29, 38], ["hemolysis", "DISEASE", 69, 78], ["hemolysis", "DISEASE", 100, 109], ["Hemolysis", "DISEASE", 131, 140], ["hemolysis", "DISEASE", 199, 208], ["HEO", "CHEMICAL", 234, 237], ["Tween 80", "CHEMICAL", 241, 249], ["HEHEO", "CHEMICAL", 10, 15], ["HEO", "CHEMICAL", 234, 237], ["Tween 80", "CHEMICAL", 241, 249], ["HEHEO", "SIMPLE_CHEMICAL", 10, 15], ["MEs", "SIMPLE_CHEMICAL", 84, 87], ["H. cordata", "ORGANISM", 166, 176], ["HEO", "SIMPLE_CHEMICAL", 234, 237], ["Tween 80", "SIMPLE_CHEMICAL", 241, 249], ["MR", "PROTEIN", 40, 42], ["H. cordata", "SPECIES", 166, 176], ["H. cordata", "SPECIES", 166, 176], ["hemolysis", "PROBLEM", 29, 38], ["MR purification", "TEST", 40, 55], ["hemolysis", "PROBLEM", 69, 78], ["hemolysis effectively", "PROBLEM", 100, 121], ["Vitro Hemolysis Tests", "TEST", 125, 146], ["H. cordata injection", "TREATMENT", 166, 186], ["hemolysis", "PROBLEM", 199, 208], ["hemolysis", "OBSERVATION", 29, 38], ["Hemolysis", "OBSERVATION", 131, 140]]], ["In vitro hemolysis tests were carried out to compare the hemolytic effect of different extracts.", [["extracts", "ANATOMY", 87, 95], ["hemolysis", "DISEASE", 9, 18], ["hemolytic", "DISEASE", 57, 66], ["extracts", "ORGANISM_SUBSTANCE", 87, 95], ["vitro hemolysis tests", "TEST", 3, 24], ["the hemolytic effect of different extracts", "PROBLEM", 53, 95], ["hemolysis", "OBSERVATION", 9, 18], ["hemolytic", "OBSERVATION", 57, 66]]], ["As shown in Table 4 , HEHEO had serious hemolytic effect and Tween 80 solution (2.5%) showed weak hemolysis, suggesting that HEHEO was toxic to erythrocyte.", [["erythrocyte", "ANATOMY", 144, 155], ["HEHEO", "CHEMICAL", 22, 27], ["hemolytic", "DISEASE", 40, 49], ["Tween 80", "CHEMICAL", 61, 69], ["hemolysis", "DISEASE", 98, 107], ["HEHEO", "CHEMICAL", 125, 130], ["Tween 80", "CHEMICAL", 61, 69], ["HEHEO", "CHEMICAL", 125, 130], ["HEHEO", "SIMPLE_CHEMICAL", 22, 27], ["Tween 80", "SIMPLE_CHEMICAL", 61, 69], ["HEHEO", "SIMPLE_CHEMICAL", 125, 130], ["erythrocyte", "CELL", 144, 155], ["serious hemolytic effect", "PROBLEM", 32, 56], ["Tween 80 solution", "TREATMENT", 61, 78], ["weak hemolysis", "PROBLEM", 93, 107], ["toxic to erythrocyte", "PROBLEM", 135, 155], ["hemolysis", "OBSERVATION", 98, 107]]], ["Compared with the crude HEO, pure HEO exhibited weak hemolysis that may result from Tween 80 in the solution, suggesting a reduced toxicity to erythrocyte after purification by D101.", [["erythrocyte", "ANATOMY", 143, 154], ["HEO", "CHEMICAL", 24, 27], ["HEO", "CHEMICAL", 34, 37], ["hemolysis", "DISEASE", 53, 62], ["Tween 80", "CHEMICAL", 84, 92], ["toxicity", "DISEASE", 131, 139], ["Tween 80", "CHEMICAL", 84, 92], ["HEO", "SIMPLE_CHEMICAL", 24, 27], ["HEO", "SIMPLE_CHEMICAL", 34, 37], ["Tween 80", "SIMPLE_CHEMICAL", 84, 92], ["erythrocyte", "CELL", 143, 154], ["D101", "SIMPLE_CHEMICAL", 177, 181], ["the crude HEO", "TEST", 14, 27], ["weak hemolysis", "PROBLEM", 48, 62], ["a reduced toxicity", "PROBLEM", 121, 139], ["erythrocyte after purification", "TREATMENT", 143, 173], ["weak", "OBSERVATION_MODIFIER", 48, 52], ["hemolysis", "OBSERVATION", 53, 62], ["reduced", "OBSERVATION_MODIFIER", 123, 130], ["toxicity", "OBSERVATION", 131, 139]]], ["However, the HME, which was prepared by encapsulation of pure HEO in ME, showed no hemolysis or agglutination.", [["HEO", "CHEMICAL", 62, 65], ["hemolysis", "DISEASE", 83, 92], ["HEO", "SIMPLE_CHEMICAL", 62, 65], ["hemolysis", "PROBLEM", 83, 92], ["agglutination", "PROBLEM", 96, 109], ["no", "UNCERTAINTY", 80, 82], ["hemolysis", "OBSERVATION", 83, 92], ["agglutination", "OBSERVATION", 96, 109]]], ["This indicated that MEs could further improve the safety of pure HEO.", [["HEO", "CHEMICAL", 65, 68], ["HEO", "CHEMICAL", 65, 68], ["MEs", "SIMPLE_CHEMICAL", 20, 23], ["HEO", "SIMPLE_CHEMICAL", 65, 68], ["MEs", "PROBLEM", 20, 23]]], ["Considering the high encapsulation rate of HME (94.7%), it could be speculated that pure HEO was fully encapsulated in the inner oil phase by the biodegradable and biocompatible shell. which could avoid the contact of HEO with erythrocyte and thus avoided hemolysis.", [["inner oil", "ANATOMY", 123, 132], ["erythrocyte", "ANATOMY", 227, 238], ["HEO", "CHEMICAL", 89, 92], ["hemolysis", "DISEASE", 256, 265], ["HEO", "CHEMICAL", 89, 92], ["HEO", "SIMPLE_CHEMICAL", 89, 92], ["HEO", "SIMPLE_CHEMICAL", 218, 221], ["erythrocyte", "CELL", 227, 238], ["the biodegradable and biocompatible shell", "TREATMENT", 142, 183], ["erythrocyte", "TREATMENT", 227, 238], ["hemolysis", "PROBLEM", 256, 265], ["high", "OBSERVATION_MODIFIER", 16, 20], ["encapsulation", "OBSERVATION_MODIFIER", 21, 34], ["inner", "OBSERVATION_MODIFIER", 123, 128], ["oil phase", "OBSERVATION", 129, 138], ["biocompatible shell", "OBSERVATION", 164, 183], ["hemolysis", "OBSERVATION", 256, 265]]], ["Furthermore, the tests indicated that hemolysis induced by HEHEO was one of the important reasons for ADR.", [["hemolysis", "DISEASE", 38, 47], ["HEHEO", "CHEMICAL", 59, 64], ["ADR", "CHEMICAL", 102, 105], ["ADR", "SIMPLE_CHEMICAL", 102, 105], ["the tests", "TEST", 13, 22], ["hemolysis", "PROBLEM", 38, 47], ["ADR", "PROBLEM", 102, 105], ["hemolysis", "OBSERVATION", 38, 47]]], ["Over all, HEHEO could induce hemolysis, MR purification could reduce hemolysis, and MEs could avoid hemolysis effectively.", [["HEHEO", "CHEMICAL", 10, 15], ["hemolysis", "DISEASE", 29, 38], ["hemolysis", "DISEASE", 69, 78], ["hemolysis", "DISEASE", 100, 109], ["HEHEO", "CHEMICAL", 10, 15], ["HEHEO", "SIMPLE_CHEMICAL", 10, 15], ["MEs", "SIMPLE_CHEMICAL", 84, 87], ["MR", "PROTEIN", 40, 42], ["hemolysis", "PROBLEM", 29, 38], ["MR purification", "TEST", 40, 55], ["hemolysis", "PROBLEM", 69, 78], ["hemolysis effectively", "PROBLEM", 100, 121], ["hemolysis", "OBSERVATION", 29, 38]]], ["Tween 80 solution (2.5%)Acute Toxicity TestAcute toxicity test was performed to compare the safety of HEHEO, crude HEO, pure HEO, and HME.", [["Toxicity TestAcute toxicity", "DISEASE", 30, 57], ["HEHEO", "CHEMICAL", 102, 107], ["HEO", "CHEMICAL", 115, 118], ["HEO", "CHEMICAL", 125, 128], ["Tween 80", "CHEMICAL", 0, 8], ["HEHEO", "SIMPLE_CHEMICAL", 102, 107], ["HEO", "SIMPLE_CHEMICAL", 115, 118], ["HEO", "SIMPLE_CHEMICAL", 125, 128], ["Acute Toxicity TestAcute toxicity test", "PROBLEM", 24, 62]]], ["Briefly, mice were intravenously injected with Hou at the dose of 30 mg/kg and observed for toxic symptoms and mortality.", [["Hou", "CHEMICAL", 47, 50], ["mice", "ORGANISM", 9, 13], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["Hou", "TREATMENT", 47, 50], ["toxic symptoms", "PROBLEM", 92, 106], ["mortality", "PROBLEM", 111, 120]]], ["As shown in Table 5 , blank Tween 80 solution and blank ME had no effect on mice.", [["ME", "CHEMICAL", 56, 58], ["Tween 80", "CHEMICAL", 28, 36], ["Tween 80", "SIMPLE_CHEMICAL", 28, 36], ["mice", "ORGANISM", 76, 80], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["blank Tween 80 solution", "TREATMENT", 22, 45]]], ["HEHEO exhibited significant acute toxicity such as tachypnea, jitter, skip, ataxia, and tic, though no death occurred.", [["HEHEO", "CHEMICAL", 0, 5], ["toxicity", "DISEASE", 34, 42], ["tachypnea", "DISEASE", 51, 60], ["ataxia", "DISEASE", 76, 82], ["tic", "DISEASE", 88, 91], ["death", "DISEASE", 103, 108], ["HEHEO", "SIMPLE_CHEMICAL", 0, 5], ["significant acute toxicity", "PROBLEM", 16, 42], ["tachypnea", "PROBLEM", 51, 60], ["jitter", "PROBLEM", 62, 68], ["ataxia", "PROBLEM", 76, 82], ["tic", "PROBLEM", 88, 91], ["death", "PROBLEM", 103, 108], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["toxicity", "OBSERVATION", 34, 42], ["no", "UNCERTAINTY", 100, 102]]], ["For the crude HEO group, nine of the 10 treated mice died after administration from severe toxicity, such as tachypnea, dyspnea, tic, and fainting.", [["HEO", "CHEMICAL", 14, 17], ["toxicity", "DISEASE", 91, 99], ["tachypnea", "DISEASE", 109, 118], ["dyspnea", "DISEASE", 120, 127], ["tic", "DISEASE", 129, 132], ["fainting", "DISEASE", 138, 146], ["HEO", "SIMPLE_CHEMICAL", 14, 17], ["mice", "ORGANISM", 48, 52], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["severe toxicity", "PROBLEM", 84, 99], ["tachypnea", "PROBLEM", 109, 118], ["dyspnea", "PROBLEM", 120, 127], ["tic", "PROBLEM", 129, 132], ["fainting", "PROBLEM", 138, 146], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["toxicity", "OBSERVATION", 91, 99]]], ["For the pure HEO group, the mice showed tachypnea, ataxia and recovered within 3 min without death.", [["tachypnea", "DISEASE", 40, 49], ["ataxia", "DISEASE", 51, 57], ["death", "DISEASE", 93, 98], ["HEO", "CHEMICAL", 13, 16], ["HEO", "CANCER", 13, 16], ["mice", "ORGANISM", 28, 32], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["tachypnea", "PROBLEM", 40, 49], ["ataxia", "PROBLEM", 51, 57], ["death", "PROBLEM", 93, 98], ["tachypnea", "OBSERVATION", 40, 49]]], ["However, there were no obvious reactions observed in the HME group.", [["HME", "CANCER", 57, 60], ["obvious reactions", "PROBLEM", 23, 40], ["no obvious", "UNCERTAINTY", 20, 30], ["reactions", "OBSERVATION", 31, 40]]], ["Therefore, we concluded that purification by D101 resin decreased the toxicity of HEO and ME encapsulation further improved its safety.", [["D101", "CHEMICAL", 45, 49], ["toxicity", "DISEASE", 70, 78], ["HEO", "CHEMICAL", 82, 85], ["HEO", "CHEMICAL", 82, 85], ["D101 resin", "SIMPLE_CHEMICAL", 45, 55], ["HEO", "SIMPLE_CHEMICAL", 82, 85], ["ME", "SIMPLE_CHEMICAL", 90, 92], ["purification", "TREATMENT", 29, 41], ["D101 resin", "TREATMENT", 45, 55], ["the toxicity of HEO", "TREATMENT", 66, 85], ["ME encapsulation", "TREATMENT", 90, 106]]], ["In addition, the results indicated that the impurities in the crude HEO were seriously toxic and the purification by D101 resin could effectively remove the toxic impurities in the crude extract.Acute Toxicity TestBoth in vitro hemolysis test and acute toxicity test proved that the HEHEO extracted by hydrodistillation showed serious toxicity, whereas purification followed by ME encapsulation could effectively improve the safety of HEO.", [["extract", "ANATOMY", 187, 194], ["HEO", "CHEMICAL", 68, 71], ["D101 resin", "CHEMICAL", 117, 127], ["hemolysis", "DISEASE", 228, 237], ["toxicity", "DISEASE", 253, 261], ["HEHEO", "CHEMICAL", 283, 288], ["hydrodistillation", "CHEMICAL", 302, 319], ["toxicity", "DISEASE", 335, 343], ["HEO", "CHEMICAL", 435, 438], ["HEO", "CHEMICAL", 68, 71], ["HEO", "CHEMICAL", 435, 438], ["HEO", "SIMPLE_CHEMICAL", 68, 71], ["D101 resin", "SIMPLE_CHEMICAL", 117, 127], ["HEHEO", "SIMPLE_CHEMICAL", 283, 288], ["ME", "SIMPLE_CHEMICAL", 378, 380], ["HEO", "SIMPLE_CHEMICAL", 435, 438], ["seriously toxic", "PROBLEM", 77, 92], ["the purification", "TREATMENT", 97, 113], ["D101 resin", "TREATMENT", 117, 127], ["the toxic impurities", "PROBLEM", 153, 173], ["Acute Toxicity", "PROBLEM", 195, 209], ["vitro hemolysis test", "TEST", 222, 242], ["acute toxicity test", "PROBLEM", 247, 266], ["serious toxicity", "PROBLEM", 327, 343], ["toxic impurities", "OBSERVATION", 157, 173], ["Toxicity", "OBSERVATION", 201, 209]]], ["Acute toxicities of HEHEO, crude HEO, pure HEO, and HME in mice.In Vitro Antiviral ActivityThe in vitro antiviral activities of HEHEO, crude HEO, pure HEO, and HME against CVB3 and B6 were evaluated by using the conventional CPE method [37] .", [["toxicities", "DISEASE", 6, 16], ["HEHEO", "CHEMICAL", 20, 25], ["HEO", "CHEMICAL", 33, 36], ["HEO", "CHEMICAL", 43, 46], ["HEHEO", "CHEMICAL", 128, 133], ["HEO", "CHEMICAL", 141, 144], ["HEO", "CHEMICAL", 151, 154], ["HEHEO", "CHEMICAL", 128, 133], ["HEHEO", "SIMPLE_CHEMICAL", 20, 25], ["HEO", "SIMPLE_CHEMICAL", 33, 36], ["HEO", "SIMPLE_CHEMICAL", 43, 46], ["mice", "ORGANISM", 59, 63], ["HEHEO", "SIMPLE_CHEMICAL", 128, 133], ["HEO", "SIMPLE_CHEMICAL", 141, 144], ["HEO", "SIMPLE_CHEMICAL", 151, 154], ["CVB3", "ORGANISM", 172, 176], ["B6", "CELL", 181, 183], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["CVB3", "SPECIES", 172, 176], ["Acute toxicities of HEHEO", "PROBLEM", 0, 25], ["HEHEO", "TREATMENT", 128, 133], ["CVB3", "PROBLEM", 172, 176], ["toxicities", "OBSERVATION", 6, 16], ["Antiviral Activity", "OBSERVATION", 73, 91]]], ["As shown in Table 6 , HEHEO exhibited weak activity against CVB3 with IC 50 of 17.24 \u00b5g/mL.", [["HEHEO", "CHEMICAL", 22, 27], ["HEHEO", "CHEMICAL", 22, 27], ["HEHEO", "SIMPLE_CHEMICAL", 22, 27], ["CVB3", "ORGANISM", 60, 64], ["CVB3", "SPECIES", 60, 64], ["IC", "TEST", 70, 72], ["weak activity", "OBSERVATION_MODIFIER", 38, 51]]], ["For the extracts prepared by solvent extraction, pure HEO (Hou 46.6%) showed significant antiviral activity with IC 50 of 7.41 \u00b5g/mL while the crude HEO (Hou 15.0%) showed relatively weak activities (IC 50 > 15 \u00b5g/mL).", [["extracts", "ANATOMY", 8, 16], ["HEO", "CHEMICAL", 54, 57], ["HEO", "CHEMICAL", 149, 152], ["HEO", "CHEMICAL", 54, 57], ["extracts", "ORGANISM_SUBSTANCE", 8, 16], ["HEO", "SIMPLE_CHEMICAL", 54, 57], ["HEO", "SIMPLE_CHEMICAL", 149, 152], ["solvent extraction", "TREATMENT", 29, 47], ["significant antiviral activity", "PROBLEM", 77, 107], ["IC", "TEST", 113, 115], ["the crude HEO", "TEST", 139, 152], ["relatively weak activities", "PROBLEM", 172, 198], ["IC", "TEST", 200, 202], ["antiviral activity", "OBSERVATION", 89, 107]]], ["This indicated that the solvent extraction following purification by D101 resin largely increased the content of Hou and, thus, improved the antiviral activity of HEO.", [["D101 resin", "CHEMICAL", 69, 79], ["HEO", "CHEMICAL", 163, 166], ["HEO", "CHEMICAL", 163, 166], ["D101 resin", "SIMPLE_CHEMICAL", 69, 79], ["HEO", "SIMPLE_CHEMICAL", 163, 166], ["the solvent extraction", "TREATMENT", 20, 42], ["purification", "TREATMENT", 53, 65], ["D101 resin", "TREATMENT", 69, 79], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["antiviral activity", "OBSERVATION", 141, 159]]], ["Furthermore, the IC 50 of HME was 0.35 \u00b5g/mL and SI was no less than 519.5 on CBV6.", [["SI", "TEST", 49, 51], ["CBV6", "TEST", 78, 82]]], ["It is worth mentioning that the SI of HME was at least 100 times higher than that of the pure HEO without ME encapsulation.", [["HEO", "CHEMICAL", 94, 97], ["HEO", "SIMPLE_CHEMICAL", 94, 97], ["ME", "SIMPLE_CHEMICAL", 106, 108]]], ["The largely increased SI indicated that ME encapsulation could simultaneously improve the safety and antiviral activity.", [["ME", "SIMPLE_CHEMICAL", 40, 42], ["The largely increased SI", "PROBLEM", 0, 24], ["ME encapsulation", "TREATMENT", 40, 56], ["antiviral activity", "TREATMENT", 101, 119], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["SI", "OBSERVATION_MODIFIER", 22, 24], ["antiviral activity", "OBSERVATION", 101, 119]]], ["The reasons could be explained as follows: HEO was wrapped in the inner oil phase and was controlled and sustained release to the virus by the shell of HME, which prolonged the action time and, thus, improved the activity.", [["inner oil", "ANATOMY", 66, 75], ["HEO", "CHEMICAL", 43, 46], ["HEO", "CHEMICAL", 43, 46], ["HEO", "SIMPLE_CHEMICAL", 43, 46], ["the inner oil phase", "TREATMENT", 62, 81]]], ["Additionally, the biodegradable and biocompatible shell (composed of phospholipids and Poloxamer 188) avoided the contact of HEO with Vero cells effectively, thereby greatly reducing the toxicity of HEO (TC 50 > 181.82 \u00b5g/mL) [38] .", [["Vero cells", "ANATOMY", 134, 144], ["Poloxamer 188", "CHEMICAL", 87, 100], ["HEO", "CHEMICAL", 125, 128], ["toxicity", "DISEASE", 187, 195], ["HEO", "CHEMICAL", 199, 202], ["TC", "CHEMICAL", 204, 206], ["Poloxamer 188", "CHEMICAL", 87, 100], ["HEO", "CHEMICAL", 125, 128], ["HEO", "CHEMICAL", 199, 202], ["phospholipids", "SIMPLE_CHEMICAL", 69, 82], ["Poloxamer 188", "SIMPLE_CHEMICAL", 87, 100], ["HEO", "SIMPLE_CHEMICAL", 125, 128], ["Vero cells", "CELL", 134, 144], ["HEO", "SIMPLE_CHEMICAL", 199, 202], ["Vero cells", "CELL_LINE", 134, 144], ["the biodegradable and biocompatible shell (composed of phospholipids and Poloxamer", "TREATMENT", 14, 96], ["Vero cells", "TREATMENT", 134, 144], ["HEO", "TEST", 199, 202], ["TC", "TEST", 204, 206]]], ["Furthermore, it was reported that nanocarriers with inherent immunogenic properties would improve its activity [39] .In Vitro Antiviral ActivityCVBs is one of the most commonly identified agents for infection that is associated with acute and chronic myocarditis.", [["infection", "DISEASE", 199, 208], ["myocarditis", "DISEASE", 251, 262], ["nanocarriers", "TREATMENT", 34, 46], ["inherent immunogenic properties", "TREATMENT", 52, 83], ["Vitro Antiviral ActivityCVBs", "TREATMENT", 120, 148], ["infection", "PROBLEM", 199, 208], ["acute and chronic myocarditis", "PROBLEM", 233, 262], ["infection", "OBSERVATION", 199, 208], ["associated with", "UNCERTAINTY", 217, 232], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["myocarditis", "OBSERVATION", 251, 262]]], ["However, there is no approved vaccine or antiviral drug for the prevention or treatment of CVB-induced diseases to date [40] .", [["CVB", "CHEMICAL", 91, 94], ["approved vaccine", "TREATMENT", 21, 37], ["antiviral drug", "TREATMENT", 41, 55], ["CVB", "PROBLEM", 91, 94], ["induced diseases", "PROBLEM", 95, 111], ["no", "UNCERTAINTY", 18, 20]]], ["HME exhibited strong antiviral activities against CVB3 and B6 with better safety, which may provide an important strategy for anti-CVB and myocarditis therapy.Macroporous Resin and SolventsD101 macroporous resin was supplied by Sinopharm Chemical Reagent Co. Ltd.", [["HME", "CHEMICAL", 0, 3], ["myocarditis", "DISEASE", 139, 150], ["CVB3", "ORGANISM", 50, 54], ["B6", "CELL", 59, 61], ["anti-CVB", "SIMPLE_CHEMICAL", 126, 134], ["Resin", "SIMPLE_CHEMICAL", 171, 176], ["CVB3", "SPECIES", 50, 54], ["anti-CVB", "SPECIES", 126, 134], ["CVB3", "TREATMENT", 50, 54], ["anti-CVB", "TREATMENT", 126, 134], ["myocarditis therapy", "TREATMENT", 139, 158], ["Macroporous Resin and SolventsD101 macroporous resin", "TREATMENT", 159, 211], ["strong", "OBSERVATION_MODIFIER", 14, 20], ["antiviral activities", "OBSERVATION", 21, 41], ["myocarditis", "OBSERVATION", 139, 150], ["Resin", "OBSERVATION_MODIFIER", 171, 176]]], ["HP-20, HPD100 and AB-8 resins were purchased from Solarbio (Beijing, China).", [["AB-8 resins", "CHEMICAL", 18, 29], ["HP-20", "CHEMICAL", 0, 5], ["HPD100", "SIMPLE_CHEMICAL", 7, 13], ["AB-8 resins", "SIMPLE_CHEMICAL", 18, 29], ["HP", "TEST", 0, 2], ["HPD100", "TEST", 7, 13], ["AB", "TEST", 18, 20]]], ["All chemicals and solvents were of analytical grade and used without further purification.Plant MaterialFresh roots of H. cordata were obtained from Yizhou (Guangxi, China).", [["roots", "ANATOMY", 110, 115], ["MaterialFresh roots", "ORGANISM", 96, 115], ["H. cordata", "ORGANISM", 119, 129], ["H. cordata", "SPECIES", 119, 129], ["H. cordata", "SPECIES", 119, 129], ["solvents", "TREATMENT", 18, 26], ["analytical grade", "TEST", 35, 51], ["further purification", "TREATMENT", 69, 89], ["H. cordata", "PROBLEM", 119, 129], ["H. cordata", "OBSERVATION", 119, 129]]], ["The botanical identification of the plant material was performed by Renyun Wang from Institute of Materia Medica and a voucher sample was sealed and stored at \u221240 \u2022 C. Fresh roots were washed, dried in the dark and cut into pieces with appropriate length before extraction.AnimalsSixty ICR mice (20 \u00b1 2 g) of both sexes and one male rabbit (2 kg) were purchased from Charles River (Beijing, China).", [["sample", "ANATOMY", 127, 133], ["roots", "ANATOMY", 174, 179], ["roots", "ORGAN", 174, 179], ["AnimalsSixty ICR mice", "ORGANISM", 273, 294], ["rabbit", "ORGANISM", 333, 339], ["mice", "SPECIES", 290, 294], ["rabbit", "SPECIES", 333, 339], ["mice", "SPECIES", 290, 294], ["rabbit", "SPECIES", 333, 339], ["appropriate length before extraction", "TREATMENT", 236, 272], ["plant material", "OBSERVATION", 36, 50], ["Fresh roots", "OBSERVATION", 168, 179]]], ["Animals were allowed to acclimate to the laboratory environment for five days.", [["Animals", "ORGANISM", 0, 7]]], ["The animal experiments were approved by the Animal Care and Welfare Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.Qualitative Analysis by GC-MSThe GC-MS system was composed of an Agilent 7890A series GC connected to an Agilent 5975C mass selective detector.", [["Qualitative Analysis", "TEST", 183, 203], ["GC", "TEST", 207, 209], ["an Agilent 5975C mass selective detector", "TREATMENT", 285, 325]]], ["An Agilent HP-5MS capillary column (30 m \u00d7 0.25 mm, 0.25 \u00b5m, Agilent Technologies, Santa Clara, CA, USA) was used for separation.", [["An Agilent HP", "TEST", 0, 13], ["HP", "OBSERVATION_MODIFIER", 11, 13], ["capillary", "ANATOMY_MODIFIER", 18, 27], ["column", "ANATOMY_MODIFIER", 28, 34]]], ["Ultrapure helium was used as the carrier gas at a flow rate of 1.0 mL/min with injector temperature of 250 \u2022 C. One microliter of sample was injected under split mode (ratio 1:20).", [["sample", "ANATOMY", 130, 136], ["helium", "CHEMICAL", 10, 16], ["helium", "CHEMICAL", 10, 16], ["Ultrapure helium", "TREATMENT", 0, 16], ["the carrier gas", "TEST", 29, 44], ["a flow rate", "TEST", 48, 59], ["injector temperature", "TEST", 79, 99], ["helium", "OBSERVATION", 10, 16]]], ["The oven temperature program was 50 \u2022 C for 2 min, rising at 4 \u2022 C/min to 150 \u2022 C for 3 min, followed by rising at 20 \u2022 C/min to 300 \u2022 C then held for 10 min.", [["The oven temperature program", "TREATMENT", 0, 28]]], ["Electronic ionization source and quadrupole temperatures were 230 \u2022 C and 150 \u2022 C, respectively.", [["Electronic ionization source", "TEST", 0, 28], ["quadrupole temperatures", "TEST", 33, 56], ["C", "TEST", 68, 69]]], ["All mass spectra were recorded in the full scan mode at 70 eV (m/z 20-800 amu) and the identifications of the compounds were conducted by comparing the obtained mass spectra (MS) with those of the NIST library.Quantitative Analysis of HEO by GCAn Agilent 6890N series GC system equipped with a hydrogen flame ionization detector (FID) was used for quantitative analysis.", [["hydrogen", "CHEMICAL", 294, 302], ["HEO", "SIMPLE_CHEMICAL", 235, 238], ["HEO", "DNA", 235, 238], ["All mass spectra", "PROBLEM", 0, 16], ["the full scan mode", "TEST", 34, 52], ["Quantitative Analysis", "TEST", 210, 231], ["HEO", "TEST", 235, 238], ["a hydrogen flame ionization detector (FID)", "TREATMENT", 292, 334], ["quantitative analysis", "TEST", 348, 369], ["mass", "OBSERVATION", 4, 8]]], ["Separation was achieved with an Agilent DB-5 capillary column (30 m \u00d7 0.25 mm, 0.25 \u00b5m, Agilent Technologies, Santa Clara, CA, USA).", [["an Agilent DB-5 capillary column", "TREATMENT", 29, 61]]], ["The carrier gas was nitrogen with a flow of 1.0 mL/min.", [["nitrogen", "CHEMICAL", 20, 28], ["nitrogen", "CHEMICAL", 20, 28], ["nitrogen", "SIMPLE_CHEMICAL", 20, 28], ["The carrier gas", "TEST", 0, 15]]], ["The oven temperature was programmed at 50 \u2022 C for 3 min, with a rise of 5 \u2022 C/min up to 150 \u2022 C and held for 3 min, followed by rising at 20 \u2022 C/min to 250 \u2022 C, and held for 5 min.", [["The oven temperature", "TEST", 0, 20]]], ["The temperature of both the injector and detector was set at 250 \u2022 C. One microliter of sample was injected under split mode (ratio 1:3).", [["sample", "ANATOMY", 88, 94]]], ["External standard calibration was used for the Hou quantitative analysis.", [["External standard calibration", "TREATMENT", 0, 29], ["the Hou quantitative analysis", "TEST", 43, 72]]], ["A series of Hou standards in the range of 4.32-216 \u00b5g/mL were prepared in ethyl acetate solution to obtain the linear response (Y = 6.587X \u2212 5.367, r = 0.9999), where Y was the peak area of Hou, and X was the concentration of Hou (\u00b5g/mL).Preparation of Hydrodistillation Extracted HEO (HEHEO)HEHEO was obtained by hydrodistillation of 300 g of fresh roots (cut into about 1 cm pieces) of H. cordata, with 0.5 L of distilled water for 3 h, using a Clevenger apparatus [10] .", [["roots", "ANATOMY", 350, 355], ["ethyl acetate", "CHEMICAL", 74, 87], ["HEO", "CHEMICAL", 281, 284], ["ethyl acetate", "CHEMICAL", 74, 87], ["ethyl acetate", "SIMPLE_CHEMICAL", 74, 87], ["HEO", "SIMPLE_CHEMICAL", 281, 284], ["HEHEO", "SIMPLE_CHEMICAL", 286, 291], ["roots", "ORGANISM_SUBDIVISION", 350, 355], ["H. cordata", "SPECIES", 388, 398], ["H. cordata", "SPECIES", 388, 398], ["ethyl acetate solution", "TREATMENT", 74, 96], ["the linear response", "TEST", 107, 126], ["Hydrodistillation", "TREATMENT", 253, 270], ["H. cordata", "PROBLEM", 388, 398], ["a Clevenger apparatus", "TREATMENT", 445, 466], ["Hydrodistillation", "OBSERVATION", 253, 270]]], ["Then, ethyl acetate was used to wash the oil and then removed by a rotary evaporator.", [["oil", "ANATOMY", 41, 44], ["ethyl acetate", "CHEMICAL", 6, 19], ["ethyl acetate", "CHEMICAL", 6, 19], ["ethyl acetate", "SIMPLE_CHEMICAL", 6, 19], ["oil", "ORGANISM_SUBSTANCE", 41, 44], ["ethyl acetate", "TREATMENT", 6, 19], ["a rotary evaporator", "TREATMENT", 65, 84]]], ["The HEHEO was stored in sealed vials protected from light at 4 \u2022 C for further analysis.Optimization for Solvent Extraction of Crude HEOA L9 (3) 4 orthogonal experimental design was used to optimize four variables (ultrasonic time, extraction time, root length, and solid-liquid ratio) with the extraction ratio as the index.", [["root", "ANATOMY", 249, 253], ["HEHEO", "SIMPLE_CHEMICAL", 4, 9], ["further analysis", "TEST", 71, 87], ["Solvent Extraction", "TREATMENT", 105, 123], ["Crude HEOA L9", "TREATMENT", 127, 140], ["ultrasonic time", "TEST", 215, 230], ["root length", "TEST", 249, 260], ["the extraction ratio", "TEST", 291, 311]]], ["The influence of the factor was determined by calculating the range of the k, which was the mean ratio of the corresponding level.", [["the mean ratio", "TEST", 88, 102]]], ["The optimized extraction process was used for further extraction.", [["The optimized extraction process", "TREATMENT", 0, 32], ["further extraction", "TREATMENT", 46, 64]]], ["The extract was further concentrated under reduced pressure at 40 \u2022 C using a rotary evaporator to remove the solvents.", [["extract", "ANATOMY", 4, 11], ["The extract", "TREATMENT", 0, 11], ["a rotary evaporator", "TREATMENT", 76, 95], ["the solvents", "TREATMENT", 106, 118], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["pressure", "OBSERVATION_MODIFIER", 51, 59]]], ["Next, the concentrated extract was dispersed in ethanol and the precipitate was removed by centrifugation.", [["extract", "ANATOMY", 23, 30], ["ethanol", "CHEMICAL", 48, 55], ["ethanol", "CHEMICAL", 48, 55], ["ethanol", "SIMPLE_CHEMICAL", 48, 55]]], ["Finally, the product was extracted by n-hexane.", [["n-hexane", "CHEMICAL", 38, 46], ["n-hexane", "CHEMICAL", 38, 46], ["n-hexane", "SIMPLE_CHEMICAL", 38, 46]]], ["After removing n-hexane, the crude HEO was obtained and stored at \u221220 \u2022 C.Static Adsorption-Desorption Tests to Optimize MR TypesFour types of MRs (D101, HP20, AB-8 and HPD100) were used in this study.", [["n-hexane", "CHEMICAL", 15, 23], ["HEO", "CHEMICAL", 35, 38], ["n-hexane", "CHEMICAL", 15, 23], ["n-hexane", "SIMPLE_CHEMICAL", 15, 23], ["HEO", "SIMPLE_CHEMICAL", 35, 38], ["MR", "PROTEIN", 121, 123], ["n-hexane", "TREATMENT", 15, 23], ["Desorption Tests", "TEST", 92, 108], ["MR", "TEST", 121, 123], ["MRs", "TEST", 143, 146], ["D101", "TEST", 148, 152], ["HP20", "TEST", 154, 158], ["AB", "TEST", 160, 162], ["this study", "TEST", 190, 200]]], ["The resins were pretreated by 95% ethanol for 24 h followed by deionized water to remove the monomers and porogenic agents trapped inside the pores during the synthesis process.", [["ethanol", "CHEMICAL", 34, 41], ["ethanol", "CHEMICAL", 34, 41], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["the monomers", "TREATMENT", 89, 101], ["porogenic agents", "TREATMENT", 106, 122], ["the synthesis process", "TREATMENT", 155, 176], ["resins", "OBSERVATION_MODIFIER", 4, 10], ["pores", "OBSERVATION_MODIFIER", 142, 147]]], ["Prior to use, the resins were wetted with ethanol and then washed with deionized water until the ethanol was thoroughly replaced.Static Adsorption-Desorption Tests to Optimize MR TypesThe moisture contents of the tested resins were determined by drying the beads at 100 \u2022 C to a constant weight in an oven.", [["ethanol", "CHEMICAL", 42, 49], ["ethanol", "CHEMICAL", 97, 104], ["ethanol", "CHEMICAL", 42, 49], ["ethanol", "CHEMICAL", 97, 104], ["ethanol", "SIMPLE_CHEMICAL", 42, 49], ["ethanol", "SIMPLE_CHEMICAL", 97, 104], ["MR", "PROTEIN", 176, 178], ["the resins", "TREATMENT", 14, 24], ["ethanol", "TREATMENT", 42, 49], ["deionized water", "TREATMENT", 71, 86], ["the ethanol", "TREATMENT", 93, 104], ["Desorption Tests", "TEST", 147, 163], ["the tested resins", "TREATMENT", 209, 226], ["moisture", "OBSERVATION_MODIFIER", 188, 196], ["contents", "OBSERVATION_MODIFIER", 197, 205]]], ["The moisture contents of D101, AB-8, HPD100 and HP20 resins were 52.12%, 62.11%, 72.17%, and 57.67%, respectively.Static Adsorption-Desorption Tests to Optimize MR TypesIn order to select the most suitable MR to purify the crude HEO, the adsorption and desorption properties of the four resins were characterized.", [["D101, AB-8", "CHEMICAL", 25, 35], ["HEO", "CHEMICAL", 229, 232], ["D101", "SIMPLE_CHEMICAL", 25, 29], ["AB-8", "CELL", 31, 35], ["HPD100", "SIMPLE_CHEMICAL", 37, 43], ["HP20 resins", "SIMPLE_CHEMICAL", 48, 59], ["HEO", "SIMPLE_CHEMICAL", 229, 232], ["MR", "PROTEIN", 161, 163], ["MR", "PROTEIN", 206, 208], ["The moisture contents", "TEST", 0, 21], ["D101", "TEST", 25, 29], ["AB", "TEST", 31, 33], ["HPD100", "TEST", 37, 43], ["HP20 resins", "TEST", 48, 59], ["Static Adsorption-Desorption Tests", "TEST", 114, 148], ["the four resins", "TREATMENT", 278, 293]]], ["One gram of each resin (dry) was placed into a conical flask and 20 mL sample solution (crude HEO 5.0 mg/mL) was added.", [["HEO", "CHEMICAL", 94, 97], ["each resin (dry)", "TREATMENT", 12, 28], ["a conical flask and 20 mL sample solution (crude HEO", "TREATMENT", 45, 97]]], ["The flask was then shaken in a shaker (120 rpm) for 12 h at 25 \u2022 C. After reaching the adsorption equilibrium, the sample solution was removed and the Hou content was analyzed by GC.", [["sample", "ANATOMY", 115, 121], ["the sample solution", "TREATMENT", 111, 130]]], ["Then, the resin was washed with deionized water and desorbed with 10 mL 80% ethanol (v/v), then shaken (120 rpm) for 12 h at 25 \u2022 C. The Hou content in desorption solution was analyzed.", [["ethanol", "CHEMICAL", 76, 83], ["ethanol", "CHEMICAL", 76, 83], ["ethanol", "SIMPLE_CHEMICAL", 76, 83], ["the resin", "TREATMENT", 6, 15], ["deionized water", "TREATMENT", 32, 47], ["desorption solution", "TREATMENT", 152, 171]]], ["The adsorption capacity, desorption capacity and desorption ratio of each resin were selected as indexes and calculated by the following formulas:Static Adsorption-Desorption Tests to Optimize MR Typeswhere adsorption capacity (mg/g) represented the amount of Hou adsorbed on 1 g of dry resin; desorption capacity (mg/g) represented the amount of Hou after adsorption equilibrium; C 0 and C e were the initial and equilibrium concentrations of Hou (mg/mL), respectively; W was the weight of the dry resin (g); V 0 and V d were the volumes of adsorption and desorption solutions (mL), respectively; and C d represented the concentration of Hou in the desorption solution (mg/mL).Dynamic Adsorption-Desorption Tests to Optimize Purification ConditionsDynamic adsorption-desorption experiments were performed in a glass columns (1.5 cm \u00d7 20 cm) (Tianjin Tianbo Glass Instrument Co. Ltd., Tianjin, China) wet packed with 12 g (wet resin) of the D101 resin.", [["Hou", "CHEMICAL", 260, 263], ["Hou", "CHEMICAL", 639, 642], ["C 0", "SIMPLE_CHEMICAL", 381, 384], ["C e", "SIMPLE_CHEMICAL", 389, 392], ["C d", "SIMPLE_CHEMICAL", 602, 605], ["MR", "PROTEIN", 193, 195], ["The adsorption capacity", "TEST", 0, 23], ["desorption capacity", "TEST", 25, 44], ["desorption ratio of each resin", "TREATMENT", 49, 79], ["Desorption Tests", "TEST", 164, 180], ["MR", "TEST", 193, 195], ["dry resin", "TREATMENT", 283, 292], ["desorption capacity", "PROBLEM", 294, 313], ["desorption solutions", "TREATMENT", 557, 577], ["the desorption solution", "TREATMENT", 646, 669], ["Dynamic Adsorption-Desorption Tests", "TEST", 678, 713], ["desorption experiments", "TEST", 768, 790], ["a glass columns", "TREATMENT", 809, 824], ["Tianjin Tianbo Glass Instrument", "TREATMENT", 843, 874], ["12 g (wet resin", "TREATMENT", 917, 932], ["the D101 resin", "TREATMENT", 937, 951]]], ["The bed volume (BV) of the resin was 20 mL.", [["bed", "TISSUE", 4, 7], ["The bed volume (BV) of the resin", "TREATMENT", 0, 32]]], ["After loading the sample, the column was washed with distilled water (2 BV) and ethanol-water (30:70, 5 BV) to remove impurities and then desorption solvents.", [["sample", "ANATOMY", 18, 24], ["ethanol", "CHEMICAL", 80, 87], ["ethanol", "CHEMICAL", 80, 87], ["ethanol", "SIMPLE_CHEMICAL", 80, 87], ["the column", "TREATMENT", 26, 36], ["distilled water", "TREATMENT", 53, 68], ["ethanol-water", "TREATMENT", 80, 93]]], ["The conditions were as follows: Hou concentration of the loading sample solution was 0.225 mg/mL; sample flow rate was 6 BV/h, desorption solvents included different ethanol/water solutions (60:40, 70:30, 80:20, 90:10, and 95:5) with an adsorption flow rate of 6 BV/h.Preparation and Characterization of HMEHME was prepared by high-pressure homogenization as previously reported by our team [29] .", [["sample", "ANATOMY", 98, 104], ["ethanol", "CHEMICAL", 166, 173], ["ethanol", "CHEMICAL", 166, 173], ["ethanol", "SIMPLE_CHEMICAL", 166, 173], ["HMEHME", "SIMPLE_CHEMICAL", 304, 310], ["the loading sample solution", "TREATMENT", 53, 80], ["sample flow rate", "TEST", 98, 114], ["desorption solvents", "TREATMENT", 127, 146], ["different ethanol/water solutions", "TREATMENT", 156, 189], ["an adsorption flow rate", "TREATMENT", 234, 257], ["high-pressure homogenization", "TREATMENT", 327, 355]]], ["The HME particle size and zeta potential were measured by a PSS NICOMP Particle Size System (PSS, Port Richey, FL, USA) after dilution with double-distilled water.", [["a PSS NICOMP Particle Size System", "TREATMENT", 58, 91], ["Port Richey", "TREATMENT", 98, 109], ["dilution", "TREATMENT", 126, 134], ["double-distilled water", "TREATMENT", 140, 162], ["particle", "OBSERVATION_MODIFIER", 8, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["zeta", "OBSERVATION_MODIFIER", 26, 30], ["Size", "OBSERVATION_MODIFIER", 80, 84]]], ["The encapsulation rate of HME was determined by measuring the free Hou in the aqueous phase through the high-speed centrifugation (Beckman XL-90, Beckman Fullerton, CA, USA) of 40,000\u00d7 g for 8 h at 4 \u2022 C.In Vitro Hemolysis TestAbout 10 mL of blood was collected from a rabbit and centrifuged at 395\u00d7 g for 10 min to remove the supernatant.", [["blood", "ANATOMY", 242, 247], ["supernatant", "ANATOMY", 327, 338], ["Hou", "CHEMICAL", 67, 70], ["blood", "ORGANISM_SUBSTANCE", 242, 247], ["rabbit", "ORGANISM", 269, 275], ["rabbit", "SPECIES", 269, 275], ["rabbit", "SPECIES", 269, 275], ["The encapsulation rate", "TEST", 0, 22], ["blood", "TEST", 242, 247], ["encapsulation", "OBSERVATION_MODIFIER", 4, 17]]], ["The precipitated blood cells were then washed with 0.9% sodium chloride several times until the supernatant was colorless.", [["blood cells", "ANATOMY", 17, 28], ["supernatant", "ANATOMY", 96, 107], ["sodium chloride", "CHEMICAL", 56, 71], ["sodium chloride", "CHEMICAL", 56, 71], ["blood cells", "CELL", 17, 28], ["sodium chloride", "SIMPLE_CHEMICAL", 56, 71], ["precipitated blood cells", "CELL_TYPE", 4, 28], ["The precipitated blood cells", "PROBLEM", 0, 28], ["0.9% sodium chloride", "TREATMENT", 51, 71], ["blood cells", "OBSERVATION", 17, 28]]], ["At last, an erythrocyte suspension (2%, v/v) was prepared by suspending the erythrocyte into the 0.9% sodium chloride.In Vitro Hemolysis TestHEHEO, crude HEO, and pure HEO were dispersed in Tween 80 solution (2.5%) to prepare samples with the extract concentration of 2.0 mg/mL, respectively.", [["erythrocyte", "ANATOMY", 12, 23], ["erythrocyte", "ANATOMY", 76, 87], ["samples", "ANATOMY", 226, 233], ["extract", "ANATOMY", 243, 250], ["sodium chloride", "CHEMICAL", 102, 117], ["Hemolysis", "DISEASE", 127, 136], ["HEO", "CHEMICAL", 154, 157], ["HEO", "CHEMICAL", 168, 171], ["sodium chloride", "CHEMICAL", 102, 117], ["Tween 80", "CHEMICAL", 190, 198], ["erythrocyte", "CELL", 12, 23], ["erythrocyte", "CELL", 76, 87], ["sodium chloride", "SIMPLE_CHEMICAL", 102, 117], ["HEO", "SIMPLE_CHEMICAL", 154, 157], ["HEO", "SIMPLE_CHEMICAL", 168, 171], ["an erythrocyte suspension", "TEST", 9, 34], ["v/v)", "TREATMENT", 40, 44], ["the erythrocyte", "TEST", 72, 87], ["the 0.9% sodium chloride", "TREATMENT", 93, 117], ["Vitro Hemolysis TestHEHEO", "TREATMENT", 121, 146], ["crude HEO", "TREATMENT", 148, 157], ["the extract concentration", "TREATMENT", 239, 264], ["Hemolysis", "OBSERVATION", 127, 136]]], ["Tubes 1-5 were filled with 0.5, 0.4, 0.3, 0.2, and 0.1 mL of sample, respectively.", [["sample", "ANATOMY", 61, 67], ["Tubes", "TREATMENT", 0, 5]]], ["Then, 2.5 mL of 2% erythrocyte suspension (v/v) and different amounts of 0.9% sodium chloride were added to make a total volume of 5 mL.", [["erythrocyte", "ANATOMY", 19, 30], ["sodium chloride", "CHEMICAL", 78, 93], ["sodium chloride", "CHEMICAL", 78, 93], ["erythrocyte", "CELL", 19, 30], ["sodium chloride", "SIMPLE_CHEMICAL", 78, 93], ["2% erythrocyte suspension (v/v)", "TREATMENT", 16, 47], ["different amounts of 0.9% sodium chloride", "TREATMENT", 52, 93], ["a total volume", "TREATMENT", 113, 127]]], ["For the tubes 6% and 7%, 0.9% sodium chloride and distilled water replaced the sample solutions as blank control and positive control, respectively.", [["sample", "ANATOMY", 79, 85], ["sodium chloride", "CHEMICAL", 30, 45], ["sodium chloride", "CHEMICAL", 30, 45], ["sodium chloride", "SIMPLE_CHEMICAL", 30, 45], ["the tubes", "TREATMENT", 4, 13], ["0.9% sodium chloride", "TREATMENT", 25, 45], ["the sample solutions", "TREATMENT", 75, 95], ["blank control", "TREATMENT", 99, 112]]], ["Then, the tubes were placed into a 37 \u2022 C water bath with gentle shaking.", [["tubes", "ANATOMY", 10, 15], ["the tubes", "TREATMENT", 6, 15], ["a 37 \u2022 C water bath", "TREATMENT", 33, 52], ["gentle shaking", "PROBLEM", 58, 72], ["tubes", "OBSERVATION", 10, 15]]], ["The results were interpreted qualitatively as follows:Acute Toxicity TestSixty mice were randomly assigned to six groups of ten animals each (five males and five females).", [["mice", "ORGANISM", 79, 83], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["Acute Toxicity", "PROBLEM", 54, 68], ["Toxicity", "OBSERVATION", 60, 68]]], ["Before the test, crude HEO and pure HEO were dispersed in Tween 80 solution (2.5%) to prepare samples with the Hou concentration of 1.5 mg/mL, respectively.", [["samples", "ANATOMY", 94, 101], ["HEO", "CHEMICAL", 23, 26], ["HEO", "CHEMICAL", 36, 39], ["Tween 80", "CHEMICAL", 58, 66], ["HEO", "SIMPLE_CHEMICAL", 23, 26], ["HEO", "SIMPLE_CHEMICAL", 36, 39], ["the test", "TEST", 7, 15], ["crude HEO and pure HEO", "TREATMENT", 17, 39], ["the Hou concentration", "TREATMENT", 107, 128]]], ["The crude HEO, pure HEO and HEM (Hou 1.5 mg/mL) were injected through the caudal vein with Hou at the doses of 30 mg/kg.", [["caudal vein", "ANATOMY", 74, 85], ["HEO", "CHEMICAL", 10, 13], ["HEO", "CHEMICAL", 20, 23], ["HEM", "CHEMICAL", 28, 31], ["Hou", "CHEMICAL", 91, 94], ["HEO", "CHEMICAL", 20, 23], ["HEM", "CHEMICAL", 28, 31], ["HEO", "SIMPLE_CHEMICAL", 10, 13], ["HEO", "SIMPLE_CHEMICAL", 20, 23], ["HEM", "SIMPLE_CHEMICAL", 28, 31], ["caudal vein", "MULTI-TISSUE_STRUCTURE", 74, 85], ["The crude HEO", "TREATMENT", 0, 13], ["HEM (Hou", "TREATMENT", 28, 36], ["Hou", "TREATMENT", 91, 94], ["HEM", "ANATOMY", 28, 31], ["caudal vein", "ANATOMY", 74, 85]]], ["For the HEHEO group, the extract was dissolved in Tween 80 solution (2.5%) with the extract concentration of 4 mg/mL.", [["extract", "ANATOMY", 25, 32], ["extract", "ANATOMY", 84, 91], ["HEHEO", "CHEMICAL", 8, 13], ["Tween 80", "CHEMICAL", 50, 58], ["Tween 80", "CHEMICAL", 50, 58], ["HEHEO", "SIMPLE_CHEMICAL", 8, 13], ["the extract concentration", "TREATMENT", 80, 105]]], ["Negative controls were blank Tween 80 (2.5%) solution and blank ME.", [["Tween 80", "CHEMICAL", 29, 37], ["blank Tween", "TREATMENT", 23, 34]]], ["Additionally, no-treatment control was set for observation of symptoms and insurance of accuracy.", [["no-treatment control", "TREATMENT", 14, 34], ["symptoms", "PROBLEM", 62, 70], ["accuracy", "TEST", 88, 96]]], ["General behaviors of mice and symptoms of toxicity were observed continuously for 24 h after injection.Cells and VirusesAfrican green monkey kidney cells (Vero) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in MEM supplemented with 10% FBS and antibiotics (100 U/mL penicillin G, 100 \u00b5g/mL streptomycin) at 37 \u2022 C in a humid atmosphere (5% CO 2 \u221295% air).", [["Cells", "ANATOMY", 103, 108], ["kidney cells", "ANATOMY", 141, 153], ["Vero", "ANATOMY", 155, 159], ["FBS", "ANATOMY", 286, 289], ["toxicity", "DISEASE", 42, 50], ["MEM", "CHEMICAL", 260, 263], ["FBS", "CHEMICAL", 286, 289], ["penicillin", "CHEMICAL", 316, 326], ["streptomycin", "CHEMICAL", 340, 352], ["penicillin G", "CHEMICAL", 316, 328], ["streptomycin", "CHEMICAL", 340, 352], ["CO", "CHEMICAL", 390, 392], ["mice", "ORGANISM", 21, 25], ["Cells", "CELL", 103, 108], ["VirusesAfrican green monkey kidney cells", "CELL", 113, 153], ["Vero", "CELL", 155, 159], ["FBS", "ORGANISM_SUBSTANCE", 286, 289], ["penicillin G", "SIMPLE_CHEMICAL", 316, 328], ["streptomycin", "SIMPLE_CHEMICAL", 340, 352], ["VirusesAfrican green monkey kidney cells", "CELL_LINE", 113, 153], ["mice", "SPECIES", 21, 25], ["green monkey", "SPECIES", 128, 140], ["mice", "SPECIES", 21, 25], ["VirusesAfrican green monkey", "SPECIES", 113, 140], ["ATCC", "SPECIES", 219, 223], ["Manassas", "SPECIES", 225, 233], ["symptoms of toxicity", "PROBLEM", 30, 50], ["Cells", "TEST", 103, 108], ["VirusesAfrican green monkey kidney cells", "PROBLEM", 113, 153], ["ATCC", "TEST", 219, 223], ["10% FBS", "TREATMENT", 282, 289], ["antibiotics", "TREATMENT", 294, 305], ["penicillin G", "TREATMENT", 316, 328], ["streptomycin", "TREATMENT", 340, 352], ["a humid atmosphere", "TREATMENT", 367, 385]]], ["Coxsackie Virus B3 (CVB3, strain Nancy) and B6 (CBV6, strain Schmitt) were obtained from ATCC and propagated in Vero cells.Cytotoxicity AssayThe cytotoxicity effects of the samples (HEHEO, crude HEO, pure, and HME) toward Vero cells were monitored by the MTT assay.", [["ATCC", "ANATOMY", 89, 93], ["Vero cells", "ANATOMY", 112, 122], ["samples", "ANATOMY", 173, 180], ["Vero cells", "ANATOMY", 222, 232], ["HEHEO", "CHEMICAL", 182, 187], ["HEO", "CHEMICAL", 195, 198], ["MTT", "CHEMICAL", 255, 258], ["Coxsackie Virus B3", "ORGANISM", 0, 18], ["CVB3", "ORGANISM", 20, 24], ["strain Nancy", "ORGANISM", 26, 38], ["B6 (CBV6", "ORGANISM", 44, 52], ["ATCC", "CELL", 89, 93], ["Vero cells", "CELL", 112, 122], ["HEHEO", "SIMPLE_CHEMICAL", 182, 187], ["HEO", "SIMPLE_CHEMICAL", 195, 198], ["Vero cells", "CELL", 222, 232], ["Vero cells", "CELL_LINE", 112, 122], ["Vero cells", "CELL_LINE", 222, 232], ["Coxsackie Virus B3", "SPECIES", 0, 18], ["Coxsackie Virus B3", "SPECIES", 0, 18], ["CVB3", "SPECIES", 20, 24], ["CBV6", "SPECIES", 48, 52], ["ATCC", "SPECIES", 89, 93], ["Coxsackie Virus B3", "PROBLEM", 0, 18], ["CVB3", "TEST", 20, 24], ["B6", "TEST", 44, 46], ["CBV6", "TEST", 48, 52], ["ATCC", "TEST", 89, 93], ["Cytotoxicity Assay", "TEST", 123, 141], ["the samples", "TEST", 169, 180], ["HEHEO", "TEST", 182, 187], ["Vero cells", "TREATMENT", 222, 232], ["the MTT assay", "TEST", 251, 264], ["Vero cells", "OBSERVATION", 112, 122], ["cytotoxicity effects", "OBSERVATION", 145, 165]]], ["Vero cells seeded in 96-well plates were incubated with various concentrations of tested samples or ribavirin and pleconaril (positive controls) for 72 h at 37 \u2022 C. The cells were then incubated with 20 \u00b5L MTT reagent (5 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) for 4 h at 37 \u2022 C. The MTT reagent was removed and 150 \u00b5L DMSO was added to each well.", [["Vero cells", "ANATOMY", 0, 10], ["samples", "ANATOMY", 89, 96], ["cells", "ANATOMY", 169, 174], ["ribavirin", "CHEMICAL", 100, 109], ["pleconaril", "CHEMICAL", 114, 124], ["DMSO", "CHEMICAL", 321, 325], ["ribavirin", "CHEMICAL", 100, 109], ["pleconaril", "CHEMICAL", 114, 124], ["MTT", "CHEMICAL", 206, 209], ["MTT", "CHEMICAL", 286, 289], ["DMSO", "CHEMICAL", 321, 325], ["Vero cells", "CELL", 0, 10], ["ribavirin", "SIMPLE_CHEMICAL", 100, 109], ["pleconaril", "SIMPLE_CHEMICAL", 114, 124], ["cells", "CELL", 169, 174], ["DMSO", "SIMPLE_CHEMICAL", 321, 325], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "TEST", 0, 10], ["tested samples", "TREATMENT", 82, 96], ["ribavirin", "TREATMENT", 100, 109], ["pleconaril", "TREATMENT", 114, 124], ["20 \u00b5L MTT reagent", "TREATMENT", 200, 217], ["The MTT reagent", "TREATMENT", 282, 297]]], ["The spectrophotometric reading was taken at 490 nm using a microplate reader (Perkin-Elmer, Waltham, MA, USA).", [["The spectrophotometric reading", "TEST", 0, 30], ["a microplate reader", "TREATMENT", 57, 76]]], ["5Fifty percent (50%) toxic concentration (TC 50 ) was defined as the concentration that inhibited 50% cellular growth in comparison with the untreated controls and calculated using the Reed-Muench method.Antiviral ActivityThe antiviral activity against CVB3 and CVB6 was evaluated using the cytopathic effect (CPE) reduction method.", [["cellular", "ANATOMY", 102, 110], ["cellular", "CELL", 102, 110], ["CVB3", "ORGANISM", 253, 257], ["CVB6", "CELL", 262, 266], ["CVB3", "SPECIES", 253, 257], ["CVB6", "SPECIES", 262, 266], ["toxic concentration (TC", "TREATMENT", 21, 44], ["the Reed-Muench method", "TREATMENT", 181, 203], ["The antiviral activity", "TREATMENT", 222, 244], ["CVB3", "PROBLEM", 253, 257], ["CVB6", "TEST", 262, 266], ["the cytopathic effect (CPE) reduction method", "TREATMENT", 287, 331], ["growth", "OBSERVATION_MODIFIER", 111, 117], ["antiviral activity", "OBSERVATION", 226, 244]]], ["Briefly, cells were plated into 96-well culture plates and incubated for 24 h.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["culture plates", "TEST", 40, 54]]], ["The medium was then removed and cells were infected with virus for 2 h.", [["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["cells", "PROBLEM", 32, 37], ["virus", "TREATMENT", 57, 62], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["Samples with different various concentrations (HEHEO, crude HEO, pure HEO, and HME) were added to each well immediately and incubated until the CPE of the control group cells reached 4.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 169, 174], ["HEO", "CHEMICAL", 60, 63], ["HEO", "CHEMICAL", 70, 73], ["HEHEO", "SIMPLE_CHEMICAL", 47, 52], ["HEO", "SIMPLE_CHEMICAL", 60, 63], ["HEO", "SIMPLE_CHEMICAL", 70, 73], ["cells", "CELL", 169, 174], ["Samples", "TEST", 0, 7], ["different various concentrations", "TREATMENT", 13, 45]]], ["The 50% inhibitory concentration (IC 50 ) was determined using the Reed-Muench method.", [["The 50% inhibitory concentration (IC", "TREATMENT", 0, 36], ["the Reed-Muench method", "TREATMENT", 63, 85]]], ["The selective index (SI) was calculated from the ratio of TC 50 /IC 50 .ConclusionsIn this study, pure HEO with high Hou content (43.4%) was prepared by solvent extraction followed by purification using D101 resin.", [["HEO", "CHEMICAL", 103, 106], ["Hou", "CHEMICAL", 117, 120], ["HEO", "CHEMICAL", 103, 106], ["HEO", "SIMPLE_CHEMICAL", 103, 106], ["this study", "TEST", 86, 96], ["solvent extraction", "TREATMENT", 153, 171], ["D101 resin", "TREATMENT", 203, 213], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["index", "OBSERVATION_MODIFIER", 14, 19]]], ["To further improve its safety and antiviral activity, the pure HEO was encapsulated into ME and then comprehensively characterized.", [["HEO", "CHEMICAL", 63, 66], ["HEO", "CHEMICAL", 63, 66], ["HEO", "SIMPLE_CHEMICAL", 63, 66], ["antiviral activity", "TREATMENT", 34, 52]]], ["The safety evaluation tests and in vitro antiviral test indicated that the safety and antiviral activity of HEO were largely improved after purification by D101 resin and were further improved by ME encapsulation.", [["HEO", "CHEMICAL", 108, 111], ["HEO", "CHEMICAL", 108, 111], ["HEO", "SIMPLE_CHEMICAL", 108, 111], ["ME", "SIMPLE_CHEMICAL", 196, 198], ["The safety evaluation tests", "TEST", 0, 27], ["vitro antiviral test", "TEST", 35, 55], ["antiviral activity of HEO", "TREATMENT", 86, 111], ["D101 resin", "TREATMENT", 156, 166]]], ["These results indicated that purification of HEO using D101 resin, followed by ME encapsulation, was of high efficiency, reduced toxicity, and enhanced effect, which was very promising for future therapy of antiviral and infectious diseases.", [["HEO", "CHEMICAL", 45, 48], ["D101 resin", "CHEMICAL", 55, 65], ["toxicity", "DISEASE", 129, 137], ["infectious diseases", "DISEASE", 221, 240], ["HEO", "SIMPLE_CHEMICAL", 45, 48], ["D101 resin", "SIMPLE_CHEMICAL", 55, 65], ["ME", "SIMPLE_CHEMICAL", 79, 81], ["HEO using D101 resin", "TREATMENT", 45, 65], ["high efficiency", "PROBLEM", 104, 119], ["reduced toxicity", "PROBLEM", 121, 137], ["future therapy", "TREATMENT", 189, 203], ["antiviral", "TREATMENT", 207, 216], ["infectious diseases", "PROBLEM", 221, 240], ["high efficiency", "OBSERVATION_MODIFIER", 104, 119], ["reduced", "OBSERVATION_MODIFIER", 121, 128], ["toxicity", "OBSERVATION", 129, 137]]], ["Hou, the major active constituent of HEO, possesses a quite simple chemical structure and high antiviral activities.", [["Hou", "CHEMICAL", 0, 3], ["HEO", "CHEMICAL", 37, 40], ["HEO", "CHEMICAL", 37, 40], ["HEO", "SIMPLE_CHEMICAL", 37, 40], ["high antiviral activities", "OBSERVATION", 90, 115]]]], "PMC7128471": [["In a loop of dynamic feedback, behavior such as the decision to vaccinate, hand washing, or avoidance influences the progression of the epidemic, yet behavior is driven by the individual's and population's perceived risk of infection during an outbreak.", [["hand", "ANATOMY", 75, 79], ["infection", "DISEASE", 224, 233], ["hand", "ORGANISM_SUBDIVISION", 75, 79], ["hand washing", "TREATMENT", 75, 87], ["the epidemic", "PROBLEM", 132, 144], ["infection", "PROBLEM", 224, 233], ["loop", "OBSERVATION_MODIFIER", 5, 9], ["infection", "OBSERVATION", 224, 233]]], ["In what we believe will become a seminal paper that stimulates future research as well as an informative teaching aid, Wang et. al. comprehensively review methodological advances that have been used to incorporate human behavior into epidemiological models on the effects of coupling disease transmission and behavior on complex social networks [1].", [["human", "ORGANISM", 214, 219], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["coupling disease transmission", "PROBLEM", 275, 304]]], ["As illustrated by the recent outbreaks of measles and Middle Eastern Respiratory Syndrome (MERS), here we highlight the importance of coupling behavior and disease transmission that Wang et al. address.", [["measles", "DISEASE", 42, 49], ["Middle Eastern Respiratory Syndrome", "DISEASE", 54, 89], ["MERS", "DISEASE", 91, 95], ["measles", "PROBLEM", 42, 49], ["Middle Eastern Respiratory Syndrome", "PROBLEM", 54, 89], ["coupling behavior", "PROBLEM", 134, 151], ["Middle", "ANATOMY_MODIFIER", 54, 60], ["Respiratory Syndrome", "OBSERVATION", 69, 89]]]], "PMC4166774": [["BackgroundMERS-CoV is an enveloped positive sense single strandedRNA virus from betacoronavirus genus.", [["betacoronavirus genus", "ORGANISM", 80, 101], ["BackgroundMERS-CoV", "TEST", 0, 18], ["an enveloped positive sense single strandedRNA virus", "PROBLEM", 22, 74], ["enveloped", "OBSERVATION_MODIFIER", 25, 34], ["positive", "OBSERVATION", 35, 43], ["strandedRNA virus", "OBSERVATION", 57, 74]]], ["Its natural reservoir isstill unidentified but similarity with other viruses suggestedthat it is of bat origin [1].", [["other viruses", "PROBLEM", 63, 76], ["natural", "OBSERVATION_MODIFIER", 4, 11], ["reservoir isstill", "OBSERVATION", 12, 29], ["viruses", "OBSERVATION", 69, 76]]], ["Infection with MERS-CoV ischaracterized mostly by severe acute respiratory syndrome(SARS).", [["acute respiratory syndrome", "DISEASE", 57, 83], ["SARS", "DISEASE", 84, 88], ["MERS-CoV", "ORGANISM", 15, 23], ["MERS-CoV", "SPECIES", 15, 23], ["Infection", "PROBLEM", 0, 9], ["MERS", "PROBLEM", 15, 19], ["severe acute respiratory syndrome", "PROBLEM", 50, 83], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["Clinical symptoms also include fever, fever with chillsor rigours, cough, shortness of breath and in some cases renalfailure.", [["fever", "DISEASE", 31, 36], ["fever", "DISEASE", 38, 43], ["chillsor rigours", "DISEASE", 49, 65], ["cough", "DISEASE", 67, 72], ["shortness of breath", "DISEASE", 74, 93], ["renalfailure", "DISEASE", 112, 124], ["Clinical symptoms", "PROBLEM", 0, 17], ["fever", "PROBLEM", 31, 36], ["fever", "PROBLEM", 38, 43], ["chillsor rigours", "PROBLEM", 49, 65], ["cough", "PROBLEM", 67, 72], ["shortness of breath", "PROBLEM", 74, 93], ["some cases renalfailure", "PROBLEM", 101, 124]]], ["Gastrointestinal symptoms were also found in infectedpatients including diarrhoea, vomiting and abdominal pain[2].The first official outbreak was recorded in Saudi Arabia onSeptember 2012.", [["Gastrointestinal", "ANATOMY", 0, 16], ["abdominal", "ANATOMY", 96, 105], ["diarrhoea", "DISEASE", 72, 81], ["vomiting", "DISEASE", 83, 91], ["abdominal pain", "DISEASE", 96, 110], ["Gastrointestinal", "ORGAN", 0, 16], ["abdominal", "ORGANISM_SUBDIVISION", 96, 105], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["infectedpatients", "PROBLEM", 45, 61], ["diarrhoea", "PROBLEM", 72, 81], ["vomiting", "PROBLEM", 83, 91], ["abdominal pain", "PROBLEM", 96, 110], ["abdominal", "ANATOMY", 96, 105]]], ["Recurrent infections of MERS-CoV has beenreported from 2012 to 2014 in Jordan, Kuwait, Oman, Qatar,Saudi Arabia (KSA), United Arab Emirates (UAE), Yemen,Egypt, Tunisia, France, Germany, Greece, Italy, and UnitedKingdom.", [["infections", "DISEASE", 10, 20], ["MERS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "SPECIES", 24, 32], ["Recurrent infections of MERS", "PROBLEM", 0, 28], ["infections", "OBSERVATION", 10, 20]]], ["According to the World Health Organization(WHO), till date a total of 536 laboratory-confirmed cases ofMERS-CoV infections have been identified, 145 of whichresulted in death (http://www.who.int /csr/disease/coronavirus infections/archive_updates/en).", [["ofMERS-CoV infections", "DISEASE", 101, 122], ["death", "DISEASE", 169, 174], ["coronavirus infections", "DISEASE", 208, 230], ["ofMERS-CoV", "ORGANISM", 101, 111], ["coronavirus", "ORGANISM", 208, 219], ["ofMERS-CoV", "SPECIES", 101, 111], ["who.int /csr/disease/coronavirus", "SPECIES", 187, 219], ["CoV infections", "PROBLEM", 108, 122], ["death", "PROBLEM", 169, 174], ["disease", "PROBLEM", 200, 207], ["coronavirus infections", "PROBLEM", 208, 230], ["archive_updates", "PROBLEM", 231, 246], ["disease", "OBSERVATION", 200, 207], ["coronavirus infections", "OBSERVATION", 208, 230]]], ["Though it hasnot hit the world population in a massive scale yet, itsprogressive invasiveness with concerning fatality rate raisesthe demand of therapeutic solutions or vaccination on anurgent basis.BackgroundThe field of Computational Immunology is developingrapidly.", [["a massive scale", "TREATMENT", 45, 60], ["itsprogressive invasiveness", "PROBLEM", 66, 93], ["therapeutic solutions", "TREATMENT", 144, 165], ["vaccination", "TREATMENT", 169, 180]]], ["Current tools enable us to predict potential epitopesfrom large protein antigens encoded by viral genomes.Identification of B- and T-cell epitopes and their respectiveMHC alleles is the crucial step for the very initial screeningprocess of immunoinformatics approach [3].BackgroundCoronavirus possess a non-structural replicase polyproteinand several structural proteins including spike (S), envelope(E), membrane (M) and nucleocapsid (N) proteins [4,5].", [["T-cell", "ANATOMY", 131, 137], ["membrane", "ANATOMY", 405, 413], ["B", "GENE_OR_GENE_PRODUCT", 124, 125], ["T-cell", "CELL", 131, 137], ["spike (S)", "GENE_OR_GENE_PRODUCT", 381, 390], ["membrane", "CELLULAR_COMPONENT", 405, 413], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 422, 438], ["protein antigens", "PROTEIN", 64, 80], ["viral genomes", "DNA", 92, 105], ["B- and T-cell epitopes", "PROTEIN", 124, 146], ["respectiveMHC alleles", "DNA", 157, 178], ["non-structural replicase polyproteinand", "PROTEIN", 303, 342], ["structural proteins", "PROTEIN", 351, 370], ["spike (S), envelope(E), membrane (M) and nucleocapsid (N) proteins", "PROTEIN", 381, 447], ["large protein antigens", "PROBLEM", 58, 80], ["Identification", "TEST", 106, 120], ["B- and T-cell epitopes", "TREATMENT", 124, 146], ["immunoinformatics approach", "TREATMENT", 240, 266], ["a non-structural replicase polyproteinand several structural proteins", "PROBLEM", 301, 370], ["spike (S), envelope(E), membrane (M) and nucleocapsid (N) proteins", "PROBLEM", 381, 447], ["viral genomes", "OBSERVATION", 92, 105], ["non-structural replicase", "OBSERVATION", 303, 327]]], ["Likeother coronaviruses, the host cell recognition of MERS-CoV byCD26 receptor is mediated by its surface anchored Sglycoprotein [6,7].", [["cell", "ANATOMY", 34, 38], ["surface", "ANATOMY", 98, 105], ["Likeother coronaviruses", "ORGANISM", 0, 23], ["cell", "CELL", 34, 38], ["MERS-CoV byCD26 receptor", "GENE_OR_GENE_PRODUCT", 54, 78], ["surface", "CELLULAR_COMPONENT", 98, 105], ["MERS-CoV byCD26 receptor", "PROTEIN", 54, 78], ["Sglycoprotein", "PROTEIN", 115, 128], ["MERS-CoV", "SPECIES", 54, 62], ["coronaviruses", "PROBLEM", 10, 23], ["CoV byCD26 receptor", "TREATMENT", 59, 78], ["host cell", "OBSERVATION", 29, 38]]], ["This S glycoprotein has S1 and S2 subunits.S1 subunit contains RBD which mediates initial host cellrecognition whereas S2 subunit mediates membrane fusion[8,9].BackgroundSeveral recent studies have revealed that the N-terminal 367-606 amino acid region of S glycoprotein of MERS-CoV isbound with human CD26 and produces significant immuneresponse.", [["membrane", "ANATOMY", 139, 147], ["amino acid", "CHEMICAL", 235, 245], ["amino acid", "CHEMICAL", 235, 245], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 5, 19], ["S1", "GENE_OR_GENE_PRODUCT", 24, 26], ["S2", "GENE_OR_GENE_PRODUCT", 31, 33], ["S1", "GENE_OR_GENE_PRODUCT", 43, 45], ["RBD", "GENE_OR_GENE_PRODUCT", 63, 66], ["S2 subunit", "GENE_OR_GENE_PRODUCT", 119, 129], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["amino acid", "AMINO_ACID", 235, 245], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 274, 282], ["human", "ORGANISM", 296, 301], ["CD26", "GENE_OR_GENE_PRODUCT", 302, 306], ["S glycoprotein", "PROTEIN", 5, 19], ["S1 and S2 subunits", "PROTEIN", 24, 42], ["S1 subunit", "PROTEIN", 43, 53], ["RBD", "PROTEIN", 63, 66], ["S2 subunit", "PROTEIN", 119, 129], ["N-terminal 367-606 amino acid region", "PROTEIN", 216, 252], ["S glycoprotein", "PROTEIN", 256, 270], ["MERS", "PROTEIN", 274, 278], ["CoV", "PROTEIN", 279, 282], ["human CD26", "PROTEIN", 296, 306], ["human", "SPECIES", 296, 301], ["MERS-CoV", "SPECIES", 274, 282], ["human", "SPECIES", 296, 301], ["S1 and S2 subunits", "TREATMENT", 24, 42], ["RBD", "PROBLEM", 63, 66], ["initial host cellrecognition", "PROBLEM", 82, 110], ["S2 subunit mediates membrane fusion", "TREATMENT", 119, 154], ["the N-terminal", "TEST", 212, 226], ["amino acid region", "TEST", 235, 252], ["human CD26", "TREATMENT", 296, 306], ["significant immuneresponse", "PROBLEM", 320, 346], ["RBD", "OBSERVATION", 63, 66], ["membrane fusion", "OBSERVATION", 139, 154]]], ["This phenomenon suggests that the receptor bindingcapacity of MERS-CoV lies in this particular region of Sglycoprotein [10,11].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["Sglycoprotein", "GENE_OR_GENE_PRODUCT", 105, 118], ["MERS-CoV", "PROTEIN", 62, 70], ["Sglycoprotein", "PROTEIN", 105, 118], ["MERS-CoV", "SPECIES", 62, 70], ["the receptor bindingcapacity of MERS", "PROBLEM", 30, 66]]], ["Considering these facts, our approachwas to choose this particular region of S glycoprotein for theprediction and identification of the potential T- and B-cellepitopes in this computational study.Retrieving protein sequence: ::: MethodologyThe sequences of S glycoprotein were retrieved from twodatabases: NCBI (National Center for BiotechnologyInformation) (http://www.ncbi.nlm.nih.gov/) and uniprot(http://www.uniprot.org/).", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 77, 91], ["B-cellepitopes", "GENE_OR_GENE_PRODUCT", 153, 167], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 257, 271], ["S glycoprotein", "PROTEIN", 77, 91], ["S glycoprotein", "PROTEIN", 257, 271], ["the potential T- and B-cellepitopes", "PROBLEM", 132, 167], ["this computational study", "TEST", 171, 195]]], ["These sequences belong todiverse demographic distributions like Saudi Arabia, England,Qatar, Spain, Germany, Jordan, and UAE with time rangesfrom 2012 to 2013.Multiple sequence alignment: ::: MethodologyThe Clustal Omega software (version 1.2.1) was utilized togenerate multiple sequence alignment for retrieved sequenceswhich was the basis for determining the conservancy of MERSCoV RBD [12].Immunogenicity of conserved peptide: ::: MethodologyDifferent tools available from the IEDB analysis resource(http://tools.immuneepitope.org/main/index.html) wereused to evaluate the immunogenicity of MERS-CoV RBD.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 594, 602], ["MERSCoV RBD", "PROTEIN", 376, 387], ["MERS-CoV RBD", "PROTEIN", 594, 606], ["MERS-CoV", "SPECIES", 594, 602], ["These sequences", "TEST", 0, 15], ["The Clustal Omega software (version", "TREATMENT", 203, 238], ["the IEDB analysis", "TEST", 476, 493], ["CoV RBD", "PROBLEM", 599, 606]]], ["TheNetCTL prediction method was utilized for identifying T-cellepitopes from this region [13,14].", [["T-cellepitopes", "GENE_OR_GENE_PRODUCT", 57, 71], ["TheNetCTL", "PROTEIN", 0, 9]]], ["The MHC class-I bindingprediction tool was used to identify MHC class-I alleles for thefinal set of T-cell epitopes based on Stabilized Matrix Method(SMM) [15].Immunogenicity of conserved peptide: ::: Methodology\u201cProteasomal cleavage/TAP transport/MHC class I combinedpredictor\u201d was utilized for determining the overall score foreach peptide's intrinsic capability to be considered as a T cellepitope (http://tools.immuneepitope.org/processing/)[15\u201317].The epitope conservancy analysis tool was utilized tocalculate the conservancy of the final set of epitopes within thesequences of S glycoprotein [18].", [["T-cell", "ANATOMY", 100, 106], ["T-cell", "CELL", 100, 106], ["TAP", "GENE_OR_GENE_PRODUCT", 234, 237], ["MHC class-I alleles", "DNA", 60, 79], ["T-cell epitopes", "PROTEIN", 100, 115], ["TAP", "PROTEIN", 234, 237], ["MHC class I", "PROTEIN", 248, 259], ["T cellepitope", "PROTEIN", 387, 400], ["epitopes", "PROTEIN", 552, 560], ["S glycoprotein", "PROTEIN", 584, 598], ["T-cell epitopes", "TREATMENT", 100, 115], ["Methodology", "TREATMENT", 201, 212], ["Proteasomal cleavage", "TREATMENT", 213, 233], ["a T cellepitope (http://tools.immuneepitope.org/processing/)[15\u201317", "TREATMENT", 385, 451], ["The epitope conservancy analysis tool", "TEST", 453, 490]]], ["In addition to this, TheProPred1 and SYFPEITHI databases were also employed toidentify the anchoring residues of the epitopes [19,20].3D structures of the predicted epitope and HLA-C12:03) wasretrieved from the Protein Data Bank (PDB) (HLA-C12:03) and ligand (CYSSLILDY) were opened in ADT.", [["ProPred1", "GENE_OR_GENE_PRODUCT", 24, 32], ["HLA-C12:03", "GENE_OR_GENE_PRODUCT", 177, 187], ["ProPred1", "PROTEIN", 24, 32], ["SYFPEITHI", "PROTEIN", 37, 46], ["epitopes", "PROTEIN", 117, 125], ["epitope", "PROTEIN", 165, 172], ["HLA", "PROTEIN", 177, 180], ["C12:03", "PROTEIN", 181, 187], ["HLA", "PROTEIN", 236, 239], ["C12:03", "PROTEIN", 240, 246], ["TheProPred1 and SYFPEITHI databases", "TEST", 21, 56], ["the epitopes", "TEST", 113, 125], ["HLA", "TEST", 177, 180], ["HLA", "TEST", 236, 239], ["PDB", "ANATOMY", 230, 233]]], ["Forthe epitope to be bound at the binding groove of HLA-C12:03 molecule.", [["HLA-C12:03 molecule", "PROTEIN", 52, 71], ["Forthe epitope", "PROBLEM", 0, 14], ["groove", "ANATOMY_MODIFIER", 42, 48], ["HLA", "ANATOMY", 52, 55], ["C12:03 molecule", "OBSERVATION", 56, 71]]], ["For both the designed and experimentalepitopes at the binding groove of HLA-C*12:03, a comparativeanalysis of their binding pattern is illustrated inFigure 4.B-cell antigenicity: ::: ResultsThe graphical depiction of B-cell antigenicity of MERS-CoVRBD is in Figure 5.", [["B-cell", "ANATOMY", 158, 164], ["B-cell", "ANATOMY", 217, 223], ["B-cell", "CELL", 158, 164], ["B-cell", "CELL", 217, 223], ["HLA-C*12:03", "DNA", 72, 83], ["-cell antigenicity", "OBSERVATION", 159, 177], ["B-cell", "OBSERVATION", 217, 223]]], ["Twelve antigenic determinants were foundfrom this region which is presented in Table 2 (Seesupplementary material).DiscussionIn recent years, in silico approach has become handy in vaccinedesigning against deadly entities as it provides clue to selecttarget protein sequence.", [["selecttarget protein sequence", "DNA", 245, 274]]], ["Till date, there is no establishedtherapeutic solution or vaccination against MERS-CoVinfection.", [["MERS-CoVinfection", "SIMPLE_CHEMICAL", 78, 95], ["establishedtherapeutic solution", "TREATMENT", 23, 54], ["vaccination", "TREATMENT", 58, 69], ["MERS", "PROBLEM", 78, 82], ["CoVinfection", "PROBLEM", 83, 95], ["no", "UNCERTAINTY", 20, 22]]], ["Several reports in recent years reveal that MERS-CoVproduces strong T-cell mediated immune responses in humanbody, inspiring us to design T-cell epitope based peptidevaccine [24].DiscussionTo be considered as a potent epitope, a peptide must containseveral key properties like well conservancy, T- or B-cellprocessivity and good binding affinity for MHC alleles.", [["T-cell", "ANATOMY", 68, 74], ["T-cell", "ANATOMY", 138, 144], ["peptidevaccine", "CHEMICAL", 159, 173], ["MERS-CoVproduces", "GENE_OR_GENE_PRODUCT", 44, 60], ["T-cell", "CELL", 68, 74], ["T-cell", "CELL", 138, 144], ["T", "GENE_OR_GENE_PRODUCT", 295, 296], ["MHC alleles", "DNA", 350, 361], ["MERS", "PROBLEM", 44, 48], ["a peptide", "TREATMENT", 227, 236]]], ["In ourstudy, the values for above mentioned parameters were foundin favour of the finally chosen epitopes.DiscussionIn this study we used NetCTL prediction tool for the primaryscreening of the RBD of S glycoprotein of MERS-CoV for T-cellepitope prediction which is based on neural networkarchitecture.", [["neural", "ANATOMY", 274, 280], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 218, 226], ["epitopes", "PROTEIN", 97, 105], ["RBD", "PROTEIN", 193, 196], ["S glycoprotein", "PROTEIN", 200, 214], ["MERS", "PROTEIN", 218, 222], ["MERS-CoV", "SPECIES", 218, 226], ["the values", "TEST", 13, 23], ["this study", "TEST", 119, 129], ["T-cellepitope prediction", "TREATMENT", 231, 255], ["neural networkarchitecture", "OBSERVATION", 274, 300]]], ["It predicts the epitopes on the basis of processingof peptide in vivo.", [["epitopes", "PROTEIN", 16, 24], ["processingof peptide", "TREATMENT", 41, 61]]], ["It gives a total score for each epitopes byusing an algorithm integrating MHC-I binding, Transporter ofAntigenic peptides (TAP) transport efficiency and proteasomalcleavage prediction [13,14].DiscussionAmong eight T-cell epitopes, CYSSLILDY was the mostsuccessful because it was found to have the maximuminteractions with different MHC class-I alleles which is aprinciple prerequisite for a potential epitope.", [["T-cell", "ANATOMY", 214, 220], ["MHC-I", "GENE_OR_GENE_PRODUCT", 74, 79], ["Transporter ofAntigenic peptides", "GENE_OR_GENE_PRODUCT", 89, 121], ["TAP", "GENE_OR_GENE_PRODUCT", 123, 126], ["T-cell", "CELL", 214, 220], ["epitopes", "PROTEIN", 32, 40], ["MHC", "PROTEIN", 74, 77], ["TAP", "PROTEIN", 123, 126], ["T-cell epitopes", "PROTEIN", 214, 229], ["CYSSLILDY", "PROTEIN", 231, 240], ["MHC class-I alleles", "DNA", 332, 351], ["each epitopes", "TREATMENT", 27, 40], ["Transporter ofAntigenic peptides", "TREATMENT", 89, 121]]], ["In addition tothis, it was found that the peptide region of 408-452 amino acids\u201cNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPLS\u201d of S glycoprotein of MERS-CoV shows the highest B-cellantigenicity peak in antigenicity plot.", [["amino acids", "CHEMICAL", 68, 79], ["amino acids", "CHEMICAL", 68, 79], ["amino acids", "AMINO_ACID", 68, 79], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 129, 143], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 147, 155], ["S glycoprotein", "PROTEIN", 129, 143], ["MERS", "PROTEIN", 147, 151], ["MERS-CoV", "SPECIES", 147, 155], ["the peptide region", "TEST", 38, 56], ["amino acids", "TEST", 68, 79], ["S glycoprotein of MERS", "TEST", 129, 151], ["CoV", "TEST", 152, 155]]], ["Most importantly, weobserved that the best successful T-cell epitope CYSSLILDY isalso a part of the region which shows highest B-cellantigenicity peak, suggesting that it may stand as a competentchoice to be a universal vaccine component against MERSCoV,the rapidly growing health concern.ConclusionThe obtained results which identified the epitopes cover asignificant number of strains with decent population coverage.To exert cellular and humoral immunity, the computer aidedresult has been found potential and expected to mountimmune response upon further in vivo and in vitro validation.The step by step analysis and progression for maximumpossible MHC coverage provides significant primary screeningresult against this fatal virus.Conflict of interestThe authors declare that there is no conflict of interests.", [["T-cell", "ANATOMY", 54, 60], ["cellular", "ANATOMY", 428, 436], ["T-cell", "CELL", 54, 60], ["cellular", "CELL", 428, 436], ["T-cell epitope", "PROTEIN", 54, 68], ["CYSSLILDY", "PROTEIN", 69, 78], ["epitopes", "PROTEIN", 341, 349], ["MHC", "PROTEIN", 653, 656], ["MERSCoV", "SPECIES", 246, 253], ["highest B-cellantigenicity peak", "PROBLEM", 119, 150], ["a universal vaccine component", "TREATMENT", 208, 237], ["the epitopes", "PROBLEM", 337, 349], ["strains", "PROBLEM", 379, 386], ["decent population coverage", "TREATMENT", 392, 418], ["step analysis", "TEST", 603, 616], ["maximumpossible MHC coverage", "TREATMENT", 637, 665], ["this fatal virus", "PROBLEM", 719, 735], ["humoral immunity", "OBSERVATION", 441, 457], ["no", "UNCERTAINTY", 790, 792]]]], "330a49685a269070206fdd0f4bba345e96bf492f": [["IntroductionHuman viruses intrinsically depend on cellular factors to successfully infect and replicate inside their host.", [["cellular", "ANATOMY", 50, 58], ["cellular", "CELL", 50, 58], ["cellular factors", "PROTEIN", 50, 66], ["IntroductionHuman viruses", "PROBLEM", 0, 25], ["cellular factors", "PROBLEM", 50, 66]]], ["Viruses hijack the cellular machinery, exploit it and often reprogram it for their own needs, both to utilize it for replication and to evade antiviral innate immune defenses.", [["cellular", "ANATOMY", 19, 27], ["cellular", "CELL", 19, 27], ["replication", "TREATMENT", 117, 128], ["cellular machinery", "OBSERVATION", 19, 37]]], ["Here, in this review, we summarize systematic approaches that have been developed to identify these key cellular determinants for viral infections.", [["cellular", "ANATOMY", 104, 112], ["viral infections", "DISEASE", 130, 146], ["cellular", "CELL", 104, 112], ["systematic approaches", "PROBLEM", 35, 56], ["viral infections", "PROBLEM", 130, 146], ["infections", "OBSERVATION", 136, 146]]], ["First of all, the knowledge of these critical host-pathogen interactions is crucial to understand the viral life cycle and moreover, will provide the basis for the development of therapeutic interventions.", [["therapeutic interventions", "TREATMENT", 179, 204]]], ["We will highlight novel concepts that arose from the comprehensive understanding of the host-viral circuitry.IntroductionA biological system, such as the evolutionary interplay between a virus and its host, functions through the combined regulatory mechanisms and entangled engagement of various classes of molecules and states (DNA, RNA, regulatory RNA, protein interactions, protein abundance, post-translational modifications, epigenetic modifications, metabolites, etc.) in a spatial and temporal order [1] .", [["DNA", "CELLULAR_COMPONENT", 329, 332], ["RNA", "RNA", 334, 337], ["regulatory RNA", "RNA", 339, 353], ["a virus", "PROBLEM", 185, 192], ["DNA, RNA, regulatory RNA, protein interactions", "PROBLEM", 329, 375], ["protein abundance", "TEST", 377, 394], ["post-translational modifications", "TREATMENT", 396, 428], ["epigenetic modifications", "TREATMENT", 430, 454], ["viral circuitry", "OBSERVATION", 93, 108]]], ["Systems-based 'omics' approaches such as genomics, proteomics, transcriptomics, metabolomics and other approaches are instrumental to capture pieces of this host-pathogen map in a comprehensive and unbiased survey (summarized in Table 1 ).", [["pathogen map", "TEST", 162, 174]]], ["Perturbation studies, RNA interference (RNAi) or cDNA overexpression, have facilitated the establishment of systematic cellbased loss-of-function or gain-of-function screening platforms, respectively.", [["Perturbation studies", "TEST", 0, 20], ["RNA interference", "PROBLEM", 22, 38], ["cDNA overexpression", "PROBLEM", 49, 68], ["systematic cellbased loss", "PROBLEM", 108, 133]]], ["These functional genomics approaches are a powerful tool informing us about the immediate relevance of the identified factors for viral replication.", [["viral replication", "TREATMENT", 130, 147]]], ["In this review we focus on the genome-wide siRNA screening approaches deciphering the host cellular repertoire affecting HIV and influenza A virus (IAV) replication providing a global cellular map of the viralhost relationship (six global RNAi screens in human cells for IAV and five for HIV) [2,3 ,4,5,6 ,7,8 ,9-12] .", [["cellular", "ANATOMY", 91, 99], ["cellular", "ANATOMY", 184, 192], ["cells", "ANATOMY", 261, 266], ["cellular", "CELL", 91, 99], ["HIV", "ORGANISM", 121, 124], ["influenza A virus", "ORGANISM", 129, 146], ["IAV", "ORGANISM", 148, 151], ["cellular", "CELL", 184, 192], ["human", "ORGANISM", 255, 260], ["cells", "CELL", 261, 266], ["2,3 ,4,5,6 ,7,8 ,9-12", "SIMPLE_CHEMICAL", 294, 315], ["human cells", "CELL_TYPE", 255, 266], ["HIV", "SPECIES", 121, 124], ["influenza A virus", "SPECIES", 129, 146], ["human", "SPECIES", 255, 260], ["HIV", "SPECIES", 121, 124], ["influenza A virus", "SPECIES", 129, 146], ["IAV", "SPECIES", 148, 151], ["human", "SPECIES", 255, 260], ["IAV", "SPECIES", 271, 274], ["HIV", "SPECIES", 288, 291], ["wide siRNA screening", "TREATMENT", 38, 58], ["HIV", "PROBLEM", 121, 124], ["influenza A virus (IAV) replication", "TREATMENT", 129, 164], ["IAV", "PROBLEM", 271, 274]]], ["Proteomics data can provide global insight into host proteins hijacked by the virus.", [["host proteins", "PROTEIN", 48, 61], ["Proteomics data", "TEST", 0, 15], ["the virus", "PROBLEM", 74, 83]]], ["Recent studies have comprehensively documented the protein complexes directly interacting with viral proteins encoded by the retrovirus HIV-1 and the herpesvirus KSHV by systematically affinity tagging and purifying all viral proteins followed by mass spectrometry [13 ,14] .", [["retrovirus HIV-1", "ORGANISM", 125, 141], ["herpesvirus", "ORGANISM", 150, 161], ["KSHV", "ORGANISM", 162, 166], ["protein complexes", "PROTEIN", 51, 68], ["viral proteins", "PROTEIN", 95, 109], ["viral proteins", "PROTEIN", 220, 234], ["HIV-1", "SPECIES", 136, 141], ["HIV-1", "SPECIES", 136, 141], ["herpesvirus KSHV", "SPECIES", 150, 166], ["Recent studies", "TEST", 0, 14], ["the protein complexes", "PROBLEM", 47, 68], ["viral proteins", "PROBLEM", 95, 109], ["the retrovirus HIV", "TEST", 121, 139], ["the herpesvirus KSHV", "PROBLEM", 146, 166], ["affinity tagging", "TEST", 185, 201], ["all viral proteins", "PROBLEM", 216, 234], ["mass spectrometry", "TEST", 247, 264]]], ["Combining the genome-wide siRNA approaches above with this kind of proteomewide strategies would add another level of confidence in selecting the relevant host factors responsible for replication that serve as immediate interconnections of viral components with the host proteome.", [["wide siRNA approaches", "TREATMENT", 21, 42], ["proteomewide strategies", "TREATMENT", 67, 90], ["replication", "TREATMENT", 184, 195], ["viral components", "TREATMENT", 240, 256], ["viral components", "OBSERVATION", 240, 256]]], ["Studies integrating proteomics and hit validation by RNAi are a starting point in achieving this goal (exemplified by [15] [16] [17] ).IntroductionRecent approaches surveyed key molecules playing roles in common antiviral strategies (summarized in Table 1 ).", [["[15] [16] [17]", "SIMPLE_CHEMICAL", 118, 132], ["Studies integrating proteomics", "TEST", 0, 30], ["hit validation", "TEST", 35, 49]]], ["For instance, Pichlmair et al. investigated the proteome of 70 viral proteins from 30 different viruses targeting virusspecific and pan-viral cellular processes as an immune escape strategy suggesting certain conserved cellular alert mechanisms [18] .", [["cellular", "ANATOMY", 142, 150], ["cellular", "ANATOMY", 219, 227], ["virusspecific", "CELL", 114, 127], ["pan-viral cellular", "CELL", 132, 150], ["cellular", "CELL", 219, 227], ["70 viral proteins", "PROTEIN", 60, 77], ["Pichlmair et al", "TREATMENT", 14, 29], ["the proteome", "TEST", 44, 56], ["viral proteins", "TEST", 63, 77], ["pan-viral cellular processes", "PROBLEM", 132, 160], ["an immune escape strategy", "PROBLEM", 164, 189], ["pan-viral cellular processes", "OBSERVATION", 132, 160]]], ["Intriguingly, a pan-viral cellular immune response strategy implying an unexpected role for the DNA sensor cGAS in controlling RNA viruses was uncovered by Schoggins et al. [19] .", [["cellular", "ANATOMY", 26, 34], ["cellular", "CELL", 26, 34], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["cGAS", "GENE_OR_GENE_PRODUCT", 107, 111], ["DNA sensor cGAS", "DNA", 96, 111], ["a pan-viral cellular immune response strategy", "TREATMENT", 14, 59], ["the DNA sensor cGAS", "TREATMENT", 92, 111], ["RNA viruses", "PROBLEM", 127, 138]]], ["They demonstrated a gain-of-function approach by screening a library of interferon-stimulated genes (ISGs) on antiviral activity against 14 different viruses.", [["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 72, 99], ["interferon-stimulated genes", "DNA", 72, 99], ["ISGs", "DNA", 101, 105], ["interferon-stimulated genes", "TREATMENT", 72, 99], ["antiviral activity", "TREATMENT", 110, 128], ["14 different viruses", "PROBLEM", 137, 157]]], ["To complete the picture of the innate response sensing viral pathogens, several studies interrogated regulators of pathways affecting viral replication (see Table 1 ).", [["viral pathogens", "PROBLEM", 55, 70], ["several studies", "TEST", 72, 87]]], ["Lee et al. integrated various complementary 'omics' approaches to identify new components of the innate response to cytosolic DNA affecting retroviral infections in mouse embryonic fibroblasts (MEFs) [20] , whereas two other studies covered the TLR interactome [21, 22] .", [["cytosolic", "ANATOMY", 116, 125], ["embryonic fibroblasts", "ANATOMY", 171, 192], ["MEFs", "ANATOMY", 194, 198], ["retroviral infections", "DISEASE", 140, 161], ["cytosolic", "CELLULAR_COMPONENT", 116, 125], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["retroviral", "ORGANISM", 140, 150], ["mouse", "ORGANISM", 165, 170], ["embryonic fibroblasts", "CELL", 171, 192], ["MEFs", "CELL", 194, 198], ["TLR", "GENE_OR_GENE_PRODUCT", 245, 248], ["cytosolic DNA", "DNA", 116, 129], ["mouse embryonic fibroblasts", "CELL_TYPE", 165, 192], ["MEFs", "CELL_TYPE", 194, 198], ["TLR", "PROTEIN", 245, 248], ["mouse", "SPECIES", 165, 170], ["mouse", "SPECIES", 165, 170], ["cytosolic DNA", "PROBLEM", 116, 129], ["retroviral infections in mouse embryonic fibroblasts", "PROBLEM", 140, 192], ["cytosolic DNA", "OBSERVATION", 116, 129], ["retroviral infections", "OBSERVATION", 140, 161], ["embryonic fibroblasts", "OBSERVATION", 171, 192]]], ["To understand the cellular complexes formed after pathogen recognition, Li et al. systematically explored the human IFN interactome responsible for regulating cellular antiviral defense and IFN production [23] .IntroductionThese recent novel systems-biology strategies have started to uncover the important framework that orchestrates the cellular defense against viral pathogens, however, important questions and answers are still outstanding.", [["cellular", "ANATOMY", 18, 26], ["cellular", "ANATOMY", 159, 167], ["cellular", "ANATOMY", 339, 347], ["Li", "CHEMICAL", 72, 74], ["cellular", "CELL", 18, 26], ["human", "ORGANISM", 110, 115], ["IFN", "GENE_OR_GENE_PRODUCT", 116, 119], ["cellular", "CELL", 159, 167], ["IFN", "GENE_OR_GENE_PRODUCT", 190, 193], ["cellular", "CELL", 339, 347], ["cellular complexes", "PROTEIN", 18, 36], ["IFN", "PROTEIN", 116, 119], ["IFN", "PROTEIN", 190, 193], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["viral pathogens", "PROBLEM", 364, 379], ["antiviral defense", "OBSERVATION", 168, 185]]], ["Non-structural viral proteins indeed protect viruses against unknown cellular proteins [24] , however none of the above mentioned studies systematically investigated how nonstructural proteins influence the results of genomics screens, for example, by comparing global screens that were performed with viruses mutated in one gene at a time.", [["cellular", "ANATOMY", 69, 77], ["cellular", "CELL", 69, 77], ["Non-structural viral proteins", "PROTEIN", 0, 29], ["cellular proteins", "PROTEIN", 69, 86], ["nonstructural proteins", "PROTEIN", 170, 192], ["Non-structural viral proteins", "TREATMENT", 0, 29], ["genomics screens", "TEST", 218, 234], ["global screens", "TEST", 262, 276], ["viruses", "PROBLEM", 302, 309]]], ["Viral proteins are known to influence innate factors by either directly leading them to proteasomal degradation [24] or changing the activation status of the restricting factors through post-translational modifications [25] .", [["proteasomal", "ANATOMY", 88, 99], ["Viral proteins", "PROTEIN", 0, 14], ["innate factors", "PROTEIN", 38, 52], ["restricting factors", "PROTEIN", 158, 177], ["Viral proteins", "PROBLEM", 0, 14], ["proteasomal degradation", "PROBLEM", 88, 111]]], ["A future systematic survey on the alteration of the global cellular protein abundance/phospho-proteome/ubiquitinome through viral modulators would significantly add to the cooperative picture of viral replication.", [["cellular", "ANATOMY", 59, 67], ["phospho", "CHEMICAL", 86, 93], ["cellular", "CELL", 59, 67], ["phospho", "PROTEIN", 86, 93], ["A future systematic survey", "TEST", 0, 26], ["the global cellular protein abundance", "TEST", 48, 85], ["phospho", "TEST", 86, 93], ["ubiquitinome", "PROBLEM", 103, 115], ["viral modulators", "PROBLEM", 124, 140], ["viral replication", "TREATMENT", 195, 212], ["viral replication", "OBSERVATION", 195, 212]]], ["A first global study on cellular rewiring successfully uncovered novel cellular factors that are differentially phosphorylated upon HIV-1 infection [26 ] .IntroductionGiven the gigantic wealth of information collected by various 'omics' studies, it becomes extremely important to gather the data in a user-friendly format, and provide 80 Host-microbe interactions: viruses Table 1 Screening approaches to identify novel cellular factors affecting viral replication (selected publications)Global viral screens InfluenzaGenomics [2,3 ,4,5,6 ,7,81,82] Proteomics and genomics [15, 16] HIV Genomics [9,8 ,83,10- In vivo screening approach Genomics [75] novel analysis tools to comb the plethora of data to be able to compare them to own lab-generated datasets.", [["cellular", "ANATOMY", 24, 32], ["cellular", "ANATOMY", 71, 79], ["cellular", "ANATOMY", 420, 428], ["HIV-1 infection", "DISEASE", 132, 147], ["cellular", "CELL", 24, 32], ["cellular", "CELL", 71, 79], ["HIV-1", "ORGANISM", 132, 137], ["cellular", "CELL", 420, 428], ["cellular factors", "PROTEIN", 71, 87], ["cellular factors", "PROTEIN", 420, 436], ["HIV-1", "SPECIES", 132, 137], ["HIV-1", "SPECIES", 132, 137], ["HIV", "SPECIES", 582, 585], ["A first global study", "TEST", 0, 20], ["cellular rewiring", "TREATMENT", 24, 41], ["novel cellular factors", "PROBLEM", 65, 87], ["HIV-1 infection", "PROBLEM", 132, 147], ["viruses Table", "TREATMENT", 365, 378], ["novel cellular factors", "PROBLEM", 414, 436], ["viral replication", "TREATMENT", 447, 464], ["Global viral screens InfluenzaGenomics", "TEST", 488, 526], ["Proteomics", "TEST", 549, 559], ["genomics", "TEST", 564, 572], ["HIV Genomics", "TEST", 582, 594], ["novel analysis", "TEST", 649, 663], ["viral replication", "OBSERVATION", 447, 464]]], ["Many global initiatives (as summarized in Table 2 ) have started to develop such tools and compendia.", [["compendia", "PROBLEM", 91, 100]]], ["An all-encompassing tool integrating various datasets in a comprehensive and unbiased model of viral-host interaction, a so-called meta-analysis, will be a big challenge but promising direction for the future.Global viral screens InfluenzaMany of the studies mentioned above revealed important novel insights into virus-host interactions and opened up new research avenues.", [["a big challenge", "TREATMENT", 154, 169], ["Global viral screens", "TEST", 209, 229], ["the studies", "TEST", 247, 258]]], ["In this review we can only highlight a few selected examples for which we illustrate how screening approaches have led to an advanced understanding of the complex virus-host interplay ( Figure 1 ).Advances in the field of influenza virus entry based on RNAi screensIn the field of IAV entry several novel host factors have been identified and characterized for their role in the early steps of virus infection as a result of RNAi screens for host factors of influenza viruses.", [["infection", "DISEASE", 400, 409], ["influenza viruses", "DISEASE", 458, 475], ["influenza virus", "ORGANISM", 222, 237], ["IAV", "ORGANISM", 281, 284], ["influenza viruses", "ORGANISM", 458, 475], ["host factors", "PROTEIN", 442, 454], ["influenza virus", "SPECIES", 222, 237], ["influenza virus", "SPECIES", 222, 237], ["IAV", "SPECIES", 281, 284], ["influenza virus entry", "TREATMENT", 222, 243], ["RNAi screens", "TEST", 253, 265], ["virus infection", "PROBLEM", 394, 409], ["RNAi screens", "TEST", 425, 437], ["influenza viruses", "PROBLEM", 458, 475], ["influenza viruses", "OBSERVATION", 458, 475]]], ["For example, the cytoplasmic dipeptidase prolidase has been found to be involved in early endosomal trafficking of the virus [27] .", [["cytoplasmic", "ANATOMY", 17, 28], ["endosomal", "ANATOMY", 90, 99], ["cytoplasmic", "ORGANISM_SUBSTANCE", 17, 28], ["prolidase", "GENE_OR_GENE_PRODUCT", 41, 50], ["early endosomal", "CELLULAR_COMPONENT", 84, 99], ["cytoplasmic dipeptidase", "PROTEIN", 17, 40], ["prolidase", "PROTEIN", 41, 50], ["the cytoplasmic dipeptidase prolidase", "TEST", 13, 50], ["early", "OBSERVATION_MODIFIER", 84, 89], ["endosomal trafficking", "OBSERVATION", 90, 111]]], ["Interestingly, also the tetraspanin CD81 which had previously been detected in influenza virions was revealed to be required for early events in virus infection, most likely at the level of fusion of viral and endosomal membranes [28, 29] .", [["endosomal membranes", "ANATOMY", 210, 229], ["infection", "DISEASE", 151, 160], ["tetraspanin CD81", "GENE_OR_GENE_PRODUCT", 24, 40], ["influenza virions", "ORGANISM", 79, 96], ["endosomal membranes", "CELLULAR_COMPONENT", 210, 229], ["tetraspanin CD81", "PROTEIN", 24, 40], ["the tetraspanin CD81", "TEST", 20, 40], ["influenza virions", "PROBLEM", 79, 96], ["early events in virus infection", "PROBLEM", 129, 160], ["viral and endosomal membranes", "PROBLEM", 200, 229], ["virus infection", "OBSERVATION", 145, 160], ["most likely", "UNCERTAINTY", 162, 173], ["fusion", "OBSERVATION", 190, 196], ["viral", "OBSERVATION", 200, 205], ["endosomal membranes", "OBSERVATION", 210, 229]]], ["Exciting progress has also been made at the stage of viral uncoating: Su and colleagues performed an shRNA screen for host factors of IAV and focused on one particular hit found to be required for early steps of Identifying host factors involved in virus replication K\u00f6 nig and Stertz 81 Overview of screening approaches.", [["IAV", "ORGANISM", 134, 137], ["host factors", "PROTEIN", 118, 130], ["IAV", "SPECIES", 134, 137], ["an shRNA screen", "TEST", 98, 113], ["IAV", "PROBLEM", 134, 137], ["screening approaches", "TEST", 300, 320]]], ["Graphical representation of the most common screening approaches used to study virus interactions. *The enrichment step is only used for certain types of screens, such as phospho-proteomic analysis or screens for viral interactors. **The enrichment of specific posttranslational modifications includes phosphorylation, ubiquitination, etc. viral infection, the E3 ubiquitin ligase ITCH [6 ] .", [["viral infection", "DISEASE", 340, 355], ["E3", "GENE_OR_GENE_PRODUCT", 361, 363], ["E3 ubiquitin ligase", "PROTEIN", 361, 380], ["ITCH [6 ]", "PROTEIN", 381, 390], ["screens", "TEST", 154, 161], ["phospho-proteomic analysis", "TEST", 171, 197], ["screens", "TEST", 201, 208], ["viral interactors", "PROBLEM", 213, 230], ["phosphorylation", "TREATMENT", 302, 317], ["viral infection", "PROBLEM", 340, 355], ["the E3 ubiquitin ligase ITCH", "PROBLEM", 357, 385], ["posttranslational modifications", "OBSERVATION", 261, 292], ["infection", "OBSERVATION", 346, 355], ["ubiquitin", "OBSERVATION_MODIFIER", 364, 373], ["ligase ITCH", "OBSERVATION", 374, 385]]], ["They could show that the virus gets trapped in the endosome upon knockdown of ITCH.", [["endosome", "ANATOMY", 51, 59], ["endosome", "CELLULAR_COMPONENT", 51, 59], ["ITCH", "GENE_OR_GENE_PRODUCT", 78, 82], ["ITCH", "PROTEIN", 78, 82], ["the virus", "PROBLEM", 21, 30], ["ITCH", "PROBLEM", 78, 82], ["virus", "OBSERVATION", 25, 30]]], ["Moreover, ITCH was found to be phosphorylated upon infection, thereby recruited to the endosome where it interacts with the viral matrix protein M1 and ubiquitinates M1.", [["endosome", "ANATOMY", 87, 95], ["ITCH", "CHEMICAL", 10, 14], ["infection", "DISEASE", 51, 60], ["ITCH", "GENE_OR_GENE_PRODUCT", 10, 14], ["endosome", "CELLULAR_COMPONENT", 87, 95], ["viral matrix protein M1", "GENE_OR_GENE_PRODUCT", 124, 147], ["ITCH", "PROTEIN", 10, 14], ["viral matrix protein", "PROTEIN", 124, 144], ["M1", "PROTEIN", 145, 147], ["M1", "PROTEIN", 166, 168], ["ITCH", "PROBLEM", 10, 14], ["phosphorylated upon infection", "PROBLEM", 31, 60], ["infection", "OBSERVATION", 51, 60], ["viral matrix", "OBSERVATION", 124, 136], ["protein M1", "OBSERVATION", 137, 147], ["M1", "ANATOMY", 166, 168]]], ["These results gave the first insight into cellular factors involved in the uncoating process of IAV and this was further elucidated by a recent study by Banerjee et al. [30 ] .", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["IAV", "ORGANISM", 96, 99], ["cellular factors", "PROTEIN", 42, 58], ["IAV", "SPECIES", 96, 99], ["IAV", "PROBLEM", 96, 99], ["a recent study", "TEST", 135, 149], ["IAV", "OBSERVATION", 96, 99]]], ["On the basis of the results of an siRNA screen for IAV host factors the class I HDACs (histone deacetylases) had emerged as regulators of IAV entry and therefore the authors followed up on HDAC6 [30 ,31] .", [["class I HDACs", "GENE_OR_GENE_PRODUCT", 72, 85], ["histone deacetylases", "GENE_OR_GENE_PRODUCT", 87, 107], ["IAV", "ORGANISM", 138, 141], ["HDAC6", "GENE_OR_GENE_PRODUCT", 189, 194], ["IAV host factors", "PROTEIN", 51, 67], ["class I HDACs", "PROTEIN", 72, 85], ["histone deacetylases", "PROTEIN", 87, 107], ["HDAC6", "PROTEIN", 189, 194], ["IAV", "SPECIES", 51, 54], ["an siRNA screen", "TEST", 31, 46], ["IAV host factors", "TREATMENT", 51, 67], ["HDACs (histone deacetylases", "TREATMENT", 80, 107], ["HDAC6", "TEST", 189, 194]]], ["They found that the incoming virus carries unanchored ubiquitin chains that become recognized by an HDAC6-dependent pathway of the aggresome machinery.", [["HDAC6", "GENE_OR_GENE_PRODUCT", 100, 105], ["unanchored ubiquitin chains", "PROTEIN", 43, 70], ["HDAC6", "PROTEIN", 100, 105], ["the incoming virus", "PROBLEM", 16, 34], ["unanchored ubiquitin chains", "TREATMENT", 43, 70], ["virus", "OBSERVATION", 29, 34], ["ubiquitin chains", "OBSERVATION", 54, 70]]], ["This leads to the recruitment of microtubules and associated motor proteins.", [["microtubules", "ANATOMY", 33, 45], ["microtubules", "CELLULAR_COMPONENT", 33, 45], ["microtubules", "PROTEIN", 33, 45], ["motor proteins", "PROTEIN", 61, 75], ["associated motor proteins", "PROBLEM", 50, 75], ["recruitment", "OBSERVATION_MODIFIER", 18, 29], ["motor proteins", "OBSERVATION", 61, 75]]], ["Their model suggests that the motor proteins can generate physical force to disrupt the virions and thereby enable complete uncoating.", [["virions", "ANATOMY", 88, 95], ["motor proteins", "PROTEIN", 30, 44], ["the motor proteins", "PROBLEM", 26, 44]]], ["Currently, it is unclear how the function of ITCH and the aggresome pathway are linked but certainly these studies have uncovered exciting new insights into the uncoating process of IAV.Advances in the field of influenza virus entry based on RNAi screensBesides the progress on cellular factors with a proviral function in IAV entry the screening approaches have also advanced the area of antiviral factors: One of the genomewide RNAi screens for IAV identified the IFITM (IFNinducible transmembrane) proteins with the family members IFITM1, IFITM2, IFITM3 and IFITM5 in humans as novel antiviral restriction factors and two other screens confirmed this result [3 ,5,15] .", [["cellular", "ANATOMY", 278, 286], ["ITCH", "GENE_OR_GENE_PRODUCT", 45, 49], ["IAV", "ORGANISM", 182, 185], ["influenza virus", "ORGANISM", 211, 226], ["cellular", "CELL", 278, 286], ["IAV", "ORGANISM", 447, 450], ["IFITM", "GENE_OR_GENE_PRODUCT", 466, 471], ["IFITM1", "GENE_OR_GENE_PRODUCT", 534, 540], ["IFITM2", "GENE_OR_GENE_PRODUCT", 542, 548], ["IFITM3", "GENE_OR_GENE_PRODUCT", 550, 556], ["IFITM5", "GENE_OR_GENE_PRODUCT", 561, 567], ["humans", "ORGANISM", 571, 577], ["ITCH", "PROTEIN", 45, 49], ["cellular factors", "PROTEIN", 278, 294], ["antiviral factors", "PROTEIN", 389, 406], ["IFITM (IFNinducible transmembrane) proteins", "PROTEIN", 466, 509], ["IFITM1", "PROTEIN", 534, 540], ["IFITM2", "PROTEIN", 542, 548], ["IFITM3", "PROTEIN", 550, 556], ["IFITM5", "PROTEIN", 561, 567], ["antiviral restriction factors", "PROTEIN", 587, 616], ["influenza virus", "SPECIES", 211, 226], ["humans", "SPECIES", 571, 577], ["influenza virus", "SPECIES", 211, 226], ["IAV", "SPECIES", 323, 326], ["IAV", "SPECIES", 447, 450], ["humans", "SPECIES", 571, 577], ["ITCH", "PROBLEM", 45, 49], ["these studies", "TEST", 101, 114], ["influenza virus entry", "TREATMENT", 211, 232], ["RNAi screens", "TEST", 242, 254], ["the genomewide RNAi screens", "TEST", 415, 442], ["IAV", "PROBLEM", 447, 450], ["novel antiviral restriction factors", "TREATMENT", 581, 616], ["two other screens", "TEST", 621, 638], ["IAV", "OBSERVATION", 182, 185], ["antiviral factors", "OBSERVATION", 389, 406]]], ["Brass and colleagues observed that knockdown of IFITM3 led to increased viral replication, whereas overexpression of the IFITMs efficiently blocked the virus.", [["IFITM3", "CHEMICAL", 48, 54], ["IFITM3", "GENE_OR_GENE_PRODUCT", 48, 54], ["IFITMs", "GENE_OR_GENE_PRODUCT", 121, 127], ["IFITM3", "PROTEIN", 48, 54], ["IFITMs", "PROTEIN", 121, 127], ["IFITM3", "PROBLEM", 48, 54], ["increased viral replication", "PROBLEM", 62, 89], ["the IFITMs", "PROBLEM", 117, 127], ["the virus", "PROBLEM", 148, 157], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["viral replication", "OBSERVATION", 72, 89], ["virus", "OBSERVATION", 152, 157]]], ["It soon became clear that the antiviral potential of IFITM3 was not limited to influenza viruses, but also included members of flaviviruses, filoviruses, bunyaviruses, coronaviruses, reoviruses and HIV-1 [3 ,32-35] .", [["IFITM3", "CHEMICAL", 53, 59], ["influenza viruses", "DISEASE", 79, 96], ["IFITM3", "GENE_OR_GENE_PRODUCT", 53, 59], ["filoviruses", "GENE_OR_GENE_PRODUCT", 141, 152], ["bunyaviruses", "GENE_OR_GENE_PRODUCT", 154, 166], ["HIV-1", "ORGANISM", 198, 203], ["IFITM3", "PROTEIN", 53, 59], ["HIV-1", "SPECIES", 198, 203], ["HIV-1", "SPECIES", 198, 203], ["IFITM3", "PROBLEM", 53, 59], ["influenza viruses", "PROBLEM", 79, 96], ["flaviviruses", "PROBLEM", 127, 139], ["filoviruses", "PROBLEM", 141, 152], ["bunyaviruses", "PROBLEM", 154, 166], ["coronaviruses", "PROBLEM", 168, 181], ["reoviruses", "PROBLEM", 183, 193], ["HIV", "TEST", 198, 201], ["clear", "OBSERVATION", 15, 20]]], ["Moreover, it was found that the IFITM proteins localize to endosomes and/or the plasma membrane and block at the stage of viral entry [32, 36] .", [["endosomes", "ANATOMY", 59, 68], ["plasma membrane", "ANATOMY", 80, 95], ["IFITM", "GENE_OR_GENE_PRODUCT", 32, 37], ["endosomes", "CELLULAR_COMPONENT", 59, 68], ["plasma membrane", "CELLULAR_COMPONENT", 80, 95], ["IFITM proteins", "PROTEIN", 32, 46], ["the IFITM proteins", "PROBLEM", 28, 46], ["the plasma membrane", "PROBLEM", 76, 95], ["block", "PROBLEM", 100, 105]]], ["Since then, a whole field of research on the antiviral potential, the mechanism of viral inhibition and the in vivo role of the IFITM proteins has opened up and flourished.", [["IFITM", "GENE_OR_GENE_PRODUCT", 128, 133], ["IFITM proteins", "PROTEIN", 128, 142], ["viral inhibition", "PROBLEM", 83, 99], ["the IFITM proteins", "TREATMENT", 124, 142], ["viral inhibition", "OBSERVATION", 83, 99]]], ["We have learnt that besides humans, other species, including pigs, chicken and mice, encode for IFITM proteins with powerful antiviral activity [37] [38] [39] [40] .", [["humans", "ORGANISM", 28, 34], ["pigs", "ORGANISM", 61, 65], ["chicken", "ORGANISM", 67, 74], ["mice", "ORGANISM", 79, 83], ["IFITM", "GENE_OR_GENE_PRODUCT", 96, 101], ["[37] [38] [39] [40", "SIMPLE_CHEMICAL", 144, 162], ["IFITM proteins", "PROTEIN", 96, 110], ["humans", "SPECIES", 28, 34], ["pigs", "SPECIES", 61, 65], ["chicken", "SPECIES", 67, 74], ["mice", "SPECIES", 79, 83], ["humans", "SPECIES", 28, 34], ["pigs", "SPECIES", 61, 65], ["chicken", "SPECIES", 67, 74], ["mice", "SPECIES", 79, 83], ["powerful antiviral activity", "TREATMENT", 116, 143]]], ["The mechanism of antiviral action is not completely understood yet but it is assumed that fusion between viral and endosomal membranes is targeted by the IFITM proteins [36, 41] .", [["endosomal membranes", "ANATOMY", 115, 134], ["endosomal membranes", "CELLULAR_COMPONENT", 115, 134], ["IFITM", "GENE_OR_GENE_PRODUCT", 154, 159], ["IFITM proteins", "PROTEIN", 154, 168], ["antiviral action", "TREATMENT", 17, 33], ["fusion between viral and endosomal membranes", "PROBLEM", 90, 134], ["antiviral", "OBSERVATION", 17, 26], ["fusion", "OBSERVATION", 90, 96], ["viral", "OBSERVATION", 105, 110], ["endosomal membranes", "OBSERVATION", 115, 134]]], ["Current models suggest that the IFITMs either impact the composition or activity of components of endosomal vesicles to which they localize and thereby hinder fusion [42] .", [["endosomal vesicles", "ANATOMY", 98, 116], ["IFITMs", "GENE_OR_GENE_PRODUCT", 32, 38], ["endosomal vesicles", "CELLULAR_COMPONENT", 98, 116], ["IFITMs", "PROTEIN", 32, 38], ["the IFITMs", "TREATMENT", 28, 38], ["endosomal vesicles", "PROBLEM", 98, 116], ["endosomal vesicles", "OBSERVATION", 98, 116]]], ["Alternatively, the IFITMs could affect the membrane properties of endosomes resulting in unfavorable conditions for fusion between cellular and viral membranes [43] .", [["membrane", "ANATOMY", 43, 51], ["endosomes", "ANATOMY", 66, 75], ["cellular", "ANATOMY", 131, 139], ["membranes", "ANATOMY", 150, 159], ["IFITMs", "GENE_OR_GENE_PRODUCT", 19, 25], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["endosomes", "CELLULAR_COMPONENT", 66, 75], ["cellular", "CELL", 131, 139], ["IFITMs", "PROTEIN", 19, 25], ["unfavorable conditions", "PROBLEM", 89, 111], ["fusion between cellular and viral membranes", "PROBLEM", 116, 159], ["viral membranes", "OBSERVATION", 144, 159]]], ["In line with both models most of the viruses that are sensitive to IFITM restriction are enveloped viruses that fuse in late endosomal compartments.", [["endosomal compartments", "ANATOMY", 125, 147], ["IFITM", "GENE_OR_GENE_PRODUCT", 67, 72], ["endosomal compartments", "CELLULAR_COMPONENT", 125, 147], ["IFITM", "PROTEIN", 67, 72], ["the viruses", "PROBLEM", 33, 44], ["IFITM restriction", "TREATMENT", 67, 84], ["viruses", "OBSERVATION", 37, 44], ["late", "OBSERVATION_MODIFIER", 120, 124], ["endosomal compartments", "OBSERVATION", 125, 147]]], ["However, also the non-enveloped reoviruses are blocked efficiently by IFITMs, whereas arenaviruses which fuse at membranes of acidic endosomal compartments are resistant to IFITM restriction [3 ,32,35] .", [["membranes", "ANATOMY", 113, 122], ["endosomal compartments", "ANATOMY", 133, 155], ["reoviruses", "GENE_OR_GENE_PRODUCT", 32, 42], ["IFITMs", "GENE_OR_GENE_PRODUCT", 70, 76], ["membranes", "CELLULAR_COMPONENT", 113, 122], ["endosomal compartments", "CELLULAR_COMPONENT", 133, 155], ["IFITMs", "PROTEIN", 70, 76], ["the non-enveloped reoviruses", "PROBLEM", 14, 42], ["arenaviruses", "PROBLEM", 86, 98], ["non-enveloped", "OBSERVATION_MODIFIER", 18, 31], ["reoviruses", "OBSERVATION", 32, 42]]], ["This highlights that we do not yet fully understand the antiviral mechanism of IFITM proteins.", [["IFITM", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFITM proteins", "PROTEIN", 79, 93], ["IFITM proteins", "PROBLEM", 79, 93]]], ["Interestingly, two new studies reported the incorporation of IFITM proteins into HIV-1 virions and inhibition of viral fusion as a result of IFITM packaging [44 ,45 ] .", [["IFITM", "GENE_OR_GENE_PRODUCT", 61, 66], ["HIV-1 virions", "ORGANISM", 81, 94], ["IFITM", "GENE_OR_GENE_PRODUCT", 141, 146], ["IFITM proteins", "PROTEIN", 61, 75], ["IFITM", "PROTEIN", 141, 146], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["new studies", "TEST", 19, 30], ["HIV-1 virions", "TREATMENT", 81, 94], ["viral fusion", "TREATMENT", 113, 125], ["IFITM packaging", "TREATMENT", 141, 156], ["viral fusion", "OBSERVATION", 113, 125]]], ["It will be important to see if other viruses incorporate IFITMs as well and if this can explain some of the open questions on the mechanism of action.Advances in the field of influenza virus entry based on RNAi screensRegarding the in vivo role of IFITMs it could be shown that ifitm3 \u00c0/\u00c0 mice are more susceptible to IAV infection than wildtype mice as evidenced by increased weight loss and mortality [37] .", [["IAV infection", "DISEASE", 318, 331], ["weight loss", "DISEASE", 377, 388], ["IFITMs", "GENE_OR_GENE_PRODUCT", 57, 63], ["influenza virus", "ORGANISM", 175, 190], ["IFITMs", "GENE_OR_GENE_PRODUCT", 248, 254], ["ifitm3 \u00c0/\u00c0 mice", "ORGANISM", 278, 293], ["IAV", "ORGANISM", 318, 321], ["mice", "ORGANISM", 346, 350], ["IFITMs", "PROTEIN", 248, 254], ["ifitm3", "PROTEIN", 278, 284], ["influenza virus", "SPECIES", 175, 190], ["mice", "SPECIES", 289, 293], ["mice", "SPECIES", 346, 350], ["influenza virus", "SPECIES", 175, 190], ["mice", "SPECIES", 289, 293], ["IAV", "SPECIES", 318, 321], ["mice", "SPECIES", 346, 350], ["influenza virus entry", "TREATMENT", 175, 196], ["RNAi screens", "TEST", 206, 218], ["IAV infection", "PROBLEM", 318, 331], ["increased weight loss", "PROBLEM", 367, 388], ["IAV", "OBSERVATION_MODIFIER", 318, 321], ["infection", "OBSERVATION", 322, 331], ["increased", "OBSERVATION_MODIFIER", 367, 376], ["weight loss", "OBSERVATION", 377, 388]]], ["Furthermore, recent findings in human patients highlighted the importance of IFITM3 in the host defense of humans against IAV [37] .", [["human", "ORGANISM", 32, 37], ["patients", "ORGANISM", 38, 46], ["IFITM3", "GENE_OR_GENE_PRODUCT", 77, 83], ["humans", "ORGANISM", 107, 113], ["IFITM3", "PROTEIN", 77, 83], ["human", "SPECIES", 32, 37], ["patients", "SPECIES", 38, 46], ["humans", "SPECIES", 107, 113], ["human", "SPECIES", 32, 37], ["humans", "SPECIES", 107, 113], ["IAV", "SPECIES", 122, 125], ["IAV", "PROBLEM", 122, 125]]], ["It was observed that patients homozygous for a polymorphism in the IFITM3 gene that results in an inactive variant of IFITM3 had an approximately 20-fold higher incidence of severe influenza than those with intact IFITM3.", [["influenza", "DISEASE", 181, 190], ["patients", "ORGANISM", 21, 29], ["IFITM3", "GENE_OR_GENE_PRODUCT", 67, 73], ["IFITM3", "GENE_OR_GENE_PRODUCT", 118, 124], ["IFITM3", "GENE_OR_GENE_PRODUCT", 214, 220], ["IFITM3 gene", "DNA", 67, 78], ["IFITM3", "PROTEIN", 118, 124], ["IFITM3", "PROTEIN", 214, 220], ["patients", "SPECIES", 21, 29], ["patients homozygous", "PROBLEM", 21, 40], ["a polymorphism", "PROBLEM", 45, 59], ["an inactive variant of IFITM3", "PROBLEM", 95, 124], ["severe influenza", "PROBLEM", 174, 190], ["inactive", "OBSERVATION_MODIFIER", 98, 106], ["approximately", "OBSERVATION_MODIFIER", 132, 145], ["20-fold", "OBSERVATION_MODIFIER", 146, 153], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["influenza", "OBSERVATION", 181, 190]]], ["Another study came to a similar conclusion but a third one could not confirm this result [46, 47] .", [["Another study", "TEST", 0, 13]]], ["Moreover, a recent study reported that the inactive version of IFITM3 described in the susceptible patients has potent antiviral activity in their experimental system [48] .", [["IFITM3", "CHEMICAL", 63, 69], ["IFITM3", "GENE_OR_GENE_PRODUCT", 63, 69], ["patients", "ORGANISM", 99, 107], ["IFITM3", "PROTEIN", 63, 69], ["patients", "SPECIES", 99, 107], ["a recent study", "TEST", 10, 24], ["IFITM3", "PROBLEM", 63, 69], ["antiviral activity", "OBSERVATION", 119, 137]]], ["In conclusion, more studies are required to resolve some of the contradictions but there is promising evidence for an important role in antiviral defense of IFITM3 in humans.Advances in the field of early events in HIV replication based on RNAi screensDetails of the early steps of lentiviral replication including uncoating, nuclear import and integration have long been incompletely understood.", [["nuclear", "ANATOMY", 326, 333], ["IFITM3", "GENE_OR_GENE_PRODUCT", 157, 163], ["humans", "ORGANISM", 167, 173], ["HIV", "ORGANISM", 215, 218], ["lentiviral", "ORGANISM", 282, 292], ["nuclear", "CELLULAR_COMPONENT", 326, 333], ["IFITM3", "PROTEIN", 157, 163], ["humans", "SPECIES", 167, 173], ["HIV", "SPECIES", 215, 218], ["humans", "SPECIES", 167, 173], ["HIV", "SPECIES", 215, 218], ["IFITM3 in humans", "PROBLEM", 157, 173], ["HIV replication", "TREATMENT", 215, 230], ["RNAi screens", "TEST", 240, 252], ["lentiviral replication", "TREATMENT", 282, 304], ["antiviral defense", "OBSERVATION", 136, 153]]], ["Recent genome-wide RNAi studies have started to shed some light and instigated new intriguing research concepts to this enigmatic field of research.", [["Recent genome-wide RNAi studies", "PROBLEM", 0, 31]]], ["The first two genome-wide siRNA screens discovered members of the nucleo-cytoplasmic transport machinery as important host factors, such as the nuclear pore proteins Nup153 and Nup358 and Transportin-SR2/TNPO3 [8 ,9] .", [["cytoplasmic", "ANATOMY", 73, 84], ["nuclear pore", "ANATOMY", 144, 156], ["cytoplasmic", "ORGANISM_SUBSTANCE", 73, 84], ["Nup153", "GENE_OR_GENE_PRODUCT", 166, 172], ["Nup358", "GENE_OR_GENE_PRODUCT", 177, 183], ["Transportin-SR2", "GENE_OR_GENE_PRODUCT", 188, 203], ["host factors", "PROTEIN", 118, 130], ["nuclear pore proteins", "PROTEIN", 144, 165], ["Nup153", "PROTEIN", 166, 172], ["Nup358", "PROTEIN", 177, 183], ["Transportin", "PROTEIN", 188, 199], ["SR2", "PROTEIN", 200, 203], ["TNPO3", "PROTEIN", 204, 209], ["wide siRNA screens", "TEST", 21, 39], ["Transportin", "TREATMENT", 188, 199]]], ["The latter was identified independently in a yeast-to-hybrid screen as an HIV-interacting protein [49] .", [["HIV-interacting protein", "PROTEIN", 74, 97], ["yeast", "SPECIES", 45, 50], ["yeast", "SPECIES", 45, 50], ["HIV", "SPECIES", 74, 77]]], ["The precise step at which these cellular factors act on viral replication had been a matter of discussion in the field (reviewed in [50] ).", [["cellular", "ANATOMY", 32, 40], ["cellular", "CELL", 32, 40], ["cellular factors", "PROTEIN", 32, 48], ["viral replication", "TREATMENT", 56, 73]]], ["However, their involvement in nuclear import of the pre-integration complex (PIC) has been heavily supported by various reports, starting with the initial mapping to the nuclear import step [8 ] up to mapping of TNPO3 by De Iaco et al. [51] .", [["nuclear", "ANATOMY", 30, 37], ["nuclear", "ANATOMY", 170, 177], ["nuclear", "CELLULAR_COMPONENT", 30, 37], ["pre-integration complex", "GENE_OR_GENE_PRODUCT", 52, 75], ["nuclear", "CELLULAR_COMPONENT", 170, 177], ["TNPO3", "GENE_OR_GENE_PRODUCT", 212, 217], ["pre-integration complex", "PROTEIN", 52, 75], ["PIC", "PROTEIN", 77, 80], ["TNPO3", "PROTEIN", 212, 217], ["the pre-integration complex (PIC", "TREATMENT", 48, 80], ["TNPO3", "TREATMENT", 212, 217]]], ["An intriguing model of import-coupled integration had been suggested based on the observations, that (i) two more members of the nucleo-cytoplasmic transport machinery, amongst them Nup98 confirmed in two screens [8 ,12] , affected unexpectedly HIV-1 integration [8 ,52] , and that (ii) integration of HIV is dependent on the nuclear transport machinery even in cycling cells where post-nuclear envelope breakdown would otherwise make the nucleus accessible to the HIV PIC [8 ] .", [["cytoplasmic", "ANATOMY", 136, 147], ["nuclear", "ANATOMY", 326, 333], ["cells", "ANATOMY", 370, 375], ["nucleus", "ANATOMY", 439, 446], ["cytoplasmic", "ORGANISM_SUBSTANCE", 136, 147], ["Nup98", "GENE_OR_GENE_PRODUCT", 182, 187], ["HIV-1", "ORGANISM", 245, 250], ["HIV", "ORGANISM", 302, 305], ["nuclear", "CELLULAR_COMPONENT", 326, 333], ["cells", "CELL", 370, 375], ["nucleus", "CELLULAR_COMPONENT", 439, 446], ["Nup98", "PROTEIN", 182, 187], ["cycling cells", "CELL_TYPE", 362, 375], ["HIV-1", "SPECIES", 245, 250], ["HIV-1", "SPECIES", 245, 250], ["HIV", "SPECIES", 302, 305], ["HIV", "SPECIES", 465, 468], ["two screens", "TEST", 201, 212], ["HIV", "PROBLEM", 302, 305], ["cycling cells", "PROBLEM", 362, 375], ["post-nuclear envelope breakdown", "PROBLEM", 382, 413], ["the HIV PIC", "TREATMENT", 461, 472], ["HIV", "OBSERVATION", 302, 305]]], ["Follow-up studies extended the finding that correct trafficking through the pore facilitates integration steps such that preferred regions of the genome for integration are targeted [53 ,54] .", [["pore", "ANATOMY", 76, 80], ["pore", "CELLULAR_COMPONENT", 76, 80], ["Follow-up studies", "TEST", 0, 17]]], ["Moreover, blocking the interaction between cyclophilin A, a long-known cellular factor relevant for HIV-1 infection [55] , and viral capsid relieves the dependence on TNPO3 and Nup358 and subsequently alters integration targeting [54] .", [["cellular", "ANATOMY", 71, 79], ["HIV-1 infection", "DISEASE", 100, 115], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 43, 56], ["cellular", "CELL", 71, 79], ["HIV-1", "ORGANISM", 100, 105], ["TNPO3", "GENE_OR_GENE_PRODUCT", 167, 172], ["Nup358", "GENE_OR_GENE_PRODUCT", 177, 183], ["cyclophilin A", "PROTEIN", 43, 56], ["cellular factor", "PROTEIN", 71, 86], ["viral capsid", "PROTEIN", 127, 139], ["TNPO3", "PROTEIN", 167, 172], ["Nup358", "PROTEIN", 177, 183], ["HIV-1", "SPECIES", 100, 105], ["HIV-1", "SPECIES", 100, 105], ["cyclophilin A", "TREATMENT", 43, 56], ["HIV", "PROBLEM", 100, 103], ["1 infection", "PROBLEM", 104, 115], ["viral capsid", "PROBLEM", 127, 139], ["the dependence", "PROBLEM", 149, 163], ["TNPO3", "TREATMENT", 167, 172], ["Nup358", "TREATMENT", 177, 183], ["viral capsid", "OBSERVATION_MODIFIER", 127, 139]]], ["Interestingly, a truncated version of the cleavage and polyadenylation specificity factor-6 (CPSF6) identified in a murine cDNA expression screen as a HIV-1 restricting gene had been shown to prevent nuclear entry [56] .", [["nuclear", "ANATOMY", 200, 207], ["polyadenylation specificity factor-6", "GENE_OR_GENE_PRODUCT", 55, 91], ["CPSF6", "GENE_OR_GENE_PRODUCT", 93, 98], ["murine", "ORGANISM", 116, 122], ["HIV-1", "ORGANISM", 151, 156], ["nuclear", "CELLULAR_COMPONENT", 200, 207], ["polyadenylation specificity factor-6", "PROTEIN", 55, 91], ["CPSF6", "PROTEIN", 93, 98], ["HIV-1 restricting gene", "DNA", 151, 173], ["murine", "SPECIES", 116, 122], ["HIV-1", "SPECIES", 151, 156], ["HIV-1", "SPECIES", 151, 156], ["the cleavage", "PROBLEM", 38, 50], ["polyadenylation specificity factor", "TEST", 55, 89], ["a murine cDNA expression screen", "TEST", 114, 145]]], ["On the basis of mutational studies, a model was proposed that binding of CPSF6 to the HIV-1 capsid mediates the dependence for TNPO3 and Nup358 [57] .", [["Nup358", "CHEMICAL", 137, 143], ["CPSF6", "GENE_OR_GENE_PRODUCT", 73, 78], ["HIV-1", "ORGANISM", 86, 91], ["capsid", "ORGANISM", 92, 98], ["TNPO3", "GENE_OR_GENE_PRODUCT", 127, 132], ["CPSF6", "PROTEIN", 73, 78], ["HIV-1 capsid", "PROTEIN", 86, 98], ["TNPO3", "PROTEIN", 127, 132], ["HIV-1", "SPECIES", 86, 91], ["HIV-1", "SPECIES", 86, 91], ["mutational studies", "TEST", 16, 34], ["the HIV", "PROBLEM", 82, 89], ["TNPO3", "TEST", 127, 132]]], ["An indirect role for TNPO3 promoting HIV-1 infection has been proposed: TNPO3, responsible for import of cargo proteins containing RS domains [58] , transports CSPF6 possessing such a domain into the nucleus [51] .", [["nucleus", "ANATOMY", 200, 207], ["TNPO3", "CHEMICAL", 21, 26], ["HIV-1 infection", "DISEASE", 37, 52], ["TNPO3", "GENE_OR_GENE_PRODUCT", 21, 26], ["HIV-1", "ORGANISM", 37, 42], ["TNPO3", "GENE_OR_GENE_PRODUCT", 72, 77], ["CSPF6", "GENE_OR_GENE_PRODUCT", 160, 165], ["nucleus", "CELLULAR_COMPONENT", 200, 207], ["TNPO3", "PROTEIN", 21, 26], ["TNPO3", "PROTEIN", 72, 77], ["cargo proteins", "PROTEIN", 105, 119], ["RS domains", "PROTEIN", 131, 141], ["CSPF6", "PROTEIN", 160, 165], ["HIV-1", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 37, 42], ["TNPO3", "TREATMENT", 21, 26], ["1 infection", "PROBLEM", 41, 52], ["TNPO3", "TREATMENT", 72, 77], ["transports CSPF6", "TREATMENT", 149, 165], ["nucleus", "ANATOMY", 200, 207]]], ["In the absence of TNPO3, CPSF6 accumulates in the cytoplasm causing a delay in nuclear import of the viral DNA [51] .", [["cytoplasm", "ANATOMY", 50, 59], ["nuclear", "ANATOMY", 79, 86], ["CPSF6", "CHEMICAL", 25, 30], ["TNPO3", "GENE_OR_GENE_PRODUCT", 18, 23], ["CPSF6", "GENE_OR_GENE_PRODUCT", 25, 30], ["cytoplasm", "ORGANISM_SUBSTANCE", 50, 59], ["nuclear", "CELLULAR_COMPONENT", 79, 86], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["TNPO3", "PROTEIN", 18, 23], ["CPSF6", "PROTEIN", 25, 30], ["TNPO3", "TREATMENT", 18, 23], ["the cytoplasm", "PROBLEM", 46, 59], ["a delay", "PROBLEM", 68, 75], ["the viral DNA", "PROBLEM", 97, 110], ["cytoplasm", "OBSERVATION_MODIFIER", 50, 59], ["delay", "OBSERVATION_MODIFIER", 70, 75]]], ["Recently, the study by Rasaiyaah et al. went a step ahead and described for the first time that cofactor usage is linked to evasion of innate sensors [59 ] .", [["the study", "TEST", 10, 19]]], ["The suggested model posits that host factors, such as Cyclophilin A together with CPSF6 and Nup358, prevent premature uncoating and improper timing of reverse transcription, thus avoiding sensing of viral DNA by the DNA sensor cGAS [60] .", [["Cyclophilin A", "GENE_OR_GENE_PRODUCT", 54, 67], ["CPSF6", "GENE_OR_GENE_PRODUCT", 82, 87], ["Nup358", "GENE_OR_GENE_PRODUCT", 92, 98], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["Cyclophilin A", "PROTEIN", 54, 67], ["CPSF6", "PROTEIN", 82, 87], ["Nup358", "PROTEIN", 92, 98], ["viral DNA", "DNA", 199, 208], ["Cyclophilin A", "TREATMENT", 54, 67], ["CPSF6", "TREATMENT", 82, 87], ["Nup358", "TREATMENT", 92, 98], ["premature uncoating", "PROBLEM", 108, 127], ["reverse transcription", "TREATMENT", 151, 172], ["viral DNA", "PROBLEM", 199, 208]]], ["Together with the engagement by other host factors, such as TNPO3 and Nup153, transport of the PICs through the nuclear pore can take place and will lead to proper integration site selection (reviewed in [61, 62] ).Advances in the field of early events in HIV replication based on RNAi screensRecently, an overexpression screening approach to discover restriction factors of viral replication identified Myxovirus resistance protein 2 (MxB) as an ISG inhibiting HIV-1 replication [63 ] .", [["nuclear pore", "ANATOMY", 112, 124], ["TNPO3", "GENE_OR_GENE_PRODUCT", 60, 65], ["Nup153", "GENE_OR_GENE_PRODUCT", 70, 76], ["PICs", "GENE_OR_GENE_PRODUCT", 95, 99], ["nuclear pore", "CELLULAR_COMPONENT", 112, 124], ["HIV", "ORGANISM", 256, 259], ["Myxovirus resistance protein 2", "GENE_OR_GENE_PRODUCT", 404, 434], ["MxB", "GENE_OR_GENE_PRODUCT", 436, 439], ["ISG", "GENE_OR_GENE_PRODUCT", 447, 450], ["HIV-1", "ORGANISM", 462, 467], ["host factors", "PROTEIN", 38, 50], ["TNPO3", "PROTEIN", 60, 65], ["Nup153", "PROTEIN", 70, 76], ["PICs", "PROTEIN", 95, 99], ["restriction factors", "PROTEIN", 352, 371], ["Myxovirus resistance protein 2", "PROTEIN", 404, 434], ["MxB", "PROTEIN", 436, 439], ["HIV", "SPECIES", 256, 259], ["HIV-1", "SPECIES", 462, 467], ["HIV", "SPECIES", 256, 259], ["HIV-1", "SPECIES", 462, 467], ["TNPO3", "TREATMENT", 60, 65], ["the PICs", "TREATMENT", 91, 99], ["HIV replication", "TREATMENT", 256, 271], ["RNAi screens", "TEST", 281, 293], ["an overexpression screening approach", "TREATMENT", 303, 339], ["restriction factors", "PROBLEM", 352, 371], ["viral replication", "TREATMENT", 375, 392], ["Myxovirus resistance protein", "PROBLEM", 404, 432]]], ["Subsequently, three reports described MxB as a potent inhibitor of early events in the life cycle [64] [65] [66] , though the precise step of inhibition still needs to be determined (summarized in [67] ).", [["MxB", "CHEMICAL", 38, 41], ["MxB", "CHEMICAL", 38, 41], ["MxB", "SIMPLE_CHEMICAL", 38, 41], ["a potent inhibitor", "TREATMENT", 45, 63]]], ["Intriguingly, the expression of MxB, a protein accumulating at the nuclear rim [68] , was shown to influence the integration site selection of the provirus, similar to cellular import factors such as TNPO3 or Nup358 [69 ] .", [["nuclear", "ANATOMY", 67, 74], ["cellular", "ANATOMY", 168, 176], ["MxB", "GENE_OR_GENE_PRODUCT", 32, 35], ["cellular", "CELL", 168, 176], ["TNPO3", "GENE_OR_GENE_PRODUCT", 200, 205], ["MxB", "PROTEIN", 32, 35], ["cellular import factors", "PROTEIN", 168, 191], ["TNPO3", "PROTEIN", 200, 205], ["Nup358", "PROTEIN", 209, 215], ["a protein", "TEST", 37, 46], ["the provirus", "PROBLEM", 143, 155], ["provirus", "OBSERVATION", 147, 155]]], ["These observations further point to the fact that HIV PIC nuclear import and integration may be functionally linked.", [["nuclear", "ANATOMY", 58, 65], ["HIV", "ORGANISM", 50, 53], ["PIC", "GENE_OR_GENE_PRODUCT", 54, 57], ["nuclear", "CELLULAR_COMPONENT", 58, 65], ["HIV", "SPECIES", 50, 53], ["HIV PIC nuclear import", "TREATMENT", 50, 72]]], ["Though much progress has been made by identification of the above mentioned host factors, still many questions are unanswered, such as the role of these factors and not yet identified co-factors in the timing and spatial model of the coupled processes of uncoating -nuclear import -integration.Current limitations and future directionsAs evidenced by the examples described above, follow-up studies from RNAi screen have led to exciting new findings and opened up new areas of research, for example, the IFITM restriction factors, or led to novel concepts, for example, the coupled processes for viral nuclear import and integration site selection.", [["nuclear", "ANATOMY", 266, 273], ["nuclear", "ANATOMY", 602, 609], ["nuclear", "CELLULAR_COMPONENT", 266, 273], ["IFITM restriction factors", "PROTEIN", 504, 529], ["follow-up studies", "TEST", 381, 398], ["RNAi screen", "TEST", 404, 415], ["the IFITM restriction factors", "PROBLEM", 500, 529], ["viral nuclear import", "PROBLEM", 596, 616]]], ["However, when looking at the numbers of host factors identified by various approaches, only very few hits have been confirmed and further characterized for their proviral or antiviral role.", [["host factors", "PROTEIN", 40, 52], ["their proviral or antiviral role", "PROBLEM", 156, 188]]], ["In order to fully exploit the potential of the screens many more follow-up studies are required.Current limitations and future directionsIt is often difficult to choose promising host factors from hit lists that contain several hundred factors.", [["the screens", "TEST", 43, 54], ["follow-up studies", "TEST", 65, 82]]], ["This has been further complicated by the observation that the overlap in hits is surprisingly small between different screens for the same virus [70] [71] [72] .", [["different screens", "TEST", 108, 125], ["small", "OBSERVATION_MODIFIER", 94, 99]]], ["This discrepancy can be partially explained by differences in experimental systems, such as virus strain, cell line or screening assay or limitations of high-throughput screenings, such as offtarget effects, false positives and false negatives [70, 73] , but a major contributing factor for variation between screens seems to be the different filtering criteria that are employed to rank the best genes [71] .", [["cell line", "ANATOMY", 106, 115], ["cell line", "CELL", 106, 115], ["experimental systems", "PROBLEM", 62, 82], ["virus strain", "PROBLEM", 92, 104], ["cell line", "TEST", 106, 115], ["screening assay", "TEST", 119, 134], ["throughput screenings", "TEST", 158, 179], ["false positives", "PROBLEM", 208, 223], ["false negatives", "TEST", 228, 243], ["variation between screens", "PROBLEM", 291, 316], ["can be partially explained", "UNCERTAINTY", 17, 43]]], ["The hit identification process will automatically introduce a bias into the otherwise unbiased genome-wide datasets.", [["The hit identification process", "PROBLEM", 0, 30]]], ["Despite the divergence in gene sets, a greater overlap was identified in shared overrepresented functional groups, pathways [71, 72] or shared protein complexes [71] .", [["protein complexes", "PROTEIN", 143, 160], ["the divergence in gene sets", "PROBLEM", 8, 35], ["a greater overlap", "PROBLEM", 37, 54]]], ["Thus, an analysis of multiple datasets will be more effective in identifying intriguing new candidates and pathways exploited by viruses.", [["an analysis", "TEST", 6, 17], ["multiple datasets", "PROBLEM", 21, 38]]], ["However, a re-analysis of the primary datasets from multiple screens would be most useful.", [["the primary datasets", "TEST", 26, 46], ["multiple screens", "TEST", 52, 68]]], ["In order to overcome this current limitation a public database for the deposit of primary screening datasets would be desirable.", [["primary screening datasets", "TEST", 82, 108]]], ["Such a repository could also help to make the integration of datasets from different methodological approaches, for example, proteomic, transcriptomic and RNAi data, possible.", [["RNAi data", "TEST", 155, 164]]], ["Single 'omics' datasets can only capture a part of the whole and thus, it will be necessary to look from various angles to define the parameters affecting virus replication.Current limitations and future directionsAn additional limitation of the currently available datasets is the need to use convenient experimental systems for high-throughput assays.", [["Single 'omics' datasets", "TREATMENT", 0, 23], ["virus replication", "TREATMENT", 155, 172], ["convenient experimental systems", "TEST", 294, 325], ["high-throughput assays", "PROBLEM", 330, 352]]], ["First, in most screens transformed cell lines that are easy to transfect have been used and it is unclear how results from these systems can be extrapolated to primary cells.", [["cell lines", "ANATOMY", 35, 45], ["primary cells", "ANATOMY", 160, 173], ["cell lines", "CELL", 35, 45], ["cells", "CELL", 168, 173], ["transformed cell lines", "CELL_LINE", 23, 45], ["primary cells", "CELL_TYPE", 160, 173], ["cell lines", "OBSERVATION", 35, 45]]], ["For instance, cGAMP responses differ in mouse versus human cells [74] and pattern recognition receptors and other pathway members are not expressed equally in all cells (e.g. STING and cGAS lack expression in 293Tcells [60] ), and thus primary sentinel cells of the immune system would be more appropriate to screen for antiviral effects than cell lines.", [["cells", "ANATOMY", 59, 64], ["cells", "ANATOMY", 163, 168], ["cells", "ANATOMY", 253, 258], ["immune system", "ANATOMY", 266, 279], ["cell lines", "ANATOMY", 343, 353], ["cGAMP", "GENE_OR_GENE_PRODUCT", 14, 19], ["mouse", "ORGANISM", 40, 45], ["human", "ORGANISM", 53, 58], ["cells", "CELL", 59, 64], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 74, 103], ["cells", "CELL", 163, 168], ["STING", "GENE_OR_GENE_PRODUCT", 175, 180], ["cGAS", "GENE_OR_GENE_PRODUCT", 185, 189], ["cells", "CELL", 253, 258], ["immune system", "ANATOMICAL_SYSTEM", 266, 279], ["cell lines", "CELL", 343, 353], ["cGAMP", "PROTEIN", 14, 19], ["human cells", "CELL_TYPE", 53, 64], ["pattern recognition receptors", "PROTEIN", 74, 103], ["STING", "PROTEIN", 175, 180], ["cGAS", "PROTEIN", 185, 189], ["primary sentinel cells", "CELL_TYPE", 236, 258], ["cell lines", "CELL_LINE", 343, 353], ["mouse", "SPECIES", 40, 45], ["human", "SPECIES", 53, 58], ["mouse", "SPECIES", 40, 45], ["human", "SPECIES", 53, 58], ["antiviral effects", "TREATMENT", 320, 337], ["cell lines", "TREATMENT", 343, 353]]], ["Improved methods to perturb experimental systems based on primary cells or tissues are expected to be developed and solve such technical problems.", [["primary cells", "ANATOMY", 58, 71], ["tissues", "ANATOMY", 75, 82], ["cells", "CELL", 66, 71], ["tissues", "TISSUE", 75, 82], ["primary cells", "CELL_TYPE", 58, 71], ["perturb experimental systems", "TREATMENT", 20, 48]]], ["Moreover, in vivo screens are already being established to address the important question which aspects of the virus-host interplay hold true in animal models [75] .Current limitations and future directionsSecond, current approaches to modulate gene expression by siRNA or shRNA come with off-target effects and usually do not block the expression of a gene completely.", [["the virus", "PROBLEM", 107, 116], ["siRNA or shRNA", "TREATMENT", 264, 278]]], ["Future screening approaches using CRISPR/cas9 methodology will overcome some of the limitations [76 ,77 ,78 ] .", [["CRISPR", "DNA", 34, 40], ["CRISPR/cas9 methodology", "TREATMENT", 34, 57]]], ["CRISPR provides an elegant way of introducing targeted loss-of-function mutations at specific sites in the genome.", [["genome", "CELLULAR_COMPONENT", 107, 113], ["CRISPR", "DNA", 0, 6], ["introducing targeted loss", "PROBLEM", 34, 59], ["function mutations", "PROBLEM", 63, 81], ["genome", "ANATOMY", 107, 113]]], ["The advantages include high screening sensitivity by homozygous knockouts, which is especially important when partial knockdown retains gene function.", [["homozygous knockouts", "PROBLEM", 53, 73]]], ["Moreover, whereas RNAi is limited to transcripts, CRISPR can target different elements across the genome, such as promoters, introns and intergenic regions.", [["CRISPR", "DNA", 50, 56], ["promoters", "DNA", 114, 123], ["introns", "DNA", 125, 132], ["intergenic regions", "DNA", 137, 155], ["introns and intergenic regions", "PROBLEM", 125, 155], ["intergenic", "OBSERVATION_MODIFIER", 137, 147]]], ["Catalytically inactive mutants of Cas9 linked to different functional domains can furthermore provide a means for genome-scale gain-of-function screening approaches using Cas9 activators, epigenetic modifiers or GFP-tagged Cas9 proteins to visualize genomic sequences [79, 80] .", [["Cas9", "GENE_OR_GENE_PRODUCT", 34, 38], ["Cas9", "GENE_OR_GENE_PRODUCT", 171, 175], ["GFP", "GENE_OR_GENE_PRODUCT", 212, 215], ["Cas9", "GENE_OR_GENE_PRODUCT", 223, 227], ["Cas9", "PROTEIN", 34, 38], ["Cas9 activators", "PROTEIN", 171, 186], ["GFP", "PROTEIN", 212, 215], ["Cas9 proteins", "PROTEIN", 223, 236], ["genomic sequences", "DNA", 250, 267], ["Catalytically inactive mutants of Cas9", "PROBLEM", 0, 38], ["Cas9 activators", "TREATMENT", 171, 186], ["epigenetic modifiers", "TREATMENT", 188, 208], ["GFP", "TEST", 212, 215], ["genomic sequences", "TEST", 250, 267]]], ["Specifically, the latter could provide a promising platform for imaging of viral sequences embedded within the native chromatin organization and dynamics in living human cells.", [["chromatin", "ANATOMY", 118, 127], ["cells", "ANATOMY", 170, 175], ["chromatin", "CELLULAR_COMPONENT", 118, 127], ["human", "ORGANISM", 164, 169], ["cells", "CELL", 170, 175], ["viral sequences", "DNA", 75, 90], ["living human cells", "CELL_TYPE", 157, 175], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["imaging of viral sequences", "TEST", 64, 90], ["native chromatin organization", "OBSERVATION", 111, 140]]], ["Current limitations of the technology include the inability to target genes essential for cell survival, for example, main regulators of the cell cycle.", [["cell", "ANATOMY", 90, 94], ["cell", "ANATOMY", 141, 145], ["cell", "CELL", 90, 94], ["cell", "CELL", 141, 145], ["the technology", "TREATMENT", 23, 37], ["cell survival", "TREATMENT", 90, 103], ["cell cycle", "OBSERVATION", 141, 151]]], ["Moreover, also for CRISPR/cas9 off-target effects have been described.", [["CRISPR", "DNA", 19, 25], ["CRISPR/cas9", "TREATMENT", 19, 30]]], ["Novel strategies to address this problem, such as the concerted action of paired nickases, are being pursued [79] .", [["Novel strategies", "TREATMENT", 0, 16], ["this problem", "PROBLEM", 28, 40], ["paired nickases", "PROBLEM", 74, 89]]], ["In sum, the CRISPR/ cas9 methodology will be complementary to RNAi and can broaden the repertoire of perturbation modalities.ConclusionsIn recent years massive efforts have been undertaken to shed light on virus-host interactions via unbiased highthroughput screening approaches.", [["CRISPR", "DNA", 12, 18], ["the CRISPR/ cas9 methodology", "TREATMENT", 8, 36], ["perturbation modalities", "TREATMENT", 101, 124], ["virus", "TREATMENT", 206, 211]]], ["Future efforts should focus on providing a framework for primary datasets and comparative and integrated analysis to uncover the full potential of the screens.", [["primary datasets", "TEST", 57, 73], ["comparative and integrated analysis", "TEST", 78, 113], ["the screens", "TEST", 147, 158]]], ["Ultimately, such a meta-analysis will shed light on the three-dimensional map of host-pathogen interactions, and support the development of novel antivirals, adjuvants, and vaccines.", [["a meta-analysis", "TEST", 17, 32], ["host-pathogen interactions", "TREATMENT", 81, 107], ["novel antivirals", "TREATMENT", 140, 156], ["adjuvants", "TREATMENT", 158, 167], ["vaccines", "TREATMENT", 173, 181]]]]}